インスリン イコデク（遺伝子組換え）

2.7.4.7. 付録
7. 特別な患者集団及び状況下における安全性

ノボ ノルディスク ファーマ株式会社

Table of contents

Page

7.7.1 Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 6
7.7.2 Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 9
7.7.3 Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 12
7.7.4 Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 112
7.7.5 Adverse events by sex and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 206
7.7.6 Adverse events by sex and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 207
7.7.7 Adverse events by sex and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 208
7.7.8 Adverse events by sex and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 209
7.7.9 Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 210
7.7.10 Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 214
7.7.11 Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 218
7.7.12 Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 343
7.7.13 Adverse events by age group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 462
7.7.14 Adverse events by age group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 463
7.7.15 Adverse events by age group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 464
7.7.16 Adverse events by age group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 465
7.7.17 Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 466
7.7.18 Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 471
7.7.19 Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 476
7.7.20 Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 654
7.7.21 Adverse events by race and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 823

7.7.22 Adverse events by race and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 824
7.7.23 Adverse events by race and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 825
7.7.24 Adverse events by race and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 826
7.7.25 Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 827
7.7.26 Adverse events by ethnicity - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 831
7.7.27 Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 835
7.7.28 Adverse events by ethnicity, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 960
7.7.29 Adverse events by ethnicity and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1079
7.7.30 Adverse events by ethnicity and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1080
7.7.31 Adverse events by ethnicity and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1081
7.7.32 Adverse events by ethnicity and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1082
7.7.33 Adverse events by region - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 1083
7.7.34 Adverse events by region - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 1088
7.7.35 Adverse events by region, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 1093
7.7.36 Adverse events by region, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 1271
7.7.37 Adverse events by region and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1440
7.7.38 Adverse events by region and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1441
7.7.39 Adverse events by region and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1442
7.7.40 Adverse events by region and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1443
7.7.41 Adverse events by baseline HbA1c group - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 1444
7.7.42 Adverse events by baseline HbA1c group - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 1448
7.7.43 Adverse events by baseline HbA1c group, system organ class and preferred term - on-treatment/main- on-treatment - summary - safety analysis set - phase 3a pool 1452
7.7.44 Adverse events by baseline HbA1c group, system organ class and preferred term - on-treatment/main- on-treatment - summary - safety analysis set - T2D pool 1552
7.7.45 Adverse events by baseline HbA1c group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1646

7.7.46 Adverse events by baseline HbA1c group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1647
7.7.47 Adverse events by baseline HbA1c group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1648
7.7.48 Adverse events by baseline HbA1c group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1649
7.7.49 Adverse events by diabetes duration - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 1650
7.7.50 Adverse events by diabetes duration - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 1653
7.7.51 Adverse events by diabetes duration, system organ class and preferred term - on-treatment/main-on- treatment - summary - safety analysis set - phase 3a pool 1656
7.7.52 Adverse events by diabetes duration, system organ class and preferred term - on-treatment/main-on- treatment - summary - safety analysis set - T2D pool 1755
7.7.53 Adverse events by diabetes duration and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1849
7.7.54 Adverse events by diabetes duration and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1850
7.7.55 Adverse events by diabetes duration and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 1851
7.7.56 Adverse events by diabetes duration and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 1852
7.7.57 Adverse events by baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 1853
7.7.58 Adverse events by baseline BMI group - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 1858
7.7.59 Adverse events by baseline BMI group, system organ class and preferred term - on-treatment/main-on- treatment - summary - safety analysis set - phase 3a pool 1863
7.7.60 Adverse events by baseline BMI group, system organ class and preferred term - on-treatment/main-on- treatment - summary - safety analysis set - T2D pool 2035
7.7.61 Adverse events by baseline BMI group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2198
7.7.62 Adverse events by baseline BMI group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2199
7.7.63 Adverse events by baseline BMI group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2200
7.7.64 Adverse events by baseline BMI group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2201
7.7.65 Adverse events by baseline renal function - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 2202
7.7.66 Adverse events by baseline renal function - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 2207
7.7.67 Adverse events by baseline renal function, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 2212
7.7.68 Adverse events by baseline renal function, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 2344
7.7.69 Adverse events by baseline renal function and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2470

7.7.70 Adverse events by baseline renal function and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2471
7.7.71 Adverse events by baseline renal function and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2472
7.7.72 Adverse events by baseline renal function and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2473
7.7.73 Adverse events by pre-trial insulin treatment - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 2474
7.7.74 Adverse events by pre-trial insulin treatment - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 2478
7.7.75 Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool 2482
7.7.76 Adverse events by pre-trial insulin treatment, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool 2610
7.7.77 Adverse events by pre-trial insulin treatment and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2731
7.7.78 Adverse events by pre-trial insulin treatment and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2732
7.7.79 Adverse events by pre-trial insulin treatment and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2733
7.7.80 Adverse events by pre-trial insulin treatment and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2734
7.7.81 Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 2735
7.7.82 Adverse events by baseline hepatic function - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 2739
7.7.83 Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - phase 3a pool 2743
7.7.84 Adverse events by baseline hepatic function, system organ class and preferred term - on-treatment/ main-on-treatment - summary - safety analysis set - T2D pool 2871
7.7.85 Adverse events by baseline hepatic function and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2992
7.7.86 Adverse events by baseline hepatic function and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2993
7.7.87 Adverse events by baseline hepatic function and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2994
7.7.88 Adverse events by baseline hepatic function and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2995
7.7.89 Adverse events by COVID-19 trial co-participation - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 2995
7.7.90 Adverse events by COVID-19 trial co-participation - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 2995
7.7.91 Adverse events by COVID-19 trial co-participation, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool 2996
7.7.92 Adverse events by COVID-19 trial co-participation, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool 2996
7.7.93 Adverse events by COVID-19 trial co-participation and system organ class - on-treatment/main-on- treatment - dot plot - safety analysis set - phase 3a pool 2996

7.7.94 Adverse events by COVID-19 trial co-participation and system organ class - on-treatment/main-on- treatment - dot plot - safety analysis set - T2D pool 2996
7.7.95 Adverse events by COVID-19 trial co-participation and preferred term - most frequent [>=5%] - on- treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool 2996
7.7.96 Adverse events by COVID-19 trial co-participation and preferred term - most frequent [>=5%] - on- treatment/main-on-treatment - dot plot - safety analysis set - T2D pool 2997

7.7 Safety in special groups and situations

7.7.1 Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Female	902				951			
Male	1268				1219			
PYE (years)								
Female	697.61				738.01			
Male	983.62				942.57			
Events								
Female	576	(64.0)	1777	274.58	577	(60.6)	1897	275.33
Male	752	(59.2)	2208	241.10	686	(56.3)	1981	231.86
Serious								
Yes								
Female	58	(6.5)	79	11.31	74	(7.8)	101	13.54
Male	108	(8.5)	166	17.35	95	(7.8)	137	13.85
No								
Female	564	(62.7)	1698	263.27	561	(58.9)	1796	261.78
Male	723	(56.9)	2042	223.75	662	(54.4)	1844	218.02
Missing								
Female	0				0			
Male	0				0			
Severity								
Severe								
Female	32	(3.5)	37	5.44	42	(4.4)	59	7.57
Male	60	(4.7)	84	9.30	47	(3.9)	74	7.16
Moderate								
Female	228	(25.4)	412	60.41	224	(23.5)	417	57.39
Male	284	(22.3)	519	54.52	254	(20.9)	439	48.63
Mild								
Female	486	(54.1)	1328	208.73	501	(52.7)	1421	210.37
Male	627	(49.4)	1605	177.29	572	(47.0)	1468	176.08
Missing								
Female	0				0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to basal insulin								
Probable								
Female	30	(3.3)	50	8.38	33	(3.5)	71	9.21
Male	52	(4.1)	70	8.20	43	(3.6)	62	7.25
Possible								
Female	53	(6.0)	83	13.71	54	(5.7)	96	15.13
Male	72	(5.7)	96	11.71	51	(4.2)	82	10.36
Unlikely								
Female	560	(62.3)	1638	251.39	565	(59.3)	1728	250.72
Male	716	(56.3)	2036	220.49	661	(54.3)	1833	213.81
Missing								
Female	4	(0.5)	6	1.11	2	(0.2)	2	0.27
Male	4	(0.3)	6	0.71	4	(0.3)	4	0.45
Related to technical complaint for basal insulin								
Yes								
Female	6	(0.7)	6	1.15	3	(0.3)	4	0.73
Male	5	(0.4)	5	0.69	4	(0.3)	4	0.56
No								
Female	575	(63.9)	1764	272.13	576	(60.5)	1891	274.32
Male	750	(59.0)	2197	239.70	682	(56.0)	1971	230.57
NA								
Female	1	(0.1)	1	0.20	0			
Male	0				1	(0.1)	1	0.15
Missing								
Female	4	(0.5)	6	1.11	2	(0.2)	2	0.27
Male	4	(0.3)	6	0.71	5	(0.4)	5	0.59

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
Female	1	(0.1)	1	0.10	5	(0.5)	5	0.59
Male	13	(1.0)	17	1.92	8	(0.7)	10	0.99
Not recovered/not resolved								
Female	249	(27.6)	464	70.75	252	(26.5)	507	72.03
Male	340	(26.8)	623	65.56	318	(26.1)	535	60.41
Recovered/resolved with sequelae								
Female	6	(0.7)	6	0.83	8	(0.8)	9	1.29
Male	4	(0.3)	4	0.31	8	(0.7)	9	0.95
Recovering/resolving								
Female	41	(4.6)	55	8.71	46	(4.8)	55	8.21
Male	55	(4.3)	81	9.35	46	(3.8)	56	6.71
Recovered/resolved								
Female	496	(55.2)	1251	194.18	494	(51.9)	1321	193.21
Male	626	(49.2)	1482	163.89	545	(44.8)	1369	162.66
Unknown								
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.15
Missing								
Female	0				0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.2 Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Female	777				831			
Male	1103				1047			
PYE (years)								
Female	636.24				678.98			
Male	902.68				857.48			
Events								
Female	491	(63.4)	1558	262.01	495	(59.4)	1655	254.77
Male	648	(58.6)	1920	223.10	578	(55.3)	1604	198.72
Serious								
Yes								
Female	54	(7.0)	74	11.80	69	(8.3)	94	13.80
Male	101	(9.1)	156	18.14	93	(8.9)	135	15.65
No								
Female	480	(62.0)	1484	250.22	481	(57.7)	1561	240.97
Male	622	(56.2)	1764	204.96	555	(53.1)	1469	183.07
Missing								
Female	0				0			
Male	0				0			
Severity								
Severe								
Female	27	(3.5)	32	5.03	39	(4.7)	55	7.69
Male	56	(5.1)	79	9.78	46	(4.4)	73	8.10
Moderate								
Female	208	(26.8)	375	60.43	203	(24.4)	380	56.58
Male	253	(22.8)	466	52.79	224	(21.4)	387	46.67
Mild								
Female	412	(53.3)	1151	196.56	423	(50.8)	1220	190.49
Male	532	(48.1)	1375	160.52	480	(46.0)	1144	143.95
Missing								
Female	0				0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to basal insulin								
Probable								
Female	23	(3.0)	42	7.67	30	(3.6)	68	9.84
Male	42	(3.8)	58	7.16	39	(3.8)	57	7.46
Possible								
Female	48	(6.3)	78	14.56	47	(5.6)	87	15.11
Male	55	(5.0)	75	9.47	41	(3.9)	50	6.08
Unlikely								
Female	478	(61.7)	1432	238.51	484	(58.1)	1498	229.50
Male	620	(56.0)	1781	205.65	553	(52.9)	1493	184.66
Missing								
Female	4	(0.5)	6	1.28	2	(0.2)	2	0.31
Male	4	(0.3)	6	0.82	4	(0.4)	4	0.52
Related to technical complaint for basal insulin								
Yes								
Female	6	(0.8)	6	1.32	3	(0.4)	4	0.84
Male	5	(0.5)	5	0.80	4	(0.4)	4	0.65
No								
Female	490	(63.3)	1545	259.18	494	(59.3)	1649	253.61
Male	646	(58.4)	1909	221.48	574	(54.9)	1594	197.22
NA								
Female	1	(0.1)	1	0.23	0			
Male	0				1	(0.1)	1	0.17
Missing								
Female	4	(0.5)	6	1.28	2	(0.2)	2	0.31
Male	4	(0.3)	6	0.82	5	(0.5)	5	0.68

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
Female	1	(0.1)	1	0.12	5	(0.6)	5	0.68
Male	12	(1.1)	16	2.02	8	(0.8)	10	1.14
Not recovered/not resolved								
Female	216	(27.8)	407	67.37	217	(26.1)	441	65.96
Male	287	(26.0)	546	60.92	270	(25.8)	457	55.50
Recovered/resolved with sequelae								
Female	6	(0.8)	6	0.96	7	(0.8)	8	1.23
Male	4	(0.4)	4	0.36	6	(0.6)	7	0.73
Recovering/resolving								
Female	36	(4.7)	50	8.79	44	(5.3)	51	8.43
Male	54	(4.9)	80	10.62	43	(4.1)	52	7.03
Recovered/resolved								
Female	424	(54.8)	1094	184.77	421	(50.5)	1150	178.47
Male	538	(48.6)	1273	149.09	457	(43.8)	1076	134.15
Unknown								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.18
Missing								
Female	0				0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.3 Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Female	902				951			
Male	1268				1219			
PYE (years)								
Female	697.61				738.01			
Male	983.62				942.57			
Events								
Female	576	(64.0)	1777	274.58	577	(60.6)	1897	275.33
Male	752	(59.2)	2208	241.10	686	(56.3)	1981	231.86
Infections and infestations								
All								
Female	312	(34.7)	462	71.81	307	(32.2)	479	70.03
Male	336	(26.5)	458	52.34	317	(26.0)	426	48.65
COVID-19								
Female	80	(8.9)	83	12.62	93	(9.8)	98	13.74
Male	101	(8.0)	102	11.48	99	(8.1)	101	11.08
Nasopharyngitis								
Female	56	(6.2)	64	10.97	57	(6.0)	65	10.71
Male	61	(4.8)	77	9.37	58	(4.8)	70	8.88
Upper respiratory tract infection								
Female	29	(3.3)	36	5.12	22	(2.3)	25	3.45
Male	39	(3.1)	45	4.71	30	(2.5)	31	3.60
Influenza								
Female	8	(0.9)	10	1.79	14	(1.5)	16	2.83
Male	21	(1.7)	22	2.75	19	(1.6)	20	2.63
Gastroenteritis								
Female	20	(2.2)	20	3.52	13	(1.4)	14	2.40
Male	12	(0.9)	13	1.68	5	(0.4)	5	0.53
Bronchitis								
Female	19	(2.1)	19	3.06	8	(0.9)	8	1.24
Male	11	(0.9)	12	1.35	11	(0.9)	11	1.19
Pneumonia								
Female	4	(0.4)	4	0.56	1	(0.1)	1	0.10
Male	11	(0.9)	11	1.25	5	(0.4)	5	0.57
Urinary tract infection								
Female	34	(3.7)	36	5.62	40	(4.2)	45	6.40
Male	9	(0.7)	10	1.16	10	(0.8)	11	1.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pharyngitis								
Female	12	(1.3)	13	2.07	7	(0.7)	9	1.46
Male	9	(0.7)	10	0.98	11	(0.9)	12	1.19
Sinusitis								
Female	12	(1.4)	14	2.13	13	(1.3)	15	2.16
Male	7	(0.6)	7	0.92	6	(0.5)	7	0.68
Herpes zoster								
Female	4	(0.4)	4	0.44	4	(0.4)	4	0.60
Male	7	(0.5)	7	0.75	13	(1.1)	14	1.41
COVID-19 pneumonia								
Female	9	(1.0)	9	1.37	6	(0.6)	6	0.82
Male	6	(0.5)	6	0.64	5	(0.4)	5	0.51
Tooth abscess								
Female	3	(0.3)	3	0.50	4	(0.4)	4	0.50
Male	6	(0.5)	6	0.75	3	(0.3)	4	0.46
Rhinitis								
Female	3	(0.3)	3	0.42	5	(0.5)	8	1.26
Male	6	(0.5)	6	0.64	6	(0.5)	6	0.84
Conjunctivitis								
Female	7	(0.8)	7	1.09	3	(0.3)	3	0.48
Male	5	(0.4)	5	0.63	4	(0.3)	4	0.40
Viral infection								
Female	2	(0.2)	2	0.31	4	(0.4)	7	0.73
Male	5	(0.4)	5	0.54	9	(0.7)	9	1.10
Otitis media								
Female	2	(0.2)	2	0.32	3	(0.3)	3	0.46
Male	5	(0.4)	5	0.61	2	(0.2)	2	0.25
Respiratory tract infection viral								
Female	8	(0.9)	8	1.40	6	(0.6)	7	1.26
Male	4	(0.3)	5	0.69	4	(0.3)	4	0.53
Fungal infection								
Female	3	(0.3)	4	0.62	2	(0.2)	2	0.29
Male	4	(0.3)	4	0.43	0			
Tooth infection								
Female	6	(0.7)	8	1.15	3	(0.3)	3	0.46
Male	3	(0.2)	3	0.35	5	(0.4)	5	0.66
Respiratory tract infection								
Female	6	(0.7)	6	0.86	3	(0.3)	3	0.39
Male	3	(0.2)	3	0.36	3	(0.3)	3	0.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Coronavirus infection								
Female	1	(0.1)	1	0.12	3	(0.3)	4	0.70
Male	3	(0.2)	3	0.23	2	(0.2)	3	0.26
Wound infection								
Female	0				1	(0.1)	1	0.18
Male	3	(0.2)	3	0.34	0			
Periodontitis								
Female	2	(0.2)	2	0.33	2	(0.2)	2	0.41
Male	3	(0.2)	3	0.35	5	(0.4)	5	0.54
Gingivitis								
Female	0				2	(0.2)	2	0.29
Male	3	(0.2)	4	0.40	3	(0.2)	3	0.45
Lower respiratory tract infection								
Female	3	(0.3)	3	0.35	2	(0.2)	4	0.53
Male	3	(0.2)	3	0.32	1	(0.1)	1	0.09
Gastroenteritis viral								
Female	3	(0.3)	3	0.45	5	(0.5)	5	0.84
Male	3	(0.2)	3	0.29	1	(0.1)	1	0.08
Fungal skin infection								
Female	1	(0.1)	1	0.20	1	(0.1)	1	0.19
Male	2	(0.2)	2	0.25	0			
Tinea cruris								
Female	0				0			
Male	2	(0.2)	2	0.25	0			
Tinea pedis								
Female	0				0			
Male	2	(0.2)	2	0.31	2	(0.2)	2	0.31
Sepsis								
Female	0				1	(0.1)	1	0.10
Male	2	(0.2)	2	0.28	0			
Gastrointestinal infection								
Female	1	(0.1)	1	0.19	2	(0.2)	3	0.31
Male	2	(0.2)	2	0.29	3	(0.2)	4	0.56
Ear infection								
Female	2	(0.2)	2	0.32	3	(0.3)	3	0.46
Male	2	(0.2)	2	0.15	2	(0.2)	2	0.16
Furuncle								
Female	0				0			
Male	2	(0.2)	3	0.29	2	(0.2)	2	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin infection								
Female	0				0			
Male	2	(0.2)	2	0.21	3	(0.2)	3	0.46
Cellulitis								
Female	2	(0.2)	2	0.22	1	(0.1)	1	0.18
Male	2	(0.2)	2	0.20	7	(0.6)	8	0.90
Helicobacter infection								
Female	0				1	(0.1)	1	0.10
Male	2	(0.2)	2	0.20	1	(0.1)	1	0.14
Subcutaneous abscess								
Female	0				0			
Male	2	(0.2)	2	0.20	2	(0.2)	3	0.25
Candida infection								
Female	0				1	(0.1)	1	0.19
Male	2	(0.2)	2	0.15	0			
Localised infection								
Female	1	(0.1)	1	0.19	2	(0.2)	2	0.39
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Onychomycosis								
Female	0				3	(0.3)	3	0.31
Male	2	(0.2)	2	0.20	1	(0.1)	1	0.08
Tonsillitis								
Female	2	(0.2)	2	0.32	1	(0.1)	1	0.10
Male	2	(0.2)	2	0.20	1	(0.1)	1	0.15
Breast abscess								
Female	0				3	(0.3)	3	0.39
Male	1	(0.1)	1	0.17	0			
Eye infection								
Female	0				1	(0.1)	1	0.19
Male	1	(0.1)	1	0.17	2	(0.2)	2	0.29
Hordeolum								
Female	2	(0.2)	2	0.24	3	(0.3)	3	0.51
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.14
Norovirus infection								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Severe acute respiratory syndrome								
Female	0				0			
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acute sinusitis								
Female	4	(0.4)	4	0.51	4	(0.4)	4	0.62
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.32
Clostridium difficile colitis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Clostridium difficile infection								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Gangrene								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Laryngitis								
Female	2	(0.2)	2	0.24	4	(0.4)	4	0.70
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Paronychia								
Female	1	(0.1)	1	0.19	2	(0.2)	3	0.56
Male	1	(0.1)	1	0.08	0			
Peritonsillar abscess								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.15
Cystitis								
Female	14	(1.6)	15	2.42	15	(1.6)	17	2.40
Male	1	(0.1)	1	0.14	2	(0.2)	2	0.17
Erysipelas								
Female	2	(0.2)	2	0.22	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.14	1	(0.1)	2	0.28
Escherichia bacteraemia								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Genital infection								
Female	2	(0.2)	2	0.21	1	(0.1)	1	0.18
Male	1	(0.1)	1	0.14	0			
Suspected COVID-19								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Cholecystitis infective								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diabetic foot infection								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.08
Infected dermal cyst								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Osteomyelitis								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.14	0			
Pharyngotonsillitis								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.14	1	(0.1)	2	0.17
Pneumonia viral								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Pulmonary tuberculoma								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Respiratory syncytial virus infection								
Female	2	(0.2)	2	0.22	0			
Male	1	(0.1)	1	0.14	0			
Abscess								
Female	1	(0.1)	1	0.19	0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Asymptomatic COVID-19								
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.23
Balanitis candida								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Chlamydial infection								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Dermatophytosis of nail								
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.16
Folliculitis								
Female	0				2	(0.2)	2	0.27
Male	1	(0.1)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Genital infection fungal								
Female	1	(0.1)	2	0.43	2	(0.2)	2	0.21
Male	1	(0.1)	1	0.08	0			
Infected bite								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Laryngopharyngitis								
Female	0				1	(0.1)	2	0.21
Male	1	(0.1)	1	0.08	0			
Pericoronitis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Tracheitis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Viral upper respiratory tract infection								
Female	0				2	(0.2)	2	0.20
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Anal abscess								
Female	0				0			
Male	1	(0.1)	1	0.13	1	(0.1)	1	0.09
Enteritis infectious								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Kidney infection								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Paraspinal abscess								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Pulpitis dental								
Female	0				2	(0.2)	2	0.36
Male	1	(0.1)	1	0.13	2	(0.2)	2	0.23
Tinea versicolour								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Varicella zoster virus infection								
Female	0				0			
Male	1	(0.1)	1	0.13	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal abscess								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Abscess limb								
Female	2	(0.2)	2	0.42	1	(0.1)	1	0.17
Male	0				1	(0.1)	2	0.32
Acarodermatitis								
Female	2	(0.2)	2	0.21	3	(0.3)	3	0.31
Male	0				1	(0.1)	1	0.08
Appendicitis								
Female	1	(0.1)	1	0.10	0			
Male	0				1	(0.1)	1	0.08
Bacteraemia								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Bacterial infection								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.09
Bartholinitis								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Body tinea								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Breast cellulitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Campylobacter gastroenteritis								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Chronic hepatitis C								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Chronic sinusitis								
Female	1	(0.1)	1	0.10	3	(0.3)	3	0.30
Male	0				0			
Chronic tonsillitis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.09

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cystitis escherichia								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Diverticulitis								
Female	0				5	(0.5)	5	0.51
Male	0				0			
Ear infection fungal								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Empyema								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Endophthalmitis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Epididymitis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Escherichia urinary tract infection								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Eye infection bacterial								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Fungal balanitis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Gastric infection								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Gastroenteritis norovirus								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Genital candidiasis								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Giardiasis								
Female	0				0			
Male	0				1	(0.1)	1	0.09

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Helicobacter gastritis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Herpes dermatitis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Herpes simplex								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				0			
Herpes virus infection								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Herpes zoster infection neurological								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Infected cyst								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Infective iritis								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Injection site abscess								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Labyrinthitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Lyme disease								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Mastitis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Nail infection								
Female	1	(0.1)	2	0.21	0			
Male	0				1	(0.1)	1	0.09
Oophoritis								
Female	0				1	(0.1)	1	0.10
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral candidiasis								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Oral herpes								
Female	2	(0.2)	3	0.57	2	(0.2)	2	0.20
Male	0				0			
Oropharyngeal candidiasis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Otitis externa								
Female	2	(0.2)	2	0.29	3	(0.3)	3	0.43
Male	0				3	(0.2)	3	0.40
Otitis media acute								
Female	0				1	(0.1)	1	0.19
Male	0				2	(0.2)	2	0.16
Otitis media chronic								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Parotitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Peri-implantitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Post procedural infection								
Female	0				0			
Male	0				2	(0.2)	2	0.23
Post-acute COVID-19 syndrome								
Female	1	(0.1)	2	0.21	0			
Male	0				0			
Postoperative wound infection								
Female	1	(0.1)	1	0.19	0			
Male	0				1	(0.1)	1	0.08
Purulence								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Pustule								
Female	1	(0.1)	1	0.20	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pyelonephritis								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Rotavirus infection								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Salpingitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Sinusitis bacterial								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Skin bacterial infection								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Skin candida								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.18
Male	0				0			
Soft tissue infection								
Female	0				0			
Male	0				2	(0.2)	2	0.29
Sweat gland infection								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Tinea infection								
Female	2	(0.2)	2	0.31	0			
Male	0				0			
Urethritis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Urosepsis								
Female	0				2	(0.2)	2	0.29
Male	0				0			
Vaginal infection								
Female	6	(0.7)	7	1.21	3	(0.3)	3	0.38
Male	0				0			
Varicella								
Female	0				1	(0.1)	1	0.10
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Viral pharyngitis								
Female	1	(0.1)	1	0.10	0			
Male	0				1	(0.1)	1	0.09
Viral rhinitis								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Viral tracheitis								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Vulvitis								
Female	2	(0.2)	2	0.42	0			
Male	0				0			
Vulvovaginal candidiasis								
Female	3	(0.4)	4	0.56	4	(0.4)	4	0.41
Male	0				0			
Vulvovaginal mycotic infection								
Female	2	(0.2)	2	0.31	0			
Male	0				0			
Vulvovaginitis								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Musculoskeletal and connective tissue disorders								
All								
Female	122	(13.7)	178	27.46	141	(14.7)	204	28.44
Male	151	(11.8)	222	22.57	143	(11.8)	197	23.78
Back pain								
Female	25	(2.8)	26	4.02	32	(3.3)	34	5.03
Male	40	(3.1)	43	4.36	40	(3.3)	55	7.22
Arthralgia								
Female	26	(3.0)	30	4.52	27	(2.8)	30	4.24
Male	25	(2.0)	29	3.16	30	(2.5)	33	4.06
Pain in extremity								
Female	16	(1.8)	18	2.54	13	(1.4)	14	1.92
Male	21	(1.6)	21	2.14	24	(2.0)	29	3.68
Muscle spasms								
Female	10	(1.1)	10	1.42	4	(0.4)	4	0.49
Male	15	(1.2)	17	2.03	5	(0.4)	5	0.54
Myalgia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	6	(0.7)	6	1.10	10	(1.1)	10	1.83
Male	10	(0.8)	10	1.08	6	(0.5)	7	0.95
Osteoarthritis								
Female	16	(1.8)	18	2.64	19	(2.0)	22	3.26
Male	8	(0.6)	8	0.85	7	(0.6)	7	0.64
Intervertebral disc protrusion								
Female	0				3	(0.3)	4	0.41
Male	8	(0.6)	12	1.04	3	(0.2)	3	0.36
Periarthritis								
Female	1	(0.1)	1	0.19	7	(0.7)	7	1.04
Male	7	(0.5)	7	0.59	2	(0.2)	2	0.25
Neck pain								
Female	10	(1.1)	10	1.57	7	(0.7)	7	0.80
Male	6	(0.5)	6	0.65	1	(0.1)	1	0.14
Tendonitis								
Female	3	(0.3)	3	0.42	0			
Male	5	(0.4)	7	0.69	5	(0.4)	5	0.61
Spinal osteoarthritis								
Female	2	(0.2)	2	0.31	2	(0.2)	2	0.21
Male	4	(0.3)	4	0.37	3	(0.2)	4	0.32
Foot deformity								
Female	0				0			
Male	3	(0.2)	5	0.45	3	(0.2)	3	0.36
Arthritis								
Female	4	(0.4)	4	0.71	2	(0.2)	2	0.27
Male	3	(0.2)	3	0.23	4	(0.3)	4	0.52
Plantar fasciitis								
Female	1	(0.1)	1	0.12	0			
Male	3	(0.2)	4	0.36	3	(0.2)	3	0.24
Muscular weakness								
Female	2	(0.2)	2	0.37	2	(0.2)	2	0.29
Male	2	(0.2)	2	0.25	1	(0.1)	1	0.14
Bursitis								
Female	2	(0.2)	2	0.32	3	(0.3)	3	0.43
Male	2	(0.2)	2	0.16	1	(0.1)	1	0.09
Joint effusion								
Female	0				2	(0.2)	2	0.21
Male	2	(0.2)	3	0.35	0			
Tendon disorder								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.19
Male	2	(0.2)	2	0.22	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Osteochondrosis								
Female	0				4	(0.4)	4	0.58
Male	2	(0.2)	2	0.22	0			
Trigger finger								
Female	7	(0.8)	7	1.24	3	(0.3)	5	0.58
Male	2	(0.2)	2	0.28	3	(0.2)	3	0.32
Chondropathy								
Female	0				0			
Male	2	(0.2)	2	0.15	0			
Musculoskeletal pain								
Female	0				1	(0.1)	1	0.10
Male	2	(0.2)	2	0.21	0			
Intervertebral disc disorder								
Female	1	(0.1)	1	0.20	0			
Male	2	(0.2)	2	0.15	2	(0.2)	2	0.23
Musculoskeletal chest pain								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.09
Musculoskeletal stiffness								
Female	3	(0.3)	3	0.52	2	(0.2)	2	0.33
Male	2	(0.2)	2	0.20	0			
Rotator cuff syndrome								
Female	3	(0.3)	3	0.43	2	(0.2)	2	0.21
Male	2	(0.2)	2	0.20	2	(0.2)	2	0.15
Spinal stenosis								
Female	2	(0.2)	3	0.52	2	(0.2)	2	0.21
Male	2	(0.2)	3	0.33	0			
Limb discomfort								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Acquired claw toe								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Diastasis recti abdominis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Exostosis								
Female	2	(0.2)	2	0.22	0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Facet joint syndrome								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Meniscopathy								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Polyarthritis								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	0			
Muscle contracture								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.14	0			
Torticollis								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.14
Back disorder								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.14	0			
Costochondritis								
Female	0				1	(0.1)	1	0.18
Male	1	(0.1)	1	0.08	0			
Fibromyalgia								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	0			
Groin pain								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.25
Lumbar spinal stenosis								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Osteopenia								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Spinal pain								
Female	0				4	(0.4)	4	0.49
Male	1	(0.1)	1	0.08	0			
Synovial cyst								
Female	2	(0.2)	2	0.33	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Axillary mass								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.13	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Arthropathy								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Bone cyst								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.14
Bone pain								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Cervical spinal stenosis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Chondromalacia								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Coccydynia								
Female	2	(0.2)	2	0.31	1	(0.1)	1	0.10
Male	0				0			
Dupuytren's contracture								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.09
Fistula								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Flank pain								
Female	1	(0.1)	1	0.20	3	(0.3)	3	0.46
Male	0				3	(0.2)	4	0.38
Haemarthrosis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Intervertebral disc degeneration								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Intervertebral disc space narrowing								
Female	0				1	(0.1)	2	0.21
Male	0				0			
Jaw disorder								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Joint swelling								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				1	(0.1)	1	0.18
Male	0				2	(0.2)	2	0.23
Limb deformity								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Limb mass								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Mastication disorder								
Female	0				1	(0.1)	2	0.20
Male	0				0			
Muscle twitching								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Myositis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.19
Male	0				0			
Neuropathic arthropathy								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Nodal osteoarthritis								
Female	0				0			
Male	0				2	(0.2)	2	0.24
Osteochondritis								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Osteoporosis								
Female	2	(0.2)	2	0.40	0			
Male	0				0			
Pain in jaw								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Periostitis								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Polymyalgia rheumatica								
Female	1	(0.1)	1	0.20	1	(0.1)	3	0.51
Male	0				0			
Psoriatic arthropathy								
Female	1	(0.1)	1	0.10	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Rheumatoid arthritis								
Female	0				3	(0.3)	3	0.62
Male	0				1	(0.1)	1	0.08
Sacroiliitis								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Scoliosis								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Soft tissue swelling								
Female	1	(0.1)	3	0.60	0			
Male	0				0			
Spinal retrolisthesis								
Female	0				1	(0.1)	2	0.21
Male	0				0			
Tenosynovitis								
Female	2	(0.2)	2	0.33	7	(0.7)	7	0.87
Male	0				2	(0.2)	3	0.25
Tenosynovitis stenosans								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Vertebral osteophyte								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Gastrointestinal disorders								
All								
Female	130	(14.5)	205	30.10	121	(12.6)	176	25.22
Male	147	(11.5)	213	22.97	124	(10.2)	167	19.56
Diarrhoea								
Female	41	(4.6)	48	6.73	28	(2.9)	30	4.38
Male	48	(3.8)	60	6.63	27	(2.2)	27	3.18
Nausea								
Female	24	(2.7)	25	3.71	19	(2.0)	20	3.34
Male	17	(1.3)	17	1.85	16	(1.3)	17	1.85
Vomiting								
Female	17	(1.9)	25	4.15	11	(1.2)	13	1.94
Male	14	(1.1)	14	1.78	10	(0.8)	11	1.27
Gastrooesophageal reflux disease								
Female	4	(0.4)	4	0.53	6	(0.6)	6	0.85

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	10	(0.8)	10	1.03	9	(0.7)	9	1.01
Toothache								
Female	5	(0.6)	5	0.79	5	(0.5)	8	1.47
Male	10	(0.8)	10	0.88	8	(0.7)	10	1.40
Constipation								
Female	10	(1.1)	11	1.73	9	(0.9)	9	1.17
Male	7	(0.6)	9	0.99	7	(0.6)	7	0.92
Dyspepsia								
Female	1	(0.1)	1	0.20	6	(0.6)	6	0.77
Male	7	(0.5)	7	0.79	3	(0.2)	3	0.38
Abdominal pain upper								
Female	10	(1.1)	12	1.82	10	(1.0)	11	1.35
Male	6	(0.5)	6	0.70	6	(0.5)	6	0.68
Abdominal pain								
Female	11	(1.2)	11	1.64	12	(1.3)	13	1.76
Male	6	(0.5)	6	0.61	6	(0.5)	6	0.72
Dental caries								
Female	6	(0.7)	7	0.88	3	(0.3)	3	0.38
Male	6	(0.5)	7	0.54	7	(0.6)	7	0.88
Gastritis								
Female	3	(0.3)	3	0.39	4	(0.4)	4	0.56
Male	5	(0.4)	5	0.65	5	(0.4)	5	0.51
Abdominal distension								
Female	3	(0.3)	3	0.34	2	(0.2)	2	0.29
Male	5	(0.4)	5	0.54	3	(0.2)	3	0.39
Chronic gastritis								
Female	4	(0.5)	4	0.61	3	(0.3)	3	0.39
Male	5	(0.4)	5	0.59	3	(0.2)	3	0.41
Large intestine polyp								
Female	0				3	(0.3)	3	0.31
Male	4	(0.3)	4	0.36	3	(0.3)	4	0.40
Diverticulum intestinal								
Female	1	(0.1)	1	0.10	0			
Male	3	(0.2)	3	0.32	1	(0.1)	1	0.08
Food poisoning								
Female	2	(0.2)	2	0.29	3	(0.3)	4	0.63
Male	3	(0.2)	3	0.28	1	(0.1)	1	0.14
Enterocolitis								
Female	0				0			
Male	3	(0.2)	4	0.31	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pancreatic failure								
Female	0				0			
Male	2	(0.2)	2	0.31	0			
Inguinal hernia								
Female	0				0			
Male	2	(0.2)	2	0.16	1	(0.1)	2	0.17
Hypoaesthesia oral								
Female	1	(0.1)	1	0.10	0			
Male	2	(0.2)	4	0.55	0			
Haemorrhoids								
Female	5	(0.6)	5	0.64	3	(0.3)	3	0.50
Male	2	(0.2)	2	0.21	1	(0.1)	1	0.15
Flatulence								
Female	2	(0.2)	2	0.31	2	(0.2)	2	0.37
Male	2	(0.2)	2	0.20	0			
Hyperaesthesia teeth								
Female	0				0			
Male	2	(0.2)	2	0.20	0			
Impaired gastric emptying								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	2	0.34	0			
Irritable bowel syndrome								
Female	0				0			
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.09
Abdominal wall disorder								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Aphthous ulcer								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.08	0			
Diabetic gastropathy								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Dry mouth								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Eosinophilic oesophagitis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Haemorrhoidal haemorrhage								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Hiatus hernia								
Female	1	(0.1)	1	0.20	2	(0.2)	2	0.33
Male	1	(0.1)	1	0.08	0			
Lip swelling								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Umbilical hernia								
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.17
Abdominal discomfort								
Female	3	(0.3)	3	0.45	3	(0.3)	3	0.43
Male	1	(0.1)	1	0.14	3	(0.2)	4	0.51
Pancreatic duct dilatation								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Pancreatitis chronic								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.14	0			
Proctalgia								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Colitis ischaemic								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Frequent bowel movements								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Gastric polyps								
Female	1	(0.1)	1	0.19	2	(0.2)	2	0.33
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.31
Haematochezia								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Loose tooth								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Tooth impacted								
Female	0				1	(0.1)	1	0.18
Male	1	(0.1)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gingival bleeding								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Intra-abdominal haematoma								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.13	0			
Abdominal pain lower								
Female	4	(0.5)	4	0.62	1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.08
Acid peptic disease								
Female	0				0			
Male	0				2	(0.2)	2	0.17
Anal fissure								
Female	2	(0.2)	2	0.32	0			
Male	0				2	(0.2)	2	0.16
Anal pruritus								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Colitis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.09
Colitis microscopic								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Male	0				0			
Crohn's disease								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Diverticulum								
Female	1	(0.1)	1	0.20	2	(0.2)	2	0.20
Male	0				1	(0.1)	1	0.14
Duodenitis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Enteritis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Epigastric discomfort								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Eructation								
Female	1	(0.1)	1	0.10	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				1	(0.1)	1	0.14
Faeces pale								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Faeces soft								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Gastric dilatation								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Gastric disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Gastric dysplasia								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Gastric mucosal hypertrophy								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Gastric ulcer								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Gastritis erosive								
Female	0				2	(0.2)	2	0.45
Male	0				0			
Gastrointestinal angiodysplasia								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Gastrointestinal disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Gastrointestinal haemorrhage								
Female	1	(0.1)	1	0.10	0			
Male	0				2	(0.2)	2	0.22
Gastrointestinal inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Gastrointestinal sounds abnormal								
Female	0				0			
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gingival disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Gingival recession								
Female	0				0			
Male	0				1	(0.1)	2	0.32
Hyperchlorhydria								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Ileus								
Female	0				2	(0.2)	2	0.21
Male	0				0			
Intestinal dilatation								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Lumbar hernia								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Melaena								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Mesenteric panniculitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Noninfective gingivitis								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Odynophagia								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.14
Oesophageal pain								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Oesophagitis								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Oral discomfort								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Oral pain								
Female	1	(0.1)	1	0.19	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Pancreatic pseudocyst								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Pancreatitis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				0			
Pancreatitis acute								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Peptic ulcer								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Periodontal disease								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.17
Male	0				1	(0.1)	1	0.14
Periodontal inflammation								
Female	0				0			
Male	0				1	(0.1)	2	0.17
Pneumatosis intestinalis								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Rectal polyp								
Female	2	(0.2)	2	0.22	1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.08
Rectal prolapse								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Small intestinal obstruction								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Stomatitis								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.09
Tongue rough								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Tooth disorder								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ulcerative gastritis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Upper gastrointestinal haemorrhage								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Vomiting projectile								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
General disorders and administration site conditions								
All								
Female	98	(10.9)	163	26.97	105	(11.0)	163	23.61
Male	142	(11.1)	200	22.45	103	(8.5)	181	21.93
Pyrexia								
Female	16	(1.8)	16	2.76	21	(2.2)	22	3.18
Male	25	(1.9)	27	2.92	22	(1.8)	23	2.63
Fatigue								
Female	18	(2.0)	21	3.53	8	(0.8)	8	1.04
Male	14	(1.1)	15	1.43	8	(0.7)	8	0.79
Malaise								
Female	5	(0.6)	6	0.95	4	(0.4)	6	0.92
Male	11	(0.9)	12	1.22	11	(0.9)	54	7.95
Injection site reaction								
Female	6	(0.7)	11	2.08	3	(0.3)	3	0.46
Male	9	(0.7)	18	2.35	3	(0.2)	5	0.45
Oedema peripheral								
Female	11	(1.2)	11	1.73	3	(0.3)	3	0.43
Male	8	(0.6)	8	0.88	7	(0.6)	8	0.79
Chest pain								
Female	6	(0.7)	6	0.81	3	(0.3)	3	0.31
Male	8	(0.6)	8	0.79	4	(0.3)	4	0.47
Vaccination site pain								
Female	2	(0.2)	2	0.32	2	(0.2)	2	0.20
Male	8	(0.6)	10	1.10	7	(0.6)	7	0.97
Influenza like illness								
Female	1	(0.1)	2	0.21	4	(0.4)	4	0.54
Male	6	(0.5)	6	0.90	0			
Medical device site dermatitis								
Female	1	(0.1)	1	0.22	5	(0.5)	6	0.98

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	6	(0.5)	9	0.98	6	(0.5)	12	1.11
Medical device site bruise								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	6	(0.5)	8	0.89	0			
Medical device site rash								
Female	2	(0.2)	2	0.43	5	(0.6)	5	1.12
Male	4	(0.3)	4	0.67	3	(0.2)	3	0.47
Pain								
Female	9	(1.0)	10	1.71	8	(0.8)	8	1.05
Male	4	(0.3)	4	0.54	6	(0.5)	7	0.76
Medical device site pruritus								
Female	1	(0.1)	1	0.12	0			
Male	4	(0.3)	4	0.45	4	(0.3)	4	0.56
Medical device site haemorrhage								
Female	0				3	(0.3)	3	0.43
Male	4	(0.3)	4	0.31	0			
Injection site bruising								
Female	0				3	(0.3)	3	0.31
Male	3	(0.2)	3	0.35	2	(0.2)	2	0.22
Medical device site reaction								
Female	4	(0.4)	4	0.80	0			
Male	3	(0.2)	5	0.57	1	(0.1)	1	0.09
Peripheral swelling								
Female	2	(0.2)	2	0.22	3	(0.3)	3	0.48
Male	3	(0.2)	4	0.43	1	(0.1)	1	0.09
Chest discomfort								
Female	5	(0.6)	5	0.74	1	(0.1)	1	0.18
Male	3	(0.2)	3	0.34	1	(0.1)	1	0.09
Asthenia								
Female	7	(0.8)	7	1.03	6	(0.6)	6	0.82
Male	3	(0.2)	3	0.34	4	(0.3)	4	0.53
Hunger								
Female	4	(0.5)	4	0.65	2	(0.2)	3	0.55
Male	3	(0.2)	4	0.31	1	(0.1)	1	0.15
Swelling face								
Female	0				1	(0.1)	1	0.18
Male	2	(0.2)	2	0.25	1	(0.1)	1	0.08
Inflammation								
Female	0				2	(0.2)	2	0.29
Male	2	(0.2)	2	0.31	1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injection site haematoma								
Female	0				2	(0.2)	6	1.11
Male	2	(0.2)	6	0.83	1	(0.1)	2	0.28
Drug intolerance								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	2	0.15	0			
Injection site mass								
Female	0				1	(0.1)	1	0.22
Male	2	(0.2)	2	0.15	0			
Chills								
Female	2	(0.2)	2	0.24	0			
Male	2	(0.2)	2	0.20	1	(0.1)	1	0.09
Injection site swelling								
Female	0				1	(0.1)	1	0.18
Male	2	(0.2)	2	0.26	0			
Feeling abnormal								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.10
Male	2	(0.2)	4	0.37	0			
Medical device site haematoma								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.17	0			
Medical device site irritation								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Medical device site pain								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.33
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.14
Early satiety								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Injection site pruritus								
Female	3	(0.3)	18	3.29	0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.14
Localised oedema								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Injection site erythema								
Female	2	(0.2)	4	0.68	0			
Male	1	(0.1)	1	0.14	4	(0.3)	4	0.35
Injection site haemorrhage								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.09
Injection site pain								
Female	2	(0.2)	2	0.37	8	(0.8)	26	3.04
Male	1	(0.1)	1	0.14	5	(0.4)	5	0.66
Injection site rash								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.14
Multiple organ dysfunction syndrome								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Xerosis								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Gait disturbance								
Female	2	(0.2)	2	0.22	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Implant site pruritus								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Injection site hypersensitivity								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	0			
Medical device site eczema								
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.17
Medical device site hypersensitivity								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Vaccination site reaction								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Medical device site erythema								
Female	1	(0.1)	1	0.20	4	(0.4)	5	0.96
Male	1	(0.1)	1	0.13	1	(0.1)	1	0.16
Application site bruise								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Application site pruritus								
Female	1	(0.1)	1	0.19	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Axillary pain								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Condition aggravated								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Cyst								
Female	0				0			
Male	0				2	(0.2)	2	0.22
Death								
Female	0				3	(0.3)	3	0.31
Male	0				0			
Discomfort								
Female	2	(0.2)	2	0.31	1	(0.1)	8	1.49
Male	0				0			
Facial pain								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Feeling hot								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.08
Hernia								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hyperthermia								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Injection site dermatitis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Injection site hypertrophy								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Injection site induration								
Female	0				2	(0.2)	2	0.29
Male	0				0			
Injection site oedema								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Injection site urticaria								
Female	1	(0.1)	2	0.43	1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Medical device site inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Non-cardiac chest pain								
Female	0				2	(0.2)	2	0.21
Male	0				2	(0.2)	4	0.32
Oedema								
Female	1	(0.1)	1	0.19	0			
Male	0				3	(0.2)	3	0.31
Oedema due to renal disease								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Procedural failure								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Swelling								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				0			
Systemic inflammatory response syndrome								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Thirst								
Female	3	(0.3)	3	0.50	1	(0.1)	1	0.18
Male	0				0			
Vaccination site erythema								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Vaccination site inflammation								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Vaccination site pruritus								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Vessel puncture site bruise								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Eye disorders								
All								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	64	(7.1)	79	12.66	70	(7.4)	90	14.42
Male	112	(8.9)	146	17.15	110	(9.0)	146	17.81
Diabetic retinopathy								
Female	17	(1.9)	17	3.06	23	(2.4)	24	4.01
Male	47	(3.7)	53	6.62	49	(4.0)	52	6.53
Cataract								
Female	13	(1.4)	16	2.21	12	(1.3)	13	1.72
Male	15	(1.2)	17	1.78	15	(1.2)	17	1.90
Retinopathy hypertensive								
Female	2	(0.2)	2	0.38	0			
Male	6	(0.5)	7	0.84	5	(0.4)	5	0.64
Diabetic retinal oedema								
Female	0				6	(0.6)	7	1.25
Male	6	(0.5)	6	0.87	4	(0.3)	4	0.39
Macular oedema								
Female	7	(0.8)	8	1.54	1	(0.1)	1	0.10
Male	5	(0.4)	5	0.55	4	(0.3)	4	0.46
Dry eye								
Female	3	(0.3)	3	0.41	5	(0.5)	5	0.71
Male	4	(0.3)	4	0.40	2	(0.2)	2	0.17
Vision blurred								
Female	2	(0.2)	2	0.32	2	(0.2)	2	0.36
Male	4	(0.3)	4	0.52	3	(0.3)	3	0.25
Retinal haemorrhage								
Female	0				0			
Male	4	(0.3)	4	0.48	0			
Glaucoma								
Female	1	(0.1)	1	0.10	3	(0.3)	3	0.67
Male	3	(0.2)	3	0.32	3	(0.3)	3	0.31
Eye pain								
Female	1	(0.1)	1	0.10	2	(0.2)	2	0.29
Male	3	(0.2)	3	0.29	1	(0.1)	1	0.09
Arteriosclerotic retinopathy								
Female	0				0			
Male	2	(0.2)	2	0.25	0			
Non-proliferative retinopathy								
Female	1	(0.1)	1	0.22	0			
Male	2	(0.2)	3	0.44	4	(0.3)	4	0.60
Posterior capsule opacification								
Female	0				0			
Male	2	(0.2)	2	0.24	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cataract nuclear								
Female	0				0			
Male	2	(0.2)	2	0.29	0			
Vitreous haemorrhage								
Female	0				0			
Male	2	(0.2)	2	0.26	2	(0.2)	2	0.23
Blepharitis								
Female	3	(0.3)	3	0.41	0			
Male	2	(0.2)	2	0.15	0			
Epiretinal membrane								
Female	1	(0.1)	1	0.20	2	(0.2)	2	0.29
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.16
Retinal vascular disorder								
Female	0				1	(0.1)	1	0.19
Male	1	(0.1)	1	0.17	0			
Age-related macular degeneration								
Female	1	(0.1)	1	0.19	0			
Male	1	(0.1)	1	0.08	0			
Amaurosis fugax								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Angle closure glaucoma								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Conjunctival hyperaemia								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Maculopathy								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Vitreous detachment								
Female	2	(0.2)	2	0.31	1	(0.1)	1	0.22
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.16
Vitreous opacities								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Conjunctivitis allergic								
Female	1	(0.1)	2	0.24	0			
Male	1	(0.1)	1	0.14	0			
Eye inflammation								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.14	2	(0.2)	2	0.28
Diplopia								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.14
Presbyopia								
Female	0				0			
Male	1	(0.1)	1	0.14	3	(0.3)	3	0.45
Retinal deposits								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Retinal scar								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Acquired epiblepharon								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Asthenopia								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Astigmatism								
Female	1	(0.1)	2	0.21	2	(0.2)	2	0.29
Male	1	(0.1)	1	0.08	3	(0.2)	3	0.38
Conjunctival erosion								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Optic disc vascular disorder								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Post thrombotic retinopathy								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Retinal aneurysm								
Female	0				1	(0.1)	1	0.18
Male	1	(0.1)	1	0.08	0			
Retinal tear								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Eye irritation								
Female	0				0			
Male	1	(0.1)	1	0.13	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lacrimation increased								
Female	0				1	(0.1)	1	0.18
Male	1	(0.1)	1	0.13	0			
Ocular hyperaemia								
Female	1	(0.1)	2	0.37	0			
Male	1	(0.1)	1	0.13	1	(0.1)	2	0.28
Ocular hypertension								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.13	2	(0.2)	3	0.41
Chorioretinal atrophy								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Conjunctival haemorrhage								
Female	3	(0.3)	3	0.53	0			
Male	0				0			
Conjunctival suffusion								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Corneal bleeding								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Corneal erosion								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.19
Male	0				0			
Cystoid macular oedema								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Dacryoadenitis acquired								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Dry age-related macular degeneration								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Eye discharge								
Female	0				0			
Male	0				2	(0.2)	2	0.23
Eye pruritus								
Female	0				0			
Male	0				1	(0.1)	2	0.28
Eyelid oedema								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hypermetropia								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Macular degeneration								
Female	0				0			
Male	0				3	(0.2)	3	0.30
Macular hole								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Meibomianitis								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Myopia								
Female	1	(0.1)	1	0.20	1	(0.1)	1	0.10
Male	0				2	(0.2)	2	0.24
Normal tension glaucoma								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Ocular ischaemic syndrome								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Open angle glaucoma								
Female	0				0			
Male	0				1	(0.1)	2	0.28
Ophthalmic vein thrombosis								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Optic disc haemorrhage								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Photophobia								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Photopsia								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Pterygium								
Female	0				1	(0.1)	1	0.22
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Retinal artery occlusion								
Female	0				0			
Male	0				2	(0.2)	2	0.16
Retinal degeneration								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.18
Male	0				0			
Retinal detachment								
Female	0				0			
Male	0				2	(0.2)	2	0.23
Retinal drusen								
Female	1	(0.1)	1	0.19	0			
Male	0				1	(0.1)	1	0.14
Retinal exudates								
Female	1	(0.1)	1	0.20	0			
Male	0				2	(0.2)	2	0.28
Retinal vein occlusion								
Female	1	(0.1)	1	0.20	0			
Male	0				1	(0.1)	1	0.09
Retinopathy								
Female	0				0			
Male	0				2	(0.2)	2	0.30
Scintillating scotoma								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Uveitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Visual acuity reduced								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Visual impairment								
Female	1	(0.1)	1	0.10	2	(0.2)	10	1.78
Male	0				0			
Vitreous degeneration								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Vitreous floaters								
Female	0				0			
Male	0				3	(0.2)	3	0.46

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injury, poisoning and procedural complications								
All								
Female	82	(9.2)	108	17.14	73	(7.6)	86	12.72
Male	112	(8.8)	133	14.74	107	(8.7)	131	16.26
Vaccination complication								
Female	6	(0.7)	10	1.76	15	(1.5)	20	2.69
Male	14	(1.1)	14	1.64	14	(1.2)	18	2.41
Contusion								
Female	3	(0.3)	3	0.34	2	(0.2)	2	0.20
Male	12	(0.9)	13	1.38	7	(0.6)	7	0.80
Fall								
Female	10	(1.1)	10	1.37	5	(0.5)	5	0.78
Male	10	(0.8)	10	1.02	6	(0.5)	7	0.68
Accidental overdose								
Female	5	(0.6)	6	1.15	2	(0.2)	3	0.56
Male	9	(0.7)	9	1.31	2	(0.2)	2	0.30
Skin laceration								
Female	1	(0.1)	1	0.19	0			
Male	6	(0.5)	6	0.56	1	(0.1)	1	0.16
Hand fracture								
Female	2	(0.2)	2	0.22	1	(0.1)	1	0.10
Male	5	(0.4)	5	0.65	0			
Skin abrasion								
Female	4	(0.4)	7	1.05	1	(0.1)	1	0.22
Male	5	(0.4)	5	0.54	4	(0.3)	4	0.51
Incorrect dose administered								
Female	2	(0.2)	2	0.41	2	(0.2)	2	0.29
Male	4	(0.3)	4	0.61	3	(0.2)	5	0.70
Ligament sprain								
Female	8	(0.9)	8	1.43	4	(0.4)	4	0.64
Male	4	(0.3)	4	0.45	4	(0.3)	4	0.45
Road traffic accident								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.10
Male	4	(0.3)	5	0.62	0			
Prescribed overdose								
Female	2	(0.2)	2	0.43	0			
Male	3	(0.2)	3	0.50	0			
Joint injury								
Female	2	(0.2)	2	0.38	2	(0.2)	2	0.28
Male	3	(0.2)	3	0.28	3	(0.2)	3	0.32

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ankle fracture								
Female	2	(0.2)	2	0.22	1	(0.1)	1	0.10
Male	2	(0.2)	2	0.16	2	(0.2)	2	0.15
Back injury								
Female	0				0			
Male	2	(0.2)	2	0.16	2	(0.2)	2	0.24
Upper limb fracture								
Female	1	(0.1)	1	0.10	0			
Male	2	(0.2)	2	0.16	0			
Medication error								
Female	0				2	(0.2)	2	0.41
Male	2	(0.2)	2	0.28	1	(0.1)	1	0.14
Procedural pain								
Female	3	(0.3)	3	0.59	0			
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.14
Limb injury								
Female	4	(0.4)	4	0.64	3	(0.3)	3	0.48
Male	2	(0.2)	2	0.21	3	(0.2)	4	0.51
Thermal burn								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	2	(0.2)	2	0.26	1	(0.1)	1	0.14
Wound								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	2	0.22	6	(0.5)	6	0.81
Injury								
Female	0				0			
Male	2	(0.2)	2	0.15	0			
Meniscus injury								
Female	0				2	(0.2)	2	0.29
Male	2	(0.2)	2	0.15	3	(0.2)	3	0.23
Overdose								
Female	2	(0.2)	2	0.39	1	(0.1)	1	0.10
Male	2	(0.2)	2	0.20	2	(0.2)	2	0.28
Rib fracture								
Female	2	(0.2)	2	0.29	4	(0.4)	4	0.58
Male	2	(0.2)	2	0.20	1	(0.1)	1	0.08
Epicondylitis								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.17	0			
Product dispensing error								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Bone contusion								
Female	0				1	(0.1)	1	0.17
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Hip fracture								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	0			
Inflammation of wound								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Injury of conjunctiva								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Multiple injuries								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Muscle injury								
Female	0				1	(0.1)	1	0.19
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.15
Neck injury								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Penile contusion								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Post procedural haematuria								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Post procedural inflammation								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Tendon rupture								
Female	1	(0.1)	1	0.19	0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.15
Accidental underdose								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Arthropod bite								
Female	2	(0.2)	2	0.39	1	(0.1)	1	0.19
Male	1	(0.1)	1	0.14	3	(0.2)	3	0.38

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Foot fracture								
Female	2	(0.2)	2	0.29	3	(0.3)	3	0.37
Male	1	(0.1)	1	0.14	0			
Subdural haematoma								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Tooth fracture								
Female	3	(0.3)	3	0.41	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.14	2	(0.2)	2	0.30
Wrong product administered								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	2	0.28	5	(0.4)	5	0.76
Burns first degree								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.08	0			
Cervical vertebral fracture								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Eye injury								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Fibula fracture								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.25
Post procedural haemorrhage								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Radius fracture								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.25
Facial bones fracture								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Wrist fracture								
Female	0				0			
Male	1	(0.1)	1	0.13	1	(0.1)	1	0.09
Anaemia postoperative								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Animal bite								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.19
Male	0				2	(0.2)	2	0.16
Animal scratch								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Arthropod sting								
Female	3	(0.3)	3	0.41	0			
Male	0				1	(0.1)	1	0.15
Burn oral cavity								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Chillblains								
Female	1	(0.1)	1	0.19	0			
Male	0				1	(0.1)	1	0.09
Clavicle fracture								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Concussion								
Female	0				1	(0.1)	1	0.19
Male	0				1	(0.1)	1	0.14
Corneal abrasion								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Craniocerebral injury								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Crush injury								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Deafness traumatic								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Endotracheal intubation complication								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Exposure to SARS-CoV-2								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Extra dose administered								
Female	1	(0.1)	1	0.19	0			
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Face injury								
Female	2	(0.2)	2	0.42	0			
Male	0				1	(0.1)	1	0.16
Femoral neck fracture								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Gun shot wound								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Head injury								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Heat illness								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				2	(0.2)	3	0.32
Heat stroke								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Humerus fracture								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Intentional overdose								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Intentional product use issue								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Ligament rupture								
Female	1	(0.1)	2	0.37	0			
Male	0				0			
Lower limb fracture								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Muscle contusion								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Muscle strain								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.29
Male	0				3	(0.2)	3	0.38
Nerve injury								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	0				1	(0.1)	1	0.16
Periprocedural myocardial infarction								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Post procedural complication								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Post procedural fistula								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Post procedural hypothyroidism								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Post procedural stroke								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Post procedural swelling								
Female	0				0			
Male	0				1	(0.1)	2	0.17
Post-traumatic neck syndrome								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Procedural complication								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Product administration error								
Female	1	(0.1)	1	0.22	0			
Male	0				2	(0.2)	2	0.22
Radiation skin injury								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Scar								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Scratch								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Seroma								
Female	0				1	(0.1)	1	0.18
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Soft tissue injury								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.08
Spinal column injury								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Spinal compression fracture								
Female	1	(0.1)	1	0.10	0			
Male	0				1	(0.1)	1	0.14
Stab wound								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Subcutaneous haematoma								
Female	1	(0.1)	1	0.20	0			
Male	0				1	(0.1)	1	0.14
Sunburn								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Tendon injury								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Tibia fracture								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Traumatic haematoma								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Underdose								
Female	1	(0.1)	1	0.20	4	(0.4)	4	0.63
Male	0				1	(0.1)	1	0.15
Wound dehiscence								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Wrong dose								
Female	0				0			
Male	0				2	(0.2)	2	0.28
Nervous system disorders								
All								
Female	96	(10.8)	130	20.92	107	(11.2)	150	23.22

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	111	(8.8)	168	18.98	100	(8.3)	176	21.82
Headache								
Female	38	(4.3)	49	8.52	37	(3.9)	44	7.25
Male	32	(2.5)	43	5.21	27	(2.2)	36	3.91
Dizziness								
Female	13	(1.5)	17	2.57	19	(2.0)	22	3.11
Male	27	(2.1)	34	3.67	20	(1.7)	25	3.05
Tremor								
Female	4	(0.4)	4	0.51	5	(0.5)	9	1.58
Male	8	(0.6)	9	0.85	5	(0.4)	52	8.17
Hypoaesthesia								
Female	3	(0.3)	3	0.42	8	(0.8)	9	1.28
Male	6	(0.5)	9	0.93	2	(0.2)	2	0.22
Paraesthesia								
Female	3	(0.3)	3	0.42	7	(0.7)	7	1.05
Male	5	(0.4)	6	0.47	5	(0.4)	5	0.58
Carpal tunnel syndrome								
Female	6	(0.7)	6	0.99	7	(0.7)	7	1.18
Male	5	(0.4)	5	0.39	1	(0.1)	1	0.09
Sciatica								
Female	9	(1.0)	9	1.32	6	(0.6)	7	0.80
Male	4	(0.3)	4	0.49	6	(0.5)	6	0.69
Syncope								
Female	3	(0.3)	3	0.35	1	(0.1)	1	0.10
Male	4	(0.3)	4	0.45	0			
Migraine								
Female	5	(0.6)	5	0.92	4	(0.4)	4	0.82
Male	3	(0.2)	4	0.49	1	(0.1)	1	0.09
Diabetic neuropathy								
Female	3	(0.3)	3	0.52	5	(0.5)	5	0.75
Male	3	(0.2)	3	0.36	7	(0.6)	7	0.75
Dysgeusia								
Female	0				0			
Male	3	(0.2)	3	0.29	0			
Disturbance in attention								
Female	0				0			
Male	2	(0.2)	10	1.59	0			
Amnesia								
Female	0				0			
Male	2	(0.2)	2	0.22	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Burning sensation								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.27
Male	2	(0.2)	2	0.24	1	(0.1)	1	0.08
Cervicobrachial syndrome								
Female	0				0			
Male	2	(0.2)	2	0.29	1	(0.1)	1	0.08
Neuralgia								
Female	0				1	(0.1)	1	0.10
Male	2	(0.2)	2	0.20	0			
Neuropathy peripheral								
Female	4	(0.4)	5	0.78	5	(0.5)	5	0.80
Male	2	(0.2)	2	0.22	5	(0.4)	5	0.46
Autonomic nervous system imbalance								
Female	1	(0.1)	1	0.20	0			
Male	1	(0.1)	1	0.17	0			
Haemorrhage intracranial								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Hypoglycaemic seizure								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.17	0			
Sinus headache								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.17	0			
Speech disorder								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Carotid artery stenosis								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Cluster headache								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Intracranial pressure increased								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Transient ischaemic attack								
Female	2	(0.2)	2	0.31	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.23
Cerebral arteriosclerosis								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.14	0			
Cerebrovascular disorder								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.14	0			
Vascular encephalopathy								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Balance disorder								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Cerebral haemorrhage								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Cervical radiculopathy								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Dizziness postural								
Female	0				1	(0.1)	1	0.19
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.16
Lumbar radiculopathy								
Female	0				2	(0.2)	3	0.31
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.17
Memory impairment								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.19
Male	1	(0.1)	1	0.08	0			
Presyncope								
Female	0				2	(0.2)	2	0.20
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.15
Tension headache								
Female	2	(0.2)	2	0.32	0			
Male	1	(0.1)	2	0.15	0			
Carotid artery aneurysm								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Post herpetic neuralgia								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.13	1	(0.1)	1	0.16
Thalamic infarction								
Female	0				0			
Male	1	(0.1)	1	0.13	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ageusia								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Anosmia								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.14
Basilar migraine								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Brain injury								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Carotid arteriosclerosis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Cerebral artery embolism								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Cerebral atrophy								
Female	1	(0.1)	1	0.10	0			
Male	0				1	(0.1)	1	0.09
Cerebral infarction								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Cerebrovascular accident								
Female	0				1	(0.1)	1	0.19
Male	0				1	(0.1)	1	0.08
Cognitive disorder								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.19
Male	0				0			
Dementia Alzheimer's type								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Encephalopathy								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Essential tremor								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Facial nerve disorder								
Female	0				1	(0.1)	1	0.19

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Facial paralysis								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Hemiparesis								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Hypoglycaemic coma								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Hypoglycaemic unconsciousness								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Hyporeflexia								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Hypotonia								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Ischaemic stroke								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Lethargy								
Female	0				2	(0.2)	2	0.20
Male	0				0			
Loss of consciousness								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.16
Mental impairment								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Meralgia paraesthetica								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Morton's neuralgia								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Myelopathy								
Female	0				0			
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Neuroglycopenia								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	3	0.26
Ophthalmic migraine								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Orthostatic tremor								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Parkinsonian gait								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Peripheral paralysis								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Piriformis syndrome								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Radiculopathy								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Restless legs syndrome								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Sleep deficit								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Somnolence								
Female	2	(0.2)	2	0.42	0			
Male	0				1	(0.1)	1	0.09
Thrombotic stroke								
Female	0				0			
Male	0				2	(0.2)	2	0.23
Trigeminal neuralgia								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Vascular headache								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Vertebral artery occlusion								
Female	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
White matter lesion								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Respiratory, thoracic and mediastinal disorders								
All								
Female	55	(6.1)	70	10.86	56	(5.9)	67	10.21
Male	77	(6.0)	107	11.79	66	(5.4)	86	10.02
Cough								
Female	14	(1.5)	16	2.62	13	(1.4)	14	2.30
Male	12	(0.9)	13	1.28	15	(1.2)	16	1.87
Oropharyngeal pain								
Female	13	(1.4)	13	1.92	10	(1.0)	11	1.75
Male	11	(0.9)	13	1.36	9	(0.7)	10	1.15
Rhinorrhoea								
Female	3	(0.3)	4	0.53	3	(0.3)	3	0.55
Male	9	(0.7)	11	1.32	10	(0.8)	10	1.25
Sleep apnoea syndrome								
Female	1	(0.1)	1	0.20	0			
Male	6	(0.5)	6	0.52	0			
Dyspnoea								
Female	4	(0.4)	4	0.50	10	(1.1)	11	1.55
Male	5	(0.4)	5	0.63	3	(0.3)	3	0.31
Nasal congestion								
Female	5	(0.6)	5	0.63	2	(0.2)	2	0.21
Male	5	(0.4)	5	0.43	3	(0.2)	3	0.32
Respiratory disorder								
Female	4	(0.4)	4	0.71	5	(0.5)	5	0.80
Male	4	(0.3)	4	0.64	2	(0.2)	2	0.25
Sinus congestion								
Female	2	(0.2)	2	0.32	0			
Male	4	(0.3)	5	0.60	2	(0.2)	2	0.25
Epistaxis								
Female	2	(0.2)	2	0.39	1	(0.1)	2	0.20
Male	4	(0.3)	8	1.06	1	(0.1)	2	0.28
Chronic obstructive pulmonary disease								
Female	0				1	(0.1)	1	0.10
Male	4	(0.3)	4	0.47	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Productive cough								
Female	1	(0.1)	1	0.20	0			
Male	3	(0.2)	3	0.28	4	(0.3)	4	0.55
Dyspnoea exertional								
Female	0				1	(0.1)	1	0.10
Male	2	(0.2)	2	0.24	1	(0.1)	1	0.09
Acute respiratory failure								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	2	0.20	1	(0.1)	1	0.09
Asthma								
Female	3	(0.3)	3	0.48	0			
Male	2	(0.2)	3	0.29	1	(0.1)	1	0.14
Pulmonary fibrosis								
Female	0				0			
Male	2	(0.2)	3	0.29	0			
Nasal septum deviation								
Female	0				0			
Male	2	(0.2)	2	0.26	1	(0.1)	1	0.14
Sneezing								
Female	1	(0.1)	1	0.22	0			
Male	2	(0.2)	2	0.20	0			
Hiccups								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Rhinitis allergic								
Female	1	(0.1)	1	0.10	3	(0.3)	3	0.60
Male	1	(0.1)	1	0.17	3	(0.2)	7	0.71
Upper-airway cough syndrome								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.16
Increased viscosity of upper respiratory secretion								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Upper respiratory tract inflammation								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Emphysema								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.14
Pulmonary hypertension								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Acquired diaphragmatic eventration								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Interstitial lung disease								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	0			
Nasal dryness								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Nasal turbinate hypertrophy								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Pulmonary mass								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	3	(0.2)	3	0.35
Sinus pain								
Female	1	(0.1)	1	0.19	0			
Male	1	(0.1)	2	0.15	1	(0.1)	1	0.14
Throat irritation								
Female	0				1	(0.1)	1	0.18
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.16
Respiratory failure								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.13	1	(0.1)	1	0.08
Acute pulmonary oedema								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Allergic bronchitis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Allergic cough								
Female	0				2	(0.2)	2	0.41
Male	0				0			
Aphonia								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Bronchial hyperreactivity								
Female	1	(0.1)	1	0.22	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bronchiectasis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Bronchitis chronic								
Female	0				2	(0.2)	2	0.29
Male	0				0			
Bronchospasm								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.18
Male	0				0			
Dry throat								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Dysphonia								
Female	0				0			
Male	0				1	(0.1)	2	0.28
Haemoptysis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Laryngeal cyst								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Lung disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Nasal obstruction								
Female	1	(0.1)	1	0.20	0			
Male	0				1	(0.1)	1	0.08
Paranasal cyst								
Female	0				2	(0.2)	2	0.37
Male	0				0			
Paranasal sinus discomfort								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Pleural disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Pleural effusion								
Female	0				1	(0.1)	1	0.10
Male	0				2	(0.2)	2	0.16
Pleurisy								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.19	0			
Male	0				1	(0.1)	1	0.16
Pleuritic pain								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Pulmonary congestion								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Pulmonary embolism								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Respiratory tract inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Metabolism and nutrition disorders								
All								
Female	58	(6.4)	73	10.17	68	(7.1)	90	12.32
Male	74	(5.8)	90	9.25	66	(5.5)	79	8.83
Hypoglycaemia								
Female	6	(0.7)	7	1.25	13	(1.3)	24	3.10
Male	12	(1.0)	19	2.52	10	(0.8)	16	2.00
Dyslipidaemia								
Female	9	(1.0)	9	1.33	9	(0.9)	9	1.33
Male	12	(0.9)	13	1.37	8	(0.7)	8	1.01
Vitamin B12 deficiency								
Female	4	(0.4)	4	0.42	1	(0.1)	1	0.10
Male	7	(0.6)	7	0.55	0			
Hyperlipidaemia								
Female	7	(0.8)	7	0.99	6	(0.6)	6	0.77
Male	7	(0.5)	7	0.65	7	(0.6)	7	0.71
Hypertriglyceridaemia								
Female	5	(0.6)	5	0.72	3	(0.3)	3	0.56
Male	5	(0.4)	5	0.45	5	(0.4)	5	0.48
Vitamin D deficiency								
Female	13	(1.4)	13	1.58	10	(1.1)	10	1.36
Male	4	(0.3)	4	0.31	4	(0.3)	4	0.38
Hyperkalaemia								
Female	4	(0.5)	5	0.74	4	(0.4)	4	0.49
Male	4	(0.3)	4	0.37	6	(0.5)	6	0.74

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hyperglycaemia								
Female	2	(0.2)	2	0.29	11	(1.1)	11	1.68
Male	4	(0.3)	5	0.61	3	(0.3)	3	0.31
Hyperuricaemia								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Male	3	(0.2)	3	0.37	2	(0.2)	2	0.16
Gout								
Female	1	(0.1)	1	0.10	0			
Male	3	(0.2)	4	0.31	6	(0.5)	7	0.57
Iron deficiency								
Female	2	(0.2)	2	0.21	2	(0.2)	2	0.21
Male	3	(0.2)	3	0.23	1	(0.1)	1	0.08
Increased appetite								
Female	0				3	(0.3)	4	0.65
Male	3	(0.2)	3	0.23	3	(0.2)	3	0.36
Decreased appetite								
Female	1	(0.1)	1	0.12	3	(0.3)	3	0.39
Male	3	(0.2)	3	0.29	2	(0.2)	2	0.15
Hyponatraemia								
Female	1	(0.1)	1	0.19	0			
Male	2	(0.2)	2	0.31	1	(0.1)	1	0.14
Dehydration								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	1	(0.1)	2	0.32
Diabetes mellitus								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Diabetes mellitus inadequate control								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Hypernatraemia								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Magnesium deficiency								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Malnutrition								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Fluid retention								
Female	1	(0.1)	1	0.12	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.14	0			
Hypercholesterolaemia								
Female	2	(0.2)	2	0.38	1	(0.1)	1	0.17
Male	1	(0.1)	1	0.08	3	(0.2)	3	0.39
Abnormal weight gain								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Appetite disorder								
Female	0				0			
Male	0				1	(0.1)	2	0.17
Electrolyte imbalance								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Folate deficiency								
Female	2	(0.2)	2	0.21	1	(0.1)	1	0.10
Male	0				0			
Food craving								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Hyperammonaemia								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Hypercalcaemia								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hypoalbuminaemia								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Hypokalaemia								
Female	2	(0.2)	2	0.31	1	(0.1)	1	0.10
Male	0				0			
Insulin resistance								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.16
Lactic acidosis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Lipomatosis								
Female	0				1	(0.1)	1	0.19
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Metabolic acidosis								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Metabolic disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Obesity								
Female	1	(0.1)	1	0.12	0			
Male	0				2	(0.2)	2	0.30
Vitamin B complex deficiency								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Zinc deficiency								
Female	2	(0.2)	2	0.22	1	(0.1)	1	0.10
Male	0				0			
Skin and subcutaneous tissue disorders								
All								
Female	51	(5.7)	54	8.81	66	(6.9)	79	10.96
Male	72	(5.6)	77	8.18	62	(5.1)	76	9.09
Rash								
Female	5	(0.5)	5	0.74	6	(0.6)	7	0.79
Male	9	(0.7)	9	1.05	5	(0.4)	5	0.48
Eczema								
Female	4	(0.5)	4	0.61	3	(0.3)	3	0.47
Male	6	(0.5)	6	0.51	4	(0.3)	4	0.52
Hyperhidrosis								
Female	3	(0.3)	3	0.58	3	(0.3)	3	0.38
Male	5	(0.4)	5	0.45	2	(0.2)	2	0.22
Pruritus								
Female	3	(0.3)	3	0.41	7	(0.7)	7	0.97
Male	5	(0.4)	5	0.51	5	(0.4)	5	0.60
Urticaria								
Female	2	(0.2)	2	0.29	6	(0.6)	6	0.70
Male	5	(0.4)	5	0.54	6	(0.5)	6	0.72
Skin ulcer								
Female	0				0			
Male	4	(0.3)	4	0.43	5	(0.4)	5	0.64
Dermatitis contact								
Female	3	(0.3)	4	0.57	10	(1.1)	10	1.67
Male	4	(0.3)	4	0.40	4	(0.3)	4	0.49

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dermatitis								
Female	4	(0.4)	4	0.75	5	(0.5)	6	0.85
Male	3	(0.2)	3	0.38	2	(0.2)	2	0.25
Cold sweat								
Female	1	(0.1)	1	0.12	5	(0.5)	5	0.84
Male	3	(0.2)	3	0.35	3	(0.2)	7	1.12
Dry skin								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	3	(0.2)	3	0.32	4	(0.3)	4	0.45
Skin irritation								
Female	1	(0.1)	1	0.22	0			
Male	3	(0.2)	4	0.40	3	(0.2)	3	0.31
Rash erythematous								
Female	0				0			
Male	2	(0.2)	2	0.31	0			
Alopecia								
Female	6	(0.7)	6	1.06	3	(0.3)	3	0.39
Male	2	(0.2)	2	0.24	0			
Dermatitis allergic								
Female	0				0			
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.14
Ingrowing nail								
Female	0				2	(0.2)	2	0.20
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Night sweats								
Female	1	(0.1)	1	0.19	0			
Male	2	(0.2)	2	0.15	0			
Blister								
Female	1	(0.1)	1	0.20	0			
Male	1	(0.1)	1	0.17	2	(0.2)	2	0.23
Dermal cyst								
Female	0				3	(0.3)	3	0.43
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.15
Hidradenitis								
Female	0				0			
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.08
Macule								
Female	0				0			
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.09
Diabetic foot								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.16
Erythema								
Female	0				3	(0.3)	3	0.39
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.16
Livedo reticularis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Nail bed inflammation								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Acne								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.14	0			
Decubitus ulcer								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.14	0			
Ecchymosis								
Female	0				2	(0.2)	2	0.20
Male	1	(0.1)	1	0.14	0			
Granuloma annulare								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Psoriasis								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.22
Skin exfoliation								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Urticaria contact								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Miliaria								
Female	1	(0.1)	1	0.20	2	(0.2)	2	0.20
Male	1	(0.1)	1	0.13	2	(0.2)	2	0.17
Actinic keratosis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Alopecia areata								
Female	0				1	(0.1)	1	0.10
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Angioedema								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				2	(0.2)	2	0.25
Asteatosis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Chronic spontaneous urticaria								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Cold urticaria								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Dermatitis atopic								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.16
Drug eruption								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Haemorrhage subcutaneous								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hyperkeratosis								
Female	2	(0.2)	2	0.31	1	(0.1)	1	0.19
Male	0				1	(0.1)	1	0.16
Ingrown hair								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Intertrigo								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Lentigo								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Leukoplakia								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Lichen sclerosus								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Lipodystrophy acquired								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Lipohypertrophy								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.14
Myxoid cyst								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Neurodermatitis								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Pruritus allergic								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Purpura								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Rash maculo-papular								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Rash papular								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Seborrhoea								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Skin discolouration								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Skin fissures								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Skin lesion								
Female	2	(0.2)	2	0.33	0			
Male	0				2	(0.2)	2	0.25
Skin odour abnormal								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Skin reaction								
Female	0				1	(0.1)	1	0.19
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Telangiectasia								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Umbilical haematoma								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Urticaria thermal								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Xeroderma								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Cardiac disorders								
All								
Female	33	(3.7)	45	6.01	33	(3.5)	50	6.77
Male	62	(4.9)	88	8.39	51	(4.2)	65	6.43
Coronary artery disease								
Female	3	(0.3)	3	0.34	4	(0.4)	4	0.58
Male	9	(0.7)	9	0.81	6	(0.5)	6	0.47
Atrial fibrillation								
Female	4	(0.4)	5	0.56	2	(0.2)	2	0.29
Male	9	(0.7)	9	0.83	4	(0.3)	4	0.34
Acute myocardial infarction								
Female	1	(0.1)	1	0.10	2	(0.2)	2	0.20
Male	8	(0.6)	8	0.79	6	(0.5)	6	0.68
Cardiac failure								
Female	2	(0.2)	2	0.22	3	(0.3)	4	0.70
Male	6	(0.5)	6	0.52	0			
Myocardial infarction								
Female	1	(0.1)	1	0.19	2	(0.2)	2	0.21
Male	5	(0.4)	5	0.50	2	(0.2)	2	0.16
Angina pectoris								
Female	3	(0.3)	3	0.33	2	(0.2)	2	0.29
Male	4	(0.3)	4	0.46	2	(0.2)	2	0.16
Ventricular extrasystoles								
Female	4	(0.4)	4	0.67	0			
Male	4	(0.3)	4	0.40	2	(0.2)	3	0.24
Cardiac failure congestive								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	4	(0.3)	4	0.36	2	(0.2)	3	0.43
Myocardial ischaemia								
Female	0				3	(0.3)	3	0.43
Male	3	(0.2)	3	0.35	0			
Acute coronary syndrome								
Female	1	(0.1)	1	0.10	0			
Male	3	(0.2)	3	0.23	0			
Arrhythmia								
Female	0				1	(0.1)	1	0.10
Male	2	(0.2)	2	0.16	2	(0.2)	2	0.23
Atrioventricular block first degree								
Female	0				0			
Male	2	(0.2)	2	0.22	0			
Bundle branch block left								
Female	0				1	(0.1)	1	0.19
Male	2	(0.2)	2	0.22	0			
Bundle branch block right								
Female	0				2	(0.2)	2	0.29
Male	2	(0.2)	2	0.24	5	(0.4)	6	0.64
Left ventricular hypertrophy								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.19
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.09
Supraventricular extrasystoles								
Female	1	(0.1)	1	0.19	0			
Male	2	(0.2)	2	0.21	2	(0.2)	2	0.16
Angina unstable								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.22
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.09
Cardiomegaly								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Palpitations								
Female	6	(0.7)	6	0.86	4	(0.4)	4	0.49
Male	1	(0.1)	1	0.08	3	(0.2)	3	0.40
Tachycardia								
Female	2	(0.2)	2	0.21	3	(0.3)	3	0.31
Male	1	(0.1)	1	0.08	4	(0.3)	4	0.50
Cardio-respiratory arrest								
Female	0				0			
Male	1	(0.1)	1	0.14	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Mitral valve stenosis								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Aortic valve sclerosis								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Aortic valve incompetence								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Atrial flutter								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Atrial thrombosis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Bradycardia								
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.23
Cardiac failure chronic								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Cardiac ventricular thrombosis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Chronic coronary syndrome								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Coronary artery occlusion								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	0			
Diastolic dysfunction								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Left ventricular dysfunction								
Female	1	(0.1)	1	0.19	0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.23
Mitral valve incompetence								
Female	2	(0.2)	2	0.29	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Sinus tachycardia								
Female	0				2	(0.2)	2	0.21

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Cardiac flutter								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Aortic valve calcification								
Female	0				2	(0.2)	2	0.29
Male	0				0			
Arteriosclerosis coronary artery								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Atrial enlargement								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Atrioventricular block complete								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Cardiac arrest								
Female	0				0			
Male	0				2	(0.2)	2	0.15
Cardiac dysfunction								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Cardiac failure acute								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Cardiac perfusion defect								
Female	0				1	(0.1)	2	0.37
Male	0				0			
Cardiovascular disorder								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Coronary artery stenosis								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Left atrial dilatation								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				0			
Left atrial enlargement								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pericardial effusion								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Pericarditis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.19
Male	0				0			
Sinus arrhythmia								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Sinus bradycardia								
Female	0				1	(0.1)	1	0.10
Male	0				2	(0.2)	2	0.23
Subendocardial ischaemia								
Female	0				2	(0.2)	2	0.21
Male	0				0			
Supraventricular tachycardia								
Female	2	(0.2)	2	0.30	0			
Male	0				0			
Tricuspid valve incompetence								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.21
Male	0				1	(0.1)	1	0.08
Ventricular arrhythmia								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Ventricular tachycardia								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Investigations								
All								
Female	33	(3.6)	37	5.78	36	(3.8)	41	6.08
Male	61	(4.8)	72	7.92	43	(3.5)	47	5.59
Weight increased								
Female	7	(0.8)	7	1.20	7	(0.7)	7	0.88
Male	13	(1.0)	13	1.25	11	(0.9)	11	1.22
SARS-CoV-2 test positive								
Female	2	(0.2)	2	0.31	2	(0.2)	2	0.45
Male	5	(0.4)	5	0.62	2	(0.2)	2	0.32
Blood creatinine increased								
Female	3	(0.3)	3	0.49	0			
Male	5	(0.4)	5	0.61	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood pressure increased								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.29
Male	4	(0.3)	4	0.55	2	(0.2)	2	0.16
Blood triglycerides increased								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Male	3	(0.2)	3	0.38	2	(0.2)	2	0.15
Weight decreased								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	3	(0.2)	3	0.23	1	(0.1)	1	0.16
Hepatic enzyme increased								
Female	0				0			
Male	2	(0.2)	2	0.25	2	(0.2)	2	0.25
Low density lipoprotein increased								
Female	0				0			
Male	2	(0.2)	2	0.25	2	(0.2)	2	0.28
Aspartate aminotransferase increased								
Female	0				0			
Male	2	(0.2)	2	0.31	1	(0.1)	1	0.09
Prostatic specific antigen increased								
Female	0				0			
Male	2	(0.2)	2	0.16	0			
Liver function test increased								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.10
Male	2	(0.2)	2	0.22	0			
Blood cholesterol increased								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.22
Male	2	(0.2)	2	0.24	0			
Alanine aminotransferase increased								
Female	2	(0.2)	2	0.39	0			
Male	2	(0.2)	2	0.21	0			
Angiogram								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Blood testosterone decreased								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Heart rate increased								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Occult blood positive								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Blood immunoglobulin E increased								
Female	2	(0.2)	2	0.21	3	(0.3)	3	0.31
Male	1	(0.1)	1	0.08	0			
Blood urine present								
Female	0				0			
Male	1	(0.1)	3	0.23	1	(0.1)	1	0.14
Electrocardiogram ST segment abnormal								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
QRS axis abnormal								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.14
Transaminases increased								
Female	0				1	(0.1)	1	0.19
Male	1	(0.1)	1	0.08	0			
Arthroscopy								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Blood glucose fluctuation								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Blood potassium increased								
Female	0				1	(0.1)	1	0.17
Male	1	(0.1)	1	0.14	0			
Monocyte count decreased								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.14
Monofilament pressure perception test								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Occult blood								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.14	0			
Blood creatine increased								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Blood creatine phosphokinase increased								
Female	0				0			
Male	1	(0.1)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Glycosylated haemoglobin increased								
Female	0				1	(0.1)	2	0.21
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
International normalised ratio abnormal								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
International normalised ratio decreased								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
International normalised ratio increased								
Female	0				0			
Male	1	(0.1)	2	0.15	0			
Transferrin saturation decreased								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Amylase increased								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Antinuclear antibody positive								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Blood alkaline phosphatase increased								
Female	3	(0.3)	3	0.56	0			
Male	0				0			
Blood glucose decreased								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Blood glucose increased								
Female	0				2	(0.2)	2	0.33
Male	0				0			
Blood pressure decreased								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Blood uric acid increased								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Body temperature increased								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Bone density decreased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Breath sounds abnormal								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Carbohydrate antigen 19-9 increased								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Cardiac murmur								
Female	0				2	(0.2)	2	0.33
Male	0				0			
Cardiac stress test abnormal								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Catheterisation cardiac								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Ejection fraction decreased								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Electrocardiogram abnormal								
Female	2	(0.2)	2	0.32	2	(0.2)	2	0.29
Male	0				0			
Electrocardiogram P wave biphasic								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Electrocardiogram repolarisation abnormality								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Electrocardiogram ST segment depression								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Electrocardiogram T wave inversion								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.19
Male	0				0			
Eosinophil count increased								
Female	1	(0.1)	1	0.19	1	(0.1)	2	0.45
Male	0				0			
Free fatty acids increased								
Female	0				0			
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Glomerular filtration rate decreased								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Grip strength decreased								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Haematocrit increased								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Haemoglobin decreased								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.16
Haemoglobin increased								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Hepatitis B virus test positive								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Intraocular pressure increased								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Lipase increased								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Lipids abnormal								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Lipids increased								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Liver function test abnormal								
Female	1	(0.1)	1	0.19	0			
Male	0				1	(0.1)	2	0.29
Mycobacterium tuberculosis complex test positive								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Platelet count decreased								
Female	0				2	(0.2)	2	0.37
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Red blood cell count decreased								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Thyroid function test abnormal								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Vitamin D decreased								
Female	0				1	(0.1)	1	0.10
Male	0				0			
White blood cell count decreased								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Vascular disorders								
All								
Female	32	(3.6)	34	4.94	34	(3.6)	45	6.47
Male	47	(3.7)	54	5.56	46	(3.8)	54	5.80
Hypertension								
Female	14	(1.5)	14	2.19	14	(1.5)	16	2.45
Male	23	(1.8)	23	2.47	24	(2.0)	27	2.94
Hypotension								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.29
Male	5	(0.4)	5	0.51	1	(0.1)	1	0.09
Peripheral arterial occlusive disease								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Male	3	(0.2)	4	0.43	1	(0.1)	1	0.09
Arteriosclerosis								
Female	2	(0.2)	2	0.22	3	(0.3)	3	0.48
Male	2	(0.2)	2	0.25	4	(0.3)	4	0.39
Superficial vein thrombosis								
Female	1	(0.1)	1	0.10	0			
Male	2	(0.2)	2	0.15	0			
Peripheral artery stenosis								
Female	0				0			
Male	2	(0.2)	5	0.57	0			
Aortic arteriosclerosis								
Female	0				3	(0.3)	3	0.47
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.14
Blood pressure inadequately controlled								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hot flush								
Female	0				1	(0.1)	1	0.18
Male	1	(0.1)	1	0.08	0			
Venous stenosis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Arterial insufficiency								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Diabetic vascular disorder								
Female	0				0			
Male	1	(0.1)	1	0.14	2	(0.2)	2	0.28
Orthostatic hypotension								
Female	1	(0.1)	1	0.20	0			
Male	1	(0.1)	1	0.14	0			
Hypertensive urgency								
Female	0				1	(0.1)	2	0.21
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.14
Peripheral coldness								
Female	2	(0.2)	2	0.24	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Peripheral venous disease								
Female	1	(0.1)	1	0.19	2	(0.2)	2	0.21
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.14
Thrombosis								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Varicose vein								
Female	0				2	(0.2)	2	0.33
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Aneurysm								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Aortic aneurysm								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Aortic dilatation								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Aortic stenosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.08
Blood pressure fluctuation								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Brachiocephalic arteriosclerosis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				2	(0.2)	2	0.17
Deep vein thrombosis								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Flushing								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Haematoma								
Female	2	(0.2)	2	0.31	1	(0.1)	1	0.10
Male	0				2	(0.2)	2	0.28
Hypertensive crisis								
Female	1	(0.1)	1	0.19	2	(0.2)	4	0.66
Male	0				0			
Iliac artery stenosis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Intermittent claudication								
Female	0				0			
Male	0				2	(0.2)	2	0.16
Macroangiopathy								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Neovascularisation								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Peripheral artery aneurysm								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Peripheral artery occlusion								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Peripheral ischaemia								
Female	0				1	(0.1)	1	0.10
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Peripheral vascular disorder								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Phlebitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Thrombophlebitis								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Varicose ulceration								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Renal and urinary disorders								
All								
Female	23	(2.6)	29	4.13	20	(2.1)	27	3.77
Male	31	(2.5)	36	4.09	34	(2.8)	43	4.32
Renal cyst								
Female	3	(0.3)	3	0.49	3	(0.3)	3	0.40
Male	4	(0.3)	4	0.43	2	(0.2)	2	0.24
Pollakiuria								
Female	2	(0.2)	2	0.32	1	(0.1)	1	0.10
Male	3	(0.2)	3	0.41	1	(0.1)	1	0.09
Acute kidney injury								
Female	0				2	(0.2)	2	0.21
Male	3	(0.2)	3	0.35	3	(0.2)	3	0.24
Chronic kidney disease								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.33
Male	3	(0.2)	3	0.41	4	(0.3)	4	0.39
Dysuria								
Female	1	(0.1)	2	0.21	1	(0.1)	1	0.19
Male	3	(0.2)	3	0.29	3	(0.3)	3	0.26
Nephrolithiasis								
Female	2	(0.2)	2	0.21	1	(0.1)	1	0.18
Male	3	(0.2)	3	0.23	3	(0.2)	5	0.52
Renal impairment								
Female	2	(0.2)	2	0.32	0			
Male	2	(0.2)	2	0.21	3	(0.3)	3	0.25
Ureterolithiasis								
Female	1	(0.1)	1	0.10	2	(0.2)	2	0.20

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	2	(0.2)	2	0.21	1	(0.1)	1	0.08
Microalbuminuria								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.17	1	(0.1)	1	0.08
Renal pain								
Female	2	(0.2)	2	0.32	0			
Male	1	(0.1)	1	0.17	0			
Nocturia								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.17
Proteinuria								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Urinary retention								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Urinary tract disorder								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Chromaturia								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Renal failure								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Haematuria								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	2	0.28	4	(0.3)	4	0.39
Renal colic								
Female	0				0			
Male	1	(0.1)	1	0.08	3	(0.2)	3	0.36
Diabetic nephropathy								
Female	2	(0.2)	2	0.24	1	(0.1)	1	0.22
Male	1	(0.1)	1	0.13	3	(0.2)	3	0.44
Nephrotic syndrome								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Bladder mass								
Female	0				0			
Male	0				1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bladder prolapse								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Calculus urinary								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				0			
Cystitis haemorrhagic								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hydrocalyx								
Female	0				2	(0.2)	2	0.41
Male	0				0			
Hydronephrosis								
Female	1	(0.1)	1	0.20	1	(0.1)	1	0.18
Male	0				0			
Hypertensive nephropathy								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Hypertonic bladder								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Micturition urgency								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Nephropathy								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Polyuria								
Female	1	(0.1)	1	0.20	0			
Male	0				1	(0.1)	1	0.08
Pyelocaliectasis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Renal mass								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Strangury								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Stress urinary incontinence								
Female	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Urethral stenosis								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Urinary incontinence								
Female	1	(0.1)	1	0.10	3	(0.3)	3	0.31
Male	0				0			
Urinary tract inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Urinary tract obstruction								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Urine odour abnormal								
Female	2	(0.2)	2	0.32	0			
Male	0				1	(0.1)	1	0.14
Psychiatric disorders								
All								
Female	17	(1.9)	19	2.96	23	(2.4)	24	3.52
Male	24	(1.9)	26	2.51	20	(1.6)	22	2.75
Insomnia								
Female	5	(0.6)	5	0.85	4	(0.4)	4	0.49
Male	6	(0.5)	6	0.57	2	(0.2)	3	0.35
Sleep disorder								
Female	0				2	(0.2)	2	0.37
Male	5	(0.4)	5	0.48	2	(0.2)	2	0.29
Anxiety								
Female	2	(0.2)	2	0.40	5	(0.5)	5	0.76
Male	4	(0.3)	4	0.31	5	(0.4)	5	0.55
Depressed mood								
Female	0				0			
Male	2	(0.2)	2	0.24	0			
Depression								
Female	6	(0.7)	6	0.82	7	(0.8)	7	1.05
Male	2	(0.2)	2	0.15	5	(0.4)	5	0.68
Attention deficit hyperactivity disorder								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Disorientation								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Irritability								
Female	1	(0.1)	1	0.19	0			
Male	1	(0.1)	1	0.08	0			
Listless								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Drug abuse								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Mental status changes								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Nightmare								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Adjustment disorder								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Adjustment disorder with depressed mood								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Adjustment disorder with mixed anxiety and depressed mood								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Affect lability								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Agitation								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Anxiety disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Bruxism								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Drug dependence								
Female	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Emotional distress								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Fear								
Female	0				1	(0.1)	1	0.19
Male	0				1	(0.1)	1	0.14
Major depression								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Mixed anxiety and depressive disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Mood swings								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Persistent depressive disorder								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Phobia								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Post-traumatic stress disorder								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Stress								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
Female	12	(1.3)	14	2.12	18	(1.9)	28	3.89
Male	23	(1.8)	29	2.92	11	(0.9)	15	1.46
Eye naevus								
Female	0				0			
Male	3	(0.2)	4	0.46	0			
Adenocarcinoma pancreas								
Female	0				0			
Male	2	(0.2)	2	0.22	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Colon adenoma								
Female	1	(0.1)	1	0.20	0			
Male	2	(0.2)	2	0.22	0			
Metastases to liver								
Female	0				0			
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.08
Bladder cancer								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Lipoma								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Pancreatic carcinoma								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.08
Squamous cell carcinoma of skin								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Bladder papilloma								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Colorectal cancer								
Female	1	(0.1)	1	0.10	0			
Male	1	(0.1)	1	0.14	0			
Lung cancer metastatic								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.08
Skin papilloma								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Osteoma								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Basal cell carcinoma								
Female	0				2	(0.2)	2	0.21
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.09
Glioblastoma multiforme								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Haemangioma of liver								
Female	1	(0.1)	1	0.22	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.08	0			
Oral fibroma								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Pancreatic neoplasm								
Female	1	(0.1)	1	0.19	0			
Male	1	(0.1)	1	0.08	0			
Prostate cancer								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Seborrhoeic keratosis								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	2	0.15	0			
Chronic myeloid leukaemia								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Gastric cancer								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Acrochordon								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Adenocarcinoma of colon								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Adrenal adenoma								
Female	0				1	(0.1)	1	0.19
Male	0				1	(0.1)	1	0.14
Benign neoplasm of thyroid gland								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Benign renal neoplasm								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.08
Bowen's disease								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Breast cancer								
Female	0				1	(0.1)	1	0.17
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Breast cancer metastatic								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Colon cancer								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Colon cancer stage II								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Dysplastic naevus								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Endometrial adenocarcinoma								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Gastrointestinal tract adenoma								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hepatocellular carcinoma								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Invasive breast carcinoma								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Invasive ductal breast carcinoma								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Invasive lobular breast carcinoma								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Lung adenocarcinoma								
Female	0				1	(0.1)	1	0.19
Male	0				1	(0.1)	1	0.14
Lymphangioma								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Malignant melanoma								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Malignant melanoma in situ								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				1	(0.1)	1	0.09
Malignant peritoneal neoplasm								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Melanocytic naevus								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Metastases to bone marrow								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Metastases to lymph nodes								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Myxoma								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Neoplasm skin								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Ovarian cancer metastatic								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Pancreatic carcinoma metastatic								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Prostatic adenoma								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Renal cell carcinoma								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Renal hamartoma								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Renal neoplasm								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Salivary gland neoplasm								
Female	1	(0.1)	1	0.12	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Small cell lung cancer								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Small intestine neuroendocrine tumour								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Uterine cancer								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Uterine leiomyoma								
Female	0				5	(0.5)	5	0.84
Male	0				0			
Blood and lymphatic system disorders								
All								
Female	19	(2.1)	21	3.22	18	(1.9)	18	2.50
Male	17	(1.3)	17	1.89	15	(1.2)	15	1.60
Anaemia								
Female	14	(1.6)	16	2.59	8	(0.8)	8	0.99
Male	6	(0.5)	6	0.61	6	(0.5)	6	0.68
Eosinophilia								
Female	1	(0.1)	1	0.19	0			
Male	2	(0.2)	2	0.15	2	(0.2)	2	0.23
Lymphadenitis								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Lymphadenopathy								
Female	2	(0.2)	2	0.22	2	(0.2)	2	0.33
Male	1	(0.1)	1	0.17	0			
Leukocytosis								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.15
Leukopenia								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Blood loss anaemia								
Female	0				0			
Male	1	(0.1)	1	0.14	2	(0.2)	2	0.16
Iron deficiency anaemia								
Female	1	(0.1)	1	0.12	3	(0.3)	3	0.51
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lymphadenopathy mediastinal								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.14
Polycythaemia								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Thrombocytopenia								
Female	0				0			
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.16
Hypochromic anaemia								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Normocytic anaemia								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Pancytopenia								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Splenomegaly								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Thrombocytosis								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Reproductive system and breast disorders								
All								
Female	17	(1.9)	17	2.51	19	(2.0)	24	3.32
Male	16	(1.3)	16	1.69	8	(0.7)	9	1.00
Benign prostatic hyperplasia								
Female	0				0			
Male	6	(0.5)	6	0.67	3	(0.2)	3	0.31
Erectile dysfunction								
Female	0				0			
Male	5	(0.4)	5	0.44	1	(0.1)	1	0.14
Prostatomegaly								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Ejaculation failure								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.08	0			
Prostatic calcification								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Pruritus genital								
Female	0				2	(0.2)	2	0.27
Male	1	(0.1)	1	0.08	0			
Prostatitis								
Female	0				0			
Male	1	(0.1)	1	0.13	1	(0.1)	1	0.15
Atrophic vulvovaginitis								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Male	0				0			
Breast mass								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				0			
Breast pain								
Female	1	(0.1)	1	0.19	1	(0.1)	1	0.10
Male	0				0			
Cervical polyp								
Female	1	(0.1)	1	0.20	0			
Male	0				0			
Colpocele								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Dysmenorrhoea								
Female	1	(0.1)	1	0.22	2	(0.2)	2	0.33
Male	0				0			
Ectropion of cervix								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Fibrocystic breast disease								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Galactorrhoea								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Genital prolapse								
Female	0				1	(0.1)	1	0.10
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Intermenstrual bleeding								
Female	2	(0.2)	2	0.37	0			
Male	0				0			
Menopausal disorder								
Female	0				1	(0.1)	1	0.19
Male	0				0			
Menopausal symptoms								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Menstruation delayed								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Menstruation irregular								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Ovarian cyst								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Ovarian disorder								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Pelvic discomfort								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Penile pain								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Penile rash								
Female	0				0			
Male	0				1	(0.1)	2	0.17
Premenstrual syndrome								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.22
Male	0				0			
Testicular cyst								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Uterine enlargement								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Uterine polyp								
Female	2	(0.2)	2	0.22	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Uterine prolapse								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	0				0			
Vaginal discharge								
Female	0				2	(0.2)	2	0.29
Male	0				0			
Vaginal haemorrhage								
Female	0				2	(0.2)	2	0.21
Male	0				0			
Vulvovaginal dryness								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Vulvovaginal pruritus								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.21
Male	0				0			
Ear and labyrinth disorders								
All								
Female	13	(1.4)	13	1.97	12	(1.2)	12	1.86
Male	15	(1.2)	18	1.60	12	(1.0)	13	1.39
Vertigo								
Female	5	(0.6)	5	0.73	5	(0.5)	5	0.80
Male	5	(0.4)	6	0.57	4	(0.3)	5	0.49
Ear pain								
Female	3	(0.3)	3	0.51	2	(0.2)	2	0.39
Male	3	(0.2)	3	0.28	0			
Deafness bilateral								
Female	0				0			
Male	2	(0.2)	2	0.16	0			
Tinnitus								
Female	0				1	(0.1)	1	0.10
Male	2	(0.2)	2	0.15	1	(0.1)	1	0.15
Hypoacusis								
Female	0				2	(0.2)	2	0.21
Male	2	(0.2)	2	0.20	1	(0.1)	1	0.08
External ear pain								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Meniere's disease								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Ear inflammation								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Cerumen impaction								
Female	1	(0.1)	1	0.19	0			
Male	0				1	(0.1)	1	0.14
Deafness neurosensory								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Deafness unilateral								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Ear discomfort								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Eustachian tube dysfunction								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.18
Male	0				0			
Middle ear inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Motion sickness								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Presbyacusis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Vertigo positional								
Female	2	(0.2)	2	0.21	0			
Male	0				1	(0.1)	1	0.09
Hepatobiliary disorders								
All								
Female	9	(1.0)	11	1.87	13	(1.4)	15	1.99
Male	15	(1.2)	20	2.01	12	(1.0)	14	1.72
Hepatic steatosis								
Female	4	(0.4)	4	0.74	4	(0.4)	4	0.41
Male	7	(0.5)	7	0.63	6	(0.5)	6	0.73

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hepatomegaly								
Female	0				0			
Male	2	(0.2)	2	0.22	0			
Hepatic calcification								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Hepatic function abnormal								
Female	0				0			
Male	1	(0.1)	1	0.14	2	(0.2)	2	0.23
Cholecystitis chronic								
Female	0				1	(0.1)	1	0.19
Male	1	(0.1)	1	0.14	0			
Hyperplastic cholecystopathy								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Cholelithiasis								
Female	2	(0.2)	2	0.21	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	0			
Gallbladder cholesterolosis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Hypertransaminasaemia								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	2	0.15	0			
Liver disorder								
Female	0				1	(0.1)	1	0.19
Male	1	(0.1)	1	0.08	0			
Non-alcoholic steatohepatitis								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Alcoholic liver disease								
Female	0				0			
Male	1	(0.1)	1	0.13	0			
Bile duct stone								
Female	0				1	(0.1)	2	0.21
Male	0				0			
Biliary colic								
Female	0				0			
Male	0				1	(0.1)	1	0.14
Biliary dyskinesia								
Female	0				1	(0.1)	1	0.19

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Cholecystitis								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Gallbladder disorder								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Gallbladder polyp								
Female	2	(0.2)	2	0.42	0			
Male	0				3	(0.2)	3	0.46
Hepatic cirrhosis								
Female	0				1	(0.1)	1	0.17
Male	0				1	(0.1)	1	0.09
Hepatic cyst								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hepatic mass								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Nonalcoholic fatty liver disease								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.08
Steatohepatitis								
Female	0				1	(0.1)	1	0.10
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
Female	1	(0.1)	1	0.19	3	(0.3)	3	0.39
Male	5	(0.4)	5	0.57	2	(0.2)	2	0.15
Type V hyperlipidaemia								
Female	0				1	(0.1)	1	0.18
Male	3	(0.2)	3	0.35	0			
Cystic fibrosis lung								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Hydrocele								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Atrial septal defect								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Congenital syphilitic osteochondritis								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Corneal dystrophy								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Hypertrophic cardiomyopathy								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Myotonic dystrophy								
Female	0				1	(0.1)	1	0.10
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
Female	9	(1.0)	9	1.36	11	(1.1)	12	1.68
Male	5	(0.4)	6	0.63	5	(0.4)	5	0.68
Seasonal allergy								
Female	5	(0.6)	5	0.63	6	(0.6)	6	0.85
Male	3	(0.2)	3	0.29	3	(0.3)	3	0.39
Drug hypersensitivity								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Allergy to arthropod bite								
Female	0				0			
Male	1	(0.1)	1	0.08	2	(0.2)	2	0.29
Anaphylactic reaction								
Female	0				1	(0.1)	1	0.17
Male	1	(0.1)	1	0.13	0			
Allergy to arthropod sting								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Food allergy								
Female	1	(0.1)	1	0.10	1	(0.1)	1	0.10
Male	0				0			
Hypersensitivity								
Female	3	(0.3)	3	0.62	1	(0.1)	1	0.18
Male	0				0			
Immunisation reaction								
Female	0				1	(0.1)	2	0.20
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Surgical and medical procedures								
All								
Female	2	(0.2)	2	0.29	2	(0.2)	2	0.21
Male	4	(0.3)	4	0.55	4	(0.3)	4	0.45
Cardiac ablation								
Female	0				0			
Male	1	(0.1)	1	0.17	0			
Skin neoplasm excision								
Female	0				1	(0.1)	1	0.10
Male	1	(0.1)	1	0.17	0			
Tooth extraction								
Female	0				0			
Male	1	(0.1)	1	0.14	0			
Knee operation								
Female	0				0			
Male	1	(0.1)	1	0.08	0			
Cardiac pacemaker replacement								
Female	1	(0.1)	1	0.10	0			
Male	0				1	(0.1)	1	0.14
Large intestinal polypectomy								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Removal of foreign body								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Shoulder operation								
Female	1	(0.1)	1	0.19	0			
Male	0				0			
Spinal operation								
Female	0				0			
Male	0				1	(0.1)	1	0.08
Toe amputation								
Female	0				0			
Male	0				1	(0.1)	1	0.15
Endocrine disorders								
All								
Female	3	(0.3)	3	0.33	11	(1.1)	11	1.54
Male	3	(0.2)	3	0.35	8	(0.7)	8	0.77

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypogonadism								
Female	0				0			
Male	1	(0.1)	1	0.14	1	(0.1)	1	0.08
Hypothyroidism								
Female	1	(0.1)	1	0.10	2	(0.2)	2	0.39
Male	1	(0.1)	1	0.14	3	(0.2)	3	0.24
Thyroid mass								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.10
Male	1	(0.1)	1	0.08	1	(0.1)	1	0.14
Adrenal mass								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Adrenocortical insufficiency acute								
Female	0				2	(0.2)	2	0.36
Male	0				0			
Autoimmune thyroiditis								
Female	1	(0.1)	1	0.10	0			
Male	0				0			
Goitre								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.09
Hyperplasia adrenal								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hyperprolactinaemia								
Female	0				1	(0.1)	1	0.10
Male	0				0			
Hyperthyroidism								
Female	0				1	(0.1)	1	0.10
Male	0				1	(0.1)	1	0.09
Inappropriate antidiuretic hormone secretion								
Female	0				1	(0.1)	1	0.17
Male	0				0			
Secondary hypogonadism								
Female	0				0			
Male	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Social circumstances								
All								
Female	0				1	(0.1)	1	0.18
Male	0				0			
Menopause								
Female	0				1	(0.1)	1	0.18
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.4 Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
Female	777				831			
Male	1103				1047			
PYE (years)								
Female	636.24				678.98			
Male	902.68				857.48			
Events								
Female	491	(63.4)	1558	262.01	495	(59.4)	1655	254.77
Male	648	(58.6)	1920	223.10	578	(55.3)	1604	198.72
Infections and infestations								
All								
Female	261	(33.8)	387	64.11	262	(31.4)	408	62.36
Male	283	(25.6)	386	46.59	261	(25.0)	349	42.08
COVID-19								
Female	68	(8.8)	70	11.31	81	(9.7)	86	12.73
Male	84	(7.7)	85	9.99	79	(7.5)	79	8.76
Nasopharyngitis								
Female	38	(5.0)	43	7.41	40	(4.8)	46	7.43
Male	45	(4.0)	56	6.77	39	(3.8)	46	5.85
Upper respiratory tract infection								
Female	26	(3.4)	33	5.16	19	(2.3)	21	2.94
Male	36	(3.3)	42	4.87	26	(2.5)	27	3.43
Influenza								
Female	8	(1.0)	10	2.07	11	(1.3)	13	2.48
Male	20	(1.9)	21	2.99	17	(1.6)	18	2.68
Pneumonia								
Female	3	(0.4)	3	0.39	1	(0.1)	1	0.12
Male	11	(1.0)	11	1.45	5	(0.5)	5	0.66
Gastroenteritis								
Female	16	(2.1)	16	3.07	11	(1.3)	12	2.24
Male	10	(0.9)	10	1.36	5	(0.5)	5	0.61
Urinary tract infection								
Female	28	(3.6)	30	4.98	34	(4.1)	37	5.31
Male	9	(0.8)	10	1.35	10	(1.0)	11	1.32
Bronchitis								
Female	17	(2.2)	17	3.03	6	(0.7)	6	0.91
Male	9	(0.8)	10	1.18	11	(1.0)	11	1.38

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pharyngitis								
Female	8	(1.1)	9	1.39	6	(0.7)	8	1.42
Male	8	(0.7)	9	0.94	11	(1.1)	12	1.38
COVID-19 pneumonia								
Female	8	(1.0)	8	1.33	5	(0.6)	5	0.68
Male	6	(0.6)	6	0.74	5	(0.5)	5	0.59
Herpes zoster								
Female	4	(0.5)	4	0.51	3	(0.4)	3	0.43
Male	6	(0.5)	6	0.68	12	(1.2)	13	1.45
Otitis media								
Female	2	(0.3)	2	0.37	3	(0.4)	3	0.53
Male	5	(0.5)	5	0.70	1	(0.1)	1	0.10
Fungal infection								
Female	3	(0.4)	4	0.72	2	(0.2)	2	0.33
Male	4	(0.4)	4	0.50	0			
Sinusitis								
Female	10	(1.3)	12	1.96	11	(1.3)	13	1.98
Male	4	(0.4)	4	0.49	6	(0.6)	7	0.79
Viral infection								
Female	2	(0.3)	2	0.36	4	(0.5)	7	0.84
Male	4	(0.4)	4	0.43	5	(0.5)	5	0.54
Tooth abscess								
Female	3	(0.4)	3	0.57	4	(0.5)	4	0.57
Male	4	(0.4)	4	0.48	3	(0.3)	4	0.53
Rhinitis								
Female	3	(0.4)	3	0.49	4	(0.5)	6	0.94
Male	4	(0.4)	4	0.35	3	(0.3)	3	0.42
Tooth infection								
Female	5	(0.6)	7	1.08	3	(0.4)	3	0.53
Male	3	(0.3)	3	0.41	5	(0.5)	5	0.76
Respiratory tract infection								
Female	5	(0.7)	5	0.75	3	(0.4)	3	0.45
Male	3	(0.3)	3	0.41	3	(0.3)	3	0.36
Coronavirus infection								
Female	1	(0.1)	1	0.14	2	(0.2)	3	0.55
Male	3	(0.3)	3	0.27	2	(0.2)	3	0.30
Wound infection								
Female	0				1	(0.1)	1	0.21
Male	3	(0.3)	3	0.40	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Conjunctivitis								
Female	5	(0.7)	5	0.76	3	(0.4)	3	0.55
Male	3	(0.3)	3	0.34	4	(0.4)	4	0.46
Periodontitis								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.21
Male	3	(0.3)	3	0.41	5	(0.5)	5	0.62
Gastroenteritis viral								
Female	2	(0.3)	2	0.27	3	(0.4)	3	0.45
Male	3	(0.3)	3	0.34	1	(0.1)	1	0.09
Sepsis								
Female	0				1	(0.1)	1	0.12
Male	2	(0.2)	2	0.32	0			
Ear infection								
Female	2	(0.3)	2	0.37	3	(0.4)	3	0.53
Male	2	(0.2)	2	0.18	2	(0.2)	2	0.19
Furuncle								
Female	0				0			
Male	2	(0.2)	3	0.34	2	(0.2)	2	0.19
Skin infection								
Female	0				0			
Male	2	(0.2)	2	0.25	1	(0.1)	1	0.16
Cellulitis								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.21
Male	2	(0.2)	2	0.24	7	(0.7)	8	1.04
Helicobacter infection								
Female	0				1	(0.1)	1	0.12
Male	2	(0.2)	2	0.24	1	(0.1)	1	0.16
Subcutaneous abscess								
Female	0				0			
Male	2	(0.2)	2	0.24	2	(0.2)	3	0.29
Respiratory tract infection viral								
Female	7	(0.9)	7	1.37	5	(0.6)	6	1.19
Male	2	(0.2)	3	0.41	3	(0.3)	3	0.42
Candida infection								
Female	0				1	(0.1)	1	0.22
Male	2	(0.2)	2	0.18	0			
Gingivitis								
Female	0				2	(0.2)	2	0.33
Male	2	(0.2)	3	0.27	2	(0.2)	2	0.33

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Localised infection								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.20
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.09
Lower respiratory tract infection								
Female	3	(0.4)	3	0.41	1	(0.1)	3	0.35
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.10
Onychomycosis								
Female	0				3	(0.4)	3	0.36
Male	2	(0.2)	2	0.23	1	(0.1)	1	0.09
Tonsillitis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.23	1	(0.1)	1	0.17
Acute sinusitis								
Female	4	(0.5)	4	0.59	3	(0.4)	3	0.45
Male	1	(0.1)	1	0.09	0			
Clostridium difficile colitis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Clostridium difficile infection								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Fungal skin infection								
Female	1	(0.1)	1	0.23	1	(0.1)	1	0.22
Male	1	(0.1)	1	0.09	0			
Gangrene								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Laryngitis								
Female	2	(0.3)	2	0.27	3	(0.4)	3	0.54
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Paronychia								
Female	1	(0.1)	1	0.22	2	(0.2)	3	0.64
Male	1	(0.1)	1	0.09	0			
Peritonsillar abscess								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.17
Tinea cruris								
Female	0				0			
Male	1	(0.1)	1	0.09	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cystitis								
Female	11	(1.4)	12	2.04	14	(1.7)	16	2.51
Male	1	(0.1)	1	0.16	2	(0.2)	2	0.20
Erysipelas								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.16	1	(0.1)	2	0.32
Escherichia bacteraemia								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Genital infection								
Female	2	(0.2)	2	0.24	1	(0.1)	1	0.21
Male	1	(0.1)	1	0.16	0			
Suspected COVID-19								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Tinea pedis								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.17
Cholecystitis infective								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.09
Diabetic foot infection								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.09
Infected dermal cyst								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Osteomyelitis								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.16	0			
Pharyngotonsillitis								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.16	1	(0.1)	2	0.20
Pneumonia viral								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Pulmonary tuberculoma								
Female	0				0			
Male	1	(0.1)	1	0.16	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Respiratory syncytial virus infection								
Female	2	(0.3)	2	0.26	0			
Male	1	(0.1)	1	0.16	0			
Abscess								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Asymptomatic COVID-19								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.26
Balanitis candida								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Chlamydial infection								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Dermatophytosis of nail								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.19
Folliculitis								
Female	0				2	(0.2)	2	0.31
Male	1	(0.1)	1	0.09	0			
Genital infection fungal								
Female	0				2	(0.2)	2	0.24
Male	1	(0.1)	1	0.09	0			
Infected bite								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Laryngopharyngitis								
Female	0				1	(0.1)	2	0.24
Male	1	(0.1)	1	0.09	0			
Pericoronitis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Tracheitis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Viral upper respiratory tract infection								
Female	0				2	(0.2)	2	0.23
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Anal abscess								
Female	0				0			
Male	1	(0.1)	1	0.15	1	(0.1)	1	0.10
Enteritis infectious								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Gastrointestinal infection								
Female	1	(0.1)	1	0.22	2	(0.2)	3	0.36
Male	1	(0.1)	1	0.15	1	(0.1)	1	0.09
Kidney infection								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Paraspinal abscess								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Pulpitis dental								
Female	0				2	(0.2)	2	0.41
Male	1	(0.1)	1	0.15	2	(0.2)	2	0.26
Tinea versicolour								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Varicella zoster virus infection								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Abdominal abscess								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Abscess limb								
Female	1	(0.1)	1	0.23	1	(0.1)	1	0.20
Male	0				0			
Acarodermatitis								
Female	2	(0.2)	2	0.24	3	(0.4)	3	0.36
Male	0				1	(0.1)	1	0.09
Appendicitis								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.09
Bacteraemia								
Female	1	(0.1)	1	0.22	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bacterial infection								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.10
Bartholinitis								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Body tinea								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Breast abscess								
Female	0				3	(0.4)	3	0.45
Male	0				0			
Breast cellulitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Campylobacter gastroenteritis								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Chronic hepatitis C								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Chronic sinusitis								
Female	1	(0.1)	1	0.12	3	(0.3)	3	0.35
Male	0				0			
Chronic tonsillitis								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.10
Diverticulitis								
Female	0				5	(0.6)	5	0.59
Male	0				0			
Ear infection fungal								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Empyema								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Endophthalmitis								
Female	0				0			
Male	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Epididymitis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Escherichia urinary tract infection								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Eye infection								
Female	0				1	(0.1)	1	0.22
Male	0				2	(0.2)	2	0.33
Eye infection bacterial								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Fungal balanitis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Gastroenteritis norovirus								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Genital candidiasis								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Giardiasis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Helicobacter gastritis								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Herpes dermatitis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Herpes simplex								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				0			
Herpes virus infection								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Herpes zoster infection neurological								
Female	0				1	(0.1)	1	0.12
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hordeolum								
Female	2	(0.3)	2	0.27	2	(0.3)	2	0.33
Male	0				1	(0.1)	1	0.16
Infective iritis								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Injection site abscess								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Labyrinthitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Lyme disease								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Mastitis								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Nail infection								
Female	1	(0.1)	2	0.24	0			
Male	0				1	(0.1)	1	0.10
Oophoritis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Oral candidiasis								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Oral herpes								
Female	2	(0.3)	3	0.65	2	(0.2)	2	0.23
Male	0				0			
Oropharyngeal candidiasis								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Otitis externa								
Female	2	(0.2)	2	0.34	2	(0.2)	2	0.24
Male	0				1	(0.1)	1	0.09
Otitis media acute								
Female	0				1	(0.1)	1	0.22
Male	0				2	(0.2)	2	0.19

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Otitis media chronic								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Parotitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Peri-implantitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Post procedural infection								
Female	0				0			
Male	0				2	(0.2)	2	0.26
Post-acute COVID-19 syndrome								
Female	1	(0.1)	2	0.24	0			
Male	0				0			
Postoperative wound infection								
Female	1	(0.1)	1	0.22	0			
Male	0				1	(0.1)	1	0.09
Purulence								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Pustule								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Pyelonephritis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Rotavirus infection								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Salpingitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Sinusitis bacterial								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Skin bacterial infection								
Female	0				1	(0.1)	1	0.12
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin candida								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.21
Male	0				0			
Soft tissue infection								
Female	0				0			
Male	0				2	(0.2)	2	0.33
Sweat gland infection								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Tinea infection								
Female	2	(0.3)	2	0.35	0			
Male	0				0			
Urethritis								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Urosepsis								
Female	0				2	(0.3)	2	0.33
Male	0				0			
Vaginal infection								
Female	5	(0.6)	5	0.90	3	(0.4)	3	0.43
Male	0				0			
Varicella								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Viral pharyngitis								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.10
Viral rhinitis								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Viral tracheitis								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Vulvitis								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Vulvovaginal candidiasis								
Female	3	(0.4)	4	0.64	4	(0.5)	4	0.47
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vulvovaginal mycotic infection								
Female	2	(0.3)	2	0.36	0			
Male	0				0			
Musculoskeletal and connective tissue disorders								
All								
Female	109	(14.3)	163	27.92	125	(14.9)	184	27.61
Male	137	(12.3)	206	23.01	120	(11.5)	154	19.59
Back pain								
Female	25	(3.3)	26	4.64	28	(3.3)	30	4.76
Male	37	(3.3)	40	4.46	33	(3.2)	34	4.48
Arthralgia								
Female	23	(3.1)	27	4.46	25	(3.0)	28	4.37
Male	22	(2.0)	26	3.07	23	(2.2)	26	3.40
Pain in extremity								
Female	14	(1.8)	16	2.43	11	(1.3)	12	1.69
Male	17	(1.5)	17	1.70	20	(1.9)	25	3.52
Muscle spasms								
Female	9	(1.2)	9	1.38	4	(0.5)	4	0.57
Male	14	(1.2)	16	2.15	5	(0.5)	5	0.62
Myalgia								
Female	5	(0.6)	5	1.02	6	(0.7)	6	1.07
Male	9	(0.8)	9	1.06	3	(0.3)	3	0.36
Intervertebral disc protrusion								
Female	0				3	(0.4)	4	0.47
Male	8	(0.7)	12	1.20	3	(0.3)	3	0.42
Periarthritis								
Female	1	(0.1)	1	0.22	5	(0.6)	5	0.69
Male	7	(0.6)	7	0.68	1	(0.1)	1	0.10
Neck pain								
Female	9	(1.2)	9	1.57	7	(0.8)	7	0.92
Male	6	(0.5)	6	0.75	1	(0.1)	1	0.16
Osteoarthritis								
Female	15	(2.0)	17	2.79	17	(2.1)	20	3.24
Male	6	(0.5)	6	0.59	7	(0.7)	7	0.74
Tendonitis								
Female	3	(0.4)	3	0.49	0			
Male	5	(0.5)	7	0.80	4	(0.4)	4	0.52
Spinal osteoarthritis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	2	(0.3)	2	0.36	2	(0.3)	2	0.24
Male	4	(0.4)	4	0.43	3	(0.3)	4	0.37
Foot deformity								
Female	0				0			
Male	3	(0.3)	5	0.52	3	(0.3)	3	0.41
Arthritis								
Female	3	(0.4)	3	0.57	2	(0.2)	2	0.31
Male	3	(0.3)	3	0.27	4	(0.4)	4	0.60
Plantar fasciitis								
Female	1	(0.1)	1	0.14	0			
Male	3	(0.3)	4	0.41	3	(0.3)	3	0.28
Bursitis								
Female	2	(0.3)	2	0.37	2	(0.2)	2	0.23
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.10
Joint effusion								
Female	0				2	(0.2)	2	0.24
Male	2	(0.2)	3	0.41	0			
Tendon disorder								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.22
Male	2	(0.2)	2	0.25	0			
Osteochondrosis								
Female	0				4	(0.5)	4	0.67
Male	2	(0.2)	2	0.25	0			
Trigger finger								
Female	5	(0.6)	5	0.93	3	(0.4)	5	0.67
Male	2	(0.2)	2	0.32	2	(0.2)	2	0.19
Chondropathy								
Female	0				0			
Male	2	(0.2)	2	0.18	0			
Musculoskeletal pain								
Female	0				1	(0.1)	1	0.12
Male	2	(0.2)	2	0.25	0			
Intervertebral disc disorder								
Female	1	(0.1)	1	0.23	0			
Male	2	(0.2)	2	0.18	2	(0.2)	2	0.26
Musculoskeletal chest pain								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.10
Musculoskeletal stiffness								
Female	2	(0.3)	2	0.35	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.23	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Rotator cuff syndrome								
Female	3	(0.4)	3	0.49	2	(0.3)	2	0.24
Male	2	(0.2)	2	0.23	2	(0.2)	2	0.18
Spinal stenosis								
Female	2	(0.3)	3	0.60	2	(0.2)	2	0.24
Male	2	(0.2)	3	0.38	0			
Acquired claw toe								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Diastasis recti abdominis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Exostosis								
Female	2	(0.3)	2	0.26	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Facet joint syndrome								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Meniscopathy								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Muscular weakness								
Female	2	(0.3)	2	0.43	2	(0.2)	2	0.33
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.16
Polyarthritis								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	0			
Muscle contracture								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.16	0			
Torticollis								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16
Back disorder								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.16	0			
Costochondritis								
Female	0				1	(0.1)	1	0.21
Male	1	(0.1)	1	0.09	0			
Fibromyalgia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	0			
Groin pain								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Lumbar spinal stenosis								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Osteopenia								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Spinal pain								
Female	0				4	(0.5)	4	0.56
Male	1	(0.1)	1	0.09	0			
Synovial cyst								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Axillary mass								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.15	0			
Arthropathy								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Bone cyst								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.16
Bone pain								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Cervical spinal stenosis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Coccydynia								
Female	2	(0.3)	2	0.36	1	(0.1)	1	0.12
Male	0				0			
Dupuytren's contracture								
Female	0				1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.10
Fistula								
Female	1	(0.1)	1	0.14	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Flank pain								
Female	1	(0.1)	1	0.23	3	(0.4)	3	0.53
Male	0				3	(0.3)	4	0.44
Haemarthrosis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Intervertebral disc degeneration								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Intervertebral disc space narrowing								
Female	0				1	(0.1)	2	0.24
Male	0				0			
Jaw disorder								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Joint swelling								
Female	0				1	(0.1)	1	0.21
Male	0				2	(0.2)	2	0.26
Limb deformity								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Mastication disorder								
Female	0				1	(0.1)	2	0.23
Male	0				0			
Muscle twitching								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Myositis								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.22
Male	0				0			
Neuropathic arthropathy								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Nodal osteoarthritis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Osteochondritis								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Osteoporosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	2	(0.3)	2	0.46	0			
Male	0				0			
Pain in jaw								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Periostitis								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Polymyalgia rheumatica								
Female	1	(0.1)	1	0.23	1	(0.1)	3	0.59
Male	0				0			
Psoriatic arthropathy								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Rheumatoid arthritis								
Female	0				1	(0.1)	1	0.20
Male	0				1	(0.1)	1	0.09
Sacroiliitis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Scoliosis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Soft tissue swelling								
Female	1	(0.1)	3	0.69	0			
Male	0				0			
Spinal retrolisthesis								
Female	0				1	(0.1)	2	0.24
Male	0				0			
Tenosynovitis								
Female	1	(0.1)	1	0.14	7	(0.8)	7	1.00
Male	0				2	(0.2)	3	0.29
Tenosynovitis stenosans								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Vertebral osteophyte								
Female	0				1	(0.1)	1	0.12
Male	0				0			

Gastrointestinal disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
Female	117	(15.1)	191	31.22	106	(12.7)	153	23.12
Male	134	(12.1)	189	21.92	115	(11.0)	149	19.31
Diarrhoea								
Female	39	(5.1)	46	7.26	26	(3.1)	27	4.28
Male	45	(4.1)	56	6.90	25	(2.4)	25	3.31
Nausea								
Female	22	(2.9)	23	3.78	13	(1.6)	14	2.30
Male	15	(1.4)	15	1.75	14	(1.3)	15	1.77
Vomiting								
Female	14	(1.8)	22	4.04	8	(1.0)	10	1.47
Male	10	(0.9)	10	1.29	8	(0.8)	9	1.10
Toothache								
Female	3	(0.4)	3	0.41	3	(0.4)	5	0.92
Male	10	(0.9)	10	1.02	7	(0.7)	8	1.25
Gastrooesophageal reflux disease								
Female	4	(0.5)	4	0.61	6	(0.7)	6	0.98
Male	9	(0.8)	9	1.00	8	(0.8)	8	0.98
Constipation								
Female	10	(1.3)	11	2.00	9	(1.1)	9	1.34
Male	6	(0.5)	8	0.96	7	(0.7)	7	1.06
Dyspepsia								
Female	1	(0.1)	1	0.23	6	(0.7)	6	0.88
Male	6	(0.5)	6	0.72	2	(0.2)	2	0.25
Dental caries								
Female	5	(0.6)	6	0.77	3	(0.4)	3	0.44
Male	6	(0.5)	7	0.62	7	(0.7)	7	1.02
Abdominal pain								
Female	11	(1.4)	11	1.88	12	(1.5)	13	2.03
Male	5	(0.5)	5	0.52	6	(0.6)	6	0.83
Gastritis								
Female	3	(0.4)	3	0.46	4	(0.5)	4	0.65
Male	4	(0.4)	4	0.56	5	(0.5)	5	0.59
Abdominal pain upper								
Female	9	(1.1)	11	1.85	10	(1.2)	11	1.56
Male	4	(0.4)	4	0.43	5	(0.5)	5	0.60
Large intestine polyp								
Female	0				3	(0.4)	3	0.36
Male	4	(0.4)	4	0.42	3	(0.3)	4	0.46
Abdominal distension								
Female	3	(0.4)	3	0.39	2	(0.2)	2	0.34

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	4	(0.4)	4	0.43	2	(0.2)	2	0.26
Chronic gastritis								
Female	4	(0.5)	4	0.71	3	(0.4)	3	0.45
Male	4	(0.4)	4	0.48	1	(0.1)	1	0.10
Food poisoning								
Female	2	(0.2)	2	0.34	3	(0.4)	4	0.72
Male	3	(0.3)	3	0.33	1	(0.1)	1	0.16
Enterocolitis								
Female	0				0			
Male	3	(0.3)	4	0.35	0			
Inguinal hernia								
Female	0				0			
Male	2	(0.2)	2	0.18	1	(0.1)	2	0.20
Hypoaesthesia oral								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	4	0.64	0			
Diverticulum intestinal								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.09
Haemorrhoids								
Female	5	(0.7)	5	0.74	2	(0.2)	2	0.31
Male	2	(0.2)	2	0.25	1	(0.1)	1	0.17
Flatulence								
Female	2	(0.3)	2	0.35	2	(0.2)	2	0.43
Male	2	(0.2)	2	0.23	0			
Hyperaesthesia teeth								
Female	0				0			
Male	2	(0.2)	2	0.23	0			
Abdominal wall disorder								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Aphthous ulcer								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.09	0			
Diabetic gastropathy								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Dry mouth								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Eosinophilic oesophagitis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Haemorrhoidal haemorrhage								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Hiatus hernia								
Female	1	(0.1)	1	0.23	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Lip swelling								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Umbilical hernia								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.20
Abdominal discomfort								
Female	2	(0.3)	2	0.27	2	(0.2)	2	0.24
Male	1	(0.1)	1	0.16	3	(0.3)	4	0.59
Pancreatic duct dilatation								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Pancreatic failure								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Pancreatitis chronic								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.16	0			
Proctalgia								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Colitis ischaemic								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Frequent bowel movements								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Gastric polyps								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.17
Haematochezia								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.09	0			
Loose tooth								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Tooth impacted								
Female	0				1	(0.1)	1	0.21
Male	1	(0.1)	1	0.09	0			
Gingival bleeding								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Intra-abdominal haematoma								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.15	0			
Abdominal pain lower								
Female	4	(0.5)	4	0.72	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.09
Acid peptic disease								
Female	0				0			
Male	0				2	(0.2)	2	0.20
Anal fissure								
Female	1	(0.1)	1	0.12	0			
Male	0				2	(0.2)	2	0.19
Anal pruritus								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Colitis								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.10
Colitis microscopic								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	0				0			
Crohn's disease								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Diverticulum								
Female	1	(0.1)	1	0.23	2	(0.2)	2	0.23
Male	0				1	(0.1)	1	0.16
Duodenitis								
Female	0				0			
Male	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Enteritis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Epigastric discomfort								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Eructation								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.16
Faeces pale								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Gastric dilatation								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Gastric disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Gastric dysplasia								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Gastric mucosal hypertrophy								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Gastric ulcer								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Gastrointestinal angiodysplasia								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Gastrointestinal disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Gastrointestinal haemorrhage								
Female	1	(0.1)	1	0.12	0			
Male	0				2	(0.2)	2	0.25
Gastrointestinal inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Gastrointestinal sounds abnormal								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				1	(0.1)	1	0.16
Gingival disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Hyperchlorhydria								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Ileus								
Female	0				2	(0.2)	2	0.24
Male	0				0			
Impaired gastric emptying								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Intestinal dilatation								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Irritable bowel syndrome								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Melaena								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Mesenteric panniculitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Noninfective gingivitis								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Odynophagia								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Oesophageal pain								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Oesophagitis								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Oral discomfort								
Female	1	(0.1)	1	0.14	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral pain								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Pancreatic pseudocyst								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Pancreatitis								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				0			
Pancreatitis acute								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Peptic ulcer								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Periodontal disease								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.20
Male	0				1	(0.1)	1	0.16
Periodontal inflammation								
Female	0				0			
Male	0				1	(0.1)	2	0.20
Rectal polyp								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.09
Rectal prolapse								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Small intestinal obstruction								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Stomatitis								
Female	0				1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.10
Tongue rough								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Tooth disorder								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.16
Ulcerative gastritis								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				1	(0.1)	1	0.10
Upper gastrointestinal haemorrhage								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Vomiting projectile								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
General disorders and administration site conditions								
All								
Female	82	(10.6)	143	26.11	87	(10.4)	137	20.49
Male	117	(10.5)	170	20.15	87	(8.4)	124	14.86
Pyrexia								
Female	11	(1.5)	11	1.93	17	(2.0)	18	2.64
Male	21	(1.9)	22	2.41	20	(1.9)	21	2.67
Fatigue								
Female	14	(1.8)	16	2.83	8	(0.9)	8	1.20
Male	13	(1.2)	14	1.46	7	(0.7)	7	0.73
Injection site reaction								
Female	6	(0.8)	11	2.39	3	(0.4)	3	0.53
Male	9	(0.8)	18	2.72	3	(0.3)	5	0.52
Malaise								
Female	4	(0.5)	5	0.84	3	(0.3)	4	0.55
Male	9	(0.8)	10	1.02	9	(0.9)	12	1.46
Chest pain								
Female	6	(0.8)	6	0.93	3	(0.4)	3	0.35
Male	8	(0.7)	8	0.91	2	(0.2)	2	0.18
Vaccination site pain								
Female	2	(0.3)	2	0.37	2	(0.2)	2	0.23
Male	8	(0.7)	10	1.27	6	(0.6)	6	0.94
Oedema peripheral								
Female	10	(1.3)	10	1.75	2	(0.2)	2	0.24
Male	7	(0.6)	7	0.82	7	(0.7)	8	0.92
Medical device site dermatitis								
Female	0				3	(0.3)	3	0.35
Male	4	(0.4)	7	0.75	5	(0.5)	11	1.10
Medical device site haemorrhage								
Female	0				2	(0.2)	2	0.23
Male	4	(0.4)	4	0.35	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Medical device site bruise								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	4	(0.4)	6	0.65	0			
Injection site bruising								
Female	0				3	(0.4)	3	0.35
Male	3	(0.3)	3	0.41	2	(0.2)	2	0.25
Peripheral swelling								
Female	2	(0.3)	2	0.26	3	(0.4)	3	0.55
Male	3	(0.3)	4	0.50	1	(0.1)	1	0.10
Chest discomfort								
Female	5	(0.7)	5	0.86	1	(0.1)	1	0.21
Male	3	(0.3)	3	0.40	1	(0.1)	1	0.10
Influenza like illness								
Female	1	(0.1)	2	0.24	3	(0.4)	3	0.36
Male	3	(0.3)	3	0.46	0			
Asthenia								
Female	7	(0.9)	7	1.18	5	(0.6)	5	0.68
Male	3	(0.3)	3	0.39	3	(0.3)	3	0.43
Hunger								
Female	3	(0.4)	3	0.50	1	(0.1)	1	0.12
Male	3	(0.3)	4	0.35	1	(0.1)	1	0.17
Medical device site pruritus								
Female	1	(0.1)	1	0.14	0			
Male	3	(0.3)	3	0.32	1	(0.1)	1	0.10
Injection site haematoma								
Female	0				2	(0.2)	6	1.28
Male	2	(0.2)	6	0.96	1	(0.1)	2	0.32
Drug intolerance								
Female	1	(0.1)	1	0.14	0			
Male	2	(0.2)	2	0.18	0			
Injection site mass								
Female	0				0			
Male	2	(0.2)	2	0.18	0			
Chills								
Female	2	(0.3)	2	0.27	0			
Male	2	(0.2)	2	0.24	1	(0.1)	1	0.10
Injection site swelling								
Female	0				1	(0.1)	1	0.21
Male	2	(0.2)	2	0.31	0			
Feeling abnormal								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	2	(0.2)	4	0.43	0			
Pain								
Female	8	(1.0)	9	1.72	8	(1.0)	8	1.21
Male	2	(0.2)	2	0.23	6	(0.6)	7	0.87
Early satiety								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Injection site pruritus								
Female	3	(0.4)	18	3.79	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.16
Localised oedema								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Swelling face								
Female	0				1	(0.1)	1	0.21
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Inflammation								
Female	0				2	(0.2)	2	0.33
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.09
Injection site erythema								
Female	2	(0.3)	4	0.78	0			
Male	1	(0.1)	1	0.16	4	(0.4)	4	0.40
Injection site haemorrhage								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.21
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.10
Injection site pain								
Female	2	(0.3)	2	0.43	8	(1.0)	26	3.50
Male	1	(0.1)	1	0.16	4	(0.4)	4	0.57
Injection site rash								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16
Multiple organ dysfunction syndrome								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Xerosis								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Gait disturbance								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Implant site pruritus								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Injection site hypersensitivity								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	0			
Medical device site eczema								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.20
Medical device site hypersensitivity								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Medical device site reaction								
Female	3	(0.4)	3	0.67	0			
Male	1	(0.1)	3	0.27	1	(0.1)	1	0.10
Vaccination site reaction								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Medical device site erythema								
Female	1	(0.1)	1	0.23	2	(0.2)	2	0.33
Male	1	(0.1)	1	0.15	0			
Application site bruise								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Application site pruritus								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Axillary pain								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Condition aggravated								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Cyst								
Female	0				0			
Male	0				2	(0.2)	2	0.25
Death								
Female	0				3	(0.4)	3	0.36
Male	0				0			
Discomfort								
Female	2	(0.3)	2	0.35	1	(0.1)	8	1.72

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Facial pain								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Feeling hot								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.09
Hernia								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Injection site dermatitis								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Injection site hypertrophy								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Injection site induration								
Female	0				2	(0.3)	2	0.33
Male	0				0			
Injection site oedema								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Injection site urticaria								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Medical device site haematoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Medical device site inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Medical device site pain								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.16
Medical device site rash								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Non-cardiac chest pain								
Female	0				2	(0.3)	2	0.24
Male	0				2	(0.2)	4	0.37

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oedema								
Female	1	(0.1)	1	0.22	0			
Male	0				3	(0.3)	3	0.35
Oedema due to renal disease								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Procedural failure								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Swelling								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				0			
Systemic inflammatory response syndrome								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Thirst								
Female	3	(0.4)	3	0.57	1	(0.1)	1	0.21
Male	0				0			
Vaccination site erythema								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Vaccination site inflammation								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Vaccination site pruritus								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Vessel puncture site bruise								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Eye disorders								
All								
Female	53	(6.8)	66	11.35	60	(7.3)	80	14.03
Male	94	(8.5)	122	15.19	92	(8.8)	119	15.62
Diabetic retinopathy								
Female	14	(1.8)	14	2.78	20	(2.4)	21	3.84
Male	38	(3.5)	44	5.92	38	(3.6)	41	5.53
Cataract								
Female	11	(1.4)	14	2.05	12	(1.5)	13	1.98
Male	13	(1.2)	15	1.67	13	(1.2)	15	1.83

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Macular oedema								
Female	4	(0.5)	4	0.77	1	(0.1)	1	0.12
Male	5	(0.4)	5	0.63	3	(0.3)	3	0.34
Retinopathy hypertensive								
Female	2	(0.3)	2	0.44	0			
Male	4	(0.4)	5	0.59	5	(0.5)	5	0.75
Retinal haemorrhage								
Female	0				0			
Male	4	(0.4)	4	0.56	0			
Diabetic retinal oedema								
Female	0				5	(0.6)	6	1.18
Male	4	(0.4)	4	0.61	4	(0.4)	4	0.45
Eye pain								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.33
Male	3	(0.3)	3	0.34	1	(0.1)	1	0.10
Dry eye								
Female	3	(0.4)	3	0.47	4	(0.5)	4	0.56
Male	3	(0.3)	3	0.27	2	(0.2)	2	0.20
Vision blurred								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.41
Male	3	(0.3)	3	0.41	3	(0.3)	3	0.29
Glaucoma								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	2	0.18	3	(0.3)	3	0.36
Vitreous haemorrhage								
Female	0				0			
Male	2	(0.2)	2	0.31	2	(0.2)	2	0.26
Blepharitis								
Female	3	(0.4)	3	0.47	0			
Male	2	(0.2)	2	0.18	0			
Age-related macular degeneration								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	1	0.09	0			
Amaurosis fugax								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Angle closure glaucoma								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Arteriosclerotic retinopathy								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Conjunctival hyperaemia								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Maculopathy								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Vitreous detachment								
Female	2	(0.3)	2	0.36	0			
Male	1	(0.1)	1	0.09	0			
Vitreous opacities								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Conjunctivitis allergic								
Female	1	(0.1)	2	0.27	0			
Male	1	(0.1)	1	0.16	0			
Eye inflammation								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.16	2	(0.2)	2	0.33
Non-proliferative retinopathy								
Female	0				0			
Male	1	(0.1)	2	0.32	2	(0.2)	2	0.33
Diplopia								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16
Presbyopia								
Female	0				0			
Male	1	(0.1)	1	0.16	2	(0.2)	2	0.34
Retinal deposits								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Retinal scar								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Acquired epiblepharon								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Asthenopia								
Female	0				0			
Male	1	(0.1)	1	0.09	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Astigmatism								
Female	1	(0.1)	2	0.24	2	(0.2)	2	0.34
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.26
Conjunctival erosion								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Optic disc vascular disorder								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Post thrombotic retinopathy								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Posterior capsule opacification								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Retinal aneurysm								
Female	0				1	(0.1)	1	0.21
Male	1	(0.1)	1	0.09	0			
Retinal tear								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Cataract nuclear								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Eye irritation								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Lacrimation increased								
Female	0				1	(0.1)	1	0.21
Male	1	(0.1)	1	0.15	0			
Ocular hyperaemia								
Female	1	(0.1)	2	0.43	0			
Male	1	(0.1)	1	0.15	1	(0.1)	2	0.32
Ocular hypertension								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.15	1	(0.1)	1	0.10
Chorioretinal atrophy								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Conjunctival haemorrhage								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	2	(0.3)	2	0.37	0			
Male	0				0			
Conjunctival suffusion								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Corneal bleeding								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Corneal erosion								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Cystoid macular oedema								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Dacryoadenitis acquired								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Dry age-related macular degeneration								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Epiretinal membrane								
Female	1	(0.1)	1	0.23	2	(0.3)	2	0.33
Male	0				0			
Eye discharge								
Female	0				0			
Male	0				2	(0.2)	2	0.26
Eye pruritus								
Female	0				0			
Male	0				1	(0.1)	2	0.32
Eyelid oedema								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hypermetropia								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Macular degeneration								
Female	0				0			
Male	0				3	(0.3)	3	0.34
Macular hole								
Female	0				1	(0.1)	1	0.21
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Meibomianitis								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Myopia								
Female	1	(0.1)	1	0.23	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.09
Normal tension glaucoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Ocular ischaemic syndrome								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Open angle glaucoma								
Female	0				0			
Male	0				1	(0.1)	2	0.33
Ophthalmic vein thrombosis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Optic disc haemorrhage								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Photophobia								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Retinal artery occlusion								
Female	0				0			
Male	0				2	(0.2)	2	0.19
Retinal degeneration								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.21
Male	0				0			
Retinal detachment								
Female	0				0			
Male	0				2	(0.2)	2	0.26
Retinal drusen								
Female	1	(0.1)	1	0.22	0			
Male	0				1	(0.1)	1	0.16
Retinal exudates								
Female	1	(0.1)	1	0.23	0			
Male	0				2	(0.2)	2	0.33
Retinal vascular disorder								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				1	(0.1)	1	0.22
Male	0				0			
Retinal vein occlusion								
Female	1	(0.1)	1	0.23	0			
Male	0				1	(0.1)	1	0.10
Retinopathy								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Scintillating scotoma								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Uveitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Visual acuity reduced								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Visual impairment								
Female	1	(0.1)	1	0.12	2	(0.2)	10	2.05
Male	0				0			
Vitreous degeneration								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Vitreous floaters								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Nervous system disorders								
All								
Female	87	(11.4)	118	21.13	90	(10.8)	128	21.08
Male	93	(8.4)	134	15.37	93	(9.0)	120	14.92
Dizziness								
Female	13	(1.7)	17	2.96	19	(2.3)	22	3.58
Male	25	(2.3)	31	3.66	18	(1.7)	22	2.97
Headache								
Female	33	(4.3)	41	7.83	28	(3.4)	32	5.25
Male	24	(2.2)	32	3.90	26	(2.5)	35	4.34
Tremor								
Female	4	(0.5)	4	0.59	5	(0.6)	9	1.82
Male	7	(0.6)	8	0.78	3	(0.3)	3	0.42

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypoaesthesia								
Female	3	(0.4)	3	0.49	7	(0.8)	8	1.21
Male	6	(0.5)	9	1.08	2	(0.2)	2	0.25
Paraesthesia								
Female	3	(0.4)	3	0.49	7	(0.9)	7	1.21
Male	5	(0.5)	6	0.54	5	(0.5)	5	0.67
Carpal tunnel syndrome								
Female	6	(0.8)	6	1.14	6	(0.7)	6	1.10
Male	5	(0.5)	5	0.45	1	(0.1)	1	0.10
Sciatica								
Female	9	(1.2)	9	1.53	6	(0.7)	7	0.92
Male	4	(0.4)	4	0.57	6	(0.6)	6	0.80
Diabetic neuropathy								
Female	2	(0.3)	2	0.35	5	(0.6)	5	0.87
Male	3	(0.3)	3	0.41	7	(0.7)	7	0.87
Dysgeusia								
Female	0				0			
Male	3	(0.3)	3	0.34	0			
Syncope								
Female	3	(0.4)	3	0.41	1	(0.1)	1	0.12
Male	3	(0.3)	3	0.32	0			
Migraine								
Female	4	(0.5)	4	0.81	2	(0.2)	2	0.43
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.10
Amnesia								
Female	0				0			
Male	2	(0.2)	2	0.25	0			
Neuralgia								
Female	0				1	(0.1)	1	0.12
Male	2	(0.2)	2	0.24	0			
Neuropathy peripheral								
Female	4	(0.5)	5	0.90	4	(0.5)	4	0.66
Male	2	(0.2)	2	0.25	5	(0.5)	5	0.54
Carotid artery stenosis								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Cluster headache								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Disturbance in attention								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.09	0			
Intracranial pressure increased								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Transient ischaemic attack								
Female	2	(0.3)	2	0.35	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.26
Cerebral arteriosclerosis								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Cerebrovascular disorder								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.16	0			
Vascular encephalopathy								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Balance disorder								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Burning sensation								
Female	1	(0.1)	1	0.14	2	(0.2)	2	0.31
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Cerebral haemorrhage								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Cervical radiculopathy								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Dizziness postural								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.09	0			
Lumbar radiculopathy								
Female	0				2	(0.2)	3	0.36
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.20
Memory impairment								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.22
Male	1	(0.1)	1	0.09	0			
Presyncope								
Female	0				2	(0.2)	2	0.23
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tension headache								
Female	2	(0.3)	2	0.37	0			
Male	1	(0.1)	2	0.18	0			
Carotid artery aneurysm								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Cervicobrachial syndrome								
Female	0				0			
Male	1	(0.1)	1	0.15	1	(0.1)	1	0.09
Post herpetic neuralgia								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.15	0			
Thalamic infarction								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Ageusia								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Anosmia								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.16
Autonomic nervous system imbalance								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Basilar migraine								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Brain injury								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Carotid arteriosclerosis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Cerebral artery embolism								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Cerebral atrophy								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.10
Cerebral infarction								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				1	(0.1)	1	0.17
Cerebrovascular accident								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.09
Cognitive disorder								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.22
Male	0				0			
Dementia Alzheimer's type								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Essential tremor								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Facial nerve disorder								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Facial paralysis								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Hemiparesis								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Hypoglycaemic coma								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Hyporeflexia								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Ischaemic stroke								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Lethargy								
Female	0				2	(0.2)	2	0.23
Male	0				0			
Loss of consciousness								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Mental impairment								
Female	0				0			
Male	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Meralgia paraesthetica								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Morton's neuralgia								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Myelopathy								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Neuroglycopenia								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	3	0.30
Ophthalmic migraine								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Orthostatic tremor								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Parkinsonian gait								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Peripheral paralysis								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Piriformis syndrome								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Radiculopathy								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Restless legs syndrome								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Sleep deficit								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Somnolence								
Female	1	(0.1)	1	0.23	0			
Male	0				1	(0.1)	1	0.10
Thrombotic stroke								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				2	(0.2)	2	0.27
Trigeminal neuralgia								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Vascular headache								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Vertebral artery occlusion								
Female	0				1	(0.1)	1	0.12
Male	0				0			
White matter lesion								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Injury, poisoning and procedural complications								
All								
Female	72	(9.4)	94	16.28	63	(7.5)	74	11.56
Male	92	(8.3)	110	12.59	84	(8.0)	104	13.83
Contusion								
Female	3	(0.4)	3	0.39	2	(0.2)	2	0.23
Male	11	(1.0)	12	1.40	5	(0.5)	5	0.55
Fall								
Female	10	(1.3)	10	1.58	4	(0.5)	4	0.63
Male	9	(0.8)	9	0.99	6	(0.6)	7	0.78
Vaccination complication								
Female	6	(0.8)	10	2.03	12	(1.4)	16	2.07
Male	9	(0.8)	9	0.93	9	(0.9)	11	1.50
Skin laceration								
Female	1	(0.1)	1	0.22	0			
Male	6	(0.5)	6	0.65	0			
Skin abrasion								
Female	3	(0.4)	5	0.71	0			
Male	5	(0.4)	5	0.63	4	(0.4)	4	0.59
Hand fracture								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.12
Male	4	(0.4)	4	0.55	0			
Accidental overdose								
Female	3	(0.4)	3	0.58	2	(0.2)	3	0.64
Male	4	(0.4)	4	0.54	1	(0.1)	1	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ligament sprain								
Female	6	(0.8)	6	1.15	4	(0.5)	4	0.74
Male	3	(0.3)	3	0.33	4	(0.4)	4	0.52
Road traffic accident								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.12
Male	3	(0.3)	3	0.33	0			
Joint injury								
Female	2	(0.3)	2	0.44	2	(0.2)	2	0.32
Male	3	(0.3)	3	0.32	2	(0.2)	2	0.19
Ankle fracture								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.18	2	(0.2)	2	0.18
Back injury								
Female	0				0			
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.09
Upper limb fracture								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	2	0.18	0			
Medication error								
Female	0				1	(0.1)	1	0.21
Male	2	(0.2)	2	0.32	1	(0.1)	1	0.16
Incorrect dose administered								
Female	1	(0.1)	1	0.22	2	(0.3)	2	0.33
Male	2	(0.2)	2	0.32	3	(0.3)	5	0.81
Procedural pain								
Female	2	(0.3)	2	0.43	0			
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.16
Limb injury								
Female	3	(0.4)	3	0.49	3	(0.4)	3	0.55
Male	2	(0.2)	2	0.25	3	(0.3)	4	0.59
Thermal burn								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.31	1	(0.1)	1	0.16
Wound								
Female	1	(0.1)	1	0.14	0			
Male	2	(0.2)	2	0.25	5	(0.5)	5	0.75
Injury								
Female	0				0			
Male	2	(0.2)	2	0.18	0			
Meniscus injury								
Female	0				2	(0.2)	2	0.34

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	2	(0.2)	2	0.18	3	(0.3)	3	0.27
Overdose								
Female	2	(0.3)	2	0.45	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.23	2	(0.2)	2	0.32
Rib fracture								
Female	2	(0.2)	2	0.34	4	(0.5)	4	0.66
Male	2	(0.2)	2	0.23	1	(0.1)	1	0.09
Bone contusion								
Female	0				1	(0.1)	1	0.20
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Hip fracture								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	0			
Inflammation of wound								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Injury of conjunctiva								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Multiple injuries								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Muscle injury								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.17
Neck injury								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Penile contusion								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Post procedural haematuria								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Post procedural inflammation								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Tendon rupture								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.17

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Accidental underdose								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Arthropod bite								
Female	2	(0.3)	2	0.45	1	(0.1)	1	0.22
Male	1	(0.1)	1	0.16	2	(0.2)	2	0.26
Foot fracture								
Female	2	(0.2)	2	0.34	3	(0.3)	3	0.43
Male	1	(0.1)	1	0.16	0			
Subdural haematoma								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Tooth fracture								
Female	3	(0.4)	3	0.48	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16
Wrong product administered								
Female	0				0			
Male	1	(0.1)	2	0.32	2	(0.2)	2	0.32
Burns first degree								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Cervical vertebral fracture								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Eye injury								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Fibula fracture								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Post procedural haemorrhage								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Radius fracture								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Facial bones fracture								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Wrist fracture								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.15	1	(0.1)	1	0.10
Animal bite								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.22
Male	0				2	(0.2)	2	0.19
Arthropod sting								
Female	3	(0.4)	3	0.48	0			
Male	0				1	(0.1)	1	0.17
Burn oral cavity								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Chillblains								
Female	1	(0.1)	1	0.22	0			
Male	0				1	(0.1)	1	0.10
Concussion								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.16
Craniocerebral injury								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Crush injury								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Deafness traumatic								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Endotracheal intubation complication								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Epicondylitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Exposure to SARS-CoV-2								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Extra dose administered								
Female	1	(0.1)	1	0.22	0			
Male	0				1	(0.1)	1	0.16
Face injury								
Female	1	(0.1)	1	0.23	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Femoral neck fracture								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Gun shot wound								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Head injury								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Heat illness								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				2	(0.2)	3	0.37
Humerus fracture								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Intentional overdose								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Intentional product use issue								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Ligament rupture								
Female	1	(0.1)	2	0.43	0			
Male	0				0			
Lower limb fracture								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Muscle contusion								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Muscle strain								
Female	1	(0.1)	1	0.14	2	(0.2)	2	0.33
Male	0				2	(0.2)	2	0.25
Periprocedural myocardial infarction								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Post procedural complication								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Post procedural fistula								
Female	1	(0.1)	1	0.14	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Post procedural hypothyroidism								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Post procedural stroke								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Post procedural swelling								
Female	0				0			
Male	0				1	(0.1)	2	0.20
Post-traumatic neck syndrome								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Procedural complication								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Product administration error								
Female	0				0			
Male	0				2	(0.2)	2	0.25
Radiation skin injury								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Scar								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Scratch								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Seroma								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Soft tissue injury								
Female	0				1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.09
Spinal column injury								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Spinal compression fracture								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Stab wound								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Subcutaneous haematoma								
Female	1	(0.1)	1	0.23	0			
Male	0				1	(0.1)	1	0.16
Sunburn								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Tendon injury								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Tibia fracture								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Traumatic haematoma								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Underdose								
Female	1	(0.1)	1	0.23	4	(0.5)	4	0.72
Male	0				1	(0.1)	1	0.17
Wrong dose								
Female	0				0			
Male	0				2	(0.2)	2	0.32
Metabolism and nutrition disorders								
All								
Female	55	(7.0)	70	10.98	65	(7.8)	87	13.43
Male	69	(6.3)	83	9.34	60	(5.8)	71	8.75
Dyslipidaemia								
Female	9	(1.2)	9	1.53	9	(1.1)	9	1.54
Male	12	(1.1)	13	1.58	8	(0.8)	8	1.17
Hypoglycaemia								
Female	4	(0.5)	5	0.94	12	(1.4)	23	3.32
Male	9	(0.8)	14	1.95	8	(0.8)	13	1.76
Vitamin B12 deficiency								
Female	4	(0.5)	4	0.48	1	(0.1)	1	0.12
Male	7	(0.7)	7	0.63	0			
Hyperlipidaemia								
Female	7	(0.9)	7	1.14	6	(0.7)	6	0.89
Male	7	(0.6)	7	0.75	7	(0.7)	7	0.82

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypertriglyceridaemia								
Female	5	(0.6)	5	0.83	3	(0.4)	3	0.64
Male	5	(0.4)	5	0.52	5	(0.5)	5	0.56
Vitamin D deficiency								
Female	12	(1.5)	12	1.57	8	(1.0)	8	1.05
Male	4	(0.4)	4	0.36	4	(0.4)	4	0.44
Hyperkalaemia								
Female	4	(0.5)	5	0.86	4	(0.5)	4	0.57
Male	4	(0.4)	4	0.43	6	(0.6)	6	0.85
Hyperglycaemia								
Female	2	(0.2)	2	0.34	11	(1.3)	11	1.94
Male	4	(0.4)	5	0.70	3	(0.3)	3	0.36
Gout								
Female	1	(0.1)	1	0.12	0			
Male	3	(0.3)	4	0.36	6	(0.6)	7	0.66
Iron deficiency								
Female	2	(0.2)	2	0.24	2	(0.3)	2	0.24
Male	3	(0.3)	3	0.27	1	(0.1)	1	0.09
Increased appetite								
Female	0				3	(0.4)	4	0.75
Male	3	(0.3)	3	0.27	3	(0.3)	3	0.41
Decreased appetite								
Female	1	(0.1)	1	0.14	3	(0.4)	3	0.45
Male	3	(0.3)	3	0.34	2	(0.2)	2	0.18
Hyperuricaemia								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.24	2	(0.2)	2	0.19
Dehydration								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Diabetes mellitus								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Diabetes mellitus inadequate control								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Hypernatraemia								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Magnesium deficiency								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Malnutrition								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Fluid retention								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.16	0			
Hyponatraemia								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16
Hypercholesterolaemia								
Female	2	(0.3)	2	0.44	1	(0.1)	1	0.20
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.26
Abnormal weight gain								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Appetite disorder								
Female	0				0			
Male	0				1	(0.1)	2	0.20
Electrolyte imbalance								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Folate deficiency								
Female	2	(0.2)	2	0.24	1	(0.1)	1	0.12
Male	0				0			
Food craving								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Hyperammonaemia								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Hypercalcaemia								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hypoalbuminaemia								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Hypokalaemia								
Female	2	(0.3)	2	0.36	1	(0.1)	1	0.12
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Insulin resistance								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Lactic acidosis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Lipomatosis								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Metabolic acidosis								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Metabolic disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Obesity								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.16
Vitamin B complex deficiency								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Zinc deficiency								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.12
Male	0				0			
Respiratory, thoracic and mediastinal disorders								
All								
Female	45	(5.8)	57	9.28	48	(5.8)	55	8.67
Male	66	(5.9)	94	11.11	53	(5.1)	69	8.46
Cough								
Female	11	(1.4)	11	1.77	9	(1.1)	9	1.36
Male	12	(1.1)	13	1.48	11	(1.1)	12	1.43
Oropharyngeal pain								
Female	10	(1.3)	10	1.47	8	(0.9)	9	1.50
Male	9	(0.8)	11	1.19	8	(0.8)	9	1.15
Rhinorrhoea								
Female	3	(0.4)	4	0.61	1	(0.1)	1	0.12
Male	7	(0.6)	9	1.14	6	(0.6)	6	0.71
Sleep apnoea syndrome								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.23	0			
Male	6	(0.5)	6	0.61	0			
Dyspnoea								
Female	4	(0.5)	4	0.57	10	(1.2)	11	1.79
Male	5	(0.5)	5	0.73	3	(0.3)	3	0.36
Nasal congestion								
Female	5	(0.6)	5	0.73	2	(0.2)	2	0.24
Male	5	(0.4)	5	0.50	2	(0.2)	2	0.19
Chronic obstructive pulmonary disease								
Female	0				1	(0.1)	1	0.12
Male	4	(0.4)	4	0.54	0			
Sinus congestion								
Female	1	(0.1)	1	0.12	0			
Male	3	(0.3)	4	0.50	1	(0.1)	1	0.10
Productive cough								
Female	1	(0.1)	1	0.23	0			
Male	3	(0.3)	3	0.33	2	(0.2)	2	0.27
Epistaxis								
Female	2	(0.3)	2	0.45	1	(0.1)	2	0.23
Male	3	(0.3)	7	1.04	1	(0.1)	2	0.33
Acute respiratory failure								
Female	1	(0.1)	1	0.14	0			
Male	2	(0.2)	2	0.24	1	(0.1)	1	0.10
Asthma								
Female	3	(0.4)	3	0.55	0			
Male	2	(0.2)	3	0.34	1	(0.1)	1	0.16
Pulmonary fibrosis								
Female	0				0			
Male	2	(0.2)	3	0.34	0			
Nasal septum deviation								
Female	0				0			
Male	2	(0.2)	2	0.31	1	(0.1)	1	0.16
Sneezing								
Female	0				0			
Male	2	(0.2)	2	0.23	0			
Increased viscosity of upper respiratory secretion								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Upper respiratory tract inflammation								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Emphysema								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16
Pulmonary hypertension								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Respiratory disorder								
Female	3	(0.4)	3	0.57	4	(0.5)	4	0.66
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.10
Acquired diaphragmatic eventration								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Dyspnoea exertional								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Interstitial lung disease								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	0			
Nasal dryness								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Nasal turbinate hypertrophy								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Pulmonary mass								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	3	(0.3)	3	0.41
Sinus pain								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	2	0.18	1	(0.1)	1	0.16
Throat irritation								
Female	0				1	(0.1)	1	0.21
Male	1	(0.1)	1	0.09	0			
Respiratory failure								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.15	1	(0.1)	1	0.09
Acute pulmonary oedema								
Female	0				0			
Male	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Allergic bronchitis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Allergic cough								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Aphonia								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Bronchiectasis								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Bronchitis chronic								
Female	0				2	(0.2)	2	0.33
Male	0				0			
Bronchospasm								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.21
Male	0				0			
Dry throat								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Dysphonia								
Female	0				0			
Male	0				1	(0.1)	2	0.32
Haemoptysis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Laryngeal cyst								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Lung disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Nasal obstruction								
Female	1	(0.1)	1	0.23	0			
Male	0				1	(0.1)	1	0.09
Paranasal cyst								
Female	0				2	(0.2)	2	0.43
Male	0				0			
Paranasal sinus discomfort								
Female	0				1	(0.1)	1	0.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Pleural disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Pleural effusion								
Female	0				1	(0.1)	1	0.12
Male	0				2	(0.2)	2	0.19
Pleurisy								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Pleuritic pain								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Pulmonary embolism								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Respiratory tract inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Rhinitis allergic								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.43
Male	0				3	(0.3)	7	0.82
Upper-airway cough syndrome								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Skin and subcutaneous tissue disorders								
All								
Female	38	(5.0)	41	6.92	57	(6.8)	70	10.30
Male	61	(5.5)	66	7.34	47	(4.5)	53	6.27
Rash								
Female	3	(0.4)	3	0.36	6	(0.7)	7	0.91
Male	8	(0.7)	8	1.03	5	(0.5)	5	0.55
Eczema								
Female	4	(0.5)	4	0.71	3	(0.4)	3	0.54
Male	6	(0.5)	6	0.59	3	(0.3)	3	0.42
Hyperhidrosis								
Female	3	(0.4)	3	0.67	3	(0.4)	3	0.43
Male	5	(0.5)	5	0.52	2	(0.2)	2	0.25
Pruritus								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	3	(0.4)	3	0.47	7	(0.9)	7	1.12
Male	5	(0.5)	5	0.59	4	(0.4)	4	0.51
Urticaria								
Female	2	(0.2)	2	0.34	6	(0.7)	6	0.81
Male	5	(0.4)	5	0.62	3	(0.3)	3	0.28
Skin ulcer								
Female	0				0			
Male	4	(0.4)	4	0.50	5	(0.5)	5	0.74
Cold sweat								
Female	1	(0.1)	1	0.14	3	(0.4)	3	0.45
Male	3	(0.3)	3	0.41	0			
Dermatitis contact								
Female	2	(0.3)	3	0.41	6	(0.7)	6	0.90
Male	3	(0.3)	3	0.27	2	(0.2)	2	0.20
Dermatitis allergic								
Female	0				0			
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.16
Ingrowing nail								
Female	0				2	(0.2)	2	0.23
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.09
Night sweats								
Female	1	(0.1)	1	0.22	0			
Male	2	(0.2)	2	0.18	0			
Dermatitis								
Female	1	(0.1)	1	0.12	5	(0.6)	6	0.98
Male	2	(0.2)	2	0.25	1	(0.1)	1	0.10
Dry skin								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.18	3	(0.3)	3	0.34
Skin irritation								
Female	0				0			
Male	2	(0.2)	3	0.27	2	(0.2)	2	0.18
Diabetic foot								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.19
Erythema								
Female	0				3	(0.4)	3	0.45
Male	1	(0.1)	1	0.09	0			
Livedo reticularis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Nail bed inflammation								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Acne								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.16	0			
Decubitus ulcer								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.16	0			
Ecchymosis								
Female	0				2	(0.2)	2	0.23
Male	1	(0.1)	1	0.16	0			
Rash erythematous								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Alopecia								
Female	4	(0.5)	4	0.72	3	(0.4)	3	0.45
Male	1	(0.1)	1	0.09	0			
Granuloma annulare								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Psoriasis								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.25
Skin exfoliation								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Urticaria contact								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Miliaria								
Female	1	(0.1)	1	0.23	2	(0.2)	2	0.23
Male	1	(0.1)	1	0.15	2	(0.2)	2	0.20
Actinic keratosis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Alopecia areata								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Angioedema								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): OTMTDURY SEX; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS AEDECOD SEX; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.10
Asteatosis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Blister								
Female	1	(0.1)	1	0.23	0			
Male	0				2	(0.2)	2	0.26
Cold urticaria								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Dermal cyst								
Female	0				2	(0.2)	2	0.23
Male	0				1	(0.1)	1	0.17
Drug eruption								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Haemorrhage subcutaneous								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hidradenitis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Hyperkeratosis								
Female	2	(0.3)	2	0.35	1	(0.1)	1	0.22
Male	0				0			
Intertrigo								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Lentigo								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Leukoplakia								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Lipodystrophy acquired								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Lipohypertrophy								
Female	0				1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Macule								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Myxoid cyst								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Neurodermatitis								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Pruritus allergic								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Purpura								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Rash maculo-papular								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Rash papular								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Seborrhoea								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Skin discolouration								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Skin fissures								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Skin lesion								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.10
Skin odour abnormal								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Skin reaction								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Umbilical haematoma								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Urticaria thermal								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Cardiac disorders								
All								
Female	29	(3.7)	41	5.93	31	(3.7)	47	7.03
Male	57	(5.2)	83	8.74	48	(4.6)	62	6.88
Coronary artery disease								
Female	3	(0.4)	3	0.39	4	(0.5)	4	0.67
Male	9	(0.8)	9	0.93	6	(0.6)	6	0.55
Acute myocardial infarction								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.23
Male	8	(0.7)	8	0.91	6	(0.6)	6	0.78
Atrial fibrillation								
Female	4	(0.5)	5	0.65	2	(0.2)	2	0.33
Male	8	(0.7)	8	0.77	4	(0.4)	4	0.39
Cardiac failure								
Female	2	(0.3)	2	0.26	2	(0.2)	3	0.55
Male	6	(0.5)	6	0.61	0			
Myocardial infarction								
Female	1	(0.1)	1	0.22	2	(0.2)	2	0.24
Male	5	(0.4)	5	0.57	2	(0.2)	2	0.19
Cardiac failure congestive								
Female	0				0			
Male	4	(0.4)	4	0.41	2	(0.2)	3	0.49
Angina pectoris								
Female	3	(0.4)	3	0.38	2	(0.2)	2	0.34
Male	3	(0.3)	3	0.34	2	(0.2)	2	0.19
Myocardial ischaemia								
Female	0				2	(0.2)	2	0.24
Male	3	(0.3)	3	0.41	0			
Acute coronary syndrome								
Female	1	(0.1)	1	0.12	0			
Male	3	(0.3)	3	0.27	0			
Ventricular extrasystoles								
Female	2	(0.3)	2	0.27	0			
Male	3	(0.3)	3	0.27	2	(0.2)	3	0.28

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Arrhythmia								
Female	0				1	(0.1)	1	0.12
Male	2	(0.2)	2	0.18	2	(0.2)	2	0.26
Atrioventricular block first degree								
Female	0				0			
Male	2	(0.2)	2	0.25	0			
Bundle branch block left								
Female	0				1	(0.1)	1	0.22
Male	2	(0.2)	2	0.25	0			
Left ventricular hypertrophy								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.22
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.10
Supraventricular extrasystoles								
Female	1	(0.1)	1	0.22	0			
Male	2	(0.2)	2	0.25	2	(0.2)	2	0.19
Angina unstable								
Female	1	(0.1)	1	0.14	0			
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.10
Palpitations								
Female	5	(0.7)	5	0.74	4	(0.5)	4	0.57
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Tachycardia								
Female	2	(0.2)	2	0.24	3	(0.4)	3	0.36
Male	1	(0.1)	1	0.09	4	(0.4)	4	0.57
Cardio-respiratory arrest								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Mitral valve stenosis								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Aortic valve sclerosis								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Aortic valve incompetence								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Atrial flutter								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Atrial thrombosis								
Female	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.09	0			
Bradycardia								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.27
Bundle branch block right								
Female	0				2	(0.2)	2	0.34
Male	1	(0.1)	1	0.09	4	(0.4)	5	0.55
Cardiac failure chronic								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Cardiac ventricular thrombosis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Chronic coronary syndrome								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Coronary artery occlusion								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	0			
Diastolic dysfunction								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Left ventricular dysfunction								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.26
Mitral valve incompetence								
Female	2	(0.2)	2	0.34	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Sinus tachycardia								
Female	0				2	(0.3)	2	0.24
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Cardiac flutter								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Aortic valve calcification								
Female	0				2	(0.2)	2	0.33
Male	0				0			
Arteriosclerosis coronary artery								
Female	1	(0.1)	1	0.12	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Atrial enlargement								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Atrioventricular block complete								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Cardiac arrest								
Female	0				0			
Male	0				2	(0.2)	2	0.18
Cardiac dysfunction								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Cardiac failure acute								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Cardiac perfusion defect								
Female	0				1	(0.1)	2	0.43
Male	0				0			
Coronary artery stenosis								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Left atrial dilatation								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				0			
Left atrial enlargement								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.16
Pericardial effusion								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Pericarditis								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.22
Male	0				0			
Sinus arrhythmia								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Sinus bradycardia								
Female	0				1	(0.1)	1	0.12
Male	0				2	(0.2)	2	0.26
Subendocardial ischaemia								
Female	0				2	(0.3)	2	0.24

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				0			
Supraventricular tachycardia								
Female	2	(0.3)	2	0.35	0			
Male	0				0			
Tricuspid valve incompetence								
Female	1	(0.1)	1	0.14	2	(0.2)	2	0.24
Male	0				1	(0.1)	1	0.09
Ventricular arrhythmia								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Ventricular tachycardia								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Investigations								
All								
Female	29	(3.7)	33	5.67	30	(3.6)	33	4.94
Male	51	(4.6)	61	7.03	36	(3.4)	40	5.17
Weight increased								
Female	6	(0.8)	6	1.13	7	(0.8)	7	1.01
Male	13	(1.2)	13	1.45	11	(1.1)	11	1.42
SARS-CoV-2 test positive								
Female	2	(0.3)	2	0.35	0			
Male	5	(0.5)	5	0.72	0			
Blood creatinine increased								
Female	3	(0.4)	3	0.57	0			
Male	5	(0.5)	5	0.70	0			
Weight decreased								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	3	(0.3)	3	0.27	0			
Prostatic specific antigen increased								
Female	0				0			
Male	2	(0.2)	2	0.18	0			
Blood pressure increased								
Female	1	(0.1)	1	0.14	2	(0.2)	2	0.33
Male	2	(0.2)	2	0.25	2	(0.2)	2	0.19
Liver function test increased								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.25	0			
Alanine aminotransferase increased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	2	(0.3)	2	0.45	0			
Male	2	(0.2)	2	0.25	0			
Blood triglycerides increased								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	2	(0.2)	2	0.25	2	(0.2)	2	0.18
Blood immunoglobulin E increased								
Female	2	(0.2)	2	0.24	3	(0.4)	3	0.36
Male	1	(0.1)	1	0.09	0			
Blood urine present								
Female	0				0			
Male	1	(0.1)	3	0.27	1	(0.1)	1	0.16
Electrocardiogram ST segment abnormal								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Hepatic enzyme increased								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Low density lipoprotein increased								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.32
QRS axis abnormal								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.16
Transaminases increased								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.09	0			
Arthroscopy								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Aspartate aminotransferase increased								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.10
Blood glucose fluctuation								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Blood potassium increased								
Female	0				1	(0.1)	1	0.20
Male	1	(0.1)	1	0.16	0			
Monocyte count decreased								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Monofilament pressure perception test								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Occult blood								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.16	0			
Blood cholesterol increased								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	0			
Blood creatine increased								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Blood creatine phosphokinase increased								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Glycosylated haemoglobin increased								
Female	0				1	(0.1)	2	0.24
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
International normalised ratio abnormal								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
International normalised ratio decreased								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
International normalised ratio increased								
Female	0				0			
Male	1	(0.1)	2	0.18	0			
Transferrin saturation decreased								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Amylase increased								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Antinuclear antibody positive								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Blood alkaline phosphatase increased								
Female	3	(0.4)	3	0.65	0			
Male	0				0			
Blood glucose decreased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	0				1	(0.1)	1	0.16
Blood glucose increased								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Blood pressure decreased								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Body temperature increased								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Bone density decreased								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Breath sounds abnormal								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Carbohydrate antigen 19-9 increased								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Cardiac murmur								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Cardiac stress test abnormal								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Catheterisation cardiac								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Ejection fraction decreased								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Electrocardiogram abnormal								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.34
Male	0				0			
Electrocardiogram P wave biphasic								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Electrocardiogram repolarisation abnormality								
Female	0				0			
Male	0				1	(0.1)	1	0.10

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Electrocardiogram ST segment depression								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Electrocardiogram T wave inversion								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.22
Male	0				0			
Eosinophil count increased								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Free fatty acids increased								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Glomerular filtration rate decreased								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Grip strength decreased								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Haematocrit increased								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Haemoglobin decreased								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Haemoglobin increased								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Intraocular pressure increased								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Lipase increased								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Lipids increased								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Liver function test abnormal								
Female	1	(0.1)	1	0.22	0			
Male	0				1	(0.1)	2	0.34
Platelet count decreased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				2	(0.2)	2	0.43
Male	0				1	(0.1)	1	0.16
Red blood cell count decreased								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Thyroid function test abnormal								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Vitamin D decreased								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Vascular disorders								
All								
Female	29	(3.8)	31	4.95	33	(4.0)	44	7.20
Male	44	(4.0)	51	5.85	43	(4.1)	51	6.16
Hypertension								
Female	11	(1.4)	11	1.78	14	(1.7)	16	2.82
Male	21	(1.9)	21	2.47	21	(2.0)	24	2.85
Hypotension								
Female	1	(0.1)	1	0.14	2	(0.2)	2	0.34
Male	5	(0.5)	5	0.59	1	(0.1)	1	0.10
Peripheral arterial occlusive disease								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	3	(0.3)	4	0.50	1	(0.1)	1	0.10
Superficial vein thrombosis								
Female	1	(0.1)	1	0.12	0			
Male	2	(0.2)	2	0.18	0			
Peripheral artery stenosis								
Female	0				0			
Male	2	(0.2)	5	0.66	0			
Aortic arteriosclerosis								
Female	0				3	(0.4)	3	0.55
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.16
Arteriosclerosis								
Female	2	(0.3)	2	0.26	3	(0.4)	3	0.55
Male	1	(0.1)	1	0.09	4	(0.4)	4	0.45
Blood pressure inadequately controlled								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.19

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hot flush								
Female	0				1	(0.1)	1	0.21
Male	1	(0.1)	1	0.09	0			
Venous stenosis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Arterial insufficiency								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Diabetic vascular disorder								
Female	0				0			
Male	1	(0.1)	1	0.16	2	(0.2)	2	0.32
Orthostatic hypotension								
Female	1	(0.1)	1	0.23	0			
Male	1	(0.1)	1	0.16	0			
Hypertensive urgency								
Female	0				1	(0.1)	2	0.24
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.16
Peripheral coldness								
Female	2	(0.3)	2	0.27	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Peripheral venous disease								
Female	1	(0.1)	1	0.22	2	(0.2)	2	0.24
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.16
Thrombosis								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Varicose vein								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Aneurysm								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Aortic aneurysm								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Aortic dilatation								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Aortic stenosis								
Female	1	(0.1)	1	0.14	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	0				1	(0.1)	1	0.09
Blood pressure fluctuation								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Brachiocephalic arteriosclerosis								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				2	(0.2)	2	0.20
Deep vein thrombosis								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Flushing								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Haematoma								
Female	2	(0.3)	2	0.36	1	(0.1)	1	0.12
Male	0				2	(0.2)	2	0.32
Hypertensive crisis								
Female	1	(0.1)	1	0.22	2	(0.2)	4	0.76
Male	0				0			
Iliac artery stenosis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Intermittent claudication								
Female	0				0			
Male	0				2	(0.2)	2	0.19
Macroangiopathy								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Neovascularisation								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Peripheral artery aneurysm								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Peripheral artery occlusion								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Peripheral ischaemia								
Female	0				1	(0.1)	1	0.12
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Peripheral vascular disorder								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Phlebitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Thrombophlebitis								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Varicose ulceration								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Renal and urinary disorders								
All								
Female	22	(2.9)	28	4.51	19	(2.3)	23	3.31
Male	29	(2.7)	34	4.35	32	(3.1)	41	4.63
Renal cyst								
Female	3	(0.4)	3	0.57	3	(0.4)	3	0.46
Male	4	(0.4)	4	0.50	1	(0.1)	1	0.09
Pollakiuria								
Female	2	(0.3)	2	0.37	1	(0.1)	1	0.12
Male	3	(0.3)	3	0.48	1	(0.1)	1	0.10
Acute kidney injury								
Female	0				2	(0.3)	2	0.24
Male	3	(0.3)	3	0.41	3	(0.3)	3	0.28
Chronic kidney disease								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	3	(0.3)	3	0.48	4	(0.4)	4	0.45
Dysuria								
Female	1	(0.1)	2	0.24	1	(0.1)	1	0.22
Male	3	(0.3)	3	0.34	3	(0.3)	3	0.30
Nephrolithiasis								
Female	2	(0.2)	2	0.24	1	(0.1)	1	0.21
Male	3	(0.3)	3	0.27	3	(0.3)	5	0.60
Renal impairment								
Female	2	(0.3)	2	0.37	0			
Male	2	(0.2)	2	0.25	3	(0.3)	3	0.29
Ureterolithiasis								
Female	1	(0.1)	1	0.12	2	(0.2)	2	0.23
Male	2	(0.2)	2	0.25	1	(0.1)	1	0.09

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Nocturia								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.20
Proteinuria								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Urinary retention								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Urinary tract disorder								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Chromaturia								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Renal failure								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Haematuria								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	2	0.32	4	(0.4)	4	0.45
Renal colic								
Female	0				0			
Male	1	(0.1)	1	0.09	3	(0.3)	3	0.41
Diabetic nephropathy								
Female	2	(0.3)	2	0.27	0			
Male	1	(0.1)	1	0.15	2	(0.2)	2	0.32
Nephrotic syndrome								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Bladder mass								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Bladder prolapse								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Calculus urinary								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				0			
Cystitis haemorrhagic								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hydrocalyx								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Hydronephrosis								
Female	1	(0.1)	1	0.23	1	(0.1)	1	0.21
Male	0				0			
Hypertonic bladder								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Microalbuminuria								
Female	1	(0.1)	1	0.14	0			
Male	0				1	(0.1)	1	0.09
Micturition urgency								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Nephropathy								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Polyuria								
Female	1	(0.1)	1	0.23	0			
Male	0				1	(0.1)	1	0.09
Pyelocaliectasis								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Renal mass								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Renal pain								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Strangury								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Stress urinary incontinence								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Urethral stenosis								
Female	1	(0.1)	1	0.23	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Urinary incontinence								
Female	1	(0.1)	1	0.12	3	(0.4)	3	0.36
Male	0				0			
Urinary tract inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Urinary tract obstruction								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Urine odour abnormal								
Female	2	(0.3)	2	0.37	0			
Male	0				1	(0.1)	1	0.16
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
Female	9	(1.2)	11	1.69	16	(1.9)	25	3.70
Male	22	(2.0)	28	3.18	11	(1.0)	15	1.69
Adenocarcinoma pancreas								
Female	0				0			
Male	2	(0.2)	2	0.25	0			
Colon adenoma								
Female	1	(0.1)	1	0.23	0			
Male	2	(0.2)	2	0.25	0			
Eye naevus								
Female	0				0			
Male	2	(0.2)	3	0.34	0			
Metastases to liver								
Female	0				0			
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.09
Bladder cancer								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Lipoma								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Pancreatic carcinoma								
Female	0				0			
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.09
Squamous cell carcinoma of skin								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Bladder papilloma								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Colorectal cancer								
Female	1	(0.1)	1	0.12	0			
Male	1	(0.1)	1	0.16	0			
Lung cancer metastatic								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.09
Skin papilloma								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Osteoma								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Basal cell carcinoma								
Female	0				2	(0.2)	2	0.24
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.10
Glioblastoma multiforme								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Haemangioma of liver								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Oral fibroma								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Pancreatic neoplasm								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	1	0.09	0			
Prostate cancer								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Seborrhoeic keratosis								
Female	1	(0.1)	1	0.14	0			
Male	1	(0.1)	2	0.18	0			
Chronic myeloid leukaemia								
Female	0				0			
Male	1	(0.1)	1	0.15	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gastric cancer								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Acrochordon								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Adenocarcinoma of colon								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Adrenal adenoma								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.16
Benign renal neoplasm								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Bowen's disease								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Breast cancer								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Breast cancer metastatic								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Colon cancer								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Colon cancer stage II								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Dysplastic naevus								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Endometrial adenocarcinoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Gastrointestinal tract adenoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hepatocellular carcinoma								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				0			
Male	0				1	(0.1)	1	0.10
Invasive breast carcinoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Invasive ductal breast carcinoma								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Invasive lobular breast carcinoma								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Lung adenocarcinoma								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.16
Lymphangioma								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Malignant melanoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Malignant melanoma in situ								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Malignant peritoneal neoplasm								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Metastases to bone marrow								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Metastases to lymph nodes								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Myxoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Neoplasm skin								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Ovarian cancer metastatic								
Female	0				1	(0.1)	1	0.12
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pancreatic carcinoma metastatic								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Prostatic adenoma								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Renal cell carcinoma								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Renal hamartoma								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Renal neoplasm								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Salivary gland neoplasm								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Small cell lung cancer								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Small intestine neuroendocrine tumour								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Uterine cancer								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Uterine leiomyoma								
Female	0				3	(0.4)	3	0.45
Male	0				0			
Psychiatric disorders								
All								
Female	15	(1.9)	17	2.92	20	(2.4)	20	3.02
Male	21	(1.9)	23	2.32	17	(1.6)	19	2.63
Insomnia								
Female	4	(0.5)	4	0.74	4	(0.5)	4	0.57
Male	6	(0.5)	6	0.66	2	(0.2)	3	0.41
Sleep disorder								
Female	0				2	(0.2)	2	0.43

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	4	(0.4)	4	0.36	2	(0.2)	2	0.34
Anxiety								
Female	1	(0.1)	1	0.22	3	(0.4)	3	0.35
Male	4	(0.4)	4	0.36	3	(0.3)	3	0.27
Depression								
Female	6	(0.8)	6	0.95	5	(0.6)	5	0.69
Male	2	(0.2)	2	0.18	4	(0.4)	4	0.60
Disorientation								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Irritability								
Female	1	(0.1)	1	0.22	0			
Male	1	(0.1)	1	0.09	0			
Listless								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Drug abuse								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Mental status changes								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Depressed mood								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Nightmare								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Adjustment disorder								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Adjustment disorder with depressed mood								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Adjustment disorder with mixed anxiety and depressed mood								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Affect lability								
Female	0				0			
Male	0				1	(0.1)	1	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Agitation								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Anxiety disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Bruxism								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Drug dependence								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Emotional distress								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Fear								
Female	0				1	(0.1)	1	0.22
Male	0				1	(0.1)	1	0.16
Major depression								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Mixed anxiety and depressive disorder								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Mood swings								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Persistent depressive disorder								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Phobia								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Post-traumatic stress disorder								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Stress								
Female	1	(0.1)	1	0.12	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ear and labyrinth disorders								
All								
Female	11	(1.4)	11	1.77	10	(1.2)	10	1.62
Male	15	(1.4)	18	1.85	12	(1.2)	13	1.61
Vertigo								
Female	5	(0.7)	5	0.84	4	(0.5)	4	0.66
Male	5	(0.4)	6	0.66	4	(0.4)	5	0.57
Ear pain								
Female	2	(0.2)	2	0.34	1	(0.1)	1	0.20
Male	3	(0.3)	3	0.33	0			
Deafness bilateral								
Female	0				0			
Male	2	(0.2)	2	0.18	0			
Tinnitus								
Female	0				1	(0.1)	1	0.12
Male	2	(0.2)	2	0.18	1	(0.1)	1	0.17
Hypoacusis								
Female	0				2	(0.2)	2	0.24
Male	2	(0.2)	2	0.24	1	(0.1)	1	0.09
External ear pain								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Meniere's disease								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Ear inflammation								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Cerumen impaction								
Female	1	(0.1)	1	0.22	0			
Male	0				1	(0.1)	1	0.16
Deafness unilateral								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Ear discomfort								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Eustachian tube dysfunction								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.21
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Middle ear inflammation								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Motion sickness								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Presbyacusis								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Vertigo positional								
Female	2	(0.2)	2	0.24	0			
Male	0				1	(0.1)	1	0.10
Blood and lymphatic system disorders								
All								
Female	19	(2.4)	21	3.71	16	(1.9)	16	2.36
Male	14	(1.3)	14	1.60	14	(1.3)	14	1.67
Anaemia								
Female	14	(1.8)	16	2.98	8	(1.0)	8	1.14
Male	5	(0.4)	5	0.52	6	(0.6)	6	0.78
Eosinophilia								
Female	1	(0.1)	1	0.22	0			
Male	2	(0.2)	2	0.18	2	(0.2)	2	0.26
Leukocytosis								
Female	0				1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.18
Leukopenia								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Blood loss anaemia								
Female	0				0			
Male	1	(0.1)	1	0.16	2	(0.2)	2	0.19
Iron deficiency anaemia								
Female	1	(0.1)	1	0.14	2	(0.2)	2	0.33
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.09
Lymphadenopathy mediastinal								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.16
Polycythaemia								
Female	0				0			
Male	1	(0.1)	1	0.09	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Thrombocytopenia								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Hypochromic anaemia								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Lymphadenopathy								
Female	2	(0.3)	2	0.26	1	(0.1)	1	0.12
Male	0				0			
Normocytic anaemia								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Pancytopenia								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Splenomegaly								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Thrombocytosis								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Reproductive system and breast disorders								
All								
Female	15	(1.9)	15	2.39	16	(1.9)	19	2.53
Male	14	(1.3)	14	1.56	7	(0.7)	8	0.97
Benign prostatic hyperplasia								
Female	0				0			
Male	5	(0.5)	5	0.58	3	(0.3)	3	0.35
Erectile dysfunction								
Female	0				0			
Male	5	(0.4)	5	0.50	1	(0.1)	1	0.16
Ejaculation failure								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Prostatic calcification								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Pruritus genital								
Female	0				2	(0.2)	2	0.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Male	1	(0.1)	1	0.09	0			
Prostatitis								
Female	0				0			
Male	1	(0.1)	1	0.15	1	(0.1)	1	0.17
Atrophic vulvovaginitis								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	0				0			
Breast mass								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				0			
Breast pain								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.12
Male	0				0			
Cervical polyp								
Female	1	(0.1)	1	0.23	0			
Male	0				0			
Colpocele								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Dysmenorrhoea								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Galactorrhoea								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Genital prolapse								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Intermenstrual bleeding								
Female	2	(0.3)	2	0.43	0			
Male	0				0			
Menopausal disorder								
Female	0				1	(0.1)	1	0.22
Male	0				0			
Menopausal symptoms								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Menstruation delayed								
Female	1	(0.1)	1	0.22	0			
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Menstruation irregular								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Ovarian cyst								
Female	1	(0.1)	1	0.14	0			
Male	0				0			
Pelvic discomfort								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Penile rash								
Female	0				0			
Male	0				1	(0.1)	2	0.20
Testicular cyst								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Uterine enlargement								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Uterine polyp								
Female	2	(0.3)	2	0.26	0			
Male	0				0			
Uterine prolapse								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	0				0			
Vaginal discharge								
Female	0				2	(0.3)	2	0.33
Male	0				0			
Vaginal haemorrhage								
Female	0				2	(0.3)	2	0.24
Male	0				0			
Vulvovaginal dryness								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Vulvovaginal pruritus								
Female	1	(0.1)	1	0.14	2	(0.2)	2	0.24
Male	0				0			
Hepatobiliary disorders								
All								
Female	6	(0.8)	7	1.16	12	(1.4)	14	2.03
Male	13	(1.2)	18	1.94	9	(0.8)	11	1.44

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hepatic steatosis								
Female	2	(0.3)	2	0.35	4	(0.5)	4	0.48
Male	6	(0.5)	6	0.53	5	(0.5)	5	0.66
Hepatomegaly								
Female	0				0			
Male	2	(0.2)	2	0.25	0			
Hepatic function abnormal								
Female	0				0			
Male	1	(0.1)	1	0.16	2	(0.2)	2	0.26
Cholecystitis chronic								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.16	0			
Hyperplastic cholecystopathy								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Cholelithiasis								
Female	2	(0.2)	2	0.24	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	0			
Gallbladder cholesterolosis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Hypertransaminasaemia								
Female	0				0			
Male	1	(0.1)	2	0.18	0			
Liver disorder								
Female	0				1	(0.1)	1	0.22
Male	1	(0.1)	1	0.09	0			
Non-alcoholic steatohepatitis								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Alcoholic liver disease								
Female	0				0			
Male	1	(0.1)	1	0.15	0			
Bile duct stone								
Female	0				1	(0.1)	2	0.24
Male	0				0			
Biliary colic								
Female	0				0			
Male	0				1	(0.1)	1	0.16
Biliary dyskinesia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Female	0				1	(0.1)	1	0.22
Male	0				0			
Cholecystitis								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Gallbladder polyp								
Female	1	(0.1)	1	0.23	0			
Male	0				1	(0.1)	1	0.16
Hepatic cirrhosis								
Female	0				1	(0.1)	1	0.20
Male	0				1	(0.1)	1	0.10
Hepatic cyst								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hepatic mass								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Nonalcoholic fatty liver disease								
Female	0				1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.09
Steatohepatitis								
Female	0				1	(0.1)	1	0.12
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
Female	1	(0.1)	1	0.22	3	(0.4)	3	0.45
Male	5	(0.5)	5	0.66	2	(0.2)	2	0.18
Type V hyperlipidaemia								
Female	0				1	(0.1)	1	0.21
Male	3	(0.3)	3	0.41	0			
Cystic fibrosis lung								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Hydrocele								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Atrial septal defect								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Congenital syphilitic osteochondritis								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Corneal dystrophy								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Hypertrophic cardiomyopathy								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Myotonic dystrophy								
Female	0				1	(0.1)	1	0.12
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
Female	7	(0.9)	7	1.07	11	(1.3)	12	1.94
Male	5	(0.4)	6	0.73	4	(0.4)	4	0.60
Seasonal allergy								
Female	5	(0.6)	5	0.73	6	(0.7)	6	0.98
Male	3	(0.3)	3	0.34	2	(0.2)	2	0.27
Drug hypersensitivity								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Allergy to arthropod bite								
Female	0				0			
Male	1	(0.1)	1	0.09	2	(0.2)	2	0.33
Anaphylactic reaction								
Female	0				1	(0.1)	1	0.20
Male	1	(0.1)	1	0.15	0			
Allergy to arthropod sting								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Food allergy								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.12
Male	0				0			
Hypersensitivity								
Female	1	(0.1)	1	0.22	1	(0.1)	1	0.21
Male	0				0			
Immunisation reaction								
Female	0				1	(0.1)	2	0.23
Male	0				0			
Endocrine disorders								
All								
Female	3	(0.4)	3	0.38	10	(1.2)	10	1.52
Male	3	(0.3)	3	0.41	8	(0.8)	8	0.89
Hypogonadism								
Female	0				0			
Male	1	(0.1)	1	0.16	1	(0.1)	1	0.09
Hypothyroidism								
Female	1	(0.1)	1	0.12	1	(0.1)	1	0.20
Male	1	(0.1)	1	0.16	3	(0.3)	3	0.28

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Thyroid mass								
Female	1	(0.1)	1	0.14	1	(0.1)	1	0.12
Male	1	(0.1)	1	0.09	1	(0.1)	1	0.16
Adrenal mass								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Adrenocortical insufficiency acute								
Female	0				2	(0.2)	2	0.41
Male	0				0			
Autoimmune thyroiditis								
Female	1	(0.1)	1	0.12	0			
Male	0				0			
Goitre								
Female	0				1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.10
Hyperplasia adrenal								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hyperprolactinaemia								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Hyperthyroidism								
Female	0				1	(0.1)	1	0.12
Male	0				1	(0.1)	1	0.10
Inappropriate antidiuretic hormone secretion								
Female	0				1	(0.1)	1	0.20
Male	0				0			
Secondary hypogonadism								
Female	0				0			
Male	0				1	(0.1)	1	0.16


%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by sex, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Surgical and medical procedures								
All								
Female	2	(0.2)	2	0.34	2	(0.2)	2	0.24
Male	2	(0.2)	2	0.25	4	(0.4)	4	0.52
Tooth extraction								
Female	0				0			
Male	1	(0.1)	1	0.16	0			
Knee operation								
Female	0				0			
Male	1	(0.1)	1	0.09	0			
Cardiac pacemaker replacement								
Female	1	(0.1)	1	0.12	0			
Male	0				1	(0.1)	1	0.16
Large intestinal polypectomy								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Removal of foreign body								
Female	0				0			
Male	0				1	(0.1)	1	0.10
Shoulder operation								
Female	1	(0.1)	1	0.22	0			
Male	0				0			
Skin neoplasm excision								
Female	0				1	(0.1)	1	0.12
Male	0				0			
Spinal operation								
Female	0				0			
Male	0				1	(0.1)	1	0.09
Toe amputation								
Female	0				0			
Male	0				1	(0.1)	1	0.17
Social circumstances								
All								
Female	0				1	(0.1)	1	0.21
Male	0				0			
Menopause								
Female	0				1	(0.1)	1	0.21
Male	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.5 Adverse events by sex and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): SEX; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS SEX; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:12 - faedotgrp/faesocgrpsexdotontp3asas.png

7.7.6 Adverse events by sex and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): SEX; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS SEX; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:17 - faedotgrp/faesocgrpsexdotontt2dsas.png

7.7.7 Adverse events by sex and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): SEX; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD SEX; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:22 - faedotgrp/faept5pctgrpsexdotontp3asas.png

7.7.8 Adverse events by sex and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool



% of subjects: Percentage of subjects with one or more events, N: Number of subjects, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): SEX; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD SEX; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:27 - faedotgrp/faept5pctgrpsexdotontt2dsas.png

7.7.9 Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
>=18 - <65 years	1501				1498			
>=65 - <75 years	569				592			
>=75 years	100				80			
PYE (years)								
>=18 - <65 years	1146.36				1152.98			
>=65 - <75 years	452.73				462.37			
>=75 years	82.14				65.23			
Events								
>=18 - <65 years	915	(61.0)	2649	249.05	868	(57.9)	2664	256.08
>=65 - <75 years	345	(60.7)	1119	267.51	345	(58.2)	1075	240.67
>=75 years	68	(67.8)	217	266.38	50	(62.4)	139	227.07
Serious								
Yes								
>=18 - <65 years	84	(5.6)	113	9.81	96	(6.4)	121	10.63
>=65 - <75 years	68	(12.0)	115	27.16	59	(10.0)	94	18.95
>=75 years	14	(13.6)	17	20.80	14	(17.7)	23	33.81
No								
>=18 - <65 years	898	(59.8)	2536	239.24	849	(56.7)	2543	245.45
>=65 - <75 years	325	(57.2)	1004	240.35	329	(55.4)	981	221.72
>=75 years	64	(63.6)	200	245.58	45	(56.0)	116	193.26
Missing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
>=18 - <65 years	50	(3.3)	58	5.42	53	(3.5)	66	5.51
>=65 - <75 years	34	(6.0)	53	12.73	28	(4.8)	55	10.90
>=75 years	8	(8.2)	10	14.43	8	(10.3)	12	15.65
Moderate								
>=18 - <65 years	336	(22.4)	594	53.26	329	(22.0)	591	53.43
>=65 - <75 years	155	(27.3)	292	68.38	131	(22.2)	226	48.51
>=75 years	21	(20.6)	45	48.68	18	(22.1)	39	62.95
Mild								
>=18 - <65 years	776	(51.7)	1997	190.38	741	(49.5)	2007	197.14
>=65 - <75 years	279	(49.1)	774	186.41	294	(49.5)	794	181.26
>=75 years	58	(57.7)	162	203.28	38	(47.7)	88	148.47
Missing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Related to basal insulin								
Probable								
>=18 - <65 years	60	(4.0)	95	9.64	55	(3.7)	91	7.62
>=65 - <75 years	18	(3.1)	19	4.73	19	(3.2)	36	8.28
>=75 years	4	(3.9)	6	6.54	2	(2.3)	6	12.43
Possible								
>=18 - <65 years	79	(5.3)	106	10.65	68	(4.5)	113	12.01
>=65 - <75 years	43	(7.6)	70	18.51	33	(5.5)	61	14.38
>=75 years	3	(3.0)	3	4.20	4	(4.8)	4	7.28
Unlikely								
>=18 - <65 years	878	(58.5)	2439	227.83	840	(56.1)	2456	236.09
>=65 - <75 years	333	(58.6)	1027	243.41	337	(56.8)	977	217.84
>=75 years	65	(64.8)	208	255.64	49	(61.1)	128	205.23
Missing								
>=18 - <65 years	5	(0.3)	9	0.93	4	(0.3)	4	0.35
>=65 - <75 years	3	(0.5)	3	0.87	1	(0.2)	1	0.17
>=75 years	0				1	(1.3)	1	2.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
>=18 - <65 years	5	(0.3)	5	0.57	6	(0.4)	7	0.82
>=65 - <75 years	6	(1.1)	6	1.85	1	(0.2)	1	0.28
>=75 years	0				0			
No								
>=18 - <65 years	913	(60.8)	2635	247.55	864	(57.7)	2651	254.68
>=65 - <75 years	344	(60.6)	1109	264.51	345	(58.2)	1073	240.23
>=75 years	68	(67.8)	217	266.38	49	(61.1)	138	224.94
NA								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Missing								
>=18 - <65 years	5	(0.3)	9	0.93	5	(0.3)	5	0.47
>=65 - <75 years	3	(0.5)	3	0.87	1	(0.2)	1	0.17
>=75 years	0				1	(1.3)	1	2.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
>=18 - <65 years	5	(0.3)	5	0.38	6	(0.4)	6	0.49
>=65 - <75 years	6	(1.1)	8	2.18	4	(0.7)	6	1.29
>=75 years	3	(3.0)	5	7.58	3	(3.9)	3	3.83
Not recovered/not resolved								
>=18 - <65 years	385	(25.7)	682	62.49	376	(25.1)	703	65.15
>=65 - <75 years	173	(30.5)	345	79.98	171	(28.8)	299	65.50
>=75 years	31	(31.0)	60	76.86	23	(28.7)	40	66.40
Recovered/resolved with sequelae								
>=18 - <65 years	5	(0.3)	5	0.38	8	(0.5)	8	0.71
>=65 - <75 years	3	(0.5)	3	0.68	8	(1.4)	10	2.28
>=75 years	2	(1.8)	2	1.79	0			
Recovering/resolving								
>=18 - <65 years	63	(4.2)	85	8.19	57	(3.8)	68	6.66
>=65 - <75 years	27	(4.7)	45	11.82	30	(5.1)	37	9.05
>=75 years	6	(5.7)	6	6.43	5	(6.3)	6	8.10
Recovered/resolved								
>=18 - <65 years	773	(51.5)	1872	177.61	722	(48.2)	1878	183.00
>=65 - <75 years	289	(50.9)	717	172.68	277	(46.7)	722	162.38
>=75 years	60	(59.4)	144	173.72	40	(50.0)	90	148.74
Unknown								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Missing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.10 Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
>=18 - <65 years	1234				1227			
>=65 - <75 years	549				574			
>=75 years	97				77			
PYE (years)								
>=18 - <65 years	1015.10				1019.39			
>=65 - <75 years	443.15				453.36			
>=75 years	80.68				63.71			
Events								
>=18 - <65 years	743	(60.2)	2196	228.05	695	(56.6)	2082	216.81
>=65 - <75 years	331	(60.4)	1074	260.68	331	(57.5)	1045	237.56
>=75 years	65	(66.7)	208	254.10	47	(61.1)	132	218.82
Serious								
Yes								
>=18 - <65 years	75	(6.1)	100	9.79	89	(7.3)	112	11.48
>=65 - <75 years	67	(12.2)	114	27.73	59	(10.3)	94	19.59
>=75 years	13	(12.9)	16	19.13	14	(18.4)	23	35.00
No								
>=18 - <65 years	729	(59.1)	2096	218.26	679	(55.3)	1970	205.33
>=65 - <75 years	311	(56.8)	960	232.96	315	(54.7)	951	217.97
>=75 years	62	(63.5)	192	234.97	42	(54.5)	109	183.82
Missing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
>=18 - <65 years	42	(3.4)	49	5.10	49	(4.0)	61	5.89
>=65 - <75 years	34	(6.2)	53	13.16	28	(4.9)	55	11.27
>=75 years	7	(7.3)	9	12.53	8	(10.6)	12	16.20
Moderate								
>=18 - <65 years	291	(23.6)	519	52.41	284	(23.1)	513	52.35
>=65 - <75 years	150	(27.4)	278	65.75	126	(22.0)	219	47.53
>=75 years	20	(20.1)	44	47.98	17	(21.7)	35	55.89
Mild								
>=18 - <65 years	622	(50.4)	1628	170.54	584	(47.6)	1508	158.57
>=65 - <75 years	266	(48.6)	743	181.77	283	(49.1)	771	178.77
>=75 years	56	(57.4)	155	193.59	36	(47.0)	85	146.74
Missing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Related to basal insulin								
Probable								
>=18 - <65 years	44	(3.6)	76	8.58	48	(3.9)	83	7.98
>=65 - <75 years	17	(3.1)	18	4.54	19	(3.3)	36	8.56
>=75 years	4	(4.0)	6	6.77	2	(2.4)	6	12.87
Possible								
>=18 - <65 years	60	(4.9)	83	9.15	52	(4.2)	73	8.09
>=65 - <75 years	41	(7.5)	68	18.43	32	(5.5)	60	14.49
>=75 years	2	(1.9)	2	1.94	4	(5.0)	4	7.54
Unlikely								
>=18 - <65 years	717	(58.1)	2028	209.18	667	(54.4)	1922	200.31
>=65 - <75 years	319	(58.2)	985	236.82	324	(56.3)	948	214.34
>=75 years	62	(63.6)	200	245.39	46	(59.8)	121	196.22
Missing								
>=18 - <65 years	5	(0.4)	9	1.14	4	(0.3)	4	0.43
>=65 - <75 years	3	(0.5)	3	0.90	1	(0.2)	1	0.18
>=75 years	0				1	(1.3)	1	2.20

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
>=18 - <65 years	5	(0.4)	5	0.69	6	(0.5)	7	1.00
>=65 - <75 years	6	(1.1)	6	1.91	1	(0.2)	1	0.29
>=75 years	0				0			
No								
>=18 - <65 years	741	(60.1)	2182	226.22	691	(56.3)	2069	215.11
>=65 - <75 years	330	(60.2)	1064	257.58	331	(57.5)	1043	237.10
>=75 years	65	(66.7)	208	254.10	46	(59.8)	131	216.62
NA								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Missing								
>=18 - <65 years	5	(0.4)	9	1.14	5	(0.4)	5	0.57
>=65 - <75 years	3	(0.5)	3	0.90	1	(0.2)	1	0.18
>=75 years	0				1	(1.3)	1	2.20

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
>=18 - <65 years	5	(0.4)	5	0.46	6	(0.5)	6	0.59
>=65 - <75 years	6	(1.1)	8	2.26	4	(0.7)	6	1.33
>=75 years	2	(1.9)	4	5.44	3	(4.1)	3	3.96
Not recovered/not resolved								
>=18 - <65 years	310	(25.1)	567	57.00	301	(24.5)	570	57.63
>=65 - <75 years	163	(29.8)	329	77.04	165	(28.7)	291	64.72
>=75 years	30	(30.9)	57	72.35	21	(27.4)	37	61.77
Recovered/resolved with sequelae								
>=18 - <65 years	5	(0.4)	5	0.46	6	(0.5)	6	0.54
>=65 - <75 years	3	(0.6)	3	0.70	7	(1.2)	9	1.98
>=75 years	2	(1.8)	2	1.85	0			
Recovering/resolving								
>=18 - <65 years	57	(4.6)	79	8.98	53	(4.3)	63	7.30
>=65 - <75 years	27	(4.9)	45	12.22	29	(5.1)	34	8.23
>=75 years	6	(5.9)	6	6.66	5	(6.6)	6	8.38
Recovered/resolved								
>=18 - <65 years	626	(50.7)	1540	161.15	575	(46.9)	1436	150.67
>=65 - <75 years	278	(50.7)	688	168.29	265	(46.0)	704	161.12
>=75 years	58	(59.1)	139	167.80	38	(49.4)	86	144.70
Unknown								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			
Missing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.11 Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
>=18 - <65 years	1501				1498			
>=65 - <75 years	569				592			
>=75 years	100				80			
PYE (years)								
>=18 - <65 years	1146.36				1152.98			
>=65 - <75 years	452.73				462.37			
>=75 years	82.14				65.23			
Events								
>=18 - <65 years	915	(61.0)	2649	249.05	868	(57.9)	2664	256.08
>=65 - <75 years	345	(60.7)	1119	267.51	345	(58.2)	1075	240.67
>=75 years	68	(67.8)	217	266.38	50	(62.4)	139	227.07
Infections and infestations								
All								
>=18 - <65 years	447	(29.8)	645	62.53	443	(29.6)	657	61.68
>=65 - <75 years	170	(30.0)	232	55.89	156	(26.3)	214	48.86
>=75 years	31	(30.3)	43	53.09	25	(31.3)	34	54.86
COVID-19								
>=18 - <65 years	132	(8.8)	134	12.47	150	(10.0)	157	14.20
>=65 - <75 years	41	(7.2)	41	10.26	37	(6.2)	37	7.99
>=75 years	8	(8.1)	10	13.22	5	(6.5)	5	7.33
Nasopharyngitis								
>=18 - <65 years	91	(6.1)	111	12.02	83	(5.5)	95	9.74
>=65 - <75 years	24	(4.2)	27	6.08	27	(4.5)	35	9.27
>=75 years	2	(2.1)	3	4.56	5	(6.1)	5	9.72
Upper respiratory tract infection								
>=18 - <65 years	51	(3.4)	62	5.36	39	(2.6)	41	3.97
>=65 - <75 years	14	(2.5)	16	3.91	12	(2.0)	14	2.60
>=75 years	3	(2.8)	3	2.77	1	(1.1)	1	1.82
Gastroenteritis								
>=18 - <65 years	27	(1.8)	28	2.96	13	(0.9)	13	1.33
>=65 - <75 years	5	(0.9)	5	1.50	5	(0.8)	6	1.57
>=75 years	0				0			
Urinary tract infection								
>=18 - <65 years	26	(1.7)	28	2.79	30	(2.0)	33	3.07
>=65 - <75 years	11	(1.9)	11	2.69	16	(2.7)	19	4.00
>=75 years	6	(5.9)	7	9.08	4	(5.0)	4	5.60

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Influenza								
>=18 - <65 years	22	(1.5)	24	2.54	27	(1.8)	30	3.22
>=65 - <75 years	6	(1.1)	7	1.90	6	(1.0)	6	1.73
>=75 years	1	(1.1)	1	1.79	0			
Bronchitis								
>=18 - <65 years	19	(1.3)	19	1.80	10	(0.7)	10	0.93
>=65 - <75 years	10	(1.8)	11	2.87	8	(1.4)	8	1.91
>=75 years	1	(0.9)	1	0.90	1	(1.4)	1	1.44
Pharyngitis								
>=18 - <65 years	18	(1.2)	20	1.79	16	(1.1)	19	1.69
>=65 - <75 years	3	(0.5)	3	0.80	2	(0.3)	2	0.47
>=75 years	0				0			
Sinusitis								
>=18 - <65 years	12	(0.8)	13	1.41	14	(0.9)	17	1.45
>=65 - <75 years	6	(1.1)	7	1.47	4	(0.7)	4	0.92
>=75 years	1	(0.9)	1	0.90	1	(1.2)	1	2.01
Respiratory tract infection viral								
>=18 - <65 years	10	(0.7)	11	1.23	9	(0.6)	10	1.16
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Conjunctivitis								
>=18 - <65 years	9	(0.6)	9	0.93	2	(0.1)	2	0.13
>=65 - <75 years	2	(0.4)	2	0.47	5	(0.8)	5	1.19
>=75 years	1	(1.0)	1	0.98	0			
Cystitis								
>=18 - <65 years	9	(0.6)	9	0.88	10	(0.7)	11	0.95
>=65 - <75 years	6	(1.1)	7	1.81	6	(1.0)	7	1.69
>=75 years	0				1	(1.4)	1	1.44
Herpes zoster								
>=18 - <65 years	8	(0.5)	8	0.70	9	(0.6)	10	0.86
>=65 - <75 years	3	(0.5)	3	0.53	7	(1.2)	7	1.52
>=75 years	0				1	(1.4)	1	1.44
Tooth abscess								
>=18 - <65 years	6	(0.4)	6	0.68	3	(0.2)	3	0.19
>=65 - <75 years	3	(0.5)	3	0.67	4	(0.7)	5	1.23
>=75 years	0				0			
Viral infection								
>=18 - <65 years	6	(0.4)	6	0.52	11	(0.7)	14	1.23
>=65 - <75 years	1	(0.2)	1	0.30	2	(0.3)	2	0.34
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
COVID-19 pneumonia								
>=18 - <65 years	6	(0.4)	6	0.56	8	(0.5)	8	0.75
>=65 - <75 years	6	(1.1)	6	1.43	2	(0.3)	2	0.34
>=75 years	3	(2.9)	3	3.60	1	(1.3)	1	1.20
Rhinitis								
>=18 - <65 years	6	(0.4)	6	0.52	9	(0.6)	10	1.11
>=65 - <75 years	3	(0.5)	3	0.70	2	(0.3)	4	1.08
>=75 years	0				0			
Respiratory tract infection								
>=18 - <65 years	6	(0.4)	6	0.57	3	(0.2)	3	0.25
>=65 - <75 years	3	(0.5)	3	0.64	3	(0.5)	3	0.64
>=75 years	0				0			
Tooth infection								
>=18 - <65 years	5	(0.3)	7	0.63	5	(0.3)	5	0.52
>=65 - <75 years	4	(0.7)	4	0.97	1	(0.2)	1	0.30
>=75 years	0				2	(2.5)	2	3.25
Pneumonia								
>=18 - <65 years	5	(0.3)	5	0.50	6	(0.4)	6	0.55
>=65 - <75 years	9	(1.6)	9	2.08	0			
>=75 years	1	(1.1)	1	1.79	0			
Lower respiratory tract infection								
>=18 - <65 years	5	(0.3)	5	0.41	2	(0.1)	4	0.34
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Fungal infection								
>=18 - <65 years	5	(0.3)	6	0.59	2	(0.1)	2	0.19
>=65 - <75 years	2	(0.4)	2	0.35	0			
>=75 years	0				0			
Tonsillitis								
>=18 - <65 years	4	(0.3)	4	0.38	2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastroenteritis viral								
>=18 - <65 years	4	(0.3)	4	0.34	5	(0.3)	5	0.52
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Vaginal infection								
>=18 - <65 years	4	(0.3)	5	0.56	2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.30
>=75 years	1	(1.0)	1	0.98	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Otitis media								
>=18 - <65 years	4	(0.3)	4	0.36	3	(0.2)	3	0.32
>=65 - <75 years	3	(0.5)	3	0.87	2	(0.3)	2	0.47
>=75 years	0				0			
Gastrointestinal infection								
>=18 - <65 years	3	(0.2)	3	0.36	3	(0.2)	4	0.32
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				1	(1.1)	2	4.48
Coronavirus infection								
>=18 - <65 years	3	(0.2)	3	0.20	5	(0.3)	7	0.64
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Laryngitis								
>=18 - <65 years	3	(0.2)	3	0.20	4	(0.3)	4	0.39
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Acute sinusitis								
>=18 - <65 years	3	(0.2)	3	0.24	5	(0.3)	5	0.58
>=65 - <75 years	2	(0.3)	2	0.33	1	(0.2)	1	0.17
>=75 years	0				0			
Vulvitis								
>=18 - <65 years	2	(0.1)	2	0.25	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Helicobacter infection								
>=18 - <65 years	2	(0.1)	2	0.18	2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Onychomycosis								
>=18 - <65 years	2	(0.1)	2	0.18	3	(0.2)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Tinea cruris								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Genital infection fungal								
>=18 - <65 years	2	(0.1)	3	0.34	2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gingivitis								
>=18 - <65 years	2	(0.1)	2	0.20	1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	2	0.36	3	(0.5)	3	0.74
>=75 years	0				1	(1.3)	1	2.12
Hordeolum								
>=18 - <65 years	2	(0.1)	2	0.20	2	(0.1)	2	0.20
>=65 - <75 years	0				2	(0.3)	2	0.55
>=75 years	1	(0.9)	1	0.90	0			
Periodontitis								
>=18 - <65 years	2	(0.1)	2	0.20	5	(0.3)	5	0.50
>=65 - <75 years	2	(0.4)	2	0.61	2	(0.3)	2	0.45
>=75 years	1	(0.9)	1	0.90	0			
Acarodermatitis								
>=18 - <65 years	2	(0.1)	2	0.13	3	(0.2)	3	0.19
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Wound infection								
>=18 - <65 years	2	(0.1)	2	0.23	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Candida infection								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Ear infection								
>=18 - <65 years	2	(0.1)	2	0.13	3	(0.2)	3	0.24
>=65 - <75 years	2	(0.3)	2	0.46	1	(0.2)	1	0.28
>=75 years	0				1	(1.4)	1	1.44
Vulvovaginal candidiasis								
>=18 - <65 years	2	(0.1)	3	0.20	4	(0.3)	4	0.27
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Respiratory syncytial virus infection								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Tinea pedis								
>=18 - <65 years	2	(0.1)	2	0.25	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				1	(1.1)	1	2.24

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Furuncle								
>=18 - <65 years	2	(0.1)	3	0.25	1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Tinea infection								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cellulitis								
>=18 - <65 years	1	(0.1)	1	0.11	6	(0.4)	7	0.71
>=65 - <75 years	3	(0.5)	3	0.51	1	(0.2)	1	0.17
>=75 years	0				1	(1.3)	1	1.20
Paraspinal abscess								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulpitis dental								
>=18 - <65 years	1	(0.1)	1	0.11	3	(0.2)	3	0.30
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Tinea versicolour								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Abscess limb								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.1)	3	0.38
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Breast abscess								
>=18 - <65 years	1	(0.1)	1	0.14	3	(0.2)	3	0.25
>=65 - <75 years	0				0			
>=75 years	0				0			
Eye infection								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.11
>=65 - <75 years	0				2	(0.3)	2	0.59
>=75 years	0				0			
Fungal skin infection								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.12
>=65 - <75 years	2	(0.3)	2	0.46	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Norovirus infection								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Severe acute respiratory syndrome								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Vulvovaginitis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Appendicitis								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Chronic sinusitis								
>=18 - <65 years	1	(0.1)	1	0.06	3	(0.2)	3	0.20
>=65 - <75 years	0				0			
>=75 years	0				0			
Ear infection fungal								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nail infection								
>=18 - <65 years	1	(0.1)	2	0.13	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Paronychia								
>=18 - <65 years	1	(0.1)	1	0.06	2	(0.1)	3	0.35
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Peritonsillar abscess								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Post-acute COVID-19 syndrome								
>=18 - <65 years	1	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin candida								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Viral pharyngitis								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Asymptomatic COVID-19								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Bacterial infection								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Balanitis candida								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Chronic tonsillitis								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Folliculitis								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Helicobacter gastritis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Laryngopharyngitis								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Localised infection								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.25
>=65 - <75 years	2	(0.4)	2	0.49	1	(0.2)	1	0.17
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Mastitis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oropharyngeal candidiasis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Otitis media chronic								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pericoronitis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Purulence								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Tracheitis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Urethritis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Bacteraemia								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic foot infection								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Pharyngotonsillitis								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	2	2.88

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pneumonia viral								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Viral tracheitis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vulvovaginal mycotic infection								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Erysipelas								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	2	0.23
>=65 - <75 years	2	(0.4)	2	0.35	1	(0.2)	1	0.17
>=75 years	0				0			
Genital candidiasis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Genital infection								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.12
>=65 - <75 years	2	(0.3)	2	0.33	0			
>=75 years	0				0			
Oral candidiasis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Otitis externa								
>=18 - <65 years	1	(0.1)	1	0.11	5	(0.3)	5	0.53
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Skin infection								
>=18 - <65 years	1	(0.1)	1	0.11	3	(0.2)	3	0.39
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Suspected COVID-19								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal abscess								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Abscess								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	2	(0.4)	2	0.49	0			
>=75 years	0				0			
Anal abscess								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.17
>=75 years	0				0			
Bartholinitis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Body tinea								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Breast cellulitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Campylobacter gastroenteritis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Chlamydial infection								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Cholecystitis infective								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	0				0			
Chronic hepatitis C								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Clostridium difficile colitis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Clostridium difficile infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	1	(1.0)	1	0.98	0			
Cystitis escherichia								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Dermatophytosis of nail								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Diverticulitis								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	0				1	(1.4)	1	1.44
Empyema								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Endophthalmitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Enteritis infectious								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Epididymitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Escherichia bacteraemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Escherichia urinary tract infection								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Eye infection bacterial								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Fungal balanitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Gangrene								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Gastric infection								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastroenteritis norovirus								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Giardiasis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Herpes dermatitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Herpes simplex								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Herpes virus infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Herpes zoster infection neurological								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Infected bite								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Infected cyst								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Infected dermal cyst								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Infective iritis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site abscess								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Kidney infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.73	0			
Labyrinthitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Lyme disease								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Oophoritis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral herpes								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	2	(0.4)	3	0.93	0			
>=75 years	0				0			
Osteomyelitis								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.49	0			
>=75 years	0				0			
Otitis media acute								
>=18 - <65 years	0				3	(0.2)	3	0.25
>=65 - <75 years	0				0			
>=75 years	0				0			
Parotitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Peri-implantitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.44
Post procedural infection								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Postoperative wound infection								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	1	(0.2)	1	0.17
>=75 years	0				0			
Pulmonary tuberculoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Pustule								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Pyelonephritis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Rotavirus infection								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Salpingitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Sepsis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	2	(0.4)	2	0.62	0			
>=75 years	0				0			
Sinusitis bacterial								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin bacterial infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Soft tissue infection								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Subcutaneous abscess								
>=18 - <65 years	0				1	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	1	(1.0)	1	1.73	0			
Sweat gland infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Urosepsis								
>=18 - <65 years	0				2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Varicella								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Varicella zoster virus infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.73	0			
Viral rhinitis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Viral upper respiratory tract infection								
>=18 - <65 years	0				3	(0.2)	3	0.20
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Musculoskeletal and connective tissue disorders								
All								
>=18 - <65 years	187	(12.5)	258	22.84	202	(13.5)	291	28.38
>=65 - <75 years	71	(12.5)	120	28.35	70	(11.8)	96	19.95
>=75 years	15	(15.2)	22	27.94	12	(14.8)	14	23.26
Back pain								
>=18 - <65 years	38	(2.5)	40	3.46	49	(3.3)	66	7.02
>=65 - <75 years	24	(4.2)	26	6.06	19	(3.2)	19	4.31
>=75 years	3	(3.1)	3	4.89	4	(4.8)	4	7.19
Arthralgia								
>=18 - <65 years	31	(2.1)	36	3.15	42	(2.8)	46	4.61
>=65 - <75 years	16	(2.8)	19	4.81	9	(1.5)	11	2.25
>=75 years	4	(3.8)	4	5.01	6	(7.8)	6	9.40
Pain in extremity								
>=18 - <65 years	26	(1.7)	27	2.37	27	(1.8)	29	2.92
>=65 - <75 years	11	(1.9)	12	2.54	10	(1.7)	14	3.25
>=75 years	0				0			
Muscle spasms								
>=18 - <65 years	17	(1.1)	19	1.98	7	(0.5)	7	0.56
>=65 - <75 years	5	(0.9)	5	1.03	2	(0.3)	2	0.47
>=75 years	3	(2.9)	3	3.60	0			
Osteoarthritis								
>=18 - <65 years	17	(1.1)	19	1.68	18	(1.2)	21	1.92
>=65 - <75 years	5	(0.9)	5	1.13	8	(1.3)	8	1.61
>=75 years	2	(2.1)	2	3.10	0			
Myalgia								
>=18 - <65 years	11	(0.7)	11	1.11	13	(0.9)	14	1.66
>=65 - <75 years	4	(0.7)	4	1.08	3	(0.5)	3	0.62
>=75 years	1	(1.0)	1	0.98	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Neck pain								
>=18 - <65 years	8	(0.5)	8	0.70	7	(0.5)	7	0.57
>=65 - <75 years	6	(1.1)	6	1.57	1	(0.2)	1	0.17
>=75 years	2	(2.1)	2	2.77	0			
Periarthritis								
>=18 - <65 years	7	(0.5)	7	0.52	7	(0.5)	7	0.72
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	0				1	(1.4)	1	1.44
Trigger finger								
>=18 - <65 years	6	(0.4)	6	0.68	6	(0.4)	8	0.64
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	2	(2.1)	2	3.10	0			
Tendonitis								
>=18 - <65 years	5	(0.3)	5	0.38	5	(0.3)	5	0.50
>=65 - <75 years	2	(0.3)	4	1.03	0			
>=75 years	1	(0.9)	1	0.90	0			
Musculoskeletal stiffness								
>=18 - <65 years	5	(0.3)	5	0.50	1	(0.1)	1	0.13
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Rotator cuff syndrome								
>=18 - <65 years	5	(0.3)	5	0.43	3	(0.2)	3	0.19
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Plantar fasciitis								
>=18 - <65 years	4	(0.3)	5	0.38	3	(0.2)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Arthritis								
>=18 - <65 years	4	(0.3)	4	0.38	3	(0.2)	3	0.30
>=65 - <75 years	3	(0.5)	3	0.64	3	(0.5)	3	0.77
>=75 years	0				0			
Muscular weakness								
>=18 - <65 years	4	(0.3)	4	0.43	2	(0.1)	2	0.18
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Intervertebral disc protrusion								
>=18 - <65 years	3	(0.2)	6	0.44	5	(0.3)	6	0.50
>=65 - <75 years	4	(0.7)	4	0.83	1	(0.2)	1	0.17
>=75 years	1	(0.9)	2	1.79	0			
Intervertebral disc disorder								
>=18 - <65 years	3	(0.2)	3	0.25	1	(0.1)	1	0.07
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				1	(1.2)	1	2.01
Bursitis								
>=18 - <65 years	3	(0.2)	3	0.20	4	(0.3)	4	0.34
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Musculoskeletal chest pain								
>=18 - <65 years	3	(0.2)	3	0.20	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				1	(1.3)	1	1.20
Tendon disorder								
>=18 - <65 years	3	(0.2)	3	0.29	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Synovial cyst								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Tenosynovitis								
>=18 - <65 years	2	(0.1)	2	0.20	6	(0.4)	7	0.56
>=65 - <75 years	0				3	(0.5)	3	0.51
>=75 years	0				0			
Chondropathy								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Exostosis								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Polyarthritis								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal stenosis								
>=18 - <65 years	2	(0.1)	2	0.13	2	(0.1)	2	0.13
>=65 - <75 years	2	(0.3)	4	1.16	0			
>=75 years	0				0			
Musculoskeletal pain								
>=18 - <65 years	2	(0.1)	2	0.18	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Axillary mass								
>=18 - <65 years	1	(0.1)	1	0.11	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Flank pain								
>=18 - <65 years	1	(0.1)	1	0.11	5	(0.3)	6	0.54
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Osteoporosis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Polymyalgia rheumatica								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	3	0.33
>=65 - <75 years	0				0			
>=75 years	0				0			
Limb discomfort								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Meniscopathy								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Osteochondrosis								
>=18 - <65 years	1	(0.1)	1	0.06	3	(0.2)	3	0.30
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	0				0			
Psoriatic arthropathy								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Sacroiliitis								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal osteoarthritis								
>=18 - <65 years	1	(0.1)	1	0.06	4	(0.3)	5	0.32
>=65 - <75 years	4	(0.7)	4	0.96	1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Back disorder								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Bone cyst								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Costochondritis								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Fibromyalgia								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Fistula								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Groin pain								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Lumbar spinal stenosis								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Myositis								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal pain								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.18
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	0				0			
Coccydynia								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Foot deformity								
>=18 - <65 years	1	(0.1)	1	0.11	3	(0.2)	3	0.30
>=65 - <75 years	2	(0.3)	4	0.67	0			
>=75 years	0				0			
Joint effusion								
>=18 - <65 years	1	(0.1)	2	0.22	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Muscle contracture								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Torticollis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Acquired claw toe								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Arthropathy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Bone pain								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Cervical spinal stenosis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Chondromalacia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.36
>=75 years	0				0			
Diastasis recti abdominis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Dupuytren's contracture								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	0				0			
Facet joint syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Haemarthrosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Intervertebral disc degeneration								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Intervertebral disc space narrowing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.34
>=75 years	0				0			
Jaw disorder								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Joint swelling								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				1	(1.2)	1	2.01
Limb deformity								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Limb mass								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Mastication disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.34
>=75 years	0				0			
Muscle twitching								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Neuropathic arthropathy								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Nodal osteoarthritis								
>=18 - <65 years	0				2	(0.1)	2	0.20
>=65 - <75 years	0				0			
>=75 years	0				0			
Osteochondritis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Osteopenia								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Pain in jaw								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Periostitis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Rheumatoid arthritis								
>=18 - <65 years	0				3	(0.2)	3	0.38
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Scoliosis								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Soft tissue swelling								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	3	0.87	0			
>=75 years	0				0			
Spinal retrolisthesis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.34
>=75 years	0				0			
Tenosynovitis stenosans								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Vertebral osteophyte								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastrointestinal disorders								
All								
>=18 - <65 years	185	(12.3)	286	25.60	173	(11.5)	248	23.54
>=65 - <75 years	72	(12.6)	106	25.74	67	(11.3)	89	20.02
>=75 years	20	(19.2)	26	28.91	5	(6.5)	6	8.48

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diarrhoea								
>=18 - <65 years	53	(3.5)	65	6.03	43	(2.9)	45	4.31
>=65 - <75 years	25	(4.4)	29	6.73	11	(1.8)	11	2.50
>=75 years	11	(10.1)	14	14.69	1	(1.3)	1	1.20
Nausea								
>=18 - <65 years	33	(2.2)	34	3.07	28	(1.9)	29	2.84
>=65 - <75 years	6	(1.1)	6	1.44	7	(1.2)	8	1.89
>=75 years	2	(1.9)	2	1.87	0			
Vomiting								
>=18 - <65 years	25	(1.7)	33	3.50	18	(1.2)	19	1.79
>=65 - <75 years	6	(1.1)	6	1.35	3	(0.5)	5	1.11
>=75 years	0				0			
Abdominal pain upper								
>=18 - <65 years	13	(0.9)	15	1.43	13	(0.9)	14	1.23
>=65 - <75 years	3	(0.5)	3	0.68	3	(0.5)	3	0.51
>=75 years	0				0			
Toothache								
>=18 - <65 years	11	(0.7)	11	0.86	8	(0.5)	12	1.42
>=65 - <75 years	4	(0.7)	4	0.99	5	(0.8)	6	1.64
>=75 years	0				0			
Gastrooesophageal reflux disease								
>=18 - <65 years	11	(0.7)	11	0.92	10	(0.7)	10	0.97
>=65 - <75 years	2	(0.3)	2	0.52	5	(0.8)	5	0.98
>=75 years	1	(1.0)	1	0.98	0			
Dental caries								
>=18 - <65 years	10	(0.7)	12	0.87	7	(0.5)	7	0.60
>=65 - <75 years	0				3	(0.5)	3	0.90
>=75 years	2	(1.8)	2	1.79	0			
Abdominal pain								
>=18 - <65 years	10	(0.7)	10	0.87	13	(0.9)	14	1.34
>=65 - <75 years	5	(0.9)	5	1.12	5	(0.8)	5	0.96
>=75 years	2	(2.2)	2	3.19	0			
Constipation								
>=18 - <65 years	10	(0.7)	10	0.92	8	(0.5)	8	0.84
>=65 - <75 years	6	(1.0)	9	2.25	7	(1.2)	7	1.53
>=75 years	1	(1.0)	1	0.98	1	(1.4)	1	1.44
Dyspepsia								
>=18 - <65 years	7	(0.5)	7	0.68	5	(0.3)	5	0.42
>=65 - <75 years	1	(0.2)	1	0.32	4	(0.7)	4	0.98
>=75 years	0				0			
Abdominal distension								
>=18 - <65 years	6	(0.4)	6	0.52	5	(0.3)	5	0.50
>=65 - <75 years	2	(0.4)	2	0.36	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Haemorrhoids								
>=18 - <65 years	5	(0.3)	5	0.38	3	(0.2)	3	0.31
>=65 - <75 years	2	(0.4)	2	0.47	1	(0.2)	1	0.30
>=75 years	0				0			
Gastritis								
>=18 - <65 years	5	(0.3)	5	0.52	6	(0.4)	6	0.59
>=65 - <75 years	3	(0.5)	3	0.67	2	(0.3)	2	0.34
>=75 years	0				1	(1.3)	1	1.20
Abdominal pain lower								
>=18 - <65 years	4	(0.3)	4	0.36	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Abdominal discomfort								
>=18 - <65 years	4	(0.3)	4	0.39	3	(0.2)	3	0.26
>=65 - <75 years	0				3	(0.5)	4	1.04
>=75 years	0				0			
Chronic gastritis								
>=18 - <65 years	4	(0.3)	4	0.31	4	(0.3)	4	0.40
>=65 - <75 years	4	(0.7)	4	1.12	2	(0.3)	2	0.47
>=75 years	1	(1.0)	1	1.73	0			
Diverticulum intestinal								
>=18 - <65 years	3	(0.2)	3	0.20	1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Enterocolitis								
>=18 - <65 years	3	(0.2)	4	0.27	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Food poisoning								
>=18 - <65 years	3	(0.2)	3	0.24	1	(0.1)	2	0.22
>=65 - <75 years	1	(0.2)	1	0.29	3	(0.5)	3	0.74
>=75 years	1	(1.0)	1	0.98	0			
Hyperaesthesia teeth								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Anal fissure								
>=18 - <65 years	2	(0.1)	2	0.20	1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Impaired gastric emptying								
>=18 - <65 years	2	(0.1)	3	0.34	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Aphthous ulcer								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Large intestine polyp								
>=18 - <65 years	2	(0.1)	2	0.13	4	(0.3)	5	0.32
>=65 - <75 years	2	(0.3)	2	0.46	2	(0.3)	2	0.48
>=75 years	0				0			
Flatulence								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.32	2	(0.3)	2	0.55
>=75 years	1	(1.0)	1	1.73	0			
Gastric polyps								
>=18 - <65 years	2	(0.1)	2	0.18	3	(0.2)	3	0.38
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Intra-abdominal haematoma								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Tongue rough								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Faeces soft								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pancreatic failure								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Eosinophilic oesophagitis								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Eructation								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric ulcer								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastrointestinal haemorrhage								
>=18 - <65 years	1	(0.1)	1	0.06	2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Haemorrhoidal haemorrhage								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Hiatus hernia								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.17
>=75 years	0				0			
Hypoaesthesia oral								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	2	(0.4)	4	1.22	0			
>=75 years	0				0			
Inguinal hernia								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Intestinal dilatation								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Lip swelling								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Rectal polyp								
>=18 - <65 years	1	(0.1)	1	0.06	2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Anal pruritus								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Colitis ischaemic								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Loose tooth								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oral discomfort								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pancreatitis								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Periodontal disease								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Tooth disorder								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Tooth impacted								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Noninfective gingivitis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vomiting projectile								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Abdominal wall disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Acid peptic disease								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Colitis								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Colitis microscopic								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Crohn's disease								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic gastropathy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Diverticulum								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.17
>=75 years	0				1	(1.2)	1	2.01
Dry mouth								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	1	(1.0)	1	0.98	0			
Duodenitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Enteritis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Epigastric discomfort								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Faeces pale								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Frequent bowel movements								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Gastric dilatation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Gastric disorder								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric dysplasia								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric mucosal hypertrophy								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastritis erosive								
>=18 - <65 years	0				2	(0.1)	2	0.27
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastrointestinal angiodysplasia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Gastrointestinal disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Gastrointestinal inflammation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Gastrointestinal sounds abnormal								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Gingival bleeding								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Gingival disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Gingival recession								
>=18 - <65 years	0				1	(0.1)	2	0.27

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Haematochezia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Hyperchlorhydria								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Ileus								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Irritable bowel syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.34	1	(0.2)	1	0.17
>=75 years	0				0			
Lumbar hernia								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Melaena								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Mesenteric panniculitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Odynophagia								
>=18 - <65 years	0				2	(0.1)	2	0.25
>=65 - <75 years	0				0			
>=75 years	0				0			
Oesophageal pain								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Oesophagitis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Oral pain								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Pancreatic duct dilatation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Pancreatic pseudocyst								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Pancreatitis acute								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Pancreatitis chronic								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Peptic ulcer								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Periodontal inflammation								
>=18 - <65 years	0				1	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Pneumatosis intestinalis								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Proctalgia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Rectal prolapse								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.44
Small intestinal obstruction								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Stomatitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Ulcerative gastritis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Umbilical hernia								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Upper gastrointestinal haemorrhage								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
General disorders and administration site conditions								
All								
>=18 - <65 years	173	(11.5)	253	24.76	139	(9.3)	239	23.35
>=65 - <75 years	59	(10.4)	93	24.05	62	(10.4)	97	22.15
>=75 years	8	(7.7)	17	18.61	7	(8.8)	8	12.28
Pyrexia								
>=18 - <65 years	31	(2.1)	33	3.37	31	(2.1)	33	3.12
>=65 - <75 years	7	(1.2)	7	1.49	12	(2.0)	12	2.62
>=75 years	3	(2.7)	3	2.69	0			
Fatigue								
>=18 - <65 years	21	(1.4)	23	2.12	13	(0.9)	13	1.11
>=65 - <75 years	8	(1.4)	10	2.49	2	(0.3)	2	0.34
>=75 years	3	(3.0)	3	4.20	1	(1.3)	1	1.20
Malaise								
>=18 - <65 years	11	(0.7)	13	1.17	8	(0.5)	52	6.54
>=65 - <75 years	4	(0.7)	4	0.96	7	(1.2)	8	1.75
>=75 years	1	(1.0)	1	0.98	0			
Oedema peripheral								
>=18 - <65 years	11	(0.7)	11	1.15	6	(0.4)	7	0.59
>=65 - <75 years	7	(1.2)	7	1.45	4	(0.7)	4	0.81
>=75 years	1	(0.9)	1	0.90	0			
Injection site reaction								
>=18 - <65 years	11	(0.7)	20	2.15	1	(0.1)	1	0.07
>=65 - <75 years	4	(0.7)	9	2.81	5	(0.8)	7	1.54
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pain								
>=18 - <65 years	10	(0.7)	10	1.07	9	(0.6)	10	0.97
>=65 - <75 years	2	(0.4)	3	0.91	4	(0.7)	4	0.68
>=75 years	1	(0.9)	1	0.90	1	(1.3)	1	1.20
Chest pain								
>=18 - <65 years	9	(0.6)	9	0.74	7	(0.5)	7	0.59
>=65 - <75 years	4	(0.7)	4	0.95	0			
>=75 years	1	(0.9)	1	0.90	0			
Asthenia								
>=18 - <65 years	7	(0.5)	7	0.61	6	(0.4)	6	0.63
>=65 - <75 years	2	(0.4)	2	0.62	3	(0.5)	3	0.51
>=75 years	1	(0.9)	1	0.90	1	(1.1)	1	1.82
Chest discomfort								
>=18 - <65 years	6	(0.4)	6	0.54	0			
>=65 - <75 years	2	(0.4)	2	0.50	2	(0.3)	2	0.45
>=75 years	0				0			
Hunger								
>=18 - <65 years	6	(0.4)	7	0.54	1	(0.1)	2	0.27
>=65 - <75 years	1	(0.2)	1	0.29	2	(0.3)	2	0.48
>=75 years	0				0			
Medical device site rash								
>=18 - <65 years	5	(0.3)	5	0.68	7	(0.5)	7	0.94
>=65 - <75 years	1	(0.2)	1	0.34	1	(0.2)	1	0.30
>=75 years	0				0			
Medical device site bruise								
>=18 - <65 years	5	(0.3)	7	0.70	0			
>=65 - <75 years	2	(0.4)	2	0.36	1	(0.2)	1	0.17
>=75 years	0				0			
Medical device site pruritus								
>=18 - <65 years	5	(0.3)	5	0.45	4	(0.3)	4	0.47
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site dermatitis								
>=18 - <65 years	5	(0.3)	8	0.77	10	(0.7)	16	1.21
>=65 - <75 years	2	(0.3)	2	0.52	1	(0.2)	2	0.72
>=75 years	0				0			
Medical device site reaction								
>=18 - <65 years	5	(0.3)	5	0.64	0			
>=65 - <75 years	2	(0.4)	4	0.83	1	(0.2)	1	0.17
>=75 years	0				0			
Influenza like illness								
>=18 - <65 years	5	(0.3)	5	0.61	4	(0.3)	4	0.33
>=65 - <75 years	2	(0.3)	3	0.67	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vaccination site pain								
>=18 - <65 years	5	(0.3)	5	0.48	5	(0.3)	5	0.50
>=65 - <75 years	4	(0.7)	5	1.35	2	(0.3)	2	0.47
>=75 years	1	(0.9)	2	1.79	2	(2.5)	2	4.25
Peripheral swelling								
>=18 - <65 years	4	(0.3)	5	0.42	4	(0.3)	4	0.37
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Injection site pruritus								
>=18 - <65 years	4	(0.3)	19	2.03	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Drug intolerance								
>=18 - <65 years	3	(0.2)	3	0.20	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site erythema								
>=18 - <65 years	2	(0.1)	2	0.23	3	(0.2)	4	0.54
>=65 - <75 years	0				2	(0.3)	2	0.47
>=75 years	0				0			
Chills								
>=18 - <65 years	2	(0.1)	2	0.18	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	1	(0.9)	1	0.90	0			
Swelling face								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	0				2	(0.3)	2	0.45
>=75 years	0				0			
Medical device site pain								
>=18 - <65 years	2	(0.1)	2	0.20	3	(0.2)	3	0.32
>=65 - <75 years	0				0			
>=75 years	0				0			
Gait disturbance								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				1	(1.3)	1	1.20
Injection site mass								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site swelling								
>=18 - <65 years	2	(0.1)	2	0.23	0			
>=65 - <75 years	0				1	(0.2)	1	0.28

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Injection site hypersensitivity								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site haemorrhage								
>=18 - <65 years	2	(0.1)	2	0.13	2	(0.1)	2	0.13
>=65 - <75 years	2	(0.4)	2	0.36	1	(0.2)	1	0.36
>=75 years	0				0			
Inflammation								
>=18 - <65 years	2	(0.1)	2	0.25	2	(0.1)	2	0.18
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Thirst								
>=18 - <65 years	2	(0.1)	2	0.18	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Injection site bruising								
>=18 - <65 years	2	(0.1)	2	0.18	3	(0.2)	3	0.25
>=65 - <75 years	1	(0.2)	1	0.32	2	(0.3)	2	0.34
>=75 years	0				0			
Injection site erythema								
>=18 - <65 years	2	(0.1)	2	0.18	3	(0.2)	3	0.20
>=65 - <75 years	1	(0.2)	3	0.95	1	(0.2)	1	0.17
>=75 years	0				0			
Injection site pain								
>=18 - <65 years	2	(0.1)	2	0.22	7	(0.5)	25	1.76
>=65 - <75 years	1	(0.2)	1	0.32	6	(1.0)	6	1.57
>=75 years	0				0			
Injection site urticaria								
>=18 - <65 years	1	(0.1)	2	0.27	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site haematoma								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Localised oedema								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Discomfort								
>=18 - <65 years	1	(0.1)	1	0.07	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.32	1	(0.2)	8	2.37
>=75 years	0				0			
Feeling abnormal								
>=18 - <65 years	1	(0.1)	3	0.20	1	(0.1)	1	0.07
>=65 - <75 years	2	(0.4)	2	0.61	0			
>=75 years	0				0			
Feeling hot								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Implant site pruritus								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site dermatitis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site eczema								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site hypersensitivity								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vaccination site reaction								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oedema due to renal disease								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Xerosis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Application site bruise								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Application site pruritus								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site haemorrhage								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.32	1	(0.2)	1	0.28
>=75 years	0				0			
Axillary pain								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Condition aggravated								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Cyst								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.3)	2	0.47
>=75 years	0				0			
Death								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				2	(2.6)	2	2.63
Early satiety								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Facial pain								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Hernia								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperthermia								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site haematoma								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	4	1.26	2	(0.3)	7	1.94
>=75 years	1	(1.1)	2	3.58	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injection site hypertrophy								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site induration								
>=18 - <65 years	0				2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site oedema								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site rash								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Medical device site inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site irritation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Multiple organ dysfunction syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Non-cardiac chest pain								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				3	(0.5)	5	0.85
>=75 years	0				0			
Oedema								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.30	2	(0.3)	2	0.47
>=75 years	0				0			
Procedural failure								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Swelling								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Systemic inflammatory response syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Vaccination site erythema								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Vaccination site inflammation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Vaccination site pruritus								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Vessel puncture site bruise								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Nervous system disorders								
All								
>=18 - <65 years	141	(9.4)	205	20.29	134	(8.9)	230	23.86
>=65 - <75 years	49	(8.6)	72	16.13	68	(11.5)	91	20.86
>=75 years	17	(17.1)	21	30.37	5	(6.2)	5	8.13
Headache								
>=18 - <65 years	54	(3.6)	73	7.72	48	(3.2)	61	6.03
>=65 - <75 years	11	(1.9)	13	3.16	14	(2.4)	17	3.81
>=75 years	5	(4.9)	6	8.16	2	(2.8)	2	2.88
Dizziness								
>=18 - <65 years	27	(1.8)	32	2.87	22	(1.5)	28	2.71
>=65 - <75 years	9	(1.6)	14	3.18	16	(2.7)	18	4.03
>=75 years	4	(4.1)	5	8.08	1	(1.1)	1	2.24
Tremor								
>=18 - <65 years	7	(0.5)	7	0.54	5	(0.3)	55	7.28
>=65 - <75 years	4	(0.7)	5	1.15	5	(0.8)	6	1.51
>=75 years	1	(1.0)	1	0.98	0			
Sciatica								
>=18 - <65 years	7	(0.5)	7	0.65	6	(0.4)	7	0.47
>=65 - <75 years	6	(1.1)	6	1.44	6	(1.0)	6	1.52
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Carpal tunnel syndrome								
>=18 - <65 years	7	(0.5)	7	0.56	4	(0.3)	4	0.44
>=65 - <75 years	3	(0.5)	3	0.64	4	(0.7)	4	0.93
>=75 years	1	(1.2)	1	2.21	0			
Hypoaesthesia								
>=18 - <65 years	7	(0.5)	10	0.90	6	(0.4)	6	0.62
>=65 - <75 years	2	(0.4)	2	0.36	4	(0.7)	5	0.96
>=75 years	0				0			
Migraine								
>=18 - <65 years	6	(0.4)	7	0.82	4	(0.3)	4	0.50
>=65 - <75 years	2	(0.4)	2	0.35	1	(0.2)	1	0.17
>=75 years	0				0			
Syncope								
>=18 - <65 years	6	(0.4)	6	0.52	0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Paraesthesia								
>=18 - <65 years	5	(0.3)	5	0.38	11	(0.7)	11	1.03
>=65 - <75 years	3	(0.5)	4	0.68	1	(0.2)	1	0.28
>=75 years	0				0			
Neuropathy peripheral								
>=18 - <65 years	4	(0.3)	5	0.47	5	(0.3)	5	0.45
>=65 - <75 years	1	(0.2)	1	0.32	4	(0.7)	4	0.92
>=75 years	1	(1.0)	1	0.98	1	(1.3)	1	1.20
Diabetic neuropathy								
>=18 - <65 years	4	(0.3)	4	0.48	8	(0.5)	8	0.68
>=65 - <75 years	2	(0.4)	2	0.35	4	(0.7)	4	1.07
>=75 years	0				0			
Tension headache								
>=18 - <65 years	2	(0.1)	3	0.25	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Disturbance in attention								
>=18 - <65 years	2	(0.1)	10	1.29	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Carotid artery stenosis								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Dysgeusia								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Carotid artery aneurysm								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Neuralgia								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Peripheral paralysis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Thalamic infarction								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Autonomic nervous system imbalance								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Burning sensation								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.1)	2	0.18
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Cervicobrachial syndrome								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Hypoglycaemic seizure								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Loss of consciousness								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.06
>=65 - <75 years	0				1	(0.2)	1	0.36
>=75 years	0				0			
Sinus headache								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Speech disorder								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Amnesia								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Cluster headache								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Intracranial pressure increased								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Transient ischaemic attack								
>=18 - <65 years	1	(0.1)	1	0.06	3	(0.2)	3	0.25
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Ageusia								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Anosmia								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Cervical radiculopathy								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Lumbar radiculopathy								
>=18 - <65 years	1	(0.1)	1	0.07	3	(0.2)	3	0.20
>=65 - <75 years	0				1	(0.2)	2	0.34
>=75 years	0				0			
Presyncope								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.13
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	0				0			
Cerebral arteriosclerosis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerebrovascular disorder								
>=18 - <65 years	1	(0.1)	1	0.11	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Memory impairment								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Vascular encephalopathy								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vascular headache								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Balance disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Basilar migraine								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Brain injury								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Carotid arteriosclerosis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerebral artery embolism								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerebral atrophy								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Cerebral haemorrhage								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Cerebral infarction								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Cerebrovascular accident								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.3)	2	0.47
>=75 years	0				0			
Cognitive disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.30
>=75 years	0				0			
Dementia Alzheimer's type								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Dizziness postural								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				1	(1.1)	1	1.82
Encephalopathy								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Essential tremor								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Facial nerve disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Facial paralysis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Haemorrhage intracranial								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.1)	1	2.32	0			
Hemiparesis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hypoglycaemic coma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Hypoglycaemic unconsciousness								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyporeflexia								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypotonia								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Ischaemic stroke								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Lethargy								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Mental impairment								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Meralgia paraesthetica								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Morton's neuralgia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Myelopathy								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Neuroglycopenia								
>=18 - <65 years	0				1	(0.1)	3	0.20
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ophthalmic migraine								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Orthostatic tremor								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Parkinsonian gait								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Piriformis syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Post herpetic neuralgia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.36
>=75 years	2	(1.9)	2	2.63	0			
Radiculopathy								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Restless legs syndrome								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Sleep deficit								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Somnolence								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	1	(1.1)	1	2.32	0			
Thrombotic stroke								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.3)	2	0.48
>=75 years	0				0			
Trigeminal neuralgia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	1	(0.9)	1	0.90	0			
Vertebral artery occlusion								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
White matter lesion								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Injury, poisoning and procedural complications								
All								
>=18 - <65 years	121	(8.1)	158	15.24	115	(7.7)	139	14.07
>=65 - <75 years	59	(10.4)	69	16.62	56	(9.5)	68	16.34
>=75 years	14	(13.5)	14	17.12	9	(11.2)	10	16.37
Vaccination complication								
>=18 - <65 years	14	(0.9)	18	1.82	22	(1.5)	30	3.00
>=65 - <75 years	4	(0.7)	4	1.02	6	(1.0)	7	1.45
>=75 years	2	(1.9)	2	2.63	1	(1.3)	1	2.12
Fall								
>=18 - <65 years	11	(0.7)	11	0.89	4	(0.3)	4	0.38
>=65 - <75 years	7	(1.2)	7	1.67	5	(0.9)	6	1.29
>=75 years	2	(1.9)	2	1.87	2	(2.5)	2	3.21
Contusion								
>=18 - <65 years	11	(0.7)	12	0.98	6	(0.4)	6	0.47
>=65 - <75 years	4	(0.7)	4	1.01	3	(0.5)	3	0.83
>=75 years	0				0			
Ligament sprain								
>=18 - <65 years	8	(0.5)	8	0.93	6	(0.4)	6	0.59
>=65 - <75 years	4	(0.7)	4	0.80	2	(0.3)	2	0.45
>=75 years	0				0			
Accidental overdose								
>=18 - <65 years	7	(0.5)	8	1.02	2	(0.1)	3	0.37
>=65 - <75 years	6	(1.0)	6	1.70	1	(0.2)	1	0.30
>=75 years	1	(1.0)	1	1.73	1	(1.2)	1	2.01
Skin abrasion								
>=18 - <65 years	6	(0.4)	9	0.83	2	(0.1)	2	0.25
>=65 - <75 years	3	(0.5)	3	0.80	3	(0.5)	3	0.76
>=75 years	0				0			
Prescribed overdose								
>=18 - <65 years	5	(0.3)	5	0.68	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Hand fracture								
>=18 - <65 years	5	(0.3)	5	0.50	1	(0.1)	1	0.06
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Incorrect dose administered								
>=18 - <65 years	5	(0.3)	5	0.64	4	(0.3)	6	0.65
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.28
>=75 years	0				0			
Road traffic accident								
>=18 - <65 years	4	(0.3)	5	0.52	0			
>=65 - <75 years	1	(0.2)	1	0.32	1	(0.2)	1	0.17
>=75 years	0				0			
Limb injury								
>=18 - <65 years	4	(0.3)	4	0.38	1	(0.1)	1	0.06
>=65 - <75 years	2	(0.4)	2	0.50	4	(0.7)	5	1.48
>=75 years	0				1	(1.3)	1	1.20
Ankle fracture								
>=18 - <65 years	3	(0.2)	3	0.20	1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.17	2	(0.3)	2	0.34
>=75 years	0				0			
Thermal burn								
>=18 - <65 years	3	(0.2)	3	0.29	1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Joint injury								
>=18 - <65 years	3	(0.2)	3	0.25	4	(0.3)	4	0.38
>=65 - <75 years	2	(0.4)	2	0.61	1	(0.2)	1	0.17
>=75 years	0				0			
Foot fracture								
>=18 - <65 years	3	(0.2)	3	0.29	1	(0.1)	1	0.07
>=65 - <75 years	0				2	(0.3)	2	0.48
>=75 years	0				0			
Tooth fracture								
>=18 - <65 years	3	(0.2)	3	0.29	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.30
>=75 years	0				0			
Rib fracture								
>=18 - <65 years	2	(0.1)	2	0.18	3	(0.2)	3	0.30
>=65 - <75 years	2	(0.4)	2	0.48	1	(0.2)	1	0.17
>=75 years	0				1	(1.3)	1	1.20
Procedural pain								
>=18 - <65 years	2	(0.1)	2	0.20	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	2	(0.4)	2	0.63	1	(0.2)	1	0.28
>=75 years	1	(0.9)	1	0.90	0			
Upper limb fracture								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Fibula fracture								
>=18 - <65 years	2	(0.1)	2	0.13	2	(0.1)	2	0.20
>=65 - <75 years	0				0			
>=75 years	0				0			
Injury								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Meniscus injury								
>=18 - <65 years	2	(0.1)	2	0.13	2	(0.1)	2	0.13
>=65 - <75 years	0				3	(0.5)	3	0.63
>=75 years	0				0			
Skin laceration								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.13
>=65 - <75 years	3	(0.5)	3	0.65	0			
>=75 years	2	(2.0)	2	3.46	0			
Arthropod sting								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.30
>=75 years	0				0			
Tendon rupture								
>=18 - <65 years	2	(0.1)	2	0.18	1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Arthropod bite								
>=18 - <65 years	2	(0.1)	2	0.23	4	(0.3)	4	0.43
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Medication error								
>=18 - <65 years	2	(0.1)	2	0.22	2	(0.1)	2	0.25
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Facial bones fracture								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Overdose								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.11	2	(0.1)	2	0.23
>=65 - <75 years	2	(0.4)	2	0.49	1	(0.2)	1	0.17
>=75 years	1	(1.0)	1	1.73	0			
Underdose								
>=18 - <65 years	1	(0.1)	1	0.11	4	(0.3)	4	0.45
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Wrist fracture								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Epicondylitis								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Face injury								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Product administration error								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.06
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Product dispensing error								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Animal bite								
>=18 - <65 years	1	(0.1)	1	0.06	2	(0.1)	2	0.19
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Back injury								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Hip fracture								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Injury of conjunctiva								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Neck injury								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Post procedural inflammation								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal compression fracture								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Burn oral cavity								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Burns first degree								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Heat illness								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	3	0.25
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Muscle strain								
>=18 - <65 years	1	(0.1)	1	0.07	3	(0.2)	3	0.32
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				1	(1.3)	1	1.20
Post procedural fistula								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Post procedural hypothyroidism								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Radius fracture								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Scar								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Traumatic haematoma								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Extra dose administered								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Wrong product administered								
>=18 - <65 years	1	(0.1)	2	0.23	4	(0.3)	4	0.54
>=65 - <75 years	0				2	(0.3)	2	0.57
>=75 years	0				0			
Gun shot wound								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Ligament rupture								
>=18 - <65 years	1	(0.1)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Procedural complication								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Accidental underdose								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Anaemia postoperative								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Animal scratch								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Bone contusion								
>=18 - <65 years	0				2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			
Cervical vertebral fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Chillblains								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Clavicle fracture								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Concussion								
>=18 - <65 years	0				2	(0.1)	2	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Corneal abrasion								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.36
>=75 years	0				0			
Craniocerebral injury								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Crush injury								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Deafness traumatic								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Endotracheal intubation complication								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Exposure to SARS-CoV-2								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Eye injury								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Femoral neck fracture								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Head injury								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Heat stroke								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.36
>=75 years	0				0			
Humerus fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Inflammation of wound								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			
Intentional overdose								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Intentional product use issue								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Lower limb fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Multiple injuries								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			
Muscle contusion								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	2.12
Muscle injury								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.30
>=75 years	0				0			
Nerve injury								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Penile contusion								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Periprocedural myocardial infarction								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Post procedural complication								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Post procedural haematuria								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			
Post procedural haemorrhage								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Post procedural stroke								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Post procedural swelling								
>=18 - <65 years	0				1	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Post-traumatic neck syndrome								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Radiation skin injury								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Scratch								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Seroma								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Soft tissue injury								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Spinal column injury								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Stab wound								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Subcutaneous haematoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.30
>=75 years	0				0			
Subdural haematoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Sunburn								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Tendon injury								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Tibia fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	2.12
Wound								
>=18 - <65 years	0				6	(0.4)	6	0.66
>=65 - <75 years	3	(0.5)	3	0.67	0			
>=75 years	0				0			
Wound dehiscence								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Wrong dose								
>=18 - <65 years	0				2	(0.1)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Eye disorders								
All								
>=18 - <65 years	110	(7.3)	149	14.90	118	(7.9)	141	14.20
>=65 - <75 years	56	(9.9)	65	16.33	56	(9.5)	84	21.35
>=75 years	10	(10.1)	11	15.90	6	(7.4)	11	18.98
Diabetic retinopathy								
>=18 - <65 years	43	(2.9)	48	5.10	51	(3.4)	55	5.86
>=65 - <75 years	17	(3.0)	18	4.99	19	(3.2)	19	4.61
>=75 years	4	(4.3)	4	7.24	2	(2.5)	2	3.32
Cataract								
>=18 - <65 years	17	(1.1)	20	1.84	17	(1.1)	19	1.88
>=65 - <75 years	9	(1.6)	11	2.34	8	(1.4)	9	1.63
>=75 years	2	(1.9)	2	1.87	2	(2.5)	2	2.39
Macular oedema								
>=18 - <65 years	10	(0.7)	11	1.20	4	(0.3)	4	0.32
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.30
>=75 years	1	(1.2)	1	2.21	0			
Retinopathy hypertensive								
>=18 - <65 years	8	(0.5)	9	0.92	3	(0.2)	3	0.30
>=65 - <75 years	0				2	(0.3)	2	0.59
>=75 years	0				0			
Vision blurred								
>=18 - <65 years	6	(0.4)	6	0.63	5	(0.3)	5	0.43
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic retinal oedema								
>=18 - <65 years	5	(0.3)	5	0.62	4	(0.3)	5	0.54
>=65 - <75 years	1	(0.2)	1	0.30	6	(1.0)	6	1.41
>=75 years	0				0			
Dry eye								
>=18 - <65 years	4	(0.3)	4	0.38	7	(0.5)	7	0.59
>=65 - <75 years	3	(0.5)	3	0.51	0			
>=75 years	0				0			
Blepharitis								
>=18 - <65 years	3	(0.2)	3	0.24	0			
>=65 - <75 years	2	(0.4)	2	0.36	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cataract nuclear								
>=18 - <65 years	2	(0.1)	2	0.25	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Ocular hypertension								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	0				2	(0.3)	3	0.90
>=75 years	0				0			
Arteriosclerotic retinopathy								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Glaucoma								
>=18 - <65 years	2	(0.1)	2	0.20	1	(0.1)	1	0.11
>=65 - <75 years	2	(0.3)	2	0.33	4	(0.7)	4	1.26
>=75 years	0				1	(1.3)	1	1.20
Conjunctival haemorrhage								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Eye pain								
>=18 - <65 years	2	(0.1)	2	0.13	2	(0.1)	2	0.13
>=65 - <75 years	2	(0.4)	2	0.48	1	(0.2)	1	0.30
>=75 years	0				0			
Retinal haemorrhage								
>=18 - <65 years	2	(0.1)	2	0.23	0			
>=65 - <75 years	2	(0.3)	2	0.47	0			
>=75 years	0				0			
Non-proliferative retinopathy								
>=18 - <65 years	2	(0.1)	3	0.36	3	(0.2)	3	0.39
>=65 - <75 years	1	(0.2)	1	0.34	1	(0.2)	1	0.30
>=75 years	0				0			
Dry age-related macular degeneration								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal exudates								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				2	(0.3)	2	0.59
>=75 years	0				0			
Corneal erosion								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Epiretinal membrane								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.17
>=75 years	0				1	(1.2)	1	2.01
Retinal vascular disorder								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Amaurosis fugax								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Angle closure glaucoma								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Astigmatism								
>=18 - <65 years	1	(0.1)	2	0.13	4	(0.3)	4	0.38
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.30
>=75 years	0				0			
Conjunctival hyperaemia								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Maculopathy								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal degeneration								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Visual impairment								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	9	2.67
>=75 years	0				0			
Vitreous detachment								
>=18 - <65 years	1	(0.1)	1	0.06	2	(0.1)	2	0.27
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	1	(0.9)	1	0.90	0			
Acquired epiblepharon								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Conjunctival erosion								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Conjunctivitis allergic								
>=18 - <65 years	1	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Optic disc vascular disorder								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Post thrombotic retinopathy								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal aneurysm								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Retinal tear								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Presbyopia								
>=18 - <65 years	1	(0.1)	1	0.11	2	(0.1)	2	0.25
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Retinal scar								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Ocular hyperaemia								
>=18 - <65 years	1	(0.1)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.73	1	(1.2)	2	4.02
Age-related macular degeneration								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	1	(1.0)	1	0.98	0			
Asthenopia								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Chorioretinal atrophy								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Conjunctival suffusion								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			
Corneal bleeding								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Cystoid macular oedema								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Dacryoadenitis acquired								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Diplopia								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	2	(0.4)	2	0.49	0			
>=75 years	0				0			
Eye discharge								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Eye inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	2	(0.4)	2	0.50	1	(0.2)	1	0.30
>=75 years	0				0			
Eye irritation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Eye pruritus								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	2	4.02
Eyelid oedema								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypermetropia								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Lacrimation increased								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Macular degeneration								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				2	(0.3)	2	0.47
>=75 years	0				0			
Macular hole								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.01
Meibomianitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Myopia								
>=18 - <65 years	0				3	(0.2)	3	0.26
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Normal tension glaucoma								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Ocular ischaemic syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Open angle glaucoma								
>=18 - <65 years	0				1	(0.1)	2	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Ophthalmic vein thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Optic disc haemorrhage								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Photophobia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Photopsia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.36
>=75 years	0				0			
Posterior capsule opacification								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.3)	2	0.52	0			
>=75 years	0				0			
Pterygium								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal artery occlusion								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal deposits								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Retinal detachment								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.3)	2	0.47
>=75 years	0				0			
Retinal drusen								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.30
>=75 years	0				0			
Retinal vein occlusion								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.17
>=75 years	0				0			
Retinopathy								
>=18 - <65 years	0				2	(0.1)	2	0.25
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Scintillating scotoma								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Uveitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Visual acuity reduced								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Vitreous degeneration								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Vitreous floaters								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				2	(0.3)	2	0.64
>=75 years	0				0			
Vitreous haemorrhage								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	2	(0.3)	2	0.59	1	(0.2)	1	0.30
>=75 years	0				0			
Vitreous opacities								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Respiratory, thoracic and mediastinal disorders								
All								
>=18 - <65 years	91	(6.1)	122	11.64	78	(5.2)	98	9.79
>=65 - <75 years	35	(6.2)	47	11.37	41	(6.9)	52	11.49
>=75 years	6	(5.9)	8	11.10	3	(3.7)	3	5.22
Cough								
>=18 - <65 years	20	(1.3)	22	2.05	18	(1.2)	19	2.02
>=65 - <75 years	6	(1.0)	7	1.70	9	(1.5)	10	2.06
>=75 years	0				1	(1.2)	1	2.01
Oropharyngeal pain								
>=18 - <65 years	16	(1.1)	16	1.46	13	(0.9)	13	1.37
>=65 - <75 years	8	(1.4)	10	2.33	6	(1.0)	8	1.74
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Rhinorrhoea								
>=18 - <65 years	10	(0.7)	13	1.25	7	(0.5)	7	0.87
>=65 - <75 years	2	(0.3)	2	0.58	6	(1.0)	6	1.28
>=75 years	0				0			
Respiratory disorder								
>=18 - <65 years	7	(0.5)	7	0.84	6	(0.4)	6	0.59
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.30
>=75 years	0				0			
Epistaxis								
>=18 - <65 years	6	(0.4)	10	1.17	1	(0.1)	2	0.13
>=65 - <75 years	0				1	(0.2)	2	0.59
>=75 years	0				0			
Dyspnoea								
>=18 - <65 years	6	(0.4)	6	0.53	8	(0.5)	9	0.80
>=65 - <75 years	2	(0.4)	2	0.62	4	(0.7)	4	0.93
>=75 years	1	(1.0)	1	0.98	1	(1.3)	1	1.20
Sleep apnoea syndrome								
>=18 - <65 years	5	(0.3)	5	0.42	0			
>=65 - <75 years	2	(0.4)	2	0.36	0			
>=75 years	0				0			
Nasal congestion								
>=18 - <65 years	4	(0.3)	4	0.26	4	(0.3)	4	0.33
>=65 - <75 years	4	(0.7)	4	0.96	1	(0.2)	1	0.17
>=75 years	2	(1.9)	2	1.87	0			
Asthma								
>=18 - <65 years	4	(0.3)	5	0.43	0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.30
>=75 years	0				0			
Sneezing								
>=18 - <65 years	3	(0.2)	3	0.32	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Sinus congestion								
>=18 - <65 years	3	(0.2)	3	0.34	2	(0.1)	2	0.20
>=65 - <75 years	3	(0.5)	4	0.98	0			
>=75 years	0				0			
Productive cough								
>=18 - <65 years	2	(0.1)	2	0.18	4	(0.3)	4	0.45
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	1	(1.0)	1	0.98	0			
Rhinitis allergic								
>=18 - <65 years	2	(0.1)	2	0.20	4	(0.3)	8	0.71
>=65 - <75 years	0				2	(0.3)	2	0.55

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Nasal septum deviation								
>=18 - <65 years	2	(0.1)	2	0.23	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Chronic obstructive pulmonary disease								
>=18 - <65 years	2	(0.1)	2	0.23	0			
>=65 - <75 years	2	(0.4)	2	0.47	1	(0.2)	1	0.17
>=75 years	0				0			
Nasal obstruction								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Bronchial hyperreactivity								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulmonary congestion								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Upper-airway cough syndrome								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Acute respiratory failure								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	1	(1.0)	1	1.73	0			
Increased viscosity of upper respiratory secretion								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Upper respiratory tract inflammation								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Acquired diaphragmatic eventration								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Bronchiectasis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Dyspnoea exertional								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	1	(1.1)	1	2.32	0			
Emphysema								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.18
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Interstitial lung disease								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Laryngeal cyst								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nasal turbinate hypertrophy								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulmonary embolism								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulmonary fibrosis								
>=18 - <65 years	1	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Pleurisy								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Sinus pain								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	1	(0.2)	2	0.36	1	(0.2)	1	0.28
>=75 years	0				0			
Bronchospasm								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Acute pulmonary oedema								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Allergic bronchitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Allergic cough								
>=18 - <65 years	0				2	(0.1)	2	0.25
>=65 - <75 years	0				0			
>=75 years	0				0			
Aphonia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Bronchitis chronic								
>=18 - <65 years	0				2	(0.1)	2	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Dry throat								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Dysphonia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.55
>=75 years	0				0			
Haemoptysis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Hiccups								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.1)	1	2.32	0			
Lung disorder								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Nasal dryness								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Paranasal cyst								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Paranasal sinus discomfort								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Pleural disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.01
Pleural effusion								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	0				0			
Pleuritic pain								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulmonary hypertension								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Pulmonary mass								
>=18 - <65 years	0				3	(0.2)	3	0.30
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Respiratory failure								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.29	1	(0.2)	1	0.17
>=75 years	0				0			
Respiratory tract inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Throat irritation								
>=18 - <65 years	0				2	(0.1)	2	0.25
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			

Metabolism and nutrition disorders

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
>=18 - <65 years	91	(6.1)	114	9.88	86	(5.8)	104	9.31
>=65 - <75 years	35	(6.2)	42	9.34	41	(6.9)	54	11.66
>=75 years	6	(5.6)	7	7.35	7	(8.6)	11	20.29
Dyslipidaemia								
>=18 - <65 years	17	(1.1)	18	1.57	11	(0.7)	11	1.04
>=65 - <75 years	3	(0.5)	3	0.81	6	(1.0)	6	1.61
>=75 years	1	(0.9)	1	0.90	0			
Hypoglycaemia								
>=18 - <65 years	16	(1.1)	24	2.60	12	(0.8)	18	1.62
>=65 - <75 years	2	(0.4)	2	0.61	7	(1.2)	14	2.76
>=75 years	0				4	(4.7)	8	16.46
Vitamin D deficiency								
>=18 - <65 years	14	(0.9)	14	1.04	11	(0.7)	11	0.95
>=65 - <75 years	2	(0.4)	2	0.35	3	(0.5)	3	0.51
>=75 years	1	(1.0)	1	0.98	0			
Hyperlipidaemia								
>=18 - <65 years	10	(0.7)	10	0.80	11	(0.7)	11	0.90
>=65 - <75 years	4	(0.7)	4	0.97	2	(0.3)	2	0.34
>=75 years	0				0			
Vitamin B12 deficiency								
>=18 - <65 years	9	(0.6)	9	0.58	1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	1	(1.0)	1	0.98	0			
Hypertriglyceridaemia								
>=18 - <65 years	8	(0.5)	8	0.68	6	(0.4)	6	0.55
>=65 - <75 years	2	(0.4)	2	0.36	2	(0.3)	2	0.45
>=75 years	0				0			
Hyperuricaemia								
>=18 - <65 years	4	(0.3)	4	0.38	3	(0.2)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Iron deficiency								
>=18 - <65 years	3	(0.2)	3	0.19	3	(0.2)	3	0.19
>=65 - <75 years	2	(0.4)	2	0.35	0			
>=75 years	0				0			
Hyperglycaemia								
>=18 - <65 years	3	(0.2)	3	0.29	11	(0.7)	11	0.99
>=65 - <75 years	2	(0.4)	3	0.80	3	(0.5)	3	0.91
>=75 years	1	(1.0)	1	1.73	0			
Hyperkalaemia								
>=18 - <65 years	3	(0.2)	3	0.29	5	(0.3)	5	0.43
>=65 - <75 years	4	(0.7)	5	1.01	5	(0.8)	5	1.24
>=75 years	1	(0.9)	1	0.90	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Folate deficiency								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Zinc deficiency								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Hyponatraemia								
>=18 - <65 years	2	(0.1)	2	0.25	0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.30
>=75 years	0				0			
Dehydration								
>=18 - <65 years	2	(0.1)	2	0.18	2	(0.1)	3	0.34
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypercholesterolaemia								
>=18 - <65 years	2	(0.1)	2	0.23	2	(0.1)	2	0.25
>=65 - <75 years	1	(0.2)	1	0.18	2	(0.3)	2	0.48
>=75 years	0				0			
Diabetes mellitus								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Diabetes mellitus inadequate control								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Gout								
>=18 - <65 years	1	(0.1)	1	0.06	2	(0.1)	3	0.19
>=65 - <75 years	3	(0.5)	4	0.70	3	(0.5)	3	0.51
>=75 years	0				1	(1.3)	1	1.20
Vitamin B complex deficiency								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Decreased appetite								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.18
>=65 - <75 years	3	(0.5)	3	0.68	2	(0.3)	2	0.34
>=75 years	0				1	(1.3)	1	1.20
Fluid retention								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Increased appetite								
>=18 - <65 years	1	(0.1)	1	0.07	4	(0.3)	4	0.42
>=65 - <75 years	2	(0.4)	2	0.35	2	(0.3)	3	0.72
>=75 years	0				0			
Obesity								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.25
>=65 - <75 years	0				0			
>=75 years	0				0			
Abnormal weight gain								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Appetite disorder								
>=18 - <65 years	0				1	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrolyte imbalance								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Food craving								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperammonaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Hypercalcaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Hypernatraemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Hypoalbuminaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Hypokalaemia								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Insulin resistance								
>=18 - <65 years	0				2	(0.1)	2	0.20
>=65 - <75 years	0				0			
>=75 years	0				0			
Lactic acidosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Lipomatosis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Magnesium deficiency								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			
Malnutrition								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Metabolic acidosis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Metabolic disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.44
Skin and subcutaneous tissue disorders								
All								
>=18 - <65 years	80	(5.3)	86	8.11	94	(6.3)	115	11.24
>=65 - <75 years	39	(6.9)	41	9.95	31	(5.2)	37	7.27
>=75 years	4	(3.9)	4	5.85	3	(3.4)	3	5.75
Rash								
>=18 - <65 years	10	(0.7)	10	1.06	6	(0.4)	7	0.51
>=65 - <75 years	4	(0.7)	4	0.82	5	(0.8)	5	0.98
>=75 years	0				0			
Eczema								
>=18 - <65 years	9	(0.6)	9	0.74	7	(0.5)	7	0.73
>=65 - <75 years	1	(0.2)	1	0.17	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Dermatitis								
>=18 - <65 years	6	(0.4)	6	0.68	4	(0.3)	5	0.54
>=65 - <75 years	1	(0.2)	1	0.32	3	(0.5)	3	0.51
>=75 years	0				0			
Dermatitis contact								
>=18 - <65 years	6	(0.4)	7	0.61	9	(0.6)	9	0.99
>=65 - <75 years	1	(0.2)	1	0.18	5	(0.8)	5	1.17
>=75 years	0				0			
Hyperhidrosis								
>=18 - <65 years	6	(0.4)	6	0.49	4	(0.3)	4	0.36
>=65 - <75 years	2	(0.4)	2	0.61	1	(0.2)	1	0.17
>=75 years	0				0			
Urticaria								
>=18 - <65 years	5	(0.3)	5	0.42	10	(0.7)	10	0.91
>=65 - <75 years	2	(0.3)	2	0.59	2	(0.3)	2	0.34
>=75 years	0				0			
Alopecia								
>=18 - <65 years	4	(0.3)	4	0.48	3	(0.2)	3	0.25
>=65 - <75 years	3	(0.5)	3	0.67	0			
>=75 years	1	(1.0)	1	1.73	0			
Pruritus								
>=18 - <65 years	4	(0.3)	4	0.31	9	(0.6)	9	0.86
>=65 - <75 years	4	(0.7)	4	0.96	2	(0.3)	2	0.34
>=75 years	0				1	(1.1)	1	1.82
Cold sweat								
>=18 - <65 years	4	(0.3)	4	0.36	6	(0.4)	10	1.26
>=65 - <75 years	0				2	(0.3)	2	0.53
>=75 years	0				0			
Dry skin								
>=18 - <65 years	3	(0.2)	3	0.27	5	(0.3)	5	0.44
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Skin irritation								
>=18 - <65 years	2	(0.1)	3	0.27	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	1	(1.1)	1	2.32	0			
Dermatitis allergic								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Rash erythematous								
>=18 - <65 years	2	(0.1)	2	0.25	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Acne								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Miliaria								
>=18 - <65 years	1	(0.1)	1	0.11	4	(0.3)	4	0.27
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Blister								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.1)	2	0.19
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Dermal cyst								
>=18 - <65 years	1	(0.1)	1	0.14	4	(0.3)	4	0.38
>=65 - <75 years	0				0			
>=75 years	0				0			
Hidradenitis								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Ingrown hair								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Lichen sclerosus								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Macule								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Xeroderma								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Erythema								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.13
>=65 - <75 years	0				3	(0.5)	3	0.62
>=75 years	0				0			
Livedo reticularis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nail bed inflammation								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Angioedema								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.20
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Granuloma annulare								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Psoriasis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	1	(0.2)	1	0.18	2	(0.3)	2	0.45
>=75 years	0				0			
Skin exfoliation								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Skin fissures								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin lesion								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	1	0.34	1	(0.2)	1	0.17
>=75 years	0				0			
Urticaria contact								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Umbilical haematoma								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Actinic keratosis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Alopecia areata								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Asteatosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Chronic spontaneous urticaria								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Cold urticaria								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Decubitus ulcer								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Dermatitis atopic								
>=18 - <65 years	0				2	(0.1)	2	0.27
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic foot								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Drug eruption								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Ecchymosis								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Haemorrhage subcutaneous								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Hyperkeratosis								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				1	(1.1)	1	1.82

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ingrowing nail								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	2	(0.4)	2	0.35	1	(0.2)	1	0.17
>=75 years	0				0			
Intertrigo								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Lentigo								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Leukoplakia								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Lipodystrophy acquired								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Lipohypertrophy								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Myxoid cyst								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Neurodermatitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	2.12
Night sweats								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.48	0			
>=75 years	1	(0.9)	1	0.90	0			
Pruritus allergic								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Purpura								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Rash maculo-papular								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Rash papular								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Seborrhoea								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin discolouration								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Skin odour abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Skin reaction								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin ulcer								
>=18 - <65 years	0				5	(0.3)	5	0.53
>=65 - <75 years	4	(0.7)	4	0.96	0			
>=75 years	0				0			
Telangiectasia								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Urticaria thermal								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Investigations								
All								
>=18 - <65 years	64	(4.3)	73	6.85	56	(3.7)	64	6.06
>=65 - <75 years	25	(4.4)	29	6.98	20	(3.4)	21	5.32
>=75 years	5	(5.0)	7	9.31	3	(3.9)	3	3.83

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Weight increased								
>=18 - <65 years	15	(1.0)	15	1.35	13	(0.9)	13	1.07
>=65 - <75 years	5	(0.9)	5	1.12	5	(0.8)	5	1.19
>=75 years	0				0			
Blood creatinine increased								
>=18 - <65 years	6	(0.4)	6	0.59	0			
>=65 - <75 years	2	(0.4)	2	0.62	0			
>=75 years	0				0			
Blood triglycerides increased								
>=18 - <65 years	4	(0.3)	4	0.38	3	(0.2)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
SARS-CoV-2 test positive								
>=18 - <65 years	4	(0.3)	4	0.36	4	(0.3)	4	0.54
>=65 - <75 years	2	(0.4)	2	0.62	0			
>=75 years	1	(1.0)	1	1.73	0			
Blood pressure increased								
>=18 - <65 years	3	(0.2)	3	0.34	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	2	(0.3)	2	0.47
>=75 years	1	(1.1)	1	1.79	1	(1.3)	1	1.20
Blood immunoglobulin E increased								
>=18 - <65 years	3	(0.2)	3	0.19	3	(0.2)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Alanine aminotransferase increased								
>=18 - <65 years	3	(0.2)	3	0.29	0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Electrocardiogram abnormal								
>=18 - <65 years	2	(0.1)	2	0.20	1	(0.1)	1	0.06
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Blood cholesterol increased								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.13
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Weight decreased								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.13
>=65 - <75 years	2	(0.4)	2	0.35	1	(0.2)	1	0.17
>=75 years	0				0			
Liver function test increased								
>=18 - <65 years	2	(0.1)	2	0.18	1	(0.1)	1	0.06
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	1	(1.2)	1	2.21	0			
Aspartate aminotransferase increased								
>=18 - <65 years	2	(0.1)	2	0.25	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Occult blood								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Angiogram								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood testosterone decreased								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Heart rate increased								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatic enzyme increased								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Hepatitis B virus test positive								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Mycobacterium tuberculosis complex test positive								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrocardiogram ST segment abnormal								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrocardiogram T wave inversion								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Low density lipoprotein increased								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.34	1	(0.2)	1	0.28
>=75 years	0				0			
Prostatic specific antigen increased								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
QRS axis abnormal								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Transaminases increased								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood creatine phosphokinase increased								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Body temperature increased								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Glycosylated haemoglobin increased								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Transferrin saturation decreased								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood alkaline phosphatase increased								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	2	(0.4)	2	0.63	0			
>=75 years	0				0			
Liver function test abnormal								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Arthroscopy								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood glucose fluctuation								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood potassium increased								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Monocyte count decreased								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Monofilament pressure perception test								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Amylase increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Antinuclear antibody positive								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood creatine increased								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Blood glucose decreased								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood glucose increased								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.44
Blood pressure decreased								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood uric acid increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.36
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood urine present								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	3	0.50	1	(0.2)	1	0.30
>=75 years	0				0			
Bone density decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Breath sounds abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Carbohydrate antigen 19-9 increased								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac murmur								
>=18 - <65 years	0				2	(0.1)	2	0.20
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac stress test abnormal								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Catheterisation cardiac								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Ejection fraction decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Electrocardiogram P wave biphasic								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrocardiogram repolarisation abnormality								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Electrocardiogram ST segment depression								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Eosinophil count increased								
>=18 - <65 years	0				1	(0.1)	2	0.27
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Free fatty acids increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Glomerular filtration rate decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Grip strength decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Haematocrit increased								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Haemoglobin decreased								
>=18 - <65 years	0				2	(0.1)	2	0.20
>=65 - <75 years	0				0			
>=75 years	0				0			
Haemoglobin increased								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
International normalised ratio abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
International normalised ratio decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
International normalised ratio increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	2	1.79	0			
Intraocular pressure increased								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Lipase increased								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Lipids abnormal								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Lipids increased								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Occult blood positive								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Platelet count decreased								
>=18 - <65 years	0				2	(0.1)	2	0.23
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Red blood cell count decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Thyroid function test abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Vitamin D decreased								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
White blood cell count decreased								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Vascular disorders								
All								
>=18 - <65 years	49	(3.3)	52	4.39	44	(2.9)	54	4.91
>=65 - <75 years	25	(4.4)	31	7.68	33	(5.5)	41	8.76

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	5	(4.9)	5	5.95	3	(3.8)	4	7.48
Hypertension								
>=18 - <65 years	26	(1.7)	26	2.45	22	(1.5)	25	2.21
>=65 - <75 years	8	(1.4)	8	2.03	15	(2.5)	17	4.07
>=75 years	3	(2.9)	3	2.85	1	(1.4)	1	1.44
Arteriosclerosis								
>=18 - <65 years	3	(0.2)	3	0.27	3	(0.2)	3	0.30
>=65 - <75 years	1	(0.2)	1	0.18	4	(0.7)	4	0.79
>=75 years	0				0			
Hypotension								
>=18 - <65 years	3	(0.2)	3	0.20	1	(0.1)	1	0.07
>=65 - <75 years	3	(0.5)	3	0.81	2	(0.3)	2	0.47
>=75 years	0				0			
Peripheral arterial occlusive disease								
>=18 - <65 years	2	(0.1)	3	0.20	1	(0.1)	1	0.07
>=65 - <75 years	2	(0.4)	2	0.62	1	(0.2)	1	0.17
>=75 years	0				0			
Superficial vein thrombosis								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Peripheral coldness								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Haematoma								
>=18 - <65 years	2	(0.1)	2	0.18	2	(0.1)	2	0.19
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.01
Blood pressure inadequately controlled								
>=18 - <65 years	1	(0.1)	1	0.06	2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Hot flush								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Venous stenosis								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic arteriosclerosis								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.19

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	1	(0.9)	1	0.90	1	(1.2)	1	2.01
Flushing								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Peripheral artery occlusion								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Peripheral artery stenosis								
>=18 - <65 years	1	(0.1)	2	0.13	0			
>=65 - <75 years	1	(0.2)	3	0.91	0			
>=75 years	0				0			
Peripheral vascular disorder								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic vascular disorder								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Varicose ulceration								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Aneurysm								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic aneurysm								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Aortic dilatation								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic stenosis								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Arterial insufficiency								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Blood pressure fluctuation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Brachiocephalic arteriosclerosis								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Deep vein thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.2)	1	2.21	0			
Hypertensive crisis								
>=18 - <65 years	0				1	(0.1)	3	0.35
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	0				0			
Hypertensive urgency								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	2	0.34
>=75 years	0				0			
Iliac artery stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Intermittent claudication								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Macroangiopathy								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Neovascularisation								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Orthostatic hypotension								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.3)	2	0.59	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Peripheral artery aneurysm								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.01
Peripheral ischaemia								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Peripheral venous disease								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	2	(0.4)	2	0.49	2	(0.3)	2	0.34
>=75 years	0				0			
Phlebitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Thrombophlebitis								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Varicose vein								
>=18 - <65 years	0				2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Cardiac disorders								
All								
>=18 - <65 years	46	(3.1)	63	5.15	47	(3.1)	70	6.04
>=65 - <75 years	40	(7.1)	55	12.07	35	(5.9)	43	8.31
>=75 years	9	(8.6)	15	14.99	2	(2.5)	2	3.68
Coronary artery disease								
>=18 - <65 years	7	(0.5)	7	0.51	5	(0.3)	5	0.43
>=65 - <75 years	5	(0.9)	5	1.01	5	(0.8)	5	0.85
>=75 years	0				0			
Cardiac failure								
>=18 - <65 years	5	(0.3)	5	0.38	3	(0.2)	4	0.43
>=65 - <75 years	3	(0.5)	3	0.53	0			
>=75 years	0				0			
Atrial fibrillation								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	4	(0.3)	4	0.31	1	(0.1)	1	0.12
>=65 - <75 years	5	(0.9)	5	1.07	5	(0.8)	5	0.85
>=75 years	4	(3.6)	5	4.56	0			
Ventricular extrasystoles								
>=18 - <65 years	4	(0.3)	4	0.41	2	(0.1)	3	0.19
>=65 - <75 years	3	(0.5)	3	0.70	0			
>=75 years	1	(0.9)	1	0.90	0			
Angina pectoris								
>=18 - <65 years	4	(0.3)	4	0.33	3	(0.2)	3	0.24
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	2	(2.2)	2	3.19	0			
Palpitations								
>=18 - <65 years	4	(0.3)	4	0.34	4	(0.3)	4	0.38
>=65 - <75 years	3	(0.5)	3	0.66	2	(0.3)	2	0.34
>=75 years	0				1	(1.1)	1	2.24
Acute myocardial infarction								
>=18 - <65 years	4	(0.3)	4	0.26	5	(0.3)	5	0.43
>=65 - <75 years	5	(0.9)	5	1.26	3	(0.5)	3	0.64
>=75 years	0				0			
Acute coronary syndrome								
>=18 - <65 years	4	(0.3)	4	0.26	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Myocardial infarction								
>=18 - <65 years	4	(0.3)	4	0.36	4	(0.3)	4	0.26
>=65 - <75 years	2	(0.4)	2	0.49	0			
>=75 years	0				0			
Tachycardia								
>=18 - <65 years	3	(0.2)	3	0.19	5	(0.3)	5	0.48
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	0				0			
Angina unstable								
>=18 - <65 years	2	(0.1)	2	0.13	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Coronary artery occlusion								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Mitral valve incompetence								
>=18 - <65 years	2	(0.1)	2	0.18	2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Myocardial ischaemia								
>=18 - <65 years	2	(0.1)	2	0.18	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.17
>=75 years	0				0			
Supraventricular extrasystoles								
>=18 - <65 years	2	(0.1)	2	0.22	0			
>=65 - <75 years	1	(0.2)	1	0.18	2	(0.3)	2	0.34
>=75 years	0				0			
Cardiac flutter								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Bundle branch block right								
>=18 - <65 years	1	(0.1)	1	0.14	4	(0.3)	5	0.45
>=65 - <75 years	0				3	(0.5)	3	0.64
>=75 years	1	(0.9)	1	0.90	0			
Cardiovascular disorder								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Arrhythmia								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.17	3	(0.5)	3	0.62
>=75 years	0				0			
Arteriosclerosis coronary artery								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Supraventricular tachycardia								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Cardiac failure chronic								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Pericardial effusion								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Bundle branch block left								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Left ventricular dysfunction								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.17
>=75 years	0				0			
Aortic valve calcification								
>=18 - <65 years	0				2	(0.1)	2	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic valve incompetence								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Aortic valve sclerosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Atrial enlargement								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Atrial flutter								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Atrial thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Atrioventricular block complete								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.44
Atrioventricular block first degree								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.48	0			
>=75 years	0				0			
Bradycardia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	2	(0.3)	2	0.48
>=75 years	0				0			
Cardiac arrest								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				1	(0.2)	1	0.17

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Cardiac dysfunction								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac failure acute								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Cardiac failure congestive								
>=18 - <65 years	0				2	(0.1)	3	0.35
>=65 - <75 years	4	(0.7)	4	0.82	0			
>=75 years	0				0			
Cardiac perfusion defect								
>=18 - <65 years	0				1	(0.1)	2	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac ventricular thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Cardio-respiratory arrest								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Cardiomegaly								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Chronic coronary syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Coronary artery stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Diastolic dysfunction								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Left atrial dilatation								
>=18 - <65 years	0				1	(0.1)	1	0.07

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Left atrial enlargement								
>=18 - <65 years	0				2	(0.1)	2	0.18
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Left ventricular hypertrophy								
>=18 - <65 years	0				0			
>=65 - <75 years	3	(0.5)	3	0.53	2	(0.3)	2	0.47
>=75 years	0				0			
Mitral valve stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Pericarditis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	1	(0.2)	1	0.30
>=75 years	0				0			
Sinus arrhythmia								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Sinus bradycardia								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				2	(0.3)	2	0.47
>=75 years	0				0			
Sinus tachycardia								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Subendocardial ischaemia								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Tricuspid valve incompetence								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Ventricular arrhythmia								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Ventricular tachycardia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal and urinary disorders								
All								
>=18 - <65 years	29	(1.9)	35	3.14	30	(2.0)	41	3.55
>=65 - <75 years	21	(3.7)	26	6.39	19	(3.2)	19	3.80
>=75 years	4	(3.7)	4	4.42	5	(6.6)	10	15.14
Renal cyst								
>=18 - <65 years	5	(0.3)	5	0.43	4	(0.3)	4	0.38
>=65 - <75 years	2	(0.4)	2	0.62	1	(0.2)	1	0.17
>=75 years	0				0			
Renal pain								
>=18 - <65 years	3	(0.2)	3	0.34	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal impairment								
>=18 - <65 years	3	(0.2)	3	0.25	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.32	1	(0.2)	1	0.17
>=75 years	0				1	(1.4)	1	1.44
Dysuria								
>=18 - <65 years	3	(0.2)	4	0.26	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.30	2	(0.3)	2	0.34
>=75 years	0				1	(1.4)	1	1.44
Nephrolithiasis								
>=18 - <65 years	3	(0.2)	3	0.20	2	(0.1)	2	0.18
>=65 - <75 years	2	(0.4)	2	0.35	0			
>=75 years	0				2	(2.5)	4	6.42
Pollakiuria								
>=18 - <65 years	3	(0.2)	3	0.34	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	1	(0.9)	1	0.90	1	(1.4)	1	1.44
Microalbuminuria								
>=18 - <65 years	2	(0.1)	2	0.20	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Ureterolithiasis								
>=18 - <65 years	2	(0.1)	2	0.18	2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				1	(1.3)	1	1.20
Bladder prolapse								
>=18 - <65 years	1	(0.1)	1	0.11	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Hydronephrosis								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Polyuria								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Urine odour abnormal								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Nocturia								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	0			
Urinary incontinence								
>=18 - <65 years	1	(0.1)	1	0.06	3	(0.2)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Urinary tract disorder								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal colic								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.18
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Chromaturia								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Chronic kidney disease								
>=18 - <65 years	1	(0.1)	1	0.11	4	(0.3)	4	0.33
>=65 - <75 years	3	(0.5)	3	0.79	2	(0.3)	2	0.47
>=75 years	0				0			
Acute kidney injury								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	3	(0.5)	3	0.79	3	(0.5)	3	0.51
>=75 years	0				1	(1.3)	1	1.20
Bladder mass								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Calculus urinary								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Cystitis haemorrhagic								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic nephropathy								
>=18 - <65 years	0				2	(0.1)	2	0.27
>=65 - <75 years	2	(0.4)	2	0.47	2	(0.3)	2	0.55
>=75 years	1	(0.9)	1	0.90	0			
Haematuria								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	2	0.61	3	(0.5)	3	0.51
>=75 years	0				1	(1.2)	1	2.01
Hydrocalyx								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Hypertensive nephropathy								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypertonic bladder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Micturition urgency								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Nephropathy								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Nephrotic syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.73	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Proteinuria								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Pyelocaliectasis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Renal failure								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Renal mass								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Strangury								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Stress urinary incontinence								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Urethral stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Urinary retention								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Urinary tract inflammation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Urinary tract obstruction								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Psychiatric disorders								
All								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	26	(1.7)	28	2.58	31	(2.1)	33	3.36
>=65 - <75 years	13	(2.3)	15	3.14	11	(1.9)	11	2.51
>=75 years	2	(1.9)	2	1.87	1	(1.3)	2	2.39
Insomnia								
>=18 - <65 years	6	(0.4)	6	0.61	4	(0.3)	5	0.49
>=65 - <75 years	4	(0.7)	4	0.83	1	(0.2)	1	0.17
>=75 years	1	(0.9)	1	0.90	1	(1.3)	1	1.20
Anxiety								
>=18 - <65 years	5	(0.3)	5	0.45	7	(0.5)	7	0.73
>=65 - <75 years	1	(0.2)	1	0.18	2	(0.3)	2	0.34
>=75 years	0				1	(1.3)	1	1.20
Depression								
>=18 - <65 years	3	(0.2)	3	0.20	11	(0.7)	11	1.07
>=65 - <75 years	5	(0.9)	5	1.12	1	(0.2)	1	0.30
>=75 years	0				0			
Depressed mood								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Irritability								
>=18 - <65 years	2	(0.1)	2	0.18	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Adjustment disorder								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Attention deficit hyperactivity disorder								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Sleep disorder								
>=18 - <65 years	1	(0.1)	1	0.14	3	(0.2)	3	0.35
>=65 - <75 years	3	(0.5)	3	0.53	1	(0.2)	1	0.30
>=75 years	1	(1.0)	1	0.98	0			
Adjustment disorder with mixed anxiety and depressed mood								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Disorientation								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Post-traumatic stress disorder								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Stress								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nightmare								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Agitation								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Drug abuse								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Adjustment disorder with depressed mood								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Affect lability								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Anxiety disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Bruxism								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Drug dependence								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Emotional distress								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.28

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Fear								
>=18 - <65 years	0				2	(0.1)	2	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Listless								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Major depression								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Mental status changes								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Mixed anxiety and depressive disorder								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Mood swings								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Persistent depressive disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Phobia								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Reproductive system and breast disorders								
All								
>=18 - <65 years	24	(1.6)	24	2.17	18	(1.2)	22	2.05
>=65 - <75 years	8	(1.4)	8	1.65	9	(1.5)	11	2.13
>=75 years	1	(1.1)	1	2.32	0			
Erectile dysfunction								
>=18 - <65 years	5	(0.3)	5	0.38	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Benign prostatic hyperplasia								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	4	(0.7)	4	0.94	3	(0.5)	3	0.64
>=75 years	0				0			
Uterine polyp								
>=18 - <65 years	2	(0.1)	2	0.13	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Intermenstrual bleeding								
>=18 - <65 years	2	(0.1)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cervical polyp								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Prostatitis								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Dysmenorrhoea								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.1)	2	0.20
>=65 - <75 years	0				0			
>=75 years	0				0			
Premenstrual syndrome								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Ejaculation failure								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Menstruation irregular								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pelvic discomfort								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Menopausal symptoms								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Ovarian cyst								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Uterine prolapse								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Breast pain								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Menstruation delayed								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Prostatic calcification								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Atrophic vulvovaginitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Breast mass								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Colpocele								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Ectropion of cervix								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Fibrocystic breast disease								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Galactorrhoea								
>=18 - <65 years	0				1	(0.1)	1	0.07

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Genital prolapse								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Menopausal disorder								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Ovarian disorder								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Penile pain								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Penile rash								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.34
>=75 years	0				0			
Prostatomegaly								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.1)	1	2.32	0			
Pruritus genital								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	2	(0.3)	2	0.48
>=75 years	0				0			
Testicular cyst								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Uterine enlargement								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Vaginal discharge								
>=18 - <65 years	0				2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Vaginal haemorrhage								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	0				0			
Vulvovaginal dryness								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Vulvovaginal pruritus								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Blood and lymphatic system disorders								
All								
>=18 - <65 years	21	(1.4)	21	1.88	26	(1.7)	26	2.31
>=65 - <75 years	14	(2.4)	16	4.01	6	(1.0)	6	1.25
>=75 years	1	(0.9)	1	0.90	1	(1.4)	1	1.44
Anaemia								
>=18 - <65 years	11	(0.7)	11	1.05	10	(0.7)	10	0.81
>=65 - <75 years	8	(1.4)	10	2.41	3	(0.5)	3	0.74
>=75 years	1	(0.9)	1	0.90	1	(1.4)	1	1.44
Lymphadenopathy								
>=18 - <65 years	2	(0.1)	2	0.13	2	(0.1)	2	0.20
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Eosinophilia								
>=18 - <65 years	2	(0.1)	2	0.18	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Lymphadenitis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Leukocytosis								
>=18 - <65 years	1	(0.1)	1	0.06	3	(0.2)	3	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Splenomegaly								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Polycythaemia								
>=18 - <65 years	1	(0.1)	1	0.07	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Thrombocytopenia								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Leukopenia								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood loss anaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	2	(0.3)	2	0.34
>=75 years	0				0			
Hypochromic anaemia								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Iron deficiency anaemia								
>=18 - <65 years	0				4	(0.3)	4	0.38
>=65 - <75 years	2	(0.4)	2	0.49	0			
>=75 years	0				0			
Lymphadenopathy mediastinal								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Normocytic anaemia								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Pancytopenia								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Thrombocytosis								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)								
All								
>=18 - <65 years	17	(1.1)	19	1.78	13	(0.9)	21	1.93

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	15	(2.7)	19	4.34	13	(2.2)	17	3.29
>=75 years	3	(2.7)	5	4.48	3	(3.7)	5	7.61
Eye naevus								
>=18 - <65 years	2	(0.1)	3	0.27	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Haemangioma of liver								
>=18 - <65 years	2	(0.1)	2	0.20	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Chronic myeloid leukaemia								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric cancer								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Benign neoplasm of thyroid gland								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Melanocytic naevus								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Metastases to liver								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	1	(1.3)	1	1.20
Pancreatic carcinoma								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Acrochordon								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Basal cell carcinoma								
>=18 - <65 years	1	(0.1)	1	0.07	2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Neoplasm skin								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oral fibroma								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Salivary gland neoplasm								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Osteoma								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Small cell lung cancer								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Colon adenoma								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	2	(0.3)	2	0.46	0			
>=75 years	0				0			
Adenocarcinoma of colon								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Adenocarcinoma pancreas								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.48	0			
>=75 years	0				0			
Adrenal adenoma								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.01
Benign renal neoplasm								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Bladder cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bladder papilloma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Bowen's disease								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Breast cancer								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Breast cancer metastatic								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Colon cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Colon cancer stage II								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Colorectal cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.48	0			
>=75 years	0				0			
Dysplastic naevus								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Endometrial adenocarcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Gastrointestinal tract adenoma								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Glioblastoma multiforme								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hepatocellular carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Invasive breast carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Invasive ductal breast carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Invasive lobular breast carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Lipoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Lung adenocarcinoma								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.01
Lung cancer metastatic								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	1	(0.2)	1	0.17
>=75 years	0				0			
Lymphangioma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Malignant melanoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Malignant melanoma in situ								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Malignant peritoneal neoplasm								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Metastases to bone marrow								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Metastases to lymph nodes								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Myxoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Ovarian cancer metastatic								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Pancreatic carcinoma metastatic								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Pancreatic neoplasm								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	1	(0.9)	1	0.90	0			
Prostate cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.90	0			
Prostatic adenoma								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal cell carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Renal hamartoma								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal neoplasm								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Seborrhoeic keratosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	1	(0.9)	2	1.79	0			
Skin papilloma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.32	0			
>=75 years	0				0			
Small intestine neuroendocrine tumour								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Squamous cell carcinoma of skin								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.17
>=75 years	0				0			
Uterine cancer								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Uterine leiomyoma								
>=18 - <65 years	0				4	(0.3)	4	0.45
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Hepatobiliary disorders								
All								
>=18 - <65 years	16	(1.1)	21	1.89	21	(1.4)	24	2.19
>=65 - <75 years	8	(1.4)	10	2.54	2	(0.3)	2	0.59
>=75 years	0				2	(2.4)	3	4.63
Hepatic steatosis								
>=18 - <65 years	9	(0.6)	9	0.86	9	(0.6)	9	0.74
>=65 - <75 years	2	(0.4)	2	0.36	0			
>=75 years	0				1	(1.1)	1	2.24
Hypertransaminasaemia								
>=18 - <65 years	2	(0.1)	3	0.27	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cholelithiasis								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.17	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Gallbladder polyp								
>=18 - <65 years	1	(0.1)	1	0.14	3	(0.2)	3	0.39
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Hepatic mass								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatomegaly								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Liver disorder								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Non-alcoholic steatohepatitis								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cholecystitis								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatic function abnormal								
>=18 - <65 years	1	(0.1)	1	0.11	2	(0.1)	2	0.19
>=65 - <75 years	0				0			
>=75 years	0				0			
Alcoholic liver disease								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.29	0			
>=75 years	0				0			
Bile duct stone								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	2	2.39
Biliary colic								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Biliary dyskinesia								
>=18 - <65 years	0				1	(0.1)	1	0.12

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Cholecystitis chronic								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.30
>=75 years	0				0			
Gallbladder cholesterolosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Gallbladder disorder								
>=18 - <65 years	0				1	(0.1)	1	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatic calcification								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Hepatic cirrhosis								
>=18 - <65 years	0				2	(0.1)	2	0.18
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatic cyst								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperplastic cholecystopathy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Nonalcoholic fatty liver disease								
>=18 - <65 years	0				2	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Steatohepatitis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Ear and labyrinth disorders								
All								
>=18 - <65 years	14	(0.9)	14	1.21	13	(0.9)	13	1.29
>=65 - <75 years	11	(1.9)	14	2.80	8	(1.3)	9	1.79

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	3	(3.2)	3	4.92	3	(3.6)	3	5.13
Ear pain								
>=18 - <65 years	3	(0.2)	3	0.32	2	(0.1)	2	0.25
>=65 - <75 years	3	(0.5)	3	0.65	0			
>=75 years	0				0			
Tinnitus								
>=18 - <65 years	2	(0.1)	2	0.13	1	(0.1)	1	0.11
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Vertigo								
>=18 - <65 years	2	(0.1)	2	0.18	4	(0.3)	4	0.39
>=65 - <75 years	7	(1.2)	8	1.65	3	(0.5)	4	0.68
>=75 years	1	(1.0)	1	1.73	2	(2.3)	2	3.94
Hypoacusis								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.06
>=65 - <75 years	0				2	(0.3)	2	0.34
>=75 years	1	(1.0)	1	0.98	0			
Deafness neurosensory								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Deafness bilateral								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Meniere's disease								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vertigo positional								
>=18 - <65 years	1	(0.1)	1	0.06	1	(0.1)	1	0.07
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Ear inflammation								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Eustachian tube dysfunction								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerumen impaction								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	1	(1.2)	1	2.21	0			
Deafness unilateral								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Ear discomfort								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
External ear pain								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Middle ear inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Motion sickness								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.20
Presbyacusis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
>=18 - <65 years	11	(0.7)	12	1.13	10	(0.7)	11	1.04
>=65 - <75 years	3	(0.5)	3	0.65	6	(1.0)	6	1.52
>=75 years	0				0			
Seasonal allergy								
>=18 - <65 years	7	(0.5)	7	0.56	6	(0.4)	6	0.61
>=65 - <75 years	1	(0.2)	1	0.18	3	(0.5)	3	0.64
>=75 years	0				0			
Hypersensitivity								
>=18 - <65 years	2	(0.1)	2	0.27	1	(0.1)	1	0.12
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Anaphylactic reaction								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Allergy to arthropod bite								
>=18 - <65 years	1	(0.1)	1	0.07	1	(0.1)	1	0.11
>=65 - <75 years	0				1	(0.2)	1	0.28
>=75 years	0				0			
Drug hypersensitivity								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Allergy to arthropod sting								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Food allergy								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Immunisation reaction								
>=18 - <65 years	0				1	(0.1)	2	0.13
>=65 - <75 years	0				0			
>=75 years	0				0			
Endocrine disorders								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
>=18 - <65 years	4	(0.3)	4	0.36	13	(0.9)	13	1.12
>=65 - <75 years	2	(0.4)	2	0.36	5	(0.8)	5	0.99
>=75 years	0				1	(1.3)	1	2.12
Hypothyroidism								
>=18 - <65 years	2	(0.1)	2	0.18	3	(0.2)	3	0.26
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				1	(1.3)	1	2.12
Autoimmune thyroiditis								
>=18 - <65 years	1	(0.1)	1	0.06	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypogonadism								
>=18 - <65 years	1	(0.1)	1	0.11	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Adrenal mass								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Adrenocortical insufficiency acute								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			
Goitre								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Hyperplasia adrenal								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Hyperprolactinaemia								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperthyroidism								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Inappropriate antidiuretic hormone secretion								
>=18 - <65 years	0				1	(0.1)	1	0.11
>=65 - <75 years	0				0			
>=75 years	0				0			
Secondary hypogonadism								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Thyroid mass								
>=18 - <65 years	0				2	(0.1)	2	0.18
>=65 - <75 years	2	(0.4)	2	0.36	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
>=18 - <65 years	4	(0.3)	4	0.40	4	(0.3)	4	0.31
>=65 - <75 years	2	(0.4)	2	0.49	1	(0.2)	1	0.17
>=75 years	0				0			
Type V hyperlipidaemia								
>=18 - <65 years	3	(0.2)	3	0.29	1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Cystic fibrosis lung								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Atrial septal defect								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.17
>=75 years	0				0			
Congenital syphilitic osteochondritis								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Corneal dystrophy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Hydrocele								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.18	0			
>=75 years	0				0			
Hypertrophic cardiomyopathy								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Myotonic dystrophy								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Surgical and medical procedures								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
>=18 - <65 years	3	(0.2)	3	0.32	5	(0.3)	5	0.38
>=65 - <75 years	2	(0.3)	2	0.65	1	(0.2)	1	0.30
>=75 years	1	(1.0)	1	0.98	0			
Skin neoplasm excision								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Knee operation								
>=18 - <65 years	1	(0.1)	1	0.07	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Shoulder operation								
>=18 - <65 years	1	(0.1)	1	0.11	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac ablation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.34	0			
>=75 years	0				0			
Cardiac pacemaker replacement								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	0.98	0			
Large intestinal polypectomy								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Removal of foreign body								
>=18 - <65 years	0				1	(0.1)	1	0.07
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal operation								
>=18 - <65 years	0				1	(0.1)	1	0.06
>=65 - <75 years	0				0			
>=75 years	0				0			
Toe amputation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.30
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tooth extraction								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Social circumstances								
All								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			
Menopause								
>=18 - <65 years	0				1	(0.1)	1	0.12
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.12 Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
>=18 - <65 years	1234				1227			
>=65 - <75 years	549				574			
>=75 years	97				77			
PYE (years)								
>=18 - <65 years	1015.10				1019.39			
>=65 - <75 years	443.15				453.36			
>=75 years	80.68				63.71			
Events								
>=18 - <65 years	743	(60.2)	2196	228.05	695	(56.6)	2082	216.81
>=65 - <75 years	331	(60.4)	1074	260.68	331	(57.5)	1045	237.56
>=75 years	65	(66.7)	208	254.10	47	(61.1)	132	218.82
Infections and infestations								
All								
>=18 - <65 years	347	(28.1)	506	53.05	349	(28.4)	520	52.74
>=65 - <75 years	166	(30.3)	224	54.95	151	(26.2)	207	47.88
>=75 years	31	(31.4)	43	54.95	23	(30.1)	30	47.52
COVID-19								
>=18 - <65 years	106	(8.6)	107	10.70	118	(9.6)	123	11.74
>=65 - <75 years	38	(7.0)	38	9.55	37	(6.5)	37	8.26
>=75 years	8	(8.4)	10	13.69	5	(6.7)	5	7.59
Nasopharyngitis								
>=18 - <65 years	58	(4.7)	70	7.81	50	(4.1)	57	5.65
>=65 - <75 years	23	(4.2)	26	5.93	25	(4.3)	31	8.08
>=75 years	2	(2.1)	3	4.72	4	(5.1)	4	7.74
Upper respiratory tract infection								
>=18 - <65 years	46	(3.7)	57	5.70	32	(2.6)	33	3.53
>=65 - <75 years	13	(2.4)	15	3.69	12	(2.1)	14	2.68
>=75 years	3	(2.9)	3	2.87	1	(1.1)	1	1.88
Gastroenteritis								
>=18 - <65 years	21	(1.7)	21	2.44	12	(1.0)	12	1.45
>=65 - <75 years	5	(0.9)	5	1.56	4	(0.7)	5	1.25
>=75 years	0				0			
Influenza								
>=18 - <65 years	21	(1.7)	23	2.92	22	(1.8)	25	3.10
>=65 - <75 years	6	(1.1)	7	1.97	6	(1.0)	6	1.79
>=75 years	1	(1.1)	1	1.85	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Urinary tract infection								
>=18 - <65 years	20	(1.6)	22	2.40	24	(2.0)	25	2.44
>=65 - <75 years	11	(2.0)	11	2.78	16	(2.8)	19	4.14
>=75 years	6	(6.2)	7	9.40	4	(5.2)	4	5.79
Bronchitis								
>=18 - <65 years	16	(1.3)	16	1.70	9	(0.7)	9	0.97
>=65 - <75 years	9	(1.7)	10	2.62	7	(1.2)	7	1.60
>=75 years	1	(0.9)	1	0.93	1	(1.4)	1	1.49
Pharyngitis								
>=18 - <65 years	13	(1.1)	15	1.34	15	(1.2)	18	1.90
>=65 - <75 years	3	(0.6)	3	0.83	2	(0.3)	2	0.48
>=75 years	0				0			
Sinusitis								
>=18 - <65 years	7	(0.6)	8	0.89	12	(1.0)	15	1.44
>=65 - <75 years	6	(1.1)	7	1.52	4	(0.7)	4	0.95
>=75 years	1	(0.9)	1	0.93	1	(1.2)	1	2.08
Herpes zoster								
>=18 - <65 years	7	(0.6)	7	0.68	8	(0.6)	9	0.89
>=65 - <75 years	3	(0.5)	3	0.55	6	(1.0)	6	1.19
>=75 years	0				1	(1.4)	1	1.49
Cystitis								
>=18 - <65 years	7	(0.6)	7	0.74	9	(0.7)	10	0.99
>=65 - <75 years	5	(0.9)	6	1.52	6	(1.0)	7	1.75
>=75 years	0				1	(1.4)	1	1.49
Respiratory tract infection viral								
>=18 - <65 years	7	(0.6)	8	1.00	7	(0.6)	8	1.09
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Conjunctivitis								
>=18 - <65 years	5	(0.4)	5	0.46	2	(0.2)	2	0.16
>=65 - <75 years	2	(0.4)	2	0.49	5	(0.9)	5	1.23
>=75 years	1	(1.0)	1	1.01	0			
Fungal infection								
>=18 - <65 years	5	(0.4)	6	0.71	2	(0.2)	2	0.23
>=65 - <75 years	2	(0.4)	2	0.36	0			
>=75 years	0				0			
Viral infection								
>=18 - <65 years	5	(0.4)	5	0.46	7	(0.6)	10	0.85
>=65 - <75 years	1	(0.2)	1	0.31	2	(0.3)	2	0.35
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
COVID-19 pneumonia								
>=18 - <65 years	5	(0.4)	5	0.52	7	(0.6)	7	0.75
>=65 - <75 years	6	(1.1)	6	1.48	2	(0.3)	2	0.35
>=75 years	3	(3.0)	3	3.73	1	(1.3)	1	1.24
Rhinitis								
>=18 - <65 years	5	(0.4)	5	0.46	5	(0.4)	5	0.53
>=65 - <75 years	2	(0.4)	2	0.37	2	(0.4)	4	1.12
>=75 years	0				0			
Respiratory tract infection								
>=18 - <65 years	5	(0.4)	5	0.52	3	(0.2)	3	0.31
>=65 - <75 years	3	(0.5)	3	0.66	3	(0.5)	3	0.66
>=75 years	0				0			
Tooth infection								
>=18 - <65 years	4	(0.3)	6	0.60	5	(0.4)	5	0.63
>=65 - <75 years	4	(0.7)	4	1.00	1	(0.2)	1	0.31
>=75 years	0				2	(2.5)	2	3.37
Pneumonia								
>=18 - <65 years	4	(0.3)	4	0.44	6	(0.5)	6	0.66
>=65 - <75 years	9	(1.6)	9	2.15	0			
>=75 years	1	(1.1)	1	1.85	0			
Lower respiratory tract infection								
>=18 - <65 years	4	(0.3)	4	0.33	1	(0.1)	3	0.25
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Tooth abscess								
>=18 - <65 years	4	(0.3)	4	0.50	3	(0.2)	3	0.24
>=65 - <75 years	3	(0.6)	3	0.69	4	(0.7)	5	1.27
>=75 years	0				0			
Otitis media								
>=18 - <65 years	4	(0.3)	4	0.44	2	(0.2)	2	0.23
>=65 - <75 years	3	(0.5)	3	0.90	2	(0.4)	2	0.49
>=75 years	0				0			
Tonsillitis								
>=18 - <65 years	3	(0.2)	3	0.30	2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Coronavirus infection								
>=18 - <65 years	3	(0.2)	3	0.24	4	(0.3)	6	0.62
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Laryngitis								
>=18 - <65 years	3	(0.2)	3	0.24	3	(0.2)	3	0.31
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Gastroenteritis viral								
>=18 - <65 years	3	(0.2)	3	0.25	3	(0.2)	3	0.30
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Acute sinusitis								
>=18 - <65 years	3	(0.2)	3	0.30	2	(0.2)	2	0.22
>=65 - <75 years	2	(0.4)	2	0.34	1	(0.2)	1	0.18
>=75 years	0				0			
Vaginal infection								
>=18 - <65 years	3	(0.2)	3	0.35	2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.31
>=75 years	1	(1.0)	1	1.01	0			
Helicobacter infection								
>=18 - <65 years	2	(0.2)	2	0.22	2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Onychomycosis								
>=18 - <65 years	2	(0.2)	2	0.22	3	(0.2)	3	0.23
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.24
Acarodermatitis								
>=18 - <65 years	2	(0.2)	2	0.16	3	(0.2)	3	0.23
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Gastrointestinal infection								
>=18 - <65 years	2	(0.2)	2	0.28	2	(0.2)	3	0.23
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Wound infection								
>=18 - <65 years	2	(0.2)	2	0.28	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Candida infection								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Ear infection								
>=18 - <65 years	2	(0.2)	2	0.16	3	(0.2)	3	0.29
>=65 - <75 years	2	(0.4)	2	0.47	1	(0.2)	1	0.29
>=75 years	0				1	(1.4)	1	1.49
Vulvovaginal candidiasis								
>=18 - <65 years	2	(0.2)	3	0.25	4	(0.3)	4	0.33
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Respiratory syncytial virus infection								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Furuncle								
>=18 - <65 years	2	(0.2)	3	0.30	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Tinea infection								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cellulitis								
>=18 - <65 years	1	(0.1)	1	0.14	6	(0.5)	7	0.86
>=65 - <75 years	3	(0.5)	3	0.53	1	(0.2)	1	0.18
>=75 years	0				1	(1.3)	1	1.24
Paraspinal abscess								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulpitis dental								
>=18 - <65 years	1	(0.1)	1	0.14	3	(0.2)	3	0.36
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Tinea versicolour								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vulvitis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Appendicitis								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Chronic sinusitis								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	3	0.25
>=65 - <75 years	0				0			
>=75 years	0				0			
Ear infection fungal								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nail infection								
>=18 - <65 years	1	(0.1)	2	0.16	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Paronychia								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	3	0.43
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Peritonsillar abscess								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Post-acute COVID-19 syndrome								
>=18 - <65 years	1	(0.1)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin candida								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Tinea cruris								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Viral pharyngitis								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asymptomatic COVID-19								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Bacterial infection								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Balanitis candida								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Chronic tonsillitis								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Folliculitis								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Genital infection fungal								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Gingivitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	2	0.37	3	(0.5)	3	0.77
>=75 years	0				1	(1.3)	1	2.20
Helicobacter gastritis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hordeolum								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				2	(0.3)	2	0.57
>=75 years	1	(0.9)	1	0.93	0			
Laryngopharyngitis								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	2	0.15
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Localised infection								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	2	(0.4)	2	0.50	1	(0.2)	1	0.18
>=75 years	0				0			
Mastitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oropharyngeal candidiasis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Otitis media chronic								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pericoronitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Periodontitis								
>=18 - <65 years	1	(0.1)	1	0.08	4	(0.3)	4	0.45
>=65 - <75 years	2	(0.4)	2	0.63	2	(0.3)	2	0.46
>=75 years	1	(0.9)	1	0.93	0			
Purulence								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Tracheitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Urethritis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Bacteraemia								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diabetic foot infection								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Pharyngotonsillitis								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	2	2.98
Pneumonia viral								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Viral tracheitis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vulvovaginal mycotic infection								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Erysipelas								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	2	0.29
>=65 - <75 years	2	(0.4)	2	0.36	1	(0.2)	1	0.18
>=75 years	0				0			
Genital candidiasis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Genital infection								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	2	(0.4)	2	0.34	0			
>=75 years	0				0			
Oral candidiasis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Otitis externa								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Skin infection								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Suspected COVID-19								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Tinea pedis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Abdominal abscess								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Abscess								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Abscess limb								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Anal abscess								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.18
>=75 years	0				0			
Bartholinitis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Body tinea								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Breast abscess								
>=18 - <65 years	0				3	(0.2)	3	0.31
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Breast cellulitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Campylobacter gastroenteritis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Chlamydial infection								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Cholecystitis infective								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	0				0			
Chronic hepatitis C								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Clostridium difficile colitis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Clostridium difficile infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	1	(1.0)	1	1.01	0			
Dermatophytosis of nail								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Diverticulitis								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	0				2	(0.3)	2	0.35
>=75 years	0				1	(1.4)	1	1.49
Empyema								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Endophthalmitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Enteritis infectious								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Epididymitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Escherichia bacteraemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Escherichia urinary tract infection								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Eye infection								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				2	(0.3)	2	0.61
>=75 years	0				0			
Eye infection bacterial								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Fungal balanitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Fungal skin infection								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	2	(0.4)	2	0.47	0			
>=75 years	0				0			
Gangrene								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gastroenteritis norovirus								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Giardiasis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Herpes dermatitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Herpes simplex								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Herpes virus infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Herpes zoster infection neurological								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.24
Infected bite								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Infected dermal cyst								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Infective iritis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site abscess								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Kidney infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.79	0			
Labyrinthitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Lyme disease								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Oophoritis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Oral herpes								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	2	(0.4)	3	0.96	0			
>=75 years	0				0			
Osteomyelitis								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Otitis media acute								
>=18 - <65 years	0				3	(0.2)	3	0.30
>=65 - <75 years	0				0			
>=75 years	0				0			
Parotitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Peri-implantitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.49
Post procedural infection								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Postoperative wound infection								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	1	(0.2)	1	0.18
>=75 years	0				0			
Pulmonary tuberculoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Pustule								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Pyelonephritis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Rotavirus infection								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Salpingitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Sepsis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.64	0			
>=75 years	0				0			
Sinusitis bacterial								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin bacterial infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Soft tissue infection								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Subcutaneous abscess								
>=18 - <65 years	0				1	(0.1)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	1	(1.0)	1	1.79	0			
Sweat gland infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Urosepsis								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Varicella								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Varicella zoster virus infection								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.79	0			
Viral rhinitis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Viral upper respiratory tract infection								
>=18 - <65 years	0				3	(0.2)	3	0.25
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Gastrointestinal disorders								
All								
>=18 - <65 years	163	(13.2)	255	26.04	150	(12.2)	208	22.14
>=65 - <75 years	68	(12.4)	99	24.14	66	(11.5)	88	20.32
>=75 years	20	(19.9)	26	29.93	5	(6.7)	6	8.78
Diarrhoea								
>=18 - <65 years	48	(3.9)	59	6.34	39	(3.2)	40	4.44
>=65 - <75 years	25	(4.6)	29	6.96	11	(1.9)	11	2.59
>=75 years	11	(10.5)	14	15.20	1	(1.3)	1	1.24
Nausea								
>=18 - <65 years	29	(2.4)	30	3.07	20	(1.6)	21	2.15
>=65 - <75 years	6	(1.1)	6	1.49	7	(1.2)	8	1.95
>=75 years	2	(1.9)	2	1.94	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vomiting								
>=18 - <65 years	19	(1.5)	27	3.27	13	(1.1)	14	1.37
>=65 - <75 years	5	(0.9)	5	1.05	3	(0.5)	5	1.15
>=75 years	0				0			
Gastrooesophageal reflux disease								
>=18 - <65 years	11	(0.9)	11	1.12	9	(0.7)	9	1.02
>=65 - <75 years	1	(0.2)	1	0.19	5	(0.9)	5	1.01
>=75 years	1	(1.0)	1	1.01	0			
Toothache								
>=18 - <65 years	10	(0.8)	10	0.88	5	(0.4)	7	0.91
>=65 - <75 years	3	(0.5)	3	0.67	5	(0.9)	6	1.70
>=75 years	0				0			
Abdominal pain upper								
>=18 - <65 years	10	(0.8)	12	1.25	12	(1.0)	13	1.34
>=65 - <75 years	3	(0.6)	3	0.70	3	(0.5)	3	0.53
>=75 years	0				0			
Dental caries								
>=18 - <65 years	9	(0.7)	11	0.89	7	(0.6)	7	0.74
>=65 - <75 years	0				3	(0.5)	3	0.93
>=75 years	2	(1.8)	2	1.85	0			
Abdominal pain								
>=18 - <65 years	9	(0.7)	9	0.90	13	(1.1)	14	1.63
>=65 - <75 years	5	(0.9)	5	1.16	5	(0.9)	5	0.99
>=75 years	2	(2.3)	2	3.30	0			
Constipation								
>=18 - <65 years	9	(0.7)	9	0.96	8	(0.7)	8	1.02
>=65 - <75 years	6	(1.1)	9	2.33	7	(1.2)	7	1.58
>=75 years	1	(1.0)	1	1.01	1	(1.4)	1	1.49
Dyspepsia								
>=18 - <65 years	6	(0.5)	6	0.66	5	(0.4)	5	0.51
>=65 - <75 years	1	(0.2)	1	0.33	3	(0.5)	3	0.64
>=75 years	0				0			
Haemorrhoids								
>=18 - <65 years	5	(0.4)	5	0.46	2	(0.2)	2	0.22
>=65 - <75 years	2	(0.4)	2	0.49	1	(0.2)	1	0.31
>=75 years	0				0			
Abdominal distension								
>=18 - <65 years	5	(0.4)	5	0.46	4	(0.3)	4	0.45
>=65 - <75 years	2	(0.4)	2	0.37	0			
>=75 years	0				0			
Gastritis								
>=18 - <65 years	5	(0.4)	5	0.63	6	(0.5)	6	0.72
>=65 - <75 years	2	(0.4)	2	0.34	2	(0.4)	2	0.35
>=75 years	0				1	(1.3)	1	1.24

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal pain lower								
>=18 - <65 years	4	(0.3)	4	0.44	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.24
Chronic gastritis								
>=18 - <65 years	4	(0.3)	4	0.38	2	(0.2)	2	0.16
>=65 - <75 years	3	(0.5)	3	0.80	2	(0.3)	2	0.48
>=75 years	1	(1.0)	1	1.79	0			
Diverticulum intestinal								
>=18 - <65 years	3	(0.2)	3	0.24	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Enterocolitis								
>=18 - <65 years	3	(0.2)	4	0.33	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Abdominal discomfort								
>=18 - <65 years	3	(0.2)	3	0.30	2	(0.2)	2	0.16
>=65 - <75 years	0				3	(0.5)	4	1.07
>=75 years	0				0			
Food poisoning								
>=18 - <65 years	3	(0.2)	3	0.30	1	(0.1)	2	0.27
>=65 - <75 years	1	(0.2)	1	0.30	3	(0.5)	3	0.77
>=75 years	1	(1.0)	1	1.01	0			
Hyperaesthesia teeth								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Aphthous ulcer								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Large intestine polyp								
>=18 - <65 years	2	(0.2)	2	0.16	4	(0.3)	5	0.40
>=65 - <75 years	2	(0.4)	2	0.47	2	(0.4)	2	0.49
>=75 years	0				0			
Flatulence								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.33	2	(0.3)	2	0.57
>=75 years	1	(1.0)	1	1.79	0			
Gastric polyps								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Intra-abdominal haematoma								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Tongue rough								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Anal fissure								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Eosinophilic oesophagitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Eructation								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric ulcer								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastrointestinal haemorrhage								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Haemorrhoidal haemorrhage								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Hiatus hernia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.18
>=75 years	0				0			
Hypoaesthesia oral								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	2	(0.4)	4	1.26	0			
>=75 years	0				0			
Impaired gastric emptying								
>=18 - <65 years	1	(0.1)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Inguinal hernia								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Intestinal dilatation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Lip swelling								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Rectal polyp								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Anal pruritus								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Colitis ischaemic								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Loose tooth								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oral discomfort								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pancreatitis								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Periodontal disease								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.28
>=65 - <75 years	0				0			
>=75 years	0				0			
Tooth disorder								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Tooth impacted								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Noninfective gingivitis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vomiting projectile								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Abdominal wall disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Acid peptic disease								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Colitis								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Colitis microscopic								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Crohn's disease								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic gastropathy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Diverticulum								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.18
>=75 years	0				1	(1.2)	1	2.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dry mouth								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	1	(1.0)	1	1.01	0			
Duodenitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Enteritis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Epigastric discomfort								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Faeces pale								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Frequent bowel movements								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Gastric dilatation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Gastric disorder								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric dysplasia								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric mucosal hypertrophy								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastrointestinal angiodysplasia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gastrointestinal disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Gastrointestinal inflammation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Gastrointestinal sounds abnormal								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Gingival bleeding								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Gingival disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Haematochezia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Hyperchlorhydria								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Ileus								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Irritable bowel syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Melaena								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Mesenteric panniculitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Odynophagia								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Oesophageal pain								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Oesophagitis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Oral pain								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Pancreatic duct dilatation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Pancreatic failure								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Pancreatic pseudocyst								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Pancreatitis acute								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Pancreatitis chronic								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Peptic ulcer								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Periodontal inflammation								
>=18 - <65 years	0				1	(0.1)	2	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Proctalgia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Rectal prolapse								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.49
Small intestinal obstruction								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Stomatitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Ulcerative gastritis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Umbilical hernia								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Upper gastrointestinal haemorrhage								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Musculoskeletal and connective tissue disorders								
All								
>=18 - <65 years	163	(13.2)	231	23.34	165	(13.4)	230	24.61
>=65 - <75 years	69	(12.6)	117	28.25	68	(11.8)	94	19.87
>=75 years	14	(14.6)	21	26.52	12	(15.3)	14	24.08
Back pain								
>=18 - <65 years	36	(2.9)	38	3.88	39	(3.2)	42	4.63
>=65 - <75 years	23	(4.2)	25	5.91	18	(3.1)	18	4.08
>=75 years	3	(3.3)	3	5.07	4	(5.0)	4	7.45
Arthralgia								
>=18 - <65 years	27	(2.2)	32	3.18	33	(2.7)	37	4.15

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	15	(2.7)	18	4.62	9	(1.6)	11	2.33
>=75 years	3	(2.7)	3	2.78	6	(8.0)	6	9.74
Pain in extremity								
>=18 - <65 years	21	(1.7)	22	2.06	21	(1.7)	23	2.58
>=65 - <75 years	10	(1.8)	11	2.27	10	(1.7)	14	3.36
>=75 years	0				0			
Muscle spasms								
>=18 - <65 years	15	(1.2)	17	2.08	7	(0.6)	7	0.68
>=65 - <75 years	5	(0.9)	5	1.06	2	(0.4)	2	0.48
>=75 years	3	(3.0)	3	3.73	0			
Osteoarthritis								
>=18 - <65 years	14	(1.1)	16	1.54	16	(1.3)	19	2.01
>=65 - <75 years	5	(0.9)	5	1.17	8	(1.4)	8	1.67
>=75 years	2	(2.1)	2	3.21	0			
Myalgia								
>=18 - <65 years	9	(0.7)	9	1.02	6	(0.5)	6	0.72
>=65 - <75 years	4	(0.7)	4	1.11	3	(0.5)	3	0.64
>=75 years	1	(1.0)	1	1.01	0			
Periarthritis								
>=18 - <65 years	7	(0.6)	7	0.63	4	(0.3)	4	0.38
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	0				1	(1.4)	1	1.49
Neck pain								
>=18 - <65 years	7	(0.6)	7	0.69	7	(0.6)	7	0.70
>=65 - <75 years	6	(1.1)	6	1.62	1	(0.2)	1	0.18
>=75 years	2	(2.1)	2	2.87	0			
Tendonitis								
>=18 - <65 years	5	(0.4)	5	0.46	4	(0.3)	4	0.45
>=65 - <75 years	2	(0.4)	4	1.07	0			
>=75 years	1	(0.9)	1	0.93	0			
Rotator cuff syndrome								
>=18 - <65 years	5	(0.4)	5	0.53	3	(0.2)	3	0.23
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Plantar fasciitis								
>=18 - <65 years	4	(0.3)	5	0.47	3	(0.2)	3	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Musculoskeletal stiffness								
>=18 - <65 years	4	(0.3)	4	0.44	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Trigger finger								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	4	(0.3)	4	0.50	5	(0.4)	7	0.62
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	2	(2.1)	2	3.21	0			
Intervertebral disc protrusion								
>=18 - <65 years	3	(0.2)	6	0.54	5	(0.4)	6	0.61
>=65 - <75 years	4	(0.7)	4	0.86	1	(0.2)	1	0.18
>=75 years	1	(0.9)	2	1.85	0			
Intervertebral disc disorder								
>=18 - <65 years	3	(0.2)	3	0.30	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.08
Bursitis								
>=18 - <65 years	3	(0.2)	3	0.24	3	(0.2)	3	0.25
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Musculoskeletal chest pain								
>=18 - <65 years	3	(0.2)	3	0.24	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				1	(1.3)	1	1.24
Arthritis								
>=18 - <65 years	3	(0.2)	3	0.29	3	(0.2)	3	0.36
>=65 - <75 years	3	(0.5)	3	0.66	3	(0.5)	3	0.80
>=75 years	0				0			
Muscular weakness								
>=18 - <65 years	3	(0.2)	3	0.35	2	(0.2)	2	0.22
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Tendon disorder								
>=18 - <65 years	3	(0.2)	3	0.35	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Chondropathy								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Exostosis								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Polyarthritis								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Spinal stenosis								
>=18 - <65 years	2	(0.2)	2	0.16	2	(0.2)	2	0.16
>=65 - <75 years	2	(0.4)	4	1.20	0			
>=75 years	0				0			
Musculoskeletal pain								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Axillary mass								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Flank pain								
>=18 - <65 years	1	(0.1)	1	0.14	5	(0.4)	6	0.66
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Osteoporosis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Polymyalgia rheumatica								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	3	0.41
>=65 - <75 years	0				0			
>=75 years	0				0			
Meniscopathy								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Osteochondrosis								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	3	0.36
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	0				0			
Psoriatic arthropathy								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Sacroiliitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal osteoarthritis								
>=18 - <65 years	1	(0.1)	1	0.08	4	(0.3)	5	0.39
>=65 - <75 years	4	(0.7)	4	0.99	1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Back disorder								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Bone cyst								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Costochondritis								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Fibromyalgia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Fistula								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Groin pain								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Lumbar spinal stenosis								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Myositis								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal pain								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.22
>=65 - <75 years	0				2	(0.3)	2	0.35
>=75 years	0				0			
Synovial cyst								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Tenosynovitis								
>=18 - <65 years	1	(0.1)	1	0.08	6	(0.5)	7	0.68
>=65 - <75 years	0				3	(0.5)	3	0.53

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Coccydynia								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Foot deformity								
>=18 - <65 years	1	(0.1)	1	0.14	3	(0.2)	3	0.36
>=65 - <75 years	2	(0.4)	4	0.69	0			
>=75 years	0				0			
Joint effusion								
>=18 - <65 years	1	(0.1)	2	0.27	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			
Muscle contracture								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Torticollis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Acquired claw toe								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Arthropathy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Bone pain								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Cervical spinal stenosis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Diastasis recti abdominis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Dupuytren's contracture								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				2	(0.3)	2	0.35
>=75 years	0				0			
Facet joint syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Haemarthrosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Intervertebral disc degeneration								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Intervertebral disc space narrowing								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.35
>=75 years	0				0			
Jaw disorder								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Joint swelling								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				1	(1.2)	1	2.08
Limb deformity								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Mastication disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.35
>=75 years	0				0			
Muscle twitching								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Neuropathic arthropathy								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Nodal osteoarthritis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Osteochondritis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Osteopenia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Pain in jaw								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Periostitis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Rheumatoid arthritis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Scoliosis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Soft tissue swelling								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	3	0.90	0			
>=75 years	0				0			
Spinal retrolisthesis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.35
>=75 years	0				0			
Tenosynovitis stenosans								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Vertebral osteophyte								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
General disorders and administration site conditions								
All								
>=18 - <65 years	138	(11.2)	210	23.01	108	(8.8)	160	15.52
>=65 - <75 years	54	(9.9)	87	22.75	59	(10.2)	93	21.40
>=75 years	7	(6.8)	16	16.86	7	(9.1)	8	12.71
Pyrexia								
>=18 - <65 years	22	(1.8)	23	2.45	26	(2.1)	28	2.99
>=65 - <75 years	7	(1.3)	7	1.54	11	(1.9)	11	2.34
>=75 years	3	(2.7)	3	2.78	0			
Fatigue								
>=18 - <65 years	18	(1.5)	20	2.08	12	(1.0)	12	1.19
>=65 - <75 years	7	(1.3)	8	1.87	2	(0.4)	2	0.35
>=75 years	2	(1.9)	2	1.94	1	(1.3)	1	1.24
Injection site reaction								
>=18 - <65 years	11	(0.9)	20	2.62	1	(0.1)	1	0.08
>=65 - <75 years	4	(0.7)	9	2.90	5	(0.9)	7	1.59
>=75 years	0				0			
Chest pain								
>=18 - <65 years	9	(0.7)	9	0.90	5	(0.4)	5	0.40
>=65 - <75 years	4	(0.7)	4	0.99	0			
>=75 years	1	(0.9)	1	0.93	0			
Oedema peripheral								
>=18 - <65 years	9	(0.7)	9	1.07	5	(0.4)	6	0.55
>=65 - <75 years	7	(1.3)	7	1.50	4	(0.7)	4	0.83
>=75 years	1	(0.9)	1	0.93	0			
Malaise								
>=18 - <65 years	8	(0.7)	10	0.92	5	(0.4)	8	0.76
>=65 - <75 years	4	(0.7)	4	0.99	7	(1.2)	8	1.81
>=75 years	1	(1.0)	1	1.01	0			
Pain								
>=18 - <65 years	7	(0.6)	7	0.80	9	(0.7)	10	1.18
>=65 - <75 years	2	(0.4)	3	0.94	4	(0.7)	4	0.70
>=75 years	1	(0.9)	1	0.93	1	(1.3)	1	1.24
Asthenia								
>=18 - <65 years	7	(0.6)	7	0.74	4	(0.3)	4	0.44
>=65 - <75 years	2	(0.4)	2	0.64	3	(0.5)	3	0.53
>=75 years	1	(0.9)	1	0.93	1	(1.1)	1	1.88
Chest discomfort								
>=18 - <65 years	6	(0.5)	6	0.66	0			
>=65 - <75 years	2	(0.4)	2	0.51	2	(0.3)	2	0.46
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hunger								
>=18 - <65 years	5	(0.4)	6	0.49	0			
>=65 - <75 years	1	(0.2)	1	0.30	2	(0.4)	2	0.49
>=75 years	0				0			
Vaccination site pain								
>=18 - <65 years	5	(0.4)	5	0.58	4	(0.3)	4	0.44
>=65 - <75 years	4	(0.7)	5	1.40	2	(0.3)	2	0.48
>=75 years	1	(0.9)	2	1.85	2	(2.6)	2	4.40
Medical device site pruritus								
>=18 - <65 years	4	(0.3)	4	0.39	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Peripheral swelling								
>=18 - <65 years	4	(0.3)	5	0.51	4	(0.3)	4	0.45
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Injection site pruritus								
>=18 - <65 years	4	(0.3)	19	2.48	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site bruise								
>=18 - <65 years	3	(0.2)	5	0.53	0			
>=65 - <75 years	2	(0.4)	2	0.37	1	(0.2)	1	0.18
>=75 years	0				0			
Medical device site dermatitis								
>=18 - <65 years	3	(0.2)	6	0.61	8	(0.7)	14	1.15
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Drug intolerance								
>=18 - <65 years	3	(0.2)	3	0.24	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Influenza like illness								
>=18 - <65 years	3	(0.2)	3	0.41	3	(0.2)	3	0.24
>=65 - <75 years	1	(0.2)	2	0.34	0			
>=75 years	0				0			
Medical device site erythema								
>=18 - <65 years	2	(0.2)	2	0.28	0			
>=65 - <75 years	0				2	(0.3)	2	0.48
>=75 years	0				0			
Chills								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	1	(0.9)	1	0.93	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gait disturbance								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				1	(1.3)	1	1.24
Injection site mass								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site swelling								
>=18 - <65 years	2	(0.2)	2	0.28	0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Injection site hypersensitivity								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site haemorrhage								
>=18 - <65 years	2	(0.2)	2	0.16	2	(0.2)	2	0.16
>=65 - <75 years	2	(0.4)	2	0.37	0			
>=75 years	0				0			
Thirst								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Injection site bruising								
>=18 - <65 years	2	(0.2)	2	0.22	3	(0.2)	3	0.30
>=65 - <75 years	1	(0.2)	1	0.33	2	(0.3)	2	0.35
>=75 years	0				0			
Injection site erythema								
>=18 - <65 years	2	(0.2)	2	0.22	3	(0.2)	3	0.25
>=65 - <75 years	1	(0.2)	3	0.98	1	(0.2)	1	0.18
>=75 years	0				0			
Medical device site reaction								
>=18 - <65 years	2	(0.2)	2	0.28	0			
>=65 - <75 years	2	(0.4)	4	0.86	1	(0.2)	1	0.18
>=75 years	0				0			
Injection site pain								
>=18 - <65 years	2	(0.2)	2	0.27	6	(0.5)	24	1.98
>=65 - <75 years	1	(0.2)	1	0.33	6	(1.0)	6	1.63
>=75 years	0				0			
Localised oedema								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Swelling face								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				2	(0.3)	2	0.46
>=75 years	0				0			
Discomfort								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.33	1	(0.2)	8	2.45
>=75 years	0				0			
Feeling abnormal								
>=18 - <65 years	1	(0.1)	3	0.25	1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.63	0			
>=75 years	0				0			
Feeling hot								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Implant site pruritus								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site dermatitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site eczema								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site hypersensitivity								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site pain								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Vaccination site reaction								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oedema due to renal disease								
>=18 - <65 years	1	(0.1)	1	0.14	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Xerosis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Application site bruise								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Application site pruritus								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Inflammation								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.2)	2	0.22
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Injection site haemorrhage								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.33	1	(0.2)	1	0.29
>=75 years	0				0			
Axillary pain								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Condition aggravated								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Cyst								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.4)	2	0.48
>=75 years	0				0			
Death								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				2	(2.7)	2	2.73
Early satiety								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Facial pain								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Hernia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site haematoma								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	4	1.31	2	(0.3)	7	2.00
>=75 years	1	(1.1)	2	3.71	0			
Injection site hypertrophy								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site induration								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site oedema								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Injection site rash								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Injection site urticaria								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site haematoma								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Medical device site rash								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Multiple organ dysfunction syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Non-cardiac chest pain								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				3	(0.5)	5	0.88
>=75 years	0				0			
Oedema								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.31	2	(0.3)	2	0.48
>=75 years	0				0			
Procedural failure								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Swelling								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Systemic inflammatory response syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Vaccination site erythema								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Vaccination site inflammation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Vaccination site pruritus								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Vessel puncture site bruise								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Nervous system disorders								
All								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	118	(9.6)	163	17.74	114	(9.3)	156	16.97
>=65 - <75 years	47	(8.6)	70	15.97	65	(11.3)	88	20.44
>=75 years	15	(15.3)	19	26.62	4	(5.3)	4	6.10
Headache								
>=18 - <65 years	42	(3.4)	55	6.41	39	(3.2)	49	5.38
>=65 - <75 years	10	(1.8)	12	2.92	13	(2.3)	16	3.56
>=75 years	5	(5.1)	6	8.45	2	(2.9)	2	2.98
Dizziness								
>=18 - <65 years	26	(2.1)	30	3.17	21	(1.7)	26	2.97
>=65 - <75 years	8	(1.5)	13	2.93	16	(2.8)	18	4.16
>=75 years	4	(4.3)	5	8.36	0			
Sciatica								
>=18 - <65 years	7	(0.6)	7	0.80	6	(0.5)	7	0.57
>=65 - <75 years	6	(1.1)	6	1.48	6	(1.0)	6	1.57
>=75 years	0				0			
Carpal tunnel syndrome								
>=18 - <65 years	7	(0.6)	7	0.68	3	(0.2)	3	0.37
>=65 - <75 years	3	(0.5)	3	0.66	4	(0.7)	4	0.96
>=75 years	1	(1.2)	1	2.28	0			
Hypoaesthesia								
>=18 - <65 years	7	(0.6)	10	1.09	5	(0.4)	5	0.59
>=65 - <75 years	2	(0.4)	2	0.37	4	(0.7)	5	0.99
>=75 years	0				0			
Tremor								
>=18 - <65 years	6	(0.5)	6	0.49	3	(0.2)	6	0.85
>=65 - <75 years	4	(0.7)	5	1.19	5	(0.9)	6	1.56
>=75 years	1	(1.0)	1	1.01	0			
Syncope								
>=18 - <65 years	5	(0.4)	5	0.47	0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Paraesthesia								
>=18 - <65 years	5	(0.4)	5	0.46	11	(0.9)	11	1.26
>=65 - <75 years	3	(0.5)	4	0.70	1	(0.2)	1	0.29
>=75 years	0				0			
Migraine								
>=18 - <65 years	4	(0.3)	4	0.49	2	(0.2)	2	0.29
>=65 - <75 years	2	(0.4)	2	0.36	1	(0.2)	1	0.18
>=75 years	0				0			
Neuropathy peripheral								
>=18 - <65 years	4	(0.3)	5	0.58	4	(0.3)	4	0.38
>=65 - <75 years	1	(0.2)	1	0.33	4	(0.7)	4	0.95
>=75 years	1	(1.0)	1	1.01	1	(1.3)	1	1.24

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Diabetic neuropathy								
>=18 - <65 years	3	(0.2)	3	0.42	8	(0.7)	8	0.82
>=65 - <75 years	2	(0.4)	2	0.36	4	(0.7)	4	1.10
>=75 years	0				0			
Tension headache								
>=18 - <65 years	2	(0.2)	3	0.30	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Carotid artery stenosis								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Dysgeusia								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Carotid artery aneurysm								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Neuralgia								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			
Peripheral paralysis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Thalamic infarction								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Amnesia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Cluster headache								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Disturbance in attention								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Intracranial pressure increased								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Transient ischaemic attack								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	3	0.31
>=65 - <75 years	2	(0.4)	2	0.51	0			
>=75 years	0				0			
Ageusia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Anosmia								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Cervical radiculopathy								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Lumbar radiculopathy								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	3	0.25
>=65 - <75 years	0				1	(0.2)	2	0.35
>=75 years	0				0			
Presyncope								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.15
>=65 - <75 years	0				2	(0.3)	2	0.35
>=75 years	0				0			
Cerebral arteriosclerosis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerebrovascular disorder								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Memory impairment								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Vascular encephalopathy								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Vascular headache								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Autonomic nervous system imbalance								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Balance disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Basilar migraine								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Brain injury								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Burning sensation								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Carotid arteriosclerosis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerebral artery embolism								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerebral atrophy								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Cerebral haemorrhage								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Cerebral infarction								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Cerebrovascular accident								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.4)	2	0.48
>=75 years	0				0			
Cervicobrachial syndrome								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Cognitive disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.31
>=75 years	0				0			
Dementia Alzheimer's type								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Dizziness postural								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				1	(1.1)	1	1.88
Essential tremor								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Facial nerve disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Facial paralysis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Hemiparesis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypoglycaemic coma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Hyporeflexia								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Ischaemic stroke								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Lethargy								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Loss of consciousness								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Mental impairment								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Meralgia paraesthetica								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Morton's neuralgia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Myelopathy								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Neuroglycopenia								
>=18 - <65 years	0				1	(0.1)	3	0.25
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Ophthalmic migraine								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Orthostatic tremor								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Parkinsonian gait								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Piriformis syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Post herpetic neuralgia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	2	(1.9)	2	2.72	0			
Radiculopathy								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Restless legs syndrome								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Sleep deficit								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Somnolence								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Thrombotic stroke								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.4)	2	0.49
>=75 years	0				0			
Trigeminal neuralgia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Vertebral artery occlusion								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
White matter lesion								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Injury, poisoning and procedural complications								
All								
>=18 - <65 years	94	(7.6)	124	12.91	85	(6.9)	103	11.26
>=65 - <75 years	56	(10.2)	66	16.12	53	(9.2)	65	15.77
>=75 years	14	(14.0)	14	17.73	9	(11.6)	10	16.95
Contusion								
>=18 - <65 years	11	(0.9)	12	1.20	5	(0.4)	5	0.41
>=65 - <75 years	3	(0.6)	3	0.69	2	(0.3)	2	0.48
>=75 years	0				0			
Vaccination complication								
>=18 - <65 years	10	(0.8)	14	1.55	14	(1.1)	19	1.85
>=65 - <75 years	3	(0.6)	3	0.70	6	(1.0)	7	1.49
>=75 years	2	(1.9)	2	2.72	1	(1.3)	1	2.20
Fall								
>=18 - <65 years	10	(0.8)	10	0.92	3	(0.2)	3	0.30
>=65 - <75 years	7	(1.3)	7	1.73	5	(0.9)	6	1.33
>=75 years	2	(1.9)	2	1.94	2	(2.5)	2	3.32
Skin abrasion								
>=18 - <65 years	5	(0.4)	7	0.68	1	(0.1)	1	0.14
>=65 - <75 years	3	(0.6)	3	0.83	3	(0.5)	3	0.79
>=75 years	0				0			
Ligament sprain								
>=18 - <65 years	5	(0.4)	5	0.63	6	(0.5)	6	0.72
>=65 - <75 years	4	(0.7)	4	0.83	2	(0.3)	2	0.46
>=75 years	0				0			
Hand fracture								
>=18 - <65 years	4	(0.3)	4	0.44	1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.51	0			
>=75 years	0				0			
Road traffic accident								
>=18 - <65 years	3	(0.2)	3	0.30	0			
>=65 - <75 years	1	(0.2)	1	0.33	1	(0.2)	1	0.18
>=75 years	0				0			
Ankle fracture								
>=18 - <65 years	3	(0.2)	3	0.24	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	2	(0.4)	2	0.35
>=75 years	0				0			
Thermal burn								
>=18 - <65 years	3	(0.2)	3	0.36	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Joint injury								
>=18 - <65 years	3	(0.2)	3	0.30	3	(0.2)	3	0.29
>=65 - <75 years	2	(0.4)	2	0.63	1	(0.2)	1	0.18
>=75 years	0				0			
Limb injury								
>=18 - <65 years	3	(0.2)	3	0.30	1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.51	4	(0.7)	5	1.53
>=75 years	0				1	(1.3)	1	1.24
Foot fracture								
>=18 - <65 years	3	(0.2)	3	0.36	1	(0.1)	1	0.08
>=65 - <75 years	0				2	(0.4)	2	0.49
>=75 years	0				0			
Tooth fracture								
>=18 - <65 years	3	(0.2)	3	0.36	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.31
>=75 years	0				0			
Rib fracture								
>=18 - <65 years	2	(0.2)	2	0.22	3	(0.2)	3	0.36
>=65 - <75 years	2	(0.4)	2	0.50	1	(0.2)	1	0.18
>=75 years	0				1	(1.3)	1	1.24
Upper limb fracture								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Fibula fracture								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Injury								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Meniscus injury								
>=18 - <65 years	2	(0.2)	2	0.16	2	(0.2)	2	0.15
>=65 - <75 years	0				3	(0.5)	3	0.66
>=75 years	0				0			
Skin laceration								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	3	(0.5)	3	0.67	0			
>=75 years	2	(2.1)	2	3.58	0			
Arthropod sting								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Tendon rupture								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Arthropod bite								
>=18 - <65 years	2	(0.2)	2	0.28	3	(0.2)	3	0.36
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Incorrect dose administered								
>=18 - <65 years	2	(0.2)	2	0.28	4	(0.3)	6	0.79
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.29
>=75 years	0				0			
Medication error								
>=18 - <65 years	2	(0.2)	2	0.27	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Facial bones fracture								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Overdose								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.2)	2	0.29
>=65 - <75 years	2	(0.4)	2	0.50	1	(0.2)	1	0.18
>=75 years	1	(1.0)	1	1.79	0			
Underdose								
>=18 - <65 years	1	(0.1)	1	0.14	4	(0.3)	4	0.55
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Wrist fracture								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Accidental overdose								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	2	0.29
>=65 - <75 years	5	(0.9)	5	1.40	1	(0.2)	1	0.31
>=75 years	1	(1.0)	1	1.79	1	(1.2)	1	2.08
Animal bite								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.24
Back injury								
>=18 - <65 years	1	(0.1)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			
Hip fracture								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Injury of conjunctiva								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Neck injury								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Post procedural inflammation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Procedural pain								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	2	(0.4)	2	0.65	1	(0.2)	1	0.29
>=75 years	1	(0.9)	1	0.93	0			
Spinal compression fracture								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Burn oral cavity								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Burns first degree								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Heat illness								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	3	0.30
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Muscle strain								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.23
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				1	(1.3)	1	1.24
Post procedural fistula								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Post procedural hypothyroidism								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Radius fracture								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Scar								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Traumatic haematoma								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Extra dose administered								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Wrong product administered								
>=18 - <65 years	1	(0.1)	2	0.28	0			
>=65 - <75 years	0				2	(0.3)	2	0.59
>=75 years	0				0			
Gun shot wound								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Ligament rupture								
>=18 - <65 years	1	(0.1)	2	0.27	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Procedural complication								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Accidental underdose								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bone contusion								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Cervical vertebral fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Chillblains								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Concussion								
>=18 - <65 years	0				2	(0.2)	2	0.29
>=65 - <75 years	0				0			
>=75 years	0				0			
Craniocerebral injury								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Crush injury								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Deafness traumatic								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Endotracheal intubation complication								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Epicondylitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Exposure to SARS-CoV-2								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Eye injury								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Face injury								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Femoral neck fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Head injury								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Humerus fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Inflammation of wound								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Intentional overdose								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Intentional product use issue								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Lower limb fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Multiple injuries								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Muscle contusion								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	2.20
Muscle injury								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Penile contusion								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Periprocedural myocardial infarction								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Post procedural complication								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Post procedural haematuria								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Post procedural haemorrhage								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Post procedural stroke								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Post procedural swelling								
>=18 - <65 years	0				1	(0.1)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Post-traumatic neck syndrome								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Product administration error								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Radiation skin injury								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Scratch								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Seroma								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Soft tissue injury								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Spinal column injury								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Stab wound								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Subcutaneous haematoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.31
>=75 years	0				0			
Subdural haematoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Sunburn								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Tendon injury								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Tibia fracture								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	2.20
Wound								
>=18 - <65 years	0				5	(0.4)	5	0.65
>=65 - <75 years	3	(0.6)	3	0.69	0			
>=75 years	0				0			
Wrong dose								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				2	(0.2)	2	0.29
>=65 - <75 years	0				0			
>=75 years	0				0			
Eye disorders								
All								
>=18 - <65 years	84	(6.8)	116	12.67	94	(7.6)	111	12.40
>=65 - <75 years	54	(9.9)	62	15.83	52	(9.1)	77	19.45
>=75 years	9	(9.3)	10	14.06	6	(7.7)	11	19.65
Diabetic retinopathy								
>=18 - <65 years	33	(2.7)	38	4.55	37	(3.0)	41	4.85
>=65 - <75 years	16	(2.9)	17	4.81	19	(3.3)	19	4.77
>=75 years	3	(3.3)	3	5.09	2	(2.6)	2	3.43
Cataract								
>=18 - <65 years	13	(1.1)	16	1.58	15	(1.2)	17	1.96
>=65 - <75 years	9	(1.7)	11	2.42	8	(1.4)	9	1.69
>=75 years	2	(1.9)	2	1.94	2	(2.6)	2	2.47
Macular oedema								
>=18 - <65 years	7	(0.6)	7	0.80	3	(0.2)	3	0.23
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.31
>=75 years	1	(1.2)	1	2.28	0			
Retinopathy hypertensive								
>=18 - <65 years	6	(0.5)	7	0.79	3	(0.2)	3	0.36
>=65 - <75 years	0				2	(0.3)	2	0.61
>=75 years	0				0			
Vision blurred								
>=18 - <65 years	4	(0.3)	4	0.43	5	(0.4)	5	0.52
>=65 - <75 years	0				0			
>=75 years	0				0			
Dry eye								
>=18 - <65 years	3	(0.2)	3	0.30	6	(0.5)	6	0.55
>=65 - <75 years	3	(0.5)	3	0.53	0			
>=75 years	0				0			
Diabetic retinal oedema								
>=18 - <65 years	3	(0.2)	3	0.42	3	(0.2)	4	0.50
>=65 - <75 years	1	(0.2)	1	0.31	6	(1.1)	6	1.45
>=75 years	0				0			
Blepharitis								
>=18 - <65 years	3	(0.2)	3	0.30	0			
>=65 - <75 years	2	(0.4)	2	0.37	0			
>=75 years	0				0			
Ocular hypertension								
>=18 - <65 years	2	(0.2)	2	0.22	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Eye pain								
>=18 - <65 years	2	(0.2)	2	0.16	2	(0.2)	2	0.16
>=65 - <75 years	2	(0.4)	2	0.50	1	(0.2)	1	0.31
>=75 years	0				0			
Retinal haemorrhage								
>=18 - <65 years	2	(0.2)	2	0.28	0			
>=65 - <75 years	2	(0.4)	2	0.49	0			
>=75 years	0				0			
Cataract nuclear								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Dry age-related macular degeneration								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal exudates								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				2	(0.3)	2	0.61
>=75 years	0				0			
Amaurosis fugax								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Angle closure glaucoma								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Arteriosclerotic retinopathy								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Astigmatism								
>=18 - <65 years	1	(0.1)	2	0.16	3	(0.2)	3	0.30
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.31
>=75 years	0				0			
Conjunctival hyperaemia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Glaucoma								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	2	(0.4)	2	0.34	1	(0.2)	1	0.18
>=75 years	0				1	(1.3)	1	1.24
Maculopathy								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal degeneration								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Visual impairment								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	9	2.76
>=75 years	0				0			
Vitreous detachment								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	1	(0.9)	1	0.93	0			
Acquired epiblepharon								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Conjunctival erosion								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Conjunctival haemorrhage								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Conjunctivitis allergic								
>=18 - <65 years	1	(0.1)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Optic disc vascular disorder								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Post thrombotic retinopathy								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Retinal aneurysm								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Retinal tear								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Presbyopia								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Retinal scar								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Non-proliferative retinopathy								
>=18 - <65 years	1	(0.1)	2	0.27	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Ocular hyperaemia								
>=18 - <65 years	1	(0.1)	2	0.27	0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.79	1	(1.2)	2	4.17
Age-related macular degeneration								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	1	(1.0)	1	1.01	0			
Asthenopia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Chorioretinal atrophy								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Conjunctival suffusion								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Corneal bleeding								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Corneal erosion								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Cystoid macular oedema								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Dacryoadenitis acquired								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Diplopia								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Epiretinal membrane								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.18
>=75 years	0				1	(1.2)	1	2.08
Eye discharge								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Eye inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	2	(0.4)	2	0.51	1	(0.2)	1	0.31
>=75 years	0				0			
Eye irritation								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Eye pruritus								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	2	4.17
Eyelid oedema								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypermetropia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Lacrimation increased								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Macular degeneration								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				2	(0.4)	2	0.48
>=75 years	0				0			
Macular hole								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.08
Meibomianitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Myopia								
>=18 - <65 years	0				2	(0.2)	2	0.15
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Normal tension glaucoma								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Ocular ischaemic syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Open angle glaucoma								
>=18 - <65 years	0				1	(0.1)	2	0.29
>=65 - <75 years	0				0			
>=75 years	0				0			
Ophthalmic vein thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Optic disc haemorrhage								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Photophobia								
>=18 - <65 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Posterior capsule opacification								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Retinal artery occlusion								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal deposits								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Retinal detachment								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.3)	2	0.48
>=75 years	0				0			
Retinal drusen								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.31
>=75 years	0				0			
Retinal vascular disorder								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Retinal vein occlusion								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.18
>=75 years	0				0			
Retinopathy								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Scintillating scotoma								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Uveitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Visual acuity reduced								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Vitreous degeneration								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Vitreous floaters								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Vitreous haemorrhage								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.61	1	(0.2)	1	0.31
>=75 years	0				0			
Vitreous opacities								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Metabolism and nutrition disorders								
All								
>=18 - <65 years	83	(6.7)	104	10.37	77	(6.3)	93	9.55
>=65 - <75 years	35	(6.4)	42	9.65	41	(7.1)	54	12.05
>=75 years	6	(5.8)	7	7.61	7	(8.9)	11	21.00
Dyslipidaemia								
>=18 - <65 years	17	(1.4)	18	1.92	11	(0.9)	11	1.27
>=65 - <75 years	3	(0.6)	3	0.84	6	(1.0)	6	1.67
>=75 years	1	(0.9)	1	0.93	0			
Vitamin D deficiency								
>=18 - <65 years	13	(1.1)	13	1.10	9	(0.7)	9	0.83
>=65 - <75 years	2	(0.4)	2	0.36	3	(0.5)	3	0.53
>=75 years	1	(1.0)	1	1.01	0			
Hypoglycaemia								
>=18 - <65 years	11	(0.9)	17	2.00	9	(0.7)	14	1.32
>=65 - <75 years	2	(0.4)	2	0.63	7	(1.2)	14	2.85
>=75 years	0				4	(4.9)	8	17.03
Hyperlipidaemia								
>=18 - <65 years	10	(0.8)	10	0.98	11	(0.9)	11	1.09
>=65 - <75 years	4	(0.7)	4	1.00	2	(0.3)	2	0.35
>=75 years	0				0			
Vitamin B12 deficiency								
>=18 - <65 years	9	(0.7)	9	0.71	1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	1	(1.0)	1	1.01	0			
Hypertriglyceridaemia								
>=18 - <65 years	8	(0.6)	8	0.82	6	(0.5)	6	0.68
>=65 - <75 years	2	(0.4)	2	0.37	2	(0.3)	2	0.46
>=75 years	0				0			
Hyperuricaemia								
>=18 - <65 years	3	(0.2)	3	0.30	3	(0.2)	3	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Iron deficiency								
>=18 - <65 years	3	(0.2)	3	0.24	3	(0.2)	3	0.23
>=65 - <75 years	2	(0.4)	2	0.36	0			
>=75 years	0				0			
Hyperglycaemia								
>=18 - <65 years	3	(0.2)	3	0.36	11	(0.9)	11	1.21
>=65 - <75 years	2	(0.4)	3	0.83	3	(0.5)	3	0.94
>=75 years	1	(1.0)	1	1.79	0			
Hyperkalaemia								
>=18 - <65 years	3	(0.2)	3	0.36	5	(0.4)	5	0.53
>=65 - <75 years	4	(0.7)	5	1.05	5	(0.9)	5	1.28
>=75 years	1	(0.9)	1	0.93	0			
Folate deficiency								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Zinc deficiency								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Dehydration								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypercholesterolaemia								
>=18 - <65 years	2	(0.2)	2	0.28	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.19	2	(0.4)	2	0.49
>=75 years	0				0			
Diabetes mellitus								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			
Diabetes mellitus inadequate control								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Gout								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	3	0.23
>=65 - <75 years	3	(0.5)	4	0.72	3	(0.5)	3	0.53
>=75 years	0				1	(1.3)	1	1.24
Vitamin B complex deficiency								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Decreased appetite								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.22
>=65 - <75 years	3	(0.6)	3	0.70	2	(0.3)	2	0.35
>=75 years	0				1	(1.3)	1	1.24
Fluid retention								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Increased appetite								
>=18 - <65 years	1	(0.1)	1	0.08	4	(0.3)	4	0.51
>=65 - <75 years	2	(0.4)	2	0.36	2	(0.3)	3	0.75
>=75 years	0				0			
Obesity								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyponatraemia								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.31
>=75 years	0				0			
Abnormal weight gain								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Appetite disorder								
>=18 - <65 years	0				1	(0.1)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrolyte imbalance								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Food craving								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperammonaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Hypercalcaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Hypernatraemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Hypoalbuminaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Hypokalaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Insulin resistance								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Lactic acidosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Lipomatosis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Magnesium deficiency								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Malnutrition								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Metabolic acidosis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Metabolic disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.49
Respiratory, thoracic and mediastinal disorders								
All								
>=18 - <65 years	72	(5.8)	100	10.52	57	(4.7)	69	7.18
>=65 - <75 years	34	(6.2)	45	11.04	41	(7.1)	52	11.88
>=75 years	5	(4.9)	6	6.68	3	(3.8)	3	5.40
Cough								
>=18 - <65 years	18	(1.5)	19	2.00	10	(0.8)	10	0.99
>=65 - <75 years	5	(0.9)	5	1.05	9	(1.6)	10	2.13
>=75 years	0				1	(1.2)	1	2.08
Oropharyngeal pain								
>=18 - <65 years	11	(0.9)	11	0.95	10	(0.8)	10	1.18
>=65 - <75 years	8	(1.5)	10	2.40	6	(1.0)	8	1.80
>=75 years	0				0			
Rhinorrhoea								
>=18 - <65 years	8	(0.7)	11	1.18	1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.60	6	(1.1)	6	1.32
>=75 years	0				0			
Dyspnoea								
>=18 - <65 years	6	(0.5)	6	0.65	8	(0.7)	9	0.97
>=65 - <75 years	2	(0.4)	2	0.64	4	(0.7)	4	0.97
>=75 years	1	(1.0)	1	1.01	1	(1.3)	1	1.24
Epistaxis								
>=18 - <65 years	5	(0.4)	9	1.26	1	(0.1)	2	0.16
>=65 - <75 years	0				1	(0.2)	2	0.61
>=75 years	0				0			
Sleep apnoea syndrome								
>=18 - <65 years	5	(0.4)	5	0.52	0			
>=65 - <75 years	2	(0.4)	2	0.37	0			
>=75 years	0				0			
Nasal congestion								
>=18 - <65 years	4	(0.3)	4	0.32	3	(0.2)	3	0.24
>=65 - <75 years	4	(0.7)	4	0.99	1	(0.2)	1	0.18
>=75 years	2	(1.9)	2	1.94	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Asthma								
>=18 - <65 years	4	(0.3)	5	0.52	0			
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.31
>=75 years	0				0			
Respiratory disorder								
>=18 - <65 years	3	(0.2)	3	0.36	4	(0.3)	4	0.39
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.31
>=75 years	0				0			
Productive cough								
>=18 - <65 years	2	(0.2)	2	0.22	2	(0.2)	2	0.22
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	1	(1.0)	1	1.01	0			
Sneezing								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nasal septum deviation								
>=18 - <65 years	2	(0.2)	2	0.28	0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Chronic obstructive pulmonary disease								
>=18 - <65 years	2	(0.2)	2	0.28	0			
>=65 - <75 years	2	(0.4)	2	0.49	1	(0.2)	1	0.18
>=75 years	0				0			
Nasal obstruction								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Acute respiratory failure								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	1	(1.0)	1	1.79	0			
Increased viscosity of upper respiratory secretion								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Rhinitis allergic								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	7	0.70
>=65 - <75 years	0				2	(0.3)	2	0.57
>=75 years	0				0			
Sinus congestion								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	3	(0.6)	4	1.02	0			
>=75 years	0				0			
Upper respiratory tract inflammation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Acquired diaphragmatic eventration								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Bronchiectasis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Dyspnoea exertional								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Emphysema								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.22
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Interstitial lung disease								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Laryngeal cyst								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nasal turbinate hypertrophy								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulmonary embolism								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulmonary fibrosis								
>=18 - <65 years	1	(0.1)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Pleurisy								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Sinus pain								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	1	(0.2)	2	0.37	1	(0.2)	1	0.29
>=75 years	0				0			
Bronchospasm								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Acute pulmonary oedema								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Allergic bronchitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Allergic cough								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Aphonia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Bronchitis chronic								
>=18 - <65 years	0				2	(0.2)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Dry throat								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Dysphonia								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.57
>=75 years	0				0			
Haemoptysis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Lung disorder								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Nasal dryness								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Paranasal cyst								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Paranasal sinus discomfort								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Pleural disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.08
Pleural effusion								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				2	(0.3)	2	0.35
>=75 years	0				0			
Pleuritic pain								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Pulmonary hypertension								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Pulmonary mass								
>=18 - <65 years	0				3	(0.2)	3	0.37
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Respiratory failure								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.30	1	(0.2)	1	0.18
>=75 years	0				0			
Respiratory tract inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Throat irritation								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Upper-airway cough syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Skin and subcutaneous tissue disorders								
All								
>=18 - <65 years	58	(4.7)	64	6.22	72	(5.9)	85	8.79
>=65 - <75 years	38	(6.9)	40	9.93	29	(5.0)	35	6.76
>=75 years	3	(2.9)	3	3.65	3	(3.5)	3	5.96
Eczema								
>=18 - <65 years	9	(0.7)	9	0.91	6	(0.5)	6	0.72
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Rash								
>=18 - <65 years	7	(0.6)	7	0.80	6	(0.5)	7	0.63
>=65 - <75 years	4	(0.7)	4	0.85	5	(0.9)	5	1.02
>=75 years	0				0			
Hyperhidrosis								
>=18 - <65 years	6	(0.5)	6	0.60	4	(0.3)	4	0.44
>=65 - <75 years	2	(0.4)	2	0.63	1	(0.2)	1	0.18
>=75 years	0				0			
Urticaria								
>=18 - <65 years	5	(0.4)	5	0.52	7	(0.6)	7	0.61
>=65 - <75 years	2	(0.4)	2	0.61	2	(0.3)	2	0.35
>=75 years	0				0			
Dermatitis contact								
>=18 - <65 years	4	(0.3)	5	0.41	4	(0.3)	4	0.39
>=65 - <75 years	1	(0.2)	1	0.19	4	(0.7)	4	0.84
>=75 years	0				0			
Pruritus								
>=18 - <65 years	4	(0.3)	4	0.37	8	(0.7)	8	0.89
>=65 - <75 years	4	(0.7)	4	0.99	2	(0.3)	2	0.35
>=75 years	0				1	(1.1)	1	1.88
Cold sweat								
>=18 - <65 years	4	(0.3)	4	0.44	2	(0.2)	2	0.23
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Dermatitis								
>=18 - <65 years	2	(0.2)	2	0.16	3	(0.2)	4	0.50
>=65 - <75 years	1	(0.2)	1	0.33	3	(0.5)	3	0.53
>=75 years	0				0			
Dermatitis allergic								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Dry skin								
>=18 - <65 years	2	(0.2)	2	0.16	4	(0.3)	4	0.37
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Acne								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Miliaria								
>=18 - <65 years	1	(0.1)	1	0.14	4	(0.3)	4	0.33
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Erythema								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				3	(0.5)	3	0.64
>=75 years	0				0			
Livedo reticularis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nail bed inflammation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Alopecia								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	3	0.31
>=65 - <75 years	3	(0.6)	3	0.69	0			
>=75 years	1	(1.0)	1	1.79	0			
Angioedema								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Granuloma annulare								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Psoriasis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.19	2	(0.3)	2	0.46
>=75 years	0				0			
Skin exfoliation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Skin fissures								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin irritation								
>=18 - <65 years	1	(0.1)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Skin lesion								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Urticaria contact								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Umbilical haematoma								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Rash erythematous								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Actinic keratosis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Alopecia areata								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Asteatosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Blister								
>=18 - <65 years	0				2	(0.2)	2	0.23
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Cold urticaria								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Decubitus ulcer								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Dermal cyst								
>=18 - <65 years	0				3	(0.2)	3	0.30
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic foot								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Drug eruption								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Ecchymosis								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Haemorrhage subcutaneous								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Hidradenitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperkeratosis								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.51	0			
>=75 years	0				1	(1.1)	1	1.88
Ingrowing nail								
>=18 - <65 years	0				2	(0.2)	2	0.16

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	2	(0.4)	2	0.36	1	(0.2)	1	0.18
>=75 years	0				0			
Intertrigo								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Lentigo								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Leukoplakia								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Lipodystrophy acquired								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Lipohypertrophy								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Macule								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Myxoid cyst								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Neurodermatitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	2.20
Night sweats								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	1	(0.9)	1	0.93	0			
Pruritus allergic								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Purpura								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Rash maculo-papular								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Rash papular								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Seborrhoea								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin discolouration								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Skin odour abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Skin reaction								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin ulcer								
>=18 - <65 years	0				5	(0.4)	5	0.65
>=65 - <75 years	4	(0.7)	4	0.99	0			
>=75 years	0				0			
Urticaria thermal								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Investigations								
All								
>=18 - <65 years	52	(4.2)	61	6.35	44	(3.6)	50	5.10
>=65 - <75 years	23	(4.2)	26	6.16	19	(3.3)	20	5.12
>=75 years	5	(5.2)	7	9.64	3	(4.1)	3	3.96
Weight increased								
>=18 - <65 years	14	(1.1)	14	1.48	13	(1.1)	13	1.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	5	(0.9)	5	1.16	5	(0.9)	5	1.23
>=75 years	0				0			
Blood creatinine increased								
>=18 - <65 years	6	(0.5)	6	0.71	0			
>=65 - <75 years	2	(0.4)	2	0.64	0			
>=75 years	0				0			
SARS-CoV-2 test positive								
>=18 - <65 years	4	(0.3)	4	0.43	0			
>=65 - <75 years	2	(0.4)	2	0.64	0			
>=75 years	1	(1.0)	1	1.79	0			
Blood immunoglobulin E increased								
>=18 - <65 years	3	(0.2)	3	0.24	3	(0.2)	3	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Alanine aminotransferase increased								
>=18 - <65 years	3	(0.2)	3	0.36	0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Blood triglycerides increased								
>=18 - <65 years	3	(0.2)	3	0.30	3	(0.2)	3	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood cholesterol increased								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Weight decreased								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	2	(0.4)	2	0.36	1	(0.2)	1	0.18
>=75 years	0				0			
Liver function test increased								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	1	(1.2)	1	2.28	0			
Occult blood								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrocardiogram abnormal								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Electrocardiogram ST segment abnormal								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrocardiogram T wave inversion								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Low density lipoprotein increased								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Prostatic specific antigen increased								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
QRS axis abnormal								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Transaminases increased								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood creatine phosphokinase increased								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood pressure increased								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	2	(0.3)	2	0.48
>=75 years	1	(1.1)	1	1.85	1	(1.3)	1	1.24
Body temperature increased								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Glycosylated haemoglobin increased								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	3	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Transferrin saturation decreased								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood alkaline phosphatase increased								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	2	(0.4)	2	0.65	0			
>=75 years	0				0			
Liver function test abnormal								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	2	0.27
>=65 - <75 years	0				0			
>=75 years	0				0			
Arthroscopy								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Aspartate aminotransferase increased								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood glucose fluctuation								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood potassium increased								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Monocyte count decreased								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Monofilament pressure perception test								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Amylase increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Antinuclear antibody positive								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood creatine increased								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Blood glucose decreased								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood glucose increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.49
Blood pressure decreased								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood urine present								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	3	0.52	1	(0.2)	1	0.31
>=75 years	0				0			
Bone density decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Breath sounds abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.24
Carbohydrate antigen 19-9 increased								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac murmur								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac stress test abnormal								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Catheterisation cardiac								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Ejection fraction decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Electrocardiogram P wave biphasic								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Electrocardiogram repolarisation abnormality								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Electrocardiogram ST segment depression								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Eosinophil count increased								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Free fatty acids increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Glomerular filtration rate decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Grip strength decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Haematocrit increased								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Haemoglobin decreased								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Haemoglobin increased								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatic enzyme increased								
>=18 - <65 years	0				1	(0.1)	1	0.08

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
International normalised ratio abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
International normalised ratio decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
International normalised ratio increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	2	1.85	0			
Intraocular pressure increased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Lipase increased								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Lipids increased								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Platelet count decreased								
>=18 - <65 years	0				2	(0.2)	2	0.29
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Red blood cell count decreased								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Thyroid function test abnormal								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Vitamin D decreased								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vascular disorders								
All								
>=18 - <65 years	43	(3.5)	46	4.35	40	(3.3)	50	5.33
>=65 - <75 years	25	(4.6)	31	7.94	33	(5.7)	41	9.06
>=75 years	5	(5.1)	5	6.16	3	(3.9)	4	7.74
Hypertension								
>=18 - <65 years	21	(1.7)	21	2.15	19	(1.5)	22	2.21
>=65 - <75 years	8	(1.5)	8	2.10	15	(2.6)	17	4.20
>=75 years	3	(3.0)	3	2.95	1	(1.4)	1	1.49
Hypotension								
>=18 - <65 years	3	(0.2)	3	0.24	1	(0.1)	1	0.08
>=65 - <75 years	3	(0.6)	3	0.84	2	(0.4)	2	0.48
>=75 years	0				0			
Arteriosclerosis								
>=18 - <65 years	2	(0.2)	2	0.16	3	(0.2)	3	0.36
>=65 - <75 years	1	(0.2)	1	0.19	4	(0.7)	4	0.81
>=75 years	0				0			
Peripheral arterial occlusive disease								
>=18 - <65 years	2	(0.2)	3	0.24	1	(0.1)	1	0.08
>=65 - <75 years	2	(0.4)	2	0.64	1	(0.2)	1	0.18
>=75 years	0				0			
Superficial vein thrombosis								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Peripheral coldness								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Haematoma								
>=18 - <65 years	2	(0.2)	2	0.22	2	(0.2)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.08
Blood pressure inadequately controlled								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Hot flush								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Venous stenosis								
>=18 - <65 years	1	(0.1)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic arteriosclerosis								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.23
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	1	(0.9)	1	0.93	1	(1.2)	1	2.08
Flushing								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Peripheral artery occlusion								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Peripheral artery stenosis								
>=18 - <65 years	1	(0.1)	2	0.16	0			
>=65 - <75 years	1	(0.2)	3	0.94	0			
>=75 years	0				0			
Peripheral vascular disorder								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic vascular disorder								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Varicose ulceration								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Aneurysm								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic aneurysm								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Aortic dilatation								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic stenosis								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Arterial insufficiency								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Blood pressure fluctuation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Brachiocephalic arteriosclerosis								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Deep vein thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.2)	1	2.28	0			
Hypertensive crisis								
>=18 - <65 years	0				1	(0.1)	3	0.43
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	0				0			
Hypertensive urgency								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	2	0.35
>=75 years	0				0			
Iliac artery stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Intermittent claudication								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Macroangiopathy								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Neovascularisation								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Orthostatic hypotension								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.61	0			
>=75 years	0				0			
Peripheral artery aneurysm								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.08
Peripheral ischaemia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Peripheral venous disease								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	2	(0.4)	2	0.50	2	(0.3)	2	0.35
>=75 years	0				0			
Phlebitis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Thrombophlebitis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Varicose vein								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			
Cardiac disorders								
All								
>=18 - <65 years	40	(3.2)	57	5.28	43	(3.5)	65	6.54
>=65 - <75 years	37	(6.8)	52	11.42	35	(6.1)	43	8.59
>=75 years	9	(8.9)	15	15.52	1	(1.4)	1	1.49
Coronary artery disease								
>=18 - <65 years	7	(0.6)	7	0.62	5	(0.4)	5	0.52
>=65 - <75 years	5	(0.9)	5	1.05	5	(0.9)	5	0.88
>=75 years	0				0			
Cardiac failure								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	5	(0.4)	5	0.46	2	(0.2)	3	0.36
>=65 - <75 years	3	(0.5)	3	0.55	0			
>=75 years	0				0			
Atrial fibrillation								
>=18 - <65 years	4	(0.3)	4	0.38	1	(0.1)	1	0.14
>=65 - <75 years	4	(0.7)	4	0.75	5	(0.9)	5	0.88
>=75 years	4	(3.8)	5	4.72	0			
Acute myocardial infarction								
>=18 - <65 years	4	(0.3)	4	0.32	5	(0.4)	5	0.52
>=65 - <75 years	5	(0.9)	5	1.30	3	(0.5)	3	0.66
>=75 years	0				0			
Acute coronary syndrome								
>=18 - <65 years	4	(0.3)	4	0.32	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Myocardial infarction								
>=18 - <65 years	4	(0.3)	4	0.44	4	(0.3)	4	0.32
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Tachycardia								
>=18 - <65 years	3	(0.2)	3	0.24	5	(0.4)	5	0.58
>=65 - <75 years	0				2	(0.3)	2	0.35
>=75 years	0				0			
Angina pectoris								
>=18 - <65 years	3	(0.2)	3	0.24	3	(0.2)	3	0.30
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	2	(2.3)	2	3.30	0			
Palpitations								
>=18 - <65 years	3	(0.2)	3	0.24	3	(0.2)	3	0.30
>=65 - <75 years	3	(0.6)	3	0.69	2	(0.3)	2	0.35
>=75 years	0				0			
Angina unstable								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Coronary artery occlusion								
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Ventricular extrasystoles								
>=18 - <65 years	2	(0.2)	2	0.16	2	(0.2)	3	0.24
>=65 - <75 years	2	(0.4)	2	0.37	0			
>=75 years	1	(0.9)	1	0.93	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Mitral valve incompetence								
>=18 - <65 years	2	(0.2)	2	0.22	2	(0.2)	2	0.15
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Myocardial ischaemia								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.18
>=75 years	0				0			
Supraventricular extrasystoles								
>=18 - <65 years	2	(0.2)	2	0.27	0			
>=65 - <75 years	1	(0.2)	1	0.19	2	(0.3)	2	0.35
>=75 years	0				0			
Cardiac flutter								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Arrhythmia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.17	3	(0.5)	3	0.64
>=75 years	0				0			
Arteriosclerosis coronary artery								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Supraventricular tachycardia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Cardiac failure chronic								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Pericardial effusion								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Bundle branch block left								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Left ventricular dysfunction								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Aortic valve calcification								
>=18 - <65 years	0				2	(0.2)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Aortic valve incompetence								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Aortic valve sclerosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Atrial enlargement								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Atrial flutter								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Atrial thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Atrioventricular block complete								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.4)	1	1.49
Atrioventricular block first degree								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Bradycardia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	2	(0.4)	2	0.49
>=75 years	0				0			
Bundle branch block right								
>=18 - <65 years	0				3	(0.2)	4	0.38
>=65 - <75 years	0				3	(0.5)	3	0.66
>=75 years	1	(0.9)	1	0.93	0			
Cardiac arrest								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Cardiac dysfunction								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac failure acute								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Cardiac failure congestive								
>=18 - <65 years	0				2	(0.2)	3	0.43
>=65 - <75 years	4	(0.7)	4	0.85	0			
>=75 years	0				0			
Cardiac perfusion defect								
>=18 - <65 years	0				1	(0.1)	2	0.29
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac ventricular thrombosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Cardio-respiratory arrest								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Chronic coronary syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Coronary artery stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Diastolic dysfunction								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Left atrial dilatation								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Left atrial enlargement								
>=18 - <65 years	0				2	(0.2)	2	0.22

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Left ventricular hypertrophy								
>=18 - <65 years	0				0			
>=65 - <75 years	3	(0.5)	3	0.55	2	(0.3)	2	0.48
>=75 years	0				0			
Mitral valve stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Pericarditis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	1	(0.2)	1	0.31
>=75 years	0				0			
Sinus arrhythmia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Sinus bradycardia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				2	(0.4)	2	0.48
>=75 years	0				0			
Sinus tachycardia								
>=18 - <65 years	0				2	(0.2)	2	0.15
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Subendocardial ischaemia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Tricuspid valve incompetence								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Ventricular arrhythmia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Ventricular tachycardia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Renal and urinary disorders								
All								
>=18 - <65 years	26	(2.1)	32	3.32	27	(2.2)	35	3.35
>=65 - <75 years	21	(3.9)	26	6.61	19	(3.3)	19	3.93
>=75 years	4	(3.8)	4	4.57	5	(6.8)	10	15.67
Renal cyst								
>=18 - <65 years	5	(0.4)	5	0.52	3	(0.2)	3	0.30
>=65 - <75 years	2	(0.4)	2	0.64	1	(0.2)	1	0.18
>=75 years	0				0			
Renal impairment								
>=18 - <65 years	3	(0.2)	3	0.30	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.33	1	(0.2)	1	0.18
>=75 years	0				1	(1.4)	1	1.49
Dysuria								
>=18 - <65 years	3	(0.2)	4	0.32	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.31	2	(0.3)	2	0.35
>=75 years	0				1	(1.4)	1	1.49
Nephrolithiasis								
>=18 - <65 years	3	(0.2)	3	0.24	2	(0.2)	2	0.22
>=65 - <75 years	2	(0.4)	2	0.36	0			
>=75 years	0				2	(2.5)	4	6.64
Pollakiuria								
>=18 - <65 years	3	(0.2)	3	0.41	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	1	(0.9)	1	0.93	1	(1.4)	1	1.49
Ureterolithiasis								
>=18 - <65 years	2	(0.2)	2	0.22	2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				1	(1.3)	1	1.24
Bladder prolapse								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hydronephrosis								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Polyuria								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Urine odour abnormal								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Nocturia								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	0			
Renal pain								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Urinary incontinence								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	3	0.24
>=65 - <75 years	0				0			
>=75 years	0				0			
Urinary tract disorder								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Microalbuminuria								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal colic								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.22
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Chromaturia								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Chronic kidney disease								
>=18 - <65 years	1	(0.1)	1	0.14	3	(0.2)	3	0.24
>=65 - <75 years	3	(0.5)	3	0.82	2	(0.3)	2	0.48
>=75 years	0				0			
Acute kidney injury								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	3	(0.6)	3	0.81	3	(0.5)	3	0.53
>=75 years	0				1	(1.3)	1	1.24
Bladder mass								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Calculus urinary								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Cystitis haemorrhagic								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Diabetic nephropathy								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.49	2	(0.3)	2	0.57
>=75 years	1	(0.9)	1	0.93	0			
Haematuria								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	2	0.63	3	(0.5)	3	0.53
>=75 years	0				1	(1.2)	1	2.08
Hydrocalyx								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Hypertonic bladder								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Micturition urgency								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Nephropathy								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Nephrotic syndrome								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.79	0			
Proteinuria								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Pyelocaliectasis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Renal failure								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Renal mass								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Strangury								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Stress urinary incontinence								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Urethral stenosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Urinary retention								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Urinary tract inflammation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Urinary tract obstruction								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Reproductive system and breast disorders								
All								
>=18 - <65 years	21	(1.7)	21	2.15	14	(1.1)	16	1.51
>=65 - <75 years	8	(1.5)	8	1.71	9	(1.6)	11	2.20
>=75 years	0				0			
Erectile dysfunction								
>=18 - <65 years	5	(0.4)	5	0.46	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Uterine polyp								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	2	(0.2)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Intermenstrual bleeding								
>=18 - <65 years	2	(0.2)	2	0.27	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cervical polyp								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Prostatitis								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Benign prostatic hyperplasia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	4	(0.7)	4	0.97	3	(0.5)	3	0.66
>=75 years	0				0			
Ejaculation failure								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Menstruation irregular								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Pelvic discomfort								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Menopausal symptoms								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Ovarian cyst								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Uterine prolapse								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Breast pain								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Menstruation delayed								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Prostatic calcification								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Atrophic vulvovaginitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Breast mass								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Colpocele								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Dysmenorrhoea								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Galactorrhoea								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Genital prolapse								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Menopausal disorder								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Penile rash								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	2	0.35
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pruritus genital								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	2	(0.4)	2	0.49
>=75 years	0				0			
Testicular cyst								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Uterine enlargement								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Vaginal discharge								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Vaginal haemorrhage								
>=18 - <65 years	0				0			
>=65 - <75 years	0				2	(0.4)	2	0.35
>=75 years	0				0			
Vulvovaginal dryness								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Vulvovaginal pruritus								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Psychiatric disorders								
All								
>=18 - <65 years	21	(1.7)	23	2.31	25	(2.0)	26	2.95
>=65 - <75 years	13	(2.4)	15	3.24	11	(1.9)	11	2.59
>=75 years	2	(1.9)	2	1.94	1	(1.3)	2	2.47
Insomnia								
>=18 - <65 years	5	(0.4)	5	0.58	4	(0.3)	5	0.59
>=65 - <75 years	4	(0.7)	4	0.86	1	(0.2)	1	0.18
>=75 years	1	(0.9)	1	0.93	1	(1.3)	1	1.24
Anxiety								
>=18 - <65 years	4	(0.3)	4	0.38	3	(0.2)	3	0.24
>=65 - <75 years	1	(0.2)	1	0.19	2	(0.3)	2	0.35
>=75 years	0				1	(1.3)	1	1.24

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Depression								
>=18 - <65 years	3	(0.2)	3	0.24	8	(0.7)	8	0.82
>=65 - <75 years	5	(0.9)	5	1.16	1	(0.2)	1	0.31
>=75 years	0				0			
Irritability								
>=18 - <65 years	2	(0.2)	2	0.22	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Adjustment disorder								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Adjustment disorder with mixed anxiety and depressed mood								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Disorientation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Post-traumatic stress disorder								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Stress								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Depressed mood								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Nightmare								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Agitation								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Drug abuse								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Adjustment disorder with depressed mood								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Affect lability								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Anxiety disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Bruxism								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Drug dependence								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Emotional distress								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Fear								
>=18 - <65 years	0				2	(0.2)	2	0.29
>=65 - <75 years	0				0			
>=75 years	0				0			
Listless								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Major depression								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Mental status changes								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Mixed anxiety and depressive disorder								
>=18 - <65 years	0				1	(0.1)	1	0.14

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Mood swings								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Persistent depressive disorder								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Phobia								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Sleep disorder								
>=18 - <65 years	0				3	(0.2)	3	0.42
>=65 - <75 years	3	(0.5)	3	0.55	1	(0.2)	1	0.31
>=75 years	1	(1.0)	1	1.01	0			
Blood and lymphatic system disorders								
All								
>=18 - <65 years	20	(1.6)	20	2.12	23	(1.9)	23	2.33
>=65 - <75 years	12	(2.2)	14	3.44	6	(1.0)	6	1.30
>=75 years	1	(0.9)	1	0.93	1	(1.4)	1	1.49
Anaemia								
>=18 - <65 years	11	(0.9)	11	1.28	10	(0.8)	10	0.99
>=65 - <75 years	7	(1.3)	9	2.13	3	(0.5)	3	0.77
>=75 years	1	(0.9)	1	0.93	1	(1.4)	1	1.49
Lymphadenopathy								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Eosinophilia								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			
Leukocytosis								
>=18 - <65 years	1	(0.1)	1	0.08	3	(0.2)	3	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Splenomegaly								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Polycythaemia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Thrombocytopenia								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Leukopenia								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Blood loss anaemia								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	2	(0.3)	2	0.35
>=75 years	0				0			
Hypochromic anaemia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Iron deficiency anaemia								
>=18 - <65 years	0				3	(0.2)	3	0.30
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Lymphadenopathy mediastinal								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Normocytic anaemia								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Pancytopenia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Thrombocytosis								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			

Neoplasms benign, malignant and unspecified

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
(incl cysts and polyps)								
All								
>=18 - <65 years	13	(1.1)	15	1.50	11	(0.9)	18	1.86
>=65 - <75 years	15	(2.7)	19	4.49	13	(2.3)	17	3.40
>=75 years	3	(2.7)	5	4.64	3	(3.9)	5	7.88
Chronic myeloid leukaemia								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Gastric cancer								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Eye naevus								
>=18 - <65 years	1	(0.1)	2	0.16	0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Metastases to liver								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	1	(1.3)	1	1.24
Pancreatic carcinoma								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.24
Acrochordon								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Basal cell carcinoma								
>=18 - <65 years	1	(0.1)	1	0.08	2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	1	1.24
Haemangioma of liver								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Neoplasm skin								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Oral fibroma								
>=18 - <65 years	1	(0.1)	1	0.08	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=65 - <75 years	0				0			
>=75 years	0				0			
Salivary gland neoplasm								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Osteoma								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Small cell lung cancer								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Colon adenoma								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	2	(0.4)	2	0.47	0			
>=75 years	0				0			
Adenocarcinoma of colon								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Adenocarcinoma pancreas								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Adrenal adenoma								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.08
Benign renal neoplasm								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Bladder cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Bladder papilloma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Bowen's disease								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Breast cancer								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Breast cancer metastatic								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Colon cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Colon cancer stage II								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Colorectal cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	2	(0.4)	2	0.50	0			
>=75 years	0				0			
Dysplastic naevus								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Endometrial adenocarcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Gastrointestinal tract adenoma								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Glioblastoma multiforme								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Hepatocellular carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Invasive breast carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Invasive ductal breast carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Invasive lobular breast carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Lipoma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Lung adenocarcinoma								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				1	(1.2)	1	2.08
Lung cancer metastatic								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	1	(0.2)	1	0.18
>=75 years	0				0			
Lymphangioma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Malignant melanoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Malignant melanoma in situ								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Malignant peritoneal neoplasm								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Metastases to bone marrow								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Metastases to lymph nodes								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Myxoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Ovarian cancer metastatic								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Pancreatic carcinoma metastatic								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Pancreatic neoplasm								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	1	(0.9)	1	0.93	0			
Prostate cancer								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	1	(0.9)	1	0.93	0			
Prostatic adenoma								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal cell carcinoma								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Renal hamartoma								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Renal neoplasm								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Seborrhoeic keratosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	1	(0.9)	2	1.85	0			
Skin papilloma								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.33	0			
>=75 years	0				0			
Small intestine neuroendocrine tumour								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Squamous cell carcinoma of skin								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	1	(0.2)	1	0.18
>=75 years	0				0			
Uterine cancer								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Uterine leiomyoma								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Ear and labyrinth disorders								
All								
>=18 - <65 years	12	(1.0)	12	1.14	11	(0.9)	11	1.25
>=65 - <75 years	11	(2.0)	14	2.89	8	(1.4)	9	1.85
>=75 years	3	(3.3)	3	5.09	3	(3.7)	3	5.31
Ear pain								
>=18 - <65 years	2	(0.2)	2	0.22	1	(0.1)	1	0.14
>=65 - <75 years	3	(0.5)	3	0.67	0			
>=75 years	0				0			
Tinnitus								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Vertigo								
>=18 - <65 years	2	(0.2)	2	0.22	3	(0.2)	3	0.31
>=65 - <75 years	7	(1.3)	8	1.70	3	(0.5)	4	0.71
>=75 years	1	(1.0)	1	1.79	2	(2.4)	2	4.08
Hypoacusis								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	0				2	(0.3)	2	0.35
>=75 years	1	(1.0)	1	1.01	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Deafness bilateral								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Meniere's disease								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Vertigo positional								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Ear inflammation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Eustachian tube dysfunction								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Cerumen impaction								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	1	(1.2)	1	2.28	0			
Deafness unilateral								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Ear discomfort								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
External ear pain								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Middle ear inflammation								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Motion sickness								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				1	(1.3)	1	1.24
Presbyacusis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatobiliary disorders								
All								
>=18 - <65 years	12	(1.0)	16	1.46	18	(1.5)	21	2.17
>=65 - <75 years	7	(1.3)	9	2.28	2	(0.3)	2	0.61
>=75 years	0				1	(1.3)	2	2.47
Hepatic steatosis								
>=18 - <65 years	6	(0.5)	6	0.54	9	(0.7)	9	0.90
>=65 - <75 years	2	(0.4)	2	0.37	0			
>=75 years	0				0			
Cholelithiasis								
>=18 - <65 years	2	(0.2)	2	0.16	1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Hepatic mass								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatomegaly								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Hypertransaminasaemia								
>=18 - <65 years	1	(0.1)	2	0.16	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Liver disorder								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Non-alcoholic steatohepatitis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cholecystitis								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Hepatic function abnormal								
>=18 - <65 years	1	(0.1)	1	0.14	2	(0.2)	2	0.23
>=65 - <75 years	0				0			
>=75 years	0				0			
Alcoholic liver disease								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Bile duct stone								
>=18 - <65 years	0				0			
>=65 - <75 years	0				0			
>=75 years	0				1	(1.3)	2	2.47
Biliary colic								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Biliary dyskinesia								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Cholecystitis chronic								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.31
>=75 years	0				0			
Gallbladder cholesterolosis								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Gallbladder polyp								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.30	0			
>=75 years	0				0			
Hepatic cirrhosis								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	0				0			
>=75 years	0				0			
Hepatic cyst								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperplastic cholecystopathy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
>=75 years	0				0			
Nonalcoholic fatty liver disease								
>=18 - <65 years	0				2	(0.2)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Steatohepatitis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Immune system disorders								
All								
>=18 - <65 years	9	(0.7)	10	1.04	9	(0.7)	10	1.10
>=65 - <75 years	3	(0.5)	3	0.67	6	(1.0)	6	1.57
>=75 years	0				0			
Seasonal allergy								
>=18 - <65 years	7	(0.6)	7	0.68	5	(0.4)	5	0.58
>=65 - <75 years	1	(0.2)	1	0.19	3	(0.5)	3	0.66
>=75 years	0				0			
Anaphylactic reaction								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Allergy to arthropod bite								
>=18 - <65 years	1	(0.1)	1	0.08	1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.29
>=75 years	0				0			
Drug hypersensitivity								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Allergy to arthropod sting								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Food allergy								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	1	(0.2)	1	0.17	0			
>=75 years	0				0			
Hypersensitivity								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Immunisation reaction								
>=18 - <65 years	0				1	(0.1)	2	0.16
>=65 - <75 years	0				0			
>=75 years	0				0			
Endocrine disorders								

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
All								
>=18 - <65 years	4	(0.3)	4	0.44	12	(1.0)	12	1.20
>=65 - <75 years	2	(0.4)	2	0.37	5	(0.9)	5	1.02
>=75 years	0				1	(1.3)	1	2.20
Hypothyroidism								
>=18 - <65 years	2	(0.2)	2	0.22	2	(0.2)	2	0.16
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				1	(1.3)	1	2.20
Autoimmune thyroiditis								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Hypogonadism								
>=18 - <65 years	1	(0.1)	1	0.14	1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Adrenal mass								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Adrenocortical insufficiency acute								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Goitre								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Hyperplasia adrenal								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Hyperprolactinaemia								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Hyperthyroidism								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Inappropriate antidiuretic hormone secretion								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Secondary hypogonadism								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Thyroid mass								
>=18 - <65 years	0				2	(0.2)	2	0.22
>=65 - <75 years	2	(0.4)	2	0.37	0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Congenital, familial and genetic disorders								
All								
>=18 - <65 years	4	(0.3)	4	0.49	4	(0.3)	4	0.38
>=65 - <75 years	2	(0.4)	2	0.50	1	(0.2)	1	0.18
>=75 years	0				0			
Type V hyperlipidaemia								
>=18 - <65 years	3	(0.2)	3	0.36	1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Cystic fibrosis lung								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Atrial septal defect								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.18
>=75 years	0				0			
Congenital syphilitic osteochondritis								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Corneal dystrophy								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			
Hydrocele								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.19	0			
>=75 years	0				0			
Hypertrophic cardiomyopathy								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Myotonic dystrophy								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Surgical and medical procedures								
All								
>=18 - <65 years	2	(0.2)	2	0.22	5	(0.4)	5	0.46
>=65 - <75 years	1	(0.2)	1	0.31	1	(0.2)	1	0.31
>=75 years	1	(1.0)	1	1.01	0			
Knee operation								
>=18 - <65 years	1	(0.1)	1	0.08	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Shoulder operation								
>=18 - <65 years	1	(0.1)	1	0.14	0			
>=65 - <75 years	0				0			
>=75 years	0				0			
Cardiac pacemaker replacement								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	1	(1.0)	1	1.01	0			
Large intestinal polypectomy								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Removal of foreign body								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Skin neoplasm excision								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Spinal operation								
>=18 - <65 years	0				1	(0.1)	1	0.08
>=65 - <75 years	0				0			
>=75 years	0				0			
Toe amputation								
>=18 - <65 years	0				0			
>=65 - <75 years	0				1	(0.2)	1	0.31
>=75 years	0				0			
Tooth extraction								
>=18 - <65 years	0				0			
>=65 - <75 years	1	(0.2)	1	0.31	0			
>=75 years	0				0			


%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by age group, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Social circumstances								
All								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			
Menopause								
>=18 - <65 years	0				1	(0.1)	1	0.14
>=65 - <75 years	0				0			
>=75 years	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.13 Adverse events by age group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): AGEGR1; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS AGEGR1; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:31 - faedotgrp/faesocgrpagedotontp3asas.png

7.7.14 Adverse events by age group and system organ class - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects, dis.: disorders, adm.: administration, con.: connective, proc.: procedural/procedures, sys.: system, resp.: respiratory, cong.: congenital, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): AGEGR1; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEBODSYS AGEGR1; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:36 - faedotgrp/faesocgrpagedotontt2dsas.png

7.7.15 Adverse events by age group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - phase 3a pool




% of subjects: Percentage of subjects with one or more events, N: Number of subjects. Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

adsl.xpt; variable(s): AGEGR1; criteria: POOLGR2N == 2 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD AGEGR1; criteria: POOLGR2N == 2 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:41 - faedotgrp/faept5pctgrpagedotontp3asas.png

7.7.16 Adverse events by age group and preferred term - most frequent [>=5%] - on-treatment/main-on-treatment - dot plot - safety analysis set - T2D pool



% of subjects: Percentage of subjects with one or more events, N: Number of subjects, Adj.: Adjusted percentages were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Safety analysis set. MedDRA version 24.1. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

adsl.xpt; variable(s): AGEGR1; criteria: POOLGR1N == 1 & SAFFL == "Y"
adae.xpt; variable(s): AEDECOD AGEGR1; criteria: POOLGR1N == 1 & SAFFL == "Y" & (ANELFL) == "Y" & (ANL06FL) == "Y"

nn1436/nn1436-iss/submission_20221024_er
05DEC2022:12:57:46 - faedotgrp/faept5pctgrpagedotontt2dsas.png

7.7.17 Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
White	1563				1522			
Black or African American	76				73			
Asian	469				524			
Other	47				34			
Missing	15				17			
PYE (years)								
White	1242.90				1219.98			
Black or African American	56.42				59.43			
Asian	331.92				364.20			
Other	40.57				26.92			
Missing	9.42				10.06			
Events								
White	960	(61.3)	2940	255.74	876	(57.6)	2602	234.94
Black or African American	47	(60.5)	169	316.04	50	(68.9)	166	337.81
Asian	279	(59.7)	761	237.47	304	(58.0)	1030	290.38
Other	37		96		20		50	
Missing	5		19		13		30	
Serious								
Yes								
White	129	(8.2)	201	16.42	130	(8.5)	181	14.60
Black or African American	8	(11.6)	13	24.30	4	(5.3)	14	19.22
Asian	23	(4.9)	24	8.11	32	(6.2)	38	10.31
Other	6		7		1		1	
Missing	0				2		4	
No								
White	928	(59.2)	2739	239.31	844	(55.5)	2421	220.34
Black or African American	45	(58.0)	156	291.74	48	(66.3)	152	318.59
Asian	274	(58.7)	737	229.36	298	(56.9)	992	280.07
Other	35		89		20		49	
Missing	5		19		13		26	
Missing								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
White	73	(4.7)	100	8.77	71	(4.6)	106	8.14
Black or African American	4	(6.0)	5	8.61	3	(3.9)	9	12.35
Asian	9	(1.9)	9	3.29	14	(2.7)	17	4.54
Other	6		7		0			
Missing	0				1		1	
Moderate								
White	414	(26.4)	784	66.30	379	(24.9)	704	62.05
Black or African American	23	(29.9)	37	66.63	27	(36.5)	40	66.17
Asian	60	(12.8)	82	22.84	63	(12.2)	97	25.04
Other	11		21		7		10	
Missing	4		7		2		5	
Mild								
White	793	(50.6)	2056	180.66	721	(47.4)	1792	164.75
Black or African American	36	(46.8)	127	240.80	42	(58.6)	117	259.28
Asian	248	(53.1)	670	211.35	280	(53.5)	916	260.80
Other	32		68		17		40	
Missing	4		12		13		24	
Missing								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to basal insulin								
Probable								
White	63	(4.0)	79	7.62	49	(3.2)	86	7.46
Black or African American	2	(2.6)	2	4.39	0			
Asian	16	(3.4)	37	11.65	25	(4.8)	45	10.83
Other	1		2		2		2	
Missing	0				0			
Possible								
White	75	(4.8)	96	9.13	57	(3.7)	70	6.23
Black or African American	7	(9.2)	13	26.64	9	(12.8)	13	29.77
Asian	39	(8.3)	62	19.85	37	(6.9)	93	28.59
Other	3		4		1		1	
Missing	1		4		1		1	
Unlikely								
White	932	(59.5)	2755	238.06	854	(56.2)	2443	220.99
Black or African American	44	(56.0)	154	285.02	48	(65.9)	152	306.66
Asian	259	(55.5)	661	205.58	292	(55.7)	890	250.35
Other	36		89		20		47	
Missing	5		15		12		29	
Missing								
White	6	(0.4)	10	0.93	3	(0.2)	3	0.25
Black or African American	0				1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.39	2	(0.4)	2	0.62
Other	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
White	8	(0.5)	8	0.89	3	(0.2)	4	0.45
Black or African American	1	(1.1)	1	1.82	3	(4.8)	3	8.84
Asian	2	(0.4)	2	0.74	1	(0.2)	1	0.36
Other	0				0			
Missing	0				0			
No								
White	957	(61.1)	2921	253.82	873	(57.4)	2594	234.12
Black or African American	47	(60.5)	168	314.22	49	(67.6)	162	327.60
Asian	279	(59.7)	758	236.35	303	(57.8)	1026	289.04
Other	37		95		20		50	
Missing	5		19		13		30	
NA								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Missing								
White	6	(0.4)	10	0.93	3	(0.2)	3	0.25
Black or African American	0				1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.39	3	(0.6)	3	0.98
Other	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
White	13	(0.8)	17	1.55	9	(0.6)	10	0.78
Black or African American	0				1	(1.3)	1	1.37
Asian	0				3	(0.6)	4	0.93
Other	1		1		0			
Missing	0				0			
Not recovered/not resolved								
White	411	(26.3)	777	64.87	382	(25.1)	714	61.78
Black or African American	20	(25.0)	43	72.89	20	(26.0)	42	66.95
Asian	143	(30.5)	244	77.09	162	(31.0)	271	76.36
Other	12		20		3		5	
Missing	3		3		3		10	
Recovered/resolved with sequelae								
White	9	(0.6)	9	0.66	13	(0.9)	14	1.32
Black or African American	0				1	(1.3)	2	2.75
Asian	0				0			
Other	1		1		2		2	
Missing	0				0			
Recovering/resolving								
White	72	(4.6)	106	9.90	61	(4.0)	78	7.20
Black or African American	6	(8.5)	6	13.09	6	(8.4)	7	16.40
Asian	13	(2.8)	15	4.69	18	(3.5)	19	5.85
Other	5		9		7		7	
Missing	0				0			
Recovered/resolved								
White	837	(53.4)	2030	178.68	733	(48.2)	1785	163.80
Black or African American	41	(52.9)	120	230.05	44	(60.3)	114	250.34
Asian	209	(44.8)	502	155.70	235	(44.8)	735	207.01
Other	31		65		16		36	
Missing	4		16		11		20	
Unknown								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	0				0			
Missing	0				0			
Missing								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

7.7.18 Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
White	1333				1304			
Black or African American	67				71			
Asian	418				452			
Other	47				34			
Missing	15				17			
PYE (years)								
White	1130.55				1112.99			
Black or African American	52.07				58.43			
Asian	306.31				328.07			
Other	40.57				26.92			
Missing	9.42				10.06			
Events								
White	808	(60.5)	2533	237.64	735	(56.4)	2220	214.20
Black or African American	42	(60.8)	155	315.76	48	(67.4)	153	290.78
Asian	247	(59.3)	675	223.89	257	(57.0)	806	244.82
Other	37		96		20		50	
Missing	5		19		13		30	
Serious								
Yes								
White	120	(9.0)	188	17.25	126	(9.7)	175	16.13
Black or African American	8	(12.1)	13	25.49	4	(5.5)	14	20.16
Asian	21	(5.1)	22	8.16	29	(6.5)	35	10.59
Other	6		7		1		1	
Missing	0				2		4	
No								
White	779	(58.3)	2345	220.39	704	(54.1)	2045	198.07
Black or African American	40	(58.1)	142	290.27	46	(64.6)	139	270.62
Asian	243	(58.4)	653	215.73	253	(56.1)	771	234.24
Other	35		89		20		49	
Missing	5		19		13		26	
Missing								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Severity								
Severe								
White	66	(5.0)	92	9.05	68	(5.2)	102	8.89
Black or African American	4	(6.3)	5	9.03	3	(4.1)	9	12.96
Asian	7	(1.6)	7	2.66	13	(2.9)	16	4.78
Other	6		7		0			
Missing	0				1		1	
Moderate								
White	368	(27.5)	701	65.02	333	(25.6)	620	59.25
Black or African American	20	(29.7)	33	65.39	26	(35.9)	39	64.51
Asian	58	(14.0)	79	24.38	59	(13.1)	93	26.97
Other	11		21		7		10	
Missing	4		7		2		5	
Mild								
White	657	(49.2)	1740	163.57	597	(45.8)	1498	146.06
Black or African American	33	(47.5)	117	241.33	40	(56.6)	105	213.30
Asian	218	(52.3)	589	196.85	236	(52.4)	697	213.07
Other	32		68		17		40	
Missing	4		12		13		24	
Missing								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to basal insulin								
Probable								
White	48	(3.6)	61	6.19	44	(3.4)	81	7.94
Black or African American	2	(2.8)	2	4.60	0			
Asian	14	(3.4)	35	12.18	23	(5.1)	42	11.18
Other	1		2		2		2	
Missing	0				0			
Possible								
White	61	(4.5)	80	8.26	50	(3.8)	63	6.18
Black or African American	6	(9.1)	12	26.81	9	(13.5)	13	31.23
Asian	32	(7.6)	53	17.74	27	(6.0)	59	19.53
Other	3		4		1		1	
Missing	1		4		1		1	
Unlikely								
White	788	(59.0)	2382	222.09	713	(54.7)	2073	199.78
Black or African American	39	(56.0)	141	284.34	46	(64.2)	139	258.11
Asian	230	(55.3)	586	193.53	246	(54.5)	703	213.41
Other	36		89		20		47	
Missing	5		15		12		29	
Missing								
White	6	(0.4)	10	1.09	3	(0.2)	3	0.29
Black or African American	0				1	(1.4)	1	1.44
Asian	1	(0.3)	1	0.44	2	(0.4)	2	0.70
Other	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Related to technical complaint for basal insulin								
Yes								
White	8	(0.6)	8	1.04	3	(0.2)	4	0.52
Black or African American	1	(1.1)	1	1.91	3	(5.1)	3	9.27
Asian	2	(0.5)	2	0.84	1	(0.2)	1	0.41
Other	0				0			
Missing	0				0			
No								
White	805	(60.3)	2514	235.39	732	(56.2)	2212	213.24
Black or African American	42	(60.8)	154	313.85	47	(66.0)	149	280.07
Asian	247	(59.3)	672	222.61	256	(56.8)	802	243.30
Other	37		95		20		50	
Missing	5		19		13		30	
NA								
White	1	(0.1)	1	0.12	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Missing								
White	6	(0.4)	10	1.09	3	(0.2)	3	0.29
Black or African American	0				1	(1.4)	1	1.44
Asian	1	(0.3)	1	0.44	3	(0.6)	3	1.11
Other	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

Adverse events by race - on-treatment/main-on-treatment - summary - safety analysis set - T2D pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Outcome								
Fatal								
White	12	(0.9)	16	1.67	9	(0.7)	10	0.91
Black or African American	0				1	(1.4)	1	1.44
Asian	0				3	(0.7)	4	1.06
Other	1		1		0			
Missing	0				0			
Not recovered/not resolved								
White	351	(26.3)	691	62.89	326	(25.0)	618	57.03
Black or African American	17	(24.5)	37	69.72	20	(27.3)	42	70.22
Asian	120	(28.5)	202	65.08	135	(30.1)	223	68.55
Other	12		20		3		5	
Missing	3		3		3		10	
Recovered/resolved with sequelae								
White	9	(0.7)	9	0.78	10	(0.8)	11	1.07
Black or African American	0				1	(1.4)	2	2.88
Asian	0				0			
Other	1		1		2		2	
Missing	0				0			
Recovering/resolving								
White	66	(4.9)	100	10.68	56	(4.3)	70	7.15
Black or African American	6	(8.9)	6	13.73	6	(8.8)	7	17.20
Asian	13	(3.2)	15	5.34	18	(4.0)	19	6.65
Other	5		9		7		7	
Missing	0				0			
Recovered/resolved								
White	699	(52.3)	1716	161.55	611	(46.9)	1510	147.96
Black or African American	37	(53.3)	112	232.31	42	(58.4)	101	199.04
Asian	191	(46.1)	458	153.47	198	(43.9)	559	168.29
Other	31		65		16		36	
Missing	4		16		11		20	
Unknown								
White	1	(0.1)	1	0.07	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.3)	1	0.27
Other	0				0			
Missing	0				0			
Missing								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, NA: Not applicable, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE), Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. T2D pool: ONWARDS 1-5, only main part of ONWARDS 1. T2D: Type 2 diabetes.

7.7.19 Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Number of subjects								
White	1563				1522			
Black or African American	76				73			
Asian	469				524			
Other	47				34			
Missing	15				17			
PYE (years)								
White	1242.90				1219.98			
Black or African American	56.42				59.43			
Asian	331.92				364.20			
Other	40.57				26.92			
Missing	9.42				10.06			
Events								
White	960	(61.3)	2940	255.74	876	(57.6)	2602	234.94
Black or African American	47	(60.5)	169	316.04	50	(68.9)	166	337.81
Asian	279	(59.7)	761	237.47	304	(58.0)	1030	290.38
Other	37		96		20		50	
Missing	5		19		13		30	
Infections and infestations								
All								
White	521	(33.2)	749	67.55	471	(31.0)	704	64.35
Black or African American	21	(25.2)	33	58.66	26	(36.8)	36	80.05
Asian	88	(18.9)	115	35.78	107	(20.5)	141	37.91
Other	15		20		13		15	
Missing	3		3		7		9	
COVID-19								
White	159	(10.2)	162	14.48	162	(10.6)	167	14.66
Black or African American	9	(11.9)	9	15.97	10	(13.0)	12	21.44
Asian	9	(1.8)	9	2.84	8	(1.5)	8	2.13
Other	4		5		8		8	
Missing	0				4		4	
Nasopharyngitis								
White	89	(5.6)	110	10.94	82	(5.4)	98	10.37
Black or African American	2	(2.6)	2	3.42	1	(2.3)	1	4.66
Asian	24	(5.3)	27	8.61	30	(5.7)	34	8.97
Other	1		1		0			
Missing	1		1		2		2	

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Upper respiratory tract infection								
White	52	(3.3)	63	4.90	38	(2.5)	41	3.55
Black or African American	2	(2.0)	3	6.03	1	(1.1)	1	1.05
Asian	13	(2.7)	14	4.55	13	(2.5)	14	4.37
Other	1		1		0			
Missing	0				0			
Urinary tract infection								
White	34	(2.2)	37	3.39	37	(2.4)	42	3.69
Black or African American	3	(3.8)	3	5.32	3	(3.7)	3	4.71
Asian	4	(0.8)	4	1.10	8	(1.7)	9	2.49
Other	1		1		2		2	
Missing	1		1		0			
Influenza								
White	27	(1.7)	29	2.93	27	(1.8)	29	3.10
Black or African American	1	(1.1)	2	3.81	3	(4.5)	4	10.84
Asian	0				2	(0.4)	2	0.69
Other	0				1		1	
Missing	1		1		0			
Gastroenteritis								
White	24	(1.5)	25	2.52	10	(0.7)	10	0.95
Black or African American	2	(2.2)	2	3.73	3	(5.9)	4	14.38
Asian	6	(1.3)	6	2.15	4	(0.8)	4	1.08
Other	0				0			
Missing	0				1		1	
Bronchitis								
White	22	(1.4)	23	2.04	11	(0.7)	11	0.96
Black or African American	1	(0.5)	1	1.07	0			
Asian	5	(1.0)	5	1.80	7	(1.4)	7	1.84
Other	2		2		1		1	
Missing	0				0			
Sinusitis								
White	18	(1.1)	19	1.71	18	(1.2)	21	1.81
Black or African American	1	(1.1)	2	3.64	1	(1.8)	1	3.24
Asian	0				0			
Other	0				0			
Missing	0				0			
COVID-19 pneumonia								
White	15	(1.0)	15	1.30	11	(0.7)	11	0.92
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Pharyngitis								
White	14	(0.9)	16	1.43	15	(1.0)	17	1.43
Black or African American	0				0			
Asian	3	(0.7)	3	1.04	2	(0.4)	3	1.05
Other	4		4		1		1	
Missing	0				0			
Pneumonia								
White	14	(0.9)	14	1.22	5	(0.3)	5	0.41
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Respiratory tract infection viral								
White	12	(0.8)	13	1.38	10	(0.7)	11	1.19
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory tract infection								
White	9	(0.6)	9	0.79	5	(0.3)	5	0.43
Black or African American	0				0			
Asian	0				0			
Other	0				1		1	
Missing	0				0			
Rhinitis								
White	9	(0.6)	9	0.75	10	(0.7)	13	1.40
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Cystitis								
White	8	(0.5)	8	0.83	10	(0.7)	11	0.96
Black or African American	1	(1.1)	1	1.91	0			
Asian	6	(1.3)	7	1.95	7	(1.3)	8	1.92
Other	0				0			
Missing	0				0			
Conjunctivitis								
White	8	(0.5)	8	0.76	3	(0.2)	3	0.24
Black or African American	0				0			
Asian	4	(0.9)	4	1.30	4	(0.8)	4	1.08
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Tooth infection								
White	8	(0.5)	10	0.87	7	(0.5)	7	0.71
Black or African American	0				0			
Asian	1	(0.2)	1	0.16	0			
Other	0				1		1	
Missing	0				0			
Tooth abscess								
White	8	(0.5)	8	0.77	6	(0.4)	7	0.60
Black or African American	0				1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Fungal infection								
White	7	(0.4)	8	0.67	2	(0.1)	2	0.18
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Viral infection								
White	6	(0.4)	6	0.49	12	(0.8)	15	1.29
Black or African American	1	(1.1)	1	1.82	0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Gastroenteritis viral								
White	6	(0.4)	6	0.50	5	(0.3)	5	0.51
Black or African American	0				1	(1.3)	1	1.37
Asian	0				0			
Other	0				0			
Missing	0				0			
Otitis media								
White	6	(0.4)	6	0.59	4	(0.3)	4	0.38
Black or African American	0				1	(1.4)	1	2.29
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Acute sinusitis								
White	5	(0.3)	5	0.36	5	(0.3)	5	0.53
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Herpes zoster								
White	5	(0.3)	5	0.43	14	(0.9)	15	1.21
Black or African American	0				0			
Asian	4	(0.8)	4	0.95	3	(0.5)	3	0.81
Other	2		2		0			
Missing	0				0			
Lower respiratory tract infection								
White	5	(0.3)	5	0.39	3	(0.2)	5	0.41
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Coronavirus infection								
White	4	(0.3)	4	0.25	5	(0.3)	7	0.63
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Cellulitis								
White	4	(0.3)	4	0.29	7	(0.5)	8	0.72
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Vaginal infection								
White	4	(0.3)	5	0.49	3	(0.2)	3	0.25
Black or African American	0				0			
Asian	2	(0.4)	2	0.74	0			
Other	0				0			
Missing	0				0			
Genital infection								
White	3	(0.2)	3	0.24	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Respiratory syncytial virus infection								
White	3	(0.2)	3	0.24	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Erysipelas								
White	3	(0.2)	3	0.24	2	(0.1)	3	0.28
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Laryngitis								
White	3	(0.2)	3	0.19	5	(0.3)	5	0.49
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tonsillitis								
White	3	(0.2)	3	0.26	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Gingivitis								
White	3	(0.2)	4	0.32	2	(0.1)	2	0.20
Black or African American	0				0			
Asian	0				3	(0.6)	3	1.01
Other	0				0			
Missing	0				0			
Wound infection								
White	3	(0.2)	3	0.27	0			
Black or African American	0				1	(1.7)	1	3.31
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear infection								
White	3	(0.2)	3	0.23	4	(0.3)	4	0.36
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.24
Other	1		1		0			
Missing	0				0			
Gastrointestinal infection								
White	3	(0.2)	3	0.34	5	(0.3)	7	0.66
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Vulvovaginal candidiasis								
White	3	(0.2)	4	0.29	3	(0.2)	3	0.20
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Acarodermatitis								
White	2	(0.1)	2	0.13	3	(0.2)	3	0.18
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Sepsis								
White	2	(0.1)	2	0.22	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Otitis externa								
White	2	(0.1)	2	0.17	5	(0.3)	5	0.46
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Abscess								
White	2	(0.1)	2	0.18	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Osteomyelitis								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vulvovaginal mycotic infection								
White	2	(0.1)	2	0.18	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Periodontitis								
White	2	(0.1)	2	0.24	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	3	(0.6)	3	0.78	5	(0.9)	5	1.41
Other	0				0			
Missing	0				1		1	
Tinea cruris								
White	2	(0.1)	2	0.19	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tinea infection								
White	2	(0.1)	2	0.17	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tinea pedis								
White	2	(0.1)	2	0.24	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Candida infection								
White	2	(0.1)	2	0.13	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Genital infection fungal								
White	2	(0.1)	3	0.32	2	(0.1)	2	0.13
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Hordeolum								
White	2	(0.1)	2	0.19	4	(0.3)	4	0.42
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Subcutaneous abscess								
White	2	(0.1)	2	0.16	0			
Black or African American	0				1	(1.3)	1	1.37
Asian	0				1	(0.2)	2	0.39
Other	0				0			
Missing	0				0			
Abscess limb								
White	2	(0.1)	2	0.23	2	(0.1)	3	0.39
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Diabetic foot infection								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pharyngotonsillitis								
White	1	(0.1)	1	0.11	2	(0.1)	3	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pneumonia viral								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pulmonary tuberculoma								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Viral tracheitis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Appendicitis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic sinusitis								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.14
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Clostridium difficile colitis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Ear infection fungal								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gangrene								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Helicobacter infection								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	2	(0.4)	2	0.54
Other	0				0			
Missing	0				0			
Nail infection								
White	1	(0.1)	2	0.13	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Paronychia								
White	1	(0.1)	1	0.06	0			
Black or African American	0				1	(1.7)	1	3.31
Asian	1	(0.2)	1	0.35	1	(0.2)	2	0.72
Other	0				0			
Missing	0				0			
Peritonsillar abscess								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.31
Other	0				0			
Missing	0				0			
Post-acute COVID-19 syndrome								
White	1	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Pyelonephritis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin candida								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Genital candidiasis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oral candidiasis								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Oral herpes								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.07
Black or African American	1	(1.1)	2	3.64	0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Postoperative wound infection								
White	1	(0.1)	1	0.11	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Suspected COVID-19								
White	1	(0.1)	1	0.11	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Asymptomatic COVID-19								
White	1	(0.1)	1	0.06	2	(0.1)	2	0.18
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Balanitis candida								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chronic tonsillitis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Escherichia urinary tract infection								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Folliculitis								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Helicobacter gastritis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Herpes simplex								
White	1	(0.1)	1	0.06	1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Herpes virus infection								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Infected bite								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Laryngopharyngitis								
White	1	(0.1)	1	0.06	1	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Localised infection								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.32
Black or African American	1	(1.1)	1	1.82	0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Mastitis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oropharyngeal candidiasis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Otitis media chronic								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin infection								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.38
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Tracheitis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urethritis								
White	1	(0.1)	1	0.06	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Viral upper respiratory tract infection								
White	1	(0.1)	1	0.06	3	(0.2)	3	0.20
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Breast abscess								
White	1	(0.1)	1	0.13	2	(0.1)	2	0.18
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Eye infection								
White	1	(0.1)	1	0.13	2	(0.1)	2	0.23
Black or African American	0				1	(1.8)	1	3.24
Asian	0				0			
Other	0				0			
Missing	0				0			
Norovirus infection								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Severe acute respiratory syndrome								
White	1	(0.1)	1	0.13	1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Vulvovaginitis								
White	1	(0.1)	1	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fungal skin infection								
White	1	(0.1)	1	0.10	1	(0.1)	1	0.11
Black or African American	1	(0.5)	1	1.07	0			
Asian	1	(0.2)	1	0.16	0			
Other	0				0			
Missing	0				0			
Kidney infection								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Onychomycosis								
White	1	(0.1)	1	0.10	3	(0.2)	3	0.18
Black or African American	0				1	(1.3)	1	1.37
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Pulpitis dental								
White	1	(0.1)	1	0.10	2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				2	(0.4)	2	0.50
Other	0				0			
Missing	0				0			
Pustule								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Tinea versicolour								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Varicella zoster virus infection								
White	1	(0.1)	1	0.10	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Abdominal abscess								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Anal abscess								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Bacteraemia								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Bacterial infection								
White	0				0			
Black or African American	0				1	(1.1)	1	1.05
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Bartholinitis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Body tinea								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Breast cellulitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Campylobacter gastroenteritis								
White	0				1	(0.1)	1	0.12
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Chlamydial infection								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Cholecystitis infective								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			
Chronic hepatitis C								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Clostridium difficile infection								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			
Cystitis escherichia								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dermatophytosis of nail								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Diverticulitis								
White	0				3	(0.2)	3	0.20
Black or African American	0				1	(1.1)	1	1.05
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Empyema								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Endophthalmitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Enteritis infectious								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.39	0			
Other	0				0			
Missing	0				0			
Epididymitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Escherichia bacteraemia								
White	0				0			
Black or African American	1	(1.1)	1	1.91	0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Eye infection bacterial								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Fungal balanitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Furuncle								
White	0				2	(0.1)	2	0.13
Black or African American	1	(1.1)	1	1.91	0			
Asian	1	(0.2)	2	0.44	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Gastric infection								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Gastroenteritis norovirus								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Giardiasis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Herpes dermatitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Herpes zoster infection neurological								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Infected cyst								
White	0				1	(0.1)	1	0.14
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Infected dermal cyst								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.35	0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Infective iritis								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Injection site abscess								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	0			
Other	0				0			
Missing	0				0			
Labyrinthitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Lyme disease								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Oophoritis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Otitis media acute								
White	0				3	(0.2)	3	0.24
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Paraspinal abscess								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	1		1		0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Parotitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Peri-implantitis								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Pericoronitis								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Post procedural infection								
White	0				1	(0.1)	1	0.11
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Purulence								
White	0				0			
Black or African American	0				0			
Asian	1	(0.2)	1	0.22	0			
Other	0				0			
Missing	0				0			
Rotavirus infection								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Salpingitis								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Sinusitis bacterial								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Skin bacterial infection								
White	0				1	(0.1)	1	0.07
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Soft tissue infection								
White	0				2	(0.1)	2	0.23
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Sweat gland infection								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Urosepsis								
White	0				1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Varicella								
White	0				0			
Black or African American	0				0			
Asian	0				1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Viral pharyngitis								
White	0				1	(0.1)	1	0.07
Black or African American	1	(1.5)	1	1.59	0			
Asian	0				0			
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Viral rhinitis								
White	0				0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				1		1	
Vulvitis								
White	0				0			
Black or African American	0				0			
Asian	2	(0.5)	2	0.86	0			
Other	0				0			
Missing	0				0			
Gastrointestinal disorders								
All								
White	196	(12.5)	300	25.09	157	(10.3)	218	19.86
Black or African American	9	(11.7)	13	24.16	13	(18.6)	17	38.99
Asian	61	(12.9)	92	27.75	70	(13.5)	102	27.84
Other	9		11		3		4	
Missing	2		2		2		2	
Diarrhoea								
White	57	(3.6)	72	5.97	36	(2.4)	37	3.51
Black or African American	6	(8.1)	6	12.52	6	(8.4)	6	12.87
Asian	19	(4.0)	23	6.88	12	(2.3)	13	3.53
Other	7		7		1		1	
Missing	0				0			
Nausea								
White	27	(1.7)	28	2.36	28	(1.8)	30	2.74
Black or African American	1	(1.8)	1	1.92	2	(4.1)	2	7.90
Asian	12	(2.6)	12	3.62	5	(0.9)	5	1.52
Other	1		1		0			
Missing	0				0			
Vomiting								
White	22	(1.4)	28	2.83	15	(1.0)	17	1.65
Black or African American	3	(3.1)	3	5.46	0			
Asian	4	(0.8)	6	1.85	5	(0.9)	6	1.42
Other	2		2		1		1	
Missing	0				0			
Abdominal pain								
White	15	(1.0)	15	1.22	12	(0.8)	13	1.12
Black or African American	1	(0.5)	1	1.07	2	(3.1)	2	4.61
Asian	1	(0.2)	1	0.16	4	(0.8)	4	1.09
Other	0				0			
Missing	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Abdominal pain upper								
White	14	(0.9)	16	1.40	10	(0.7)	11	0.86
Black or African American	0				1	(1.8)	1	3.24
Asian	2	(0.4)	2	0.64	5	(1.0)	5	1.27
Other	0				0			
Missing	0				0			
Constipation								
White	13	(0.8)	16	1.41	7	(0.5)	7	0.64
Black or African American	1	(1.5)	1	1.59	2	(2.4)	2	2.42
Asian	3	(0.7)	3	1.00	6	(1.2)	6	1.80
Other	0				0			
Missing	0				1		1	
Gastrooesophageal reflux disease								
White	11	(0.7)	11	0.80	10	(0.7)	10	0.87
Black or African American	0				0			
Asian	3	(0.7)	3	1.23	5	(1.0)	5	1.42
Other	0				0			
Missing	0				0			
Toothache								
White	10	(0.6)	10	0.82	9	(0.6)	13	1.52
Black or African American	0				1	(1.4)	1	2.29
Asian	5	(1.1)	5	1.26	3	(0.6)	4	1.41
Other	0				0			
Missing	0				0			
Dental caries								
White	8	(0.5)	10	0.70	4	(0.3)	4	0.30
Black or African American	0				1	(1.1)	1	1.05
Asian	4	(0.9)	4	0.87	5	(1.0)	5	1.70
Other	0				0			
Missing	0				0			
Gastritis								
White	6	(0.4)	6	0.51	6	(0.4)	6	0.47
Black or African American	0				0			
Asian	2	(0.4)	2	0.84	2	(0.4)	2	0.58
Other	0				1		1	
Missing	0				0			
Chronic gastritis								
White	6	(0.4)	6	0.52	2	(0.1)	2	0.18
Black or African American	0				0			
Asian	3	(0.7)	3	1.08	4	(0.7)	4	1.06
Other	0				0			
Missing	0				0			
Abdominal distension								
White	6	(0.4)	6	0.45	3	(0.2)	3	0.31

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.

Adverse events by race, system organ class and preferred term - on-treatment/main-on-treatment - summary - safety analysis set - phase 3a pool

	Insulin icodec				Daily basal insulin			
	N	(Adj.%)	E	Adj.R	N	(Adj.%)	E	Adj.R
Black or African American	0				1	(1.8)	1	3.24
Asian	2	(0.4)	2	0.59	1	(0.2)	1	0.19
Other	0				0			
Missing	0				0			
Haemorrhoids								
White	6	(0.4)	6	0.42	3	(0.2)	3	0.31
Black or African American	0				0			
Asian	1	(0.2)	1	0.37	1	(0.2)	1	0.34
Other	0				0			
Missing	0				0			
Food poisoning								
White	5	(0.3)	5	0.40	4	(0.3)	5	0.53
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Dyspepsia								
White	5	(0.3)	5	0.46	4	(0.3)	4	0.31
Black or African American	0				0			
Asian	3	(0.6)	3	0.92	5	(1.0)	5	1.46
Other	0				0			
Missing	0				0			
Diverticulum intestinal								
White	4	(0.3)	4	0.32	1	(0.1)	1	0.06
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	0				0			
Large intestine polyp								
White	4	(0.3)	4	0.29	2	(0.1)	2	0.12
Black or African American	0				0			
Asian	0				4	(0.8)	5	1.13
Other	0				0			
Missing	0				0			
Flatulence								
White	3	(0.2)	3	0.23	2	(0.1)	2	0.22
Black or African American	0				0			
Asian	0				0			
Other	0				0			
Missing	1		1		0			
Aphthous ulcer								
White	2	(0.1)	2	0.13	0			
Black or African American	0				0			
Asian	0				0			
Other	0				0			

%: Percentage of subjects with one or more events, E: Number of adverse events, N: Number of subjects with one or more events, PYE: Patient years of exposure (1 PYE = 365.25 days), R: Rate (number of adverse events per 100 PYE). Adj.: Adjusted percentages and rates were calculated using the Cochran-Mantel-Haenszel method to account for differences between trials. Adjusted percentages and rates were only derived if all trials could contribute. Other race includes American Indian or Alaska Native, and Native Hawaiian or other Pacific Islander. Subjects from France did not report race. MedDRA version 24.1. On-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit (FU2), the last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once weekly insulin or the end-date for the in-trial period. Main-on-treatment: Onset date on or after the first dose of trial product and no later than the first date of either the end-date of the on-treatment period or the last planned visit in the main part of the trial. Daily basal insulin: IDeg, IGlar U100, and IGlar U300. Phase 3a pool: ONWARDS 1-6, only main part of ONWARDS 1 and 6.